"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,KR,A,KR 20230025762 A,032-474-839-541-431,2023-02-23,2023,KR 20220100049 A,2022-08-10,US 202117402858 A,2021-08-16,COMBINATION STENTRIEVER AND MICROCATHETER,"The present invention relates to a thrombectomy system for removing a blood clot from a systemic blood vessel. According to the present invention, a combination-type stentriever and microcatheter comprises: a microcatheter including a distal segment including a first diameter and a proximal segment including a second diameter; a stentriever substantially positionable within a lumen of the distal end part of the microcatheter, and including a coupling structure configured to expand when in an extended configuration at the distal of the microcatheter and an elongated member proximal to the coupling structure and extending to the proximal end of the microcatheter; and a handwork control unit disposed on the proximal end of the microcatheter to control extension and retraction of the coupling structure with respect to the microcatheter.",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/032-474-839-541-431,Patent Application,no,0,0,5,5,0,A61B17/221;;A61B17/221;;A61B90/03;;A61B90/39;;A61B2017/22094;;A61B2017/22072;;A61B2017/22038;;A61B2090/034;;A61B2090/392;;A61B2090/392;;A61B17/221;;A61B2017/00367;;A61B2017/22038;;A61B2017/22074;;A61M2025/0042;;A61M2025/0183,A61B17/221;;A61B17/22;;A61B90/00,,0,0,,,,PENDING
2,US,A,US 1388027 A,105-071-521-374-354,1921-08-16,1921,US 25043218 A,1918-08-19,US 25043218 A,1918-08-19,Snow-melting apparatus,,PATRICK CONNOLLY,PATRICK CONNOLLY,,https://lens.org/105-071-521-374-354,Granted Patent,no,0,13,1,1,0,E01H5/102;;E01H5/102,E01H5/10,,0,0,,,,EXPIRED
3,US,A,US 5285743 A,125-814-997-503-975,1994-02-15,1994,US 85072192 A,1992-03-13,US 85072192 A;;CA 2102048 A,1992-03-13,Dry dock,"A dry dock system comprising a first floating dock able to receive at least one vessel and being controllably submersible. The second dry dock able to receive a vessel and dimensionally received in the first dock. The second dock has sea valves that, when opened, allow the second dock to fill on submerging and drain on raising and, when closed, allow the second dock to float. The first dock is dimensioned so that it can contain the first dry dock and at least one vessel simultaneously. A method of dry docking is also disclosed. The method comprising submerging the first dry dock. Positioning the second dry dock having sea valves over a chosen area of the first dock. The first dock is raised to contact the second dry dock. The sea valves of the second dry dock are open and the first dry dock is then submerged. The second dry dock submerges with the first and remains in contact with the first dry dock. The first dry dock may then be raised. The second dry dock is raised with it. The second dry dock drains on being raised and can be refloated independently of the first dry dock.",CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/125-814-997-503-975,Granted Patent,yes,4,12,2,2,0,B63C1/02;;B63B35/42;;B63C1/02;;B63B35/42,B63C1/02,114/45,0,0,,,,EXPIRED
4,AU,B3,AU 539489 B3,151-551-844-210-662,1984-10-11,1984,AU 1984/030873 A,1984-07-19,AU 1984/030873 A,1984-07-19,IMPROVEMENTS IN ENVELOPES FOR PROCESSED PHOTOGRAPHIC FILM,,CONNOLLY P,CONNOLLY PATRICK,,https://lens.org/151-551-844-210-662,Limited Patent,no,0,0,1,1,0,B42F5/04,B42F5/04,,0,0,,,,EXPIRED
5,US,A,US 896276 A,087-446-289-880-881,1908-08-18,1908,US 1908/0410443 A,1908-01-11,US 1908/0410443 A,1908-01-11,BOX OR TANK.,,CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/087-446-289-880-881,Granted Patent,no,0,4,1,1,0,B65D7/12;;B65D7/12,,,0,0,,,,EXPIRED
6,CN,A,CN 114082083 A,075-031-104-840-139,2022-02-25,2022,CN 202110862105 A,2021-07-29,US 202016942684 A,2020-07-29,Balloon guide catheter having reduced outer diameter distal and proximal bonding interface areas with the balloon,"A balloon guide catheter including a balloon and a catheter shaft having a central lumen defined axially therethrough, and an inflation lumen. An exterior surface of the catheter shaft has a distal reduced outer diameter recess area defined therein and a proximal reduced outer diameter recess area separated in an axial direction from the distal reduced outer diameter recess area with a discharge port of the inflation lumen disposed therebetween. The balloon is secured to the catheter shaft by adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area; and the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.",NEURAVI LTD,CONNOLLY PATRICK;;CONWAY SIMON;;CONNOLLY PATRICK,,https://lens.org/075-031-104-840-139,Patent Application,no,0,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10;;A61B17/22,,0,0,,,,PENDING
7,JP,A,JP 2022027587 A,115-130-426-386-103,2022-02-10,2022,JP 2021123100 A,2021-07-28,US 202016942699 A,2020-07-29,ENHANCED BALLOON BONDING FOR BALLOON GUIDE CATHETERS WHILE MINIMIZING OUTER PROFILES,"To provide a balloon guide catheter.SOLUTION: Balloon guide catheter with a balloon bonded thereto maximizes bonding strength and integrity while minimizing outer profile. A reflow jacket is melted into and embedded in a braid supporting structure of the catheter secured beneath the balloon. Radially arranged apertures and/or recesses may be defined in the balloon through which an adhesive is seepable upwards when secured about the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180°. Proximal and/or distal edges of the balloon may be flipped inwards prior to securing to the catheter shaft to form respective proximal and/or inverted bonds. During pretreatment of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the corresponding balloon or an exhaust tube secured between the exterior surface of the catheter shaft and the balloon.SELECTED DRAWING: Figure 1A",NEURAVI LTD,PATRICK CONNOLLY,,https://lens.org/115-130-426-386-103,Patent Application,no,0,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61M25/10,,0,0,,,,PENDING
8,US,A1,US 2023/0051493 A1,025-988-366-334-815,2023-02-16,2023,US 202117402858 A,2021-08-16,US 202117402858 A,2021-08-16,COMBINATION STENTRIEVER AND MICROCATHETER,"A clot removal system for removing a clot from a body vessel, the clot removal system including: a microcatheter including: a distal segment comprising a first diameter; and a proximal segment comprising a second diameter; a stentriever positionable substantially within a lumen of a distal end of the microcatheter, the stentriever including: an engagement structure configured to expand when distal of the microcatheter in an expanded configuration, and an elongated member proximal of the engagement structure and extending to a proximal end of the microcatheter; and a hand control disposed on the proximal end of the microcatheter for controlling extending and retracting the engagement structure from the microcatheter.",NEURAVI LTD,CONNOLLY PATRICK,NEURAVI LIMITED (2021-08-06),https://lens.org/025-988-366-334-815,Patent Application,yes,0,0,5,5,0,A61B17/221;;A61B17/221;;A61B90/03;;A61B90/39;;A61B2017/22094;;A61B2017/22072;;A61B2017/22038;;A61B2090/034;;A61B2090/392;;A61B2090/392;;A61B17/221;;A61B2017/00367;;A61B2017/22038;;A61B2017/22074;;A61M2025/0042;;A61M2025/0183,A61B17/221,,0,0,,,,PENDING
9,US,A,US 833025 A,041-960-866-866-223,1906-10-09,1906,US 1902/0327751 A,1902-12-18,US 1902/0327751 A,1902-12-18,FLUID-SUPPLY FITTING.,,CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/041-960-866-866-223,Granted Patent,no,0,2,1,1,0,F16L39/00;;F16L39/00,,,0,0,,,,EXPIRED
10,EP,A3,EP 3950039 A3,064-243-660-472-213,2022-06-01,2022,EP 21188147 A,2021-07-28,US 202016942699 A,2020-07-29,ENHANCED BALLOON BONDING FOR BALLOON GUIDE CATHETERS WHILE MINIMIZING OUTER PROFILES,"Balloon guide catheter (100) with a balloon maximizing bonding strength and integrity while minimizing outer profile. Reflow jacket(s) (120, 125) is melted to/embedded within a braid (110) supporting structure of the catheter securing beneath the balloon. Radially arranged apertures and/or recesses may be defined in the balloon through which adhesive is seepable upwards when secured about the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180°. Proximal and/or distal edges of the balloon may be flipped inwards prior to securing to the catheter shaft to form respective proximal and/or inverted bonds. During prepping of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the compliant balloon or an exhaust tube secured between the exterior surface of the catheter shaft and the balloon.
",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/064-243-660-472-213,Search Report,yes,3,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61M25/10;;A61B17/22;;A61M25/00;;B29C65/00,,0,0,,,,PENDING
11,US,A,US 812826 A,047-442-146-396-049,1906-02-20,1906,US 1894/0268733 A,1894-06-15,US 1894/0268733 A,1894-06-15,TUB.,,FRANK E CONNOLLY,CONNOLLY PATRICK,,https://lens.org/047-442-146-396-049,Granted Patent,no,0,1,1,1,0,E03C1/182;;E03C1/182;;Y10T137/3222;;Y10T137/3222;;Y10T137/4486;;Y10T137/4486;;Y10T137/4523;;Y10T137/4523;;Y10T137/4553;;Y10T137/4553,,,0,0,,,,EXPIRED
12,KR,A,KR 20220014842 A,077-217-729-301-811,2022-02-07,2022,KR 20210097802 A,2021-07-26,US 202016942699 A,2020-07-29,ENHANCED BALLOON BONDING FOR BALLOON GUIDE CATHETERS WHILE MINIMIZING OUTER PROFILES,"A balloon guide catheter with a balloon bonded thereto maximizes bonding strength and integrity while minimizing outer profile. A reflow jacket(s) is melted to/embedded within a braid supporting structure of the catheter fixated below the balloon. Radially arranged apertures and/or recesses may be defined in the balloon such that adhesive is penetrable upwards when secured around the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180°. Proximal and/or distal edges of the balloon may be flipped inwards prior to fixation to the catheter shaft to form respective proximal and/or inverted bonds. During preparation of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the compliant balloon or an exhaust tube fixated between the exterior surface of the catheter shaft and the balloon.",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/077-217-729-301-811,Patent Application,no,0,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61M25/10;;A61B17/22;;A61M25/00,,0,0,,,,PENDING
13,US,A1,US 2015/0091221 A1,105-948-727-477-55X,2015-04-02,2015,US 201414502449 A,2014-09-30,US 201414502449 A;;US 201361885270 P,2013-10-01,BALLOON CATHETER AND METHOD OF MANUFACTURE,"A method of manufacturing a balloon catheter in which an extruded tubular balloon parison is attached to a component of a catheter shaft prior to blow molding a balloon from the extruded tubular balloon parison. A distal end region of the tubular balloon parison is attached to the outer surface of the elongate catheter shaft component to form a distal bond region between the tubular balloon parison and the catheter shaft component, and then the assembly is positioned in a balloon mold. An annular space between an inner surface of the tubular balloon parison and the outer surface of the elongate tubular member is pressurized to expand the tubular balloon parison in the cavity of the balloon mold to form an inflatable balloon.",BOSTON SCIENT SCIMED INC,CONNOLLY PATRICK,BOSTON SCIENTIFIC SCIMED INC (2015-08-04),https://lens.org/105-948-727-477-55X,Patent Application,yes,2,6,2,2,0,B29L2031/7543;;A61M2025/1065;;A61M25/1029;;B29C49/20;;B29C49/04;;A61M25/1034;;B29C2049/2047;;B29K2105/258;;B29C48/09;;B29C48/0017;;A61M25/1029;;B29C49/20;;B29C49/04;;B29C49/4252;;A61M25/1034;;B29C2049/2047;;B29K2105/258;;B29C48/09;;B29C48/0017;;B29L2031/7543;;A61M2025/1065,A61M25/10;;B29C48/09;;B29C49/04;;B29C49/20;;B29C49/42,264/515;;264/516,0,0,,,,ACTIVE
14,US,B2,US 9533125 B2,190-345-808-219-122,2017-01-03,2017,US 201414502449 A,2014-09-30,US 201414502449 A;;US 201361885270 P,2013-10-01,Balloon catheter and method of manufacture,"A method of manufacturing a balloon catheter in which an extruded tubular balloon parison is attached to a component of a catheter shaft prior to blow molding a balloon from the extruded tubular balloon parison. A distal end region of the tubular balloon parison is attached to the outer surface of the elongate catheter shaft component to form a distal bond region between the tubular balloon parison and the catheter shaft component, and then the assembly is positioned in a balloon mold. An annular space between an inner surface of the tubular balloon parison and the outer surface of the elongate tubular member is pressurized to expand the tubular balloon parison in the cavity of the balloon mold to form an inflatable balloon.",BOSTON SCIENT SCIMED INC,CONNOLLY PATRICK,BOSTON SCIENTIFIC SCIMED INC (2015-08-04),https://lens.org/190-345-808-219-122,Granted Patent,yes,25,3,2,2,0,B29L2031/7543;;A61M2025/1065;;A61M25/1029;;B29C49/20;;B29C49/04;;A61M25/1034;;B29C2049/2047;;B29K2105/258;;B29C48/09;;B29C48/0017;;A61M25/1029;;B29C49/20;;B29C49/04;;B29C49/4252;;A61M25/1034;;B29C2049/2047;;B29K2105/258;;B29C48/09;;B29C48/0017;;B29L2031/7543;;A61M2025/1065,A61M25/10;;B29C48/09;;B29C49/04;;B29C49/20;;B29C49/42;;B29K105/00;;B29L31/00,,0,0,,,,ACTIVE
15,CA,A1,CA 2102048 A1,044-102-238-579-395,1995-04-30,1995,CA 2102048 A,1993-10-29,CA 2102048 A;;US 85072192 A,1992-03-13,DRY DOCK,"A dry dock system comprising a first floating dock able to receive at least one vessel and being controllably submersible. The second dry dock able to receive a vessel and dimensionally received in the first dock. The second dock has sea valves that, when opened, allow the second dock to fill on submerging and drain on raising and, when closed, allow the second dock to float. The first dock is dimensioned so that it can contain the first dry dock and at least one vessel simultaneously. A method of dry docking is also disclosed. The method comprising submerging the first dry dock. Positioning the second dry dock having sea valves over a chosen area of the first dock. The first dock is raised to contact the second dry dock. The sea valves of the second dry dock are open and the first dry dock is then submerged. The second dry dock submerges with the first and remains in contact with the first dry dock. The first dry dock may then be raised. The second dry dock is raised with it. The second dry dock drains on being raised and can be refloated independently of the first dry dock.",CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/044-102-238-579-395,Patent Application,no,0,0,2,2,0,B63C1/02;;B63B35/42;;B63C1/02;;B63B35/42,B63C1/02,,0,0,,,,DISCONTINUED
16,CN,A,CN 114073563 A,051-220-898-245-842,2022-02-22,2022,CN 202110862131 A,2021-07-29,US 202016942699 A,2020-07-29,Enhanced Balloon Bonding For Balloon Guide Catheters While Minimizing Outer Profiles,"The subject of the invention is a balloon guide catheter with a balloon bonded thereto maximizing bonding strength and integrity while minimizing outer profile. Reflow jacket(s) is melted to/embedded within a braid supporting structure of the catheter securing beneath the balloon. Radially arranged apertures and/or recesses may be defined in the balloon through which adhesive is seepable upwards when secured about the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180 degrees. Proximal and/or distal edges of the balloon may be flipped inwards prior to securing to the catheter shaft to form respective proximal and/or inverted bonds. During prepping of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the compliant balloon or an exhaust tube secured between the exterior surface of the catheter shaft and the balloon.",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/051-220-898-245-842,Patent Application,no,0,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61B17/22;;A61M25/10,,0,0,,,,PENDING
17,EP,A2,EP 3950039 A2,062-144-613-178-218,2022-02-09,2022,EP 21188147 A,2021-07-28,US 202016942699 A,2020-07-29,ENHANCED BALLOON BONDING FOR BALLOON GUIDE CATHETERS WHILE MINIMIZING OUTER PROFILES,"Balloon guide catheter (100) with a balloon maximizing bonding strength and integrity while minimizing outer profile. Reflow jacket(s) (120, 125) is melted to/embedded within a braid (110) supporting structure of the catheter securing beneath the balloon. Radially arranged apertures and/or recesses may be defined in the balloon through which adhesive is seepable upwards when secured about the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180°. Proximal and/or distal edges of the balloon may be flipped inwards prior to securing to the catheter shaft to form respective proximal and/or inverted bonds. During prepping of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the compliant balloon or an exhaust tube secured between the exterior surface of the catheter shaft and the balloon.
",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/062-144-613-178-218,Patent Application,yes,0,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61M25/10;;A61B17/22;;A61M25/00;;B29C65/00,,0,0,,,,PENDING
18,US,A,US 830053 A,020-182-376-050-301,1906-09-04,1906,US 1902/0135788 A,1902-12-18,US 1902/0135788 A,1902-12-18,TUB-FITTING.,,CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/020-182-376-050-301,Granted Patent,no,0,0,1,1,0,E03C1/04;;E03C1/04,,,0,0,,,,EXPIRED
19,US,A1,US 2022/0032016 A1,065-616-424-526-633,2022-02-03,2022,US 202016942699 A,2020-07-29,US 202016942699 A,2020-07-29,Enhanced Balloon Bonding For Balloon Guide Catheters While Minimizing Outer Profiles,"Balloon guide catheter with a balloon bonded thereto maximizing bonding strength and integrity while minimizing outer profile. Reflow jacket(s) is melted to/embedded within a braid supporting structure of the catheter securing beneath the balloon. Radially arranged apertures and/or recesses may be defined in the balloon through which adhesive is seepable upwards when secured about the catheter shaft. Proximal and distal bond interface areas of the balloon may be skived at right angles into two sections each extending radially 180°. Proximal and/or distal edges of the balloon may be flipped inwards prior to securing to the catheter shaft to form respective proximal and/or inverted bonds. During prepping of the catheter, residual air may be purged from the balloon via an exhaust hole defined in the compliant balloon or an exhaust tube secured between the exterior surface of the catheter shaft and the balloon.",NEURAVI LTD,CONNOLLY PATRICK,NEURAVI LIMITED (2020-07-08),https://lens.org/065-616-424-526-633,Patent Application,yes,2,0,6,6,0,A61B17/22;;A61M25/1002;;A61M25/1018;;A61B2017/22067;;A61M2025/1052;;A61M25/1034;;A61M25/1002;;A61M25/005;;A61M2025/109;;A61M25/10;;A61M2025/1065;;A61B2017/22067;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1025;;A61M25/0012;;A61M25/005;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61M25/005;;A61M25/1018;;A61M25/1034;;A61M25/104,A61M25/10;;A61M25/00,,0,0,,,,PENDING
20,US,A,US 891207 A,119-768-765-477-243,1908-06-16,1908,US 1896/0578241 A,1896-02-06,US 1896/0578241 A,1896-02-06,VALVE.,,CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/119-768-765-477-243,Granted Patent,no,0,8,1,1,0,F16K31/46;;F16K31/46;;Y10T137/7014;;Y10T137/7014,,,0,0,,,,EXPIRED
21,AU,A,AU 1983/021199 A,189-718-338-903-133,1985-03-21,1985,AU 1983/021199 A,1983-11-14,NZ 20555383 A,1983-09-12,FILM STORAGE,,CONNOLLY P,CONNOLLY PATRICK,,https://lens.org/189-718-338-903-133,Patent Application,no,0,0,1,1,0,,B42F7/04,,0,0,,,,DISCONTINUED
22,US,A,US 1416172 A,107-727-943-229-749,1922-05-16,1922,US 29105719 A,1919-04-18,US 29105719 A,1919-04-18,Fitting for tubs and sinks,,PATRICK CONNOLLY,PATRICK CONNOLLY,,https://lens.org/107-727-943-229-749,Granted Patent,no,0,2,1,1,0,E03C1/232;;E03C1/232,E03C1/232,,0,0,,,,EXPIRED
23,GB,A,GB 190218997 A,130-313-506-847-817,1903-06-25,1903,GB 190218997D A,1902-08-29,GB 190218997T A,1902-08-29,Improvements in or relating to Apparatus for Domestic Washing.,"18,997. Connolly, P. Aug. 29. Washing-machines; wash - tubs.-An ordinary wash-tub A is provided with a cover B having a close-fitting rim. In this cover is mounted a shaft N having at its lower end a dolly K, which is rotated by bevel gearing H, I, operated by hand or power. A washer f secured to the shaft N by a pin g prevents the shaft from lifting when in action. Both the cover and tub are provided with handles.",CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/130-313-506-847-817,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
24,JP,A,JP 2023027026 A,018-545-966-655-544,2023-03-01,2023,JP 2022129250 A,2022-08-15,US 202117402858 A,2021-08-16,COMBINATION OF STENTRIEVER AND MICROCATHETER,"To provide a clot removal system for removing a clot from a body vessel.SOLUTION: The clot removal system includes: a microcatheter including a distal segment comprising a first diameter and a proximal segment comprising a second diameter; a stentriever positionable substantially within a lumen of a distal end of the microcatheter, the stentriever including an engagement structure configured to expand when being distal of the microcatheter in an expanded configuration, and an elongated member proximal of the engagement structure and extending to a proximal end of the microcatheter; and a hand control disposed on the proximal end of the microcatheter for controlling extending and retracting of the engagement structure from the microcatheter.SELECTED DRAWING: Figure 1A",NEURAVI LTD,PATRICK CONNOLLY,,https://lens.org/018-545-966-655-544,Patent Application,no,0,0,5,5,0,A61B17/221;;A61B17/221;;A61B90/03;;A61B90/39;;A61B2017/22094;;A61B2017/22072;;A61B2017/22038;;A61B2090/034;;A61B2090/392;;A61B2090/392;;A61B17/221;;A61B2017/00367;;A61B2017/22038;;A61B2017/22074;;A61M2025/0042;;A61M2025/0183,A61B17/221,,0,0,,,,PENDING
25,IE,A2,IE S20030216 A2,166-779-088-438-260,2003-09-17,2003,IE S20030216 A,2003-03-24,IE S20030216 A;;IE 20020204 A,2002-03-22,A local area wireless network simulator,"A simulator (1) has virtual stacks (10,23) which simulate entirely in software behaviour of actual stacks for hardware devices. Stubs (25) are provided for resource-poor applications (21) to communicate with virtual stacks (10). A discovery service (12) simulates in software hardware devices and has a discovery function to discover these simulated devices. It responds to application calls indicating the simulated devices as if they were the actual devices within ranges, i.e. within a piconet. <Figure 1>",ROCOCO SOFTWARE LTD,CONNOLLY PATRICK,,https://lens.org/166-779-088-438-260,Patent Application,no,0,0,5,5,0,G06F9/54;;G06F9/45537,G06F9/455;;G06F9/46;;G06F11/00;;G06F17/00;;H04L12/28,,0,0,,,,DISCONTINUED
26,US,A,US 816559 A,121-514-127-727-289,1906-04-03,1906,US 1902/0276882 A,1902-12-18,US 1902/0276882 A,1902-12-18,FLUID-SUPPLY FITTING.,,CONNOLLY PATRICK,CONNOLLY PATRICK,,https://lens.org/121-514-127-727-289,Granted Patent,no,0,2,1,1,0,F16L39/00;;F16L39/00,,,0,0,,,,EXPIRED
27,EP,A1,EP 4137069 A1,166-689-348-383-691,2023-02-22,2023,EP 22190352 A,2022-08-15,US 202117402858 A,2021-08-16,COMBINATION STENTRIEVER AND MICROCATHETER,"A clot removal system for removing a clot from a body vessel, the clot removal system including: a microcatheter including: a distal segment comprising a first diameter; and a proximal segment comprising a second diameter; a stentriever positionable substantially within a lumen of a distal end of the microcatheter, the stentriever including: an engagement structure configured to expand when distal of the microcatheter in an expanded configuration, and an elongated member proximal of the engagement structure and extending to a proximal end of the microcatheter; and a hand control disposed on the proximal end of the microcatheter for controlling extending and retracting the engagement structure from the microcatheter.
",NEURAVI LTD,CONNOLLY PATRICK,,https://lens.org/166-689-348-383-691,Patent Application,yes,3,0,5,5,0,A61B17/221;;A61B17/221;;A61B90/03;;A61B90/39;;A61B2017/22094;;A61B2017/22072;;A61B2017/22038;;A61B2090/034;;A61B2090/392;;A61B2090/392;;A61B17/221;;A61B2017/00367;;A61B2017/22038;;A61B2017/22074;;A61M2025/0042;;A61M2025/0183,A61B17/221,,0,0,,,,PENDING
28,JP,A,JP 2008018268 A,025-465-047-135-824,2008-01-31,2008,JP 2007260095 A,2007-10-03,IE 950950 A,1995-12-18,THERAPEUTIC BED,"<P>PROBLEM TO BE SOLVED: To provide a therapeutic bed which enables a patient to take the prone posture thereon so as to take various kinds of physical exercise therapy. <P>SOLUTION: A therapeutic bed comprises: a support framework 2; a patient support platform which can be rotated from a supine support position to a prone support position; a supporting means for holding a patient in the prone position when the patient support platform is in the prone support position; and a motor which can move the patient support platform from the supine position to the prone position. The supporting means for holding the patient in the prone position includes a head holder, a stomach holder 37 that can be transcended, and support pad sections 36, 39 and 40. The motor makes the patient support platform rotate on its longitudinal axis so that the patient can take kinetic therapy in either supine or prone posture. <P>COPYRIGHT: (C)2008,JPO&INPIT",KCI LICENSING INC,CONNOLLY PATRICK J,,https://lens.org/025-465-047-135-824,Patent Application,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/05;;A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,INACTIVE
29,US,A,US 1219085 A,045-212-016-810-84X,1917-03-13,1917,US 6505015 A,1915-12-04,US 6505015 A,1915-12-04,CURTAIN-STRETCHER.,,EDWARD R LEWIS;;CONNOLLY PATRICK J,CONNOLLY PATRICK J,,https://lens.org/045-212-016-810-84X,Granted Patent,no,0,0,1,1,0,D06F59/08;;D06F59/08,,,0,0,,,,EXPIRED
30,US,A,US 4947496 A,038-781-783-806-186,1990-08-14,1990,US 26497388 A,1988-10-31,IE 295087 A,1987-11-02,Therapeutic bed,"A therapeutic bed (1) comprises a patient support platform (2) rotatably mounted on a base frame (5). A pair of side members (30) extend longitudinally of the patient support platform (2) and are mounted for pivotal movement about a longitudinal pivot axis from a raised operative position supporting a patient to a lowered inoperative position. Each side member (30) is carried on a pair of spaced-apart cranked support arms (34, 35) which are bridged by a bridging bar (42) to form a frame. A primary retaining device retains the side support in the raised position. Each support arm (34, 35) is pivotally mounted to a pivot support sleeve which is slidably mounted on a round bar (46) forming a track. A secondary retaining device is provided by a stop disc (48) having a slot (50) which is moved into and out of alignment with a latch (47) to control movement of the sleeve (45) on the bar (46).",ETHOS MEDICAL RESEARCH LIMITED,CONNOLLY PATRICK J,ETHOS MEDICAL RESEARCH LIMITED 10 THE CRESCENT LIMERICK IRELAND A LIMITED LIABILITY CO. OF IRELAND (1988-10-25);;KCI LICENSING INC (2001-10-09),https://lens.org/038-781-783-806-186,Granted Patent,yes,10,59,8,8,0,A61G7/0507;;A61G7/0507;;A61G7/008;;A61G7/008;;A61G7/05;;A61G7/05;;A61G7/051;;A61G7/051;;A61G7/0513;;A61G7/0513;;A61G7/0519;;A61G7/0519;;A61G7/052;;A61G7/052,A61G7/008;;A61G7/05,5/61;;5/72;;5/66;;5/430;;128/49,0,0,,,,EXPIRED
31,DE,T2,DE 69627196 T2,066-755-308-410-656,2004-02-05,2004,DE 69627196 T,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,THERAPEUTISCHE VORRICHTUNG,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,"KCI LICENSING, INC., SAN ANTONIO, TEX., US (2006-05-18)",https://lens.org/066-755-308-410-656,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
32,EP,A1,EP 0315438 A1,124-425-858-390-573,1989-05-10,1989,EP 88310322 A,1988-11-02,IE 295087 A,1987-11-02,A therapeutic bed.,"A therapeutic bed 1 comprises a patient support platform 2 rotatably mounted on a base frame 5. A pair of side members 30 extend longitudinally of the patient support platform 2 and are mounted for pivotal movement about a longitudinal pivot axis from a raised operative position supporting a patient to a lowered in-operative position. Each side member 30 is carried on a pair of spaced-apart cranked support arms 34, 35 which are bridged by a bridging bar 42 to form a frame. A primary retaining means for retaining the side support in the raised position is provided by a cross bar 65 of the patient support platform 2 on which the bridging bar 42 rests. Each support arm 34, 35 is pivotally mounted to a pivot support sleeve 45 which is slidably mounted on a round bar 46 forming a track. Secondary retaining means is provided by a stop disc 48 having a slot 50 which is moved into and out of alignment with a latch 47 to control movement of the sleeve 45 on the bar 46. An adjustable backrest 80 and a headrest 94 are also provided.  ",ETHOS MEDICAL RESEARCH LIMITED,CONNOLLY PATRICK JOSEPH,,https://lens.org/124-425-858-390-573,Patent Application,yes,6,11,8,8,0,A61G7/0507;;A61G7/0507;;A61G7/008;;A61G7/008;;A61G7/05;;A61G7/05;;A61G7/051;;A61G7/051;;A61G7/0513;;A61G7/0513;;A61G7/0519;;A61G7/0519;;A61G7/052;;A61G7/052,A61G7/008;;A61G7/05,,0,0,,,,DISCONTINUED
33,CA,A1,CA 2367855 A1,130-974-643-203-944,2000-10-12,2000,CA 2367855 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame ( 1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior spac e, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion o f the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bond ed in a first region of bonding to an inner face of the perimetral wall (8), an d a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/130-974-643-203-944,Patent Application,no,0,1,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
34,AT,T1,AT E326404 T1,075-857-180-494-865,2006-06-15,2006,AT 00920862 T,2000-04-04,IE S990279 A,1999-04-06,AUFBEWAHRUNGSBEHÄLTER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/075-857-180-494-865,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
35,AU,A,AU 2000/041279 A,089-514-564-254-098,2000-10-23,2000,AU 2000/041279 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,Storage container,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",JAMES PATRICK CONNOLLY,CONNOLLY JAMES PATRICK,,https://lens.org/089-514-564-254-098,Patent Application,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,DISCONTINUED
36,ES,T3,ES 2197957 T3,169-169-003-970-794,2004-01-16,2004,ES 96945774 T,1996-12-17,IE 950950 A,1995-12-18,DISPOSITIVO TERAPEUTICO.,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,,https://lens.org/169-169-003-970-794,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
37,PT,E,PT 1165404 E,189-832-647-485-798,2006-10-31,2006,PT 00920862 T,2000-04-04,IE S990279 A,1999-04-06,RECIPIENTE DE ARMAZENAGEM,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/189-832-647-485-798,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
38,US,A,US 3587909 A,088-012-859-738-077,1971-06-28,1971,US 3587909D A,1969-01-21,US 79258369 A,1969-01-21,STUD FEEDING APPARATUS,,VISI TROL ENG CO,CONNOLLY PATRICK W,,https://lens.org/088-012-859-738-077,Granted Patent,no,0,0,1,1,0,B23P19/003;;B23P19/003,B23P19/00,221/93,0,0,,,,EXPIRED
39,WO,A1,WO 2000/059807 A1,097-150-233-103-610,2000-10-12,2000,GB 0001260 W,2000-04-04,IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/097-150-233-103-610,Patent Application,yes,6,5,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,PATENTED
40,US,A,US 3273166 A,121-879-742-116-967,1966-09-20,1966,US 36404264 A,1964-04-30,US 36404264 A,1964-04-30,Ornamental visor strap for a uniform cap,,CONNOLLY PATRICK J,CONNOLLY PATRICK J,,https://lens.org/121-879-742-116-967,Granted Patent,no,6,1,1,1,0,A42B1/0181;;A42B1/0181,A42B1/06,,0,0,,,,EXPIRED
41,US,A,US 4868937 A,107-981-541-912-821,1989-09-26,1989,US 13037187 A,1987-12-08,IE 117086 A,1986-05-02,Therapeutic bed,"A therapeutic bed comprises a patient support platform 2 rotatably and pivotally secured within a main bed frame 3 through pivot mountings 4, the main bed frame being supported on a base frame 5 by two spaced-apart end uprights formed by a pair of hydraulic rams 6. Each ram is individually height adjustable and one of the pairs of rams is pivotally connected to the base frame by a crankshaft 7 which in turn is pivotally connected by a pivot 8 to the base frame. The other pair of rams is pivotally connected to the base frame by a shaft 9. An electric motor 10 drives a belt 15 to rotate or oscillate the patient support platform. The arc of oscillation of the patient support platform is controlled by a control unit which includes a potentiometer. Weighing means for the patient support platform is provided by a laod cell mounted between each of the pivot mountings and the main bed frame.",ETHOS MEDICAL RESEARCH LIMITED,CONNOLLY PATRICK J,JOYSTONE LIMITED (1988-03-25);;KCI LICENSING INC (2001-10-09),https://lens.org/107-981-541-912-821,Granted Patent,yes,8,66,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,5/61;;5/60;;5/62;;177/144,0,0,,,,EXPIRED
42,CA,A1,CA 2751148 A1,124-942-633-977-862,2013-02-25,2013,CA 2751148 A,2011-08-25,CA 2751148 A,2011-08-25,CHEMICAL REACTION OF CARBON DIOXIDE,"2CO2 + 3Fe + heat .fwdarw. Fe3O4 + 2C OBJECT: To determine the temperature of iron filings catalyst and carbon dioxide gas when and if the oxidation of the iron filings occurs. APPARATUS: Degreased iron filings 500 grams, dry ice, two Erlenmeyer flasks, glass tubing, rubber tubing, one hole rubber stopper, two 10 ml test tubes, centrifuge, heater. PROCEDURE: Dry ice pellets were put in one Erlenmeyer flask with one hole stopper. Tubing extended to another heated flask which contained iron filings. Carbon dioxide was emitted into the center of the iron filings for two hours, as the dry ice melted. The temperature of the iron filings was maintained at 96 degrees centigrade, as the dry ice melted. After cooling to room temperature, the solid remaining was added to water in one test tube and compared with a new similar solution of new iron filings. Both were centrifuged and the results recorded. OBSERVATION: The test tubes were centrifuged for half an hour and compared. There was a dark layer of iron oxide above the iron filings solid, in the carbon dioxide treated test tube. CONCLUSION: The carbon dioxide gas oxidized the catalyst iron partially at 96 degrees centigrade. SOURCE OF ERROR: Temperature readings were approximate.",CONNOLLY HENRY PATRICK,CONNOLLY HENRY PATRICK,,https://lens.org/124-942-633-977-862,Patent Application,no,0,0,1,1,0,C01B9/02;;C01B7/03;;C07C17/00;;C07C17/18,C07C17/18;;C01B5/00;;C01B7/03;;C07C19/041,,0,0,,,,DISCONTINUED
43,US,A,US 3599768 A,173-418-323-269-277,1971-08-17,1971,US 3599768D A,1968-12-11,US 78291768 A,1968-12-11,COMPOSITE TRACK AND METHOD OF MAKING SAME,,VISI TROL ENG CO,CONNOLLY PATRICK W,,https://lens.org/173-418-323-269-277,Granted Patent,no,6,2,1,1,0,B65G47/1421;;B65G47/1421;;Y10T29/53543;;Y10T29/53543,B65G47/14,193 25   FT,0,0,,,,EXPIRED
44,DE,T2,DE 60028019 T2,184-510-940-375-13X,2009-10-01,2009,DE 60028019 T,2000-04-04,IE S990279 A;;GB 0001260 W,1999-04-06,AUFBEWAHRUNGSBEHÄLTER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/184-510-940-375-13X,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
45,EP,B1,EP 1165404 B1,152-260-693-124-316,2006-05-17,2006,EP 00920862 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/152-260-693-124-316,Granted Patent,yes,6,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
46,AU,B2,AU 534334 B2,198-976-001-870-530,1984-01-19,1984,AU 1980/060446 A,1980-07-16,AU 1980/060446 A,1980-07-16,LARGE FLEXIBLE CONTAINER WITH SUPPORT FRAME,,CONNOLLY J P,CONNOLLY JAMES PATRICK,,https://lens.org/198-976-001-870-530,Granted Patent,no,0,2,2,2,0,B65D90/205;;B65D88/16,B65D88/16;;B65D90/20,,0,0,,,,EXPIRED
47,AT,T1,AT E68689 T1,057-433-541-968-412,1991-11-15,1991,AT 87304026 T,1987-05-05,EP 87304026 A;;IE 117086 A,1986-05-02,THERAPEUTISCHES BETT.,"A therapeutic bed (1,60) comprising a patient support platform (2) rotatably and pivotally secured within a main bed frame (3) through pivot mountings (4), the main bed frame (3) being supported on a base frame (5) by two spaced-apart end uprights formed by a pair of hydraulic rams (6). Each ram (6) is individually height adjustable and one of the pairs of rams (6) is pivotally connected to the base frame (5) by a crankshaft (7) which in turn is pivotally connected to a pivot (8) to the base frame (5). The other pair of rams (6) is pivotally connected to the base frame (5) by a shaft (9). An electric motor (10) drives a belt (15) to rotate or oscillate the patient support platform (2). The arc of oscillation of the patient support platform (2) is controlled by a control unit (30) which includes a potentiometer (36). Weighing means for the patient support platform (2) is provided by a load cell (62) mounted between each of the pivot mountings (4) and the main bed frame (3).",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH,,https://lens.org/057-433-541-968-412,Granted Patent,no,0,0,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,,0,0,,,,DISCONTINUED
48,US,A,US 6112349 A,148-898-492-155-114,2000-09-05,2000,US 9939798 A,1998-06-18,IE 950950 A;;IE 9600087 W,1995-12-18,Therapeutic device,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180.degree.. The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH,ALLIANCE INVESTMENTS LIMITED (1998-08-19);;HUNTLEIGH TECHNOLOGY LIMITED (2012-11-08);;KCI LICENSING INC (2001-10-09),https://lens.org/148-898-492-155-114,Granted Patent,yes,13,75,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,5/607;;5/608;;5/610;;5/621;;5/430,0,0,,,,EXPIRED
49,IN,B,IN 154466 B,150-292-900-538-364,1984-10-27,1984,IN 812CA1980 A,1980-07-16,IN 812CA1980 A,1980-07-16,IMPROVEMENTS IN OR RELATING TO TANKS OR LIKE LIQUID CONTAINERS,,CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/150-292-900-538-364,Granted Patent,no,0,0,1,1,0,,E03B11/00,,0,0,,,,EXPIRED
50,US,A,US 1033876 A,198-454-496-283-89X,1912-07-30,1912,US 1911/0606316 A,1911-02-03,US 1911/0606316 A,1911-02-03,FOLDING PACKING-CASE.,,CLARK JAMES,CONNOLLY MARTIN PATRICK,,https://lens.org/198-454-496-283-89X,Granted Patent,no,0,1,1,1,0,B65D9/14;;B65D9/14,B65D6/18,,0,0,,,,EXPIRED
51,US,A,US 2993734 A,053-156-072-224-235,1961-07-25,1961,US 69348757 A,1957-10-30,US 69348757 A,1957-10-30,Rotary broom filling machine,,CONNOLLY PATRICK J,CONNOLLY PATRICK J,,https://lens.org/053-156-072-224-235,Granted Patent,no,6,0,1,1,0,A46D3/05;;A46D3/05,A46D3/05,,0,0,,,,EXPIRED
52,US,B1,US 6561372 B1,163-363-727-453-267,2003-05-13,2003,US 93740201 A,2001-09-26,GB 0001260 W;;IE S990279 A,1999-04-06,Storage container,"
    An improved portable storage container comprises an exterior support frame (  1  ) defining an interior space having an upper periphery and including upright members (  3  ) spaced around the periphery of the interior space and horizontal elongate members (  6  ) disposed about the upper periphery of the interior space, the elongate members (  6  ) each extending along a corresponding side of a polygon. A flexible vessel (  2  ) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (  8  ) comprising a plurality of strips (  10  ) of elastic material, each extending over a corresponding elongate member (  6  ) of the supporting frame (  1  ), a first end portion (  11  ) of each strip (  10  ) being bonded in a first region of bonding to an inner face of the perimetral wall (  8  ), and a second end portion (  12  ) being bonded in a second region of bonding to an outer face of perimetral wall (  8  ). 
",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/163-363-727-453-267,Granted Patent,yes,8,18,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,220/9.1;;220/9.2,0,0,,,,EXPIRED
53,EP,A2,EP 0248537 A2,022-758-453-721-204,1987-12-09,1987,EP 87304026 A,1987-05-05,IE 117086 A,1986-05-02,A therapeutic bed.,"A therapeutic bed (1,60) comprising a patient support platform (2) rotatably and pivotally secured within a main bed frame (3) through pivot mountings (4), the main bed frame (3) being supported on a base frame (5) by two spaced-apart end uprights formed by a pair of hydraulic rams (6). Each ram (6) is individually height adjustable and one of the pairs of rams (6) is pivotally connected to the base frame (5) by a crankshaft (7) which in turn is pivotally connected to a pivot (8) to the base frame (5). The other pair of rams (6) is pivotally connected to the base frame (5) by a shaft (9). An electric motor (10) drives a belt (15) to rotate or oscillate the patient support platform (2). The arc of oscillation of the patient support platform (2) is controlled by a control unit (30) which includes a potentiometer (36). Weighing means for the patient support platform (2) is provided by a load cell (62) mounted between each of the pivot mountings (4) and the main bed frame (3).",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH,,https://lens.org/022-758-453-721-204,Patent Application,yes,0,5,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,,0,0,,,,EXPIRED
54,EP,A1,EP 1165404 A1,078-292-538-596-844,2002-01-02,2002,EP 00920862 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/078-292-538-596-844,Patent Application,yes,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
55,CA,C,CA 2367855 C,111-897-299-786-697,2007-10-23,2007,CA 2367855 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame ( 1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior spac e, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion o f the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bond ed in a first region of bonding to an inner face of the perimetral wall (8), an d a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/111-897-299-786-697,Granted Patent,no,0,1,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14;;E04H7/00,,0,0,,,,EXPIRED
56,MX,A,MX 150876 A,110-194-409-085-051,1984-08-08,1984,MX 18322980 A,1980-07-18,MX 18322980 A,1980-07-18,MEJORAS EN UN RECIPIENTE PARA MATERIALES SUSCEPTIBLES DE FLUIR,,JAMES PATRICK CONNOLLY,CONNOLLY JAMES PATRICK,,https://lens.org/110-194-409-085-051,Granted Patent,no,0,0,1,1,0,,,57-2,0,0,,,,EXPIRED
57,NZ,A,NZ 514608 A,197-117-091-407-141,2003-04-29,2003,NZ 51460800 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,Storage container comprising a flexible vessel held within an exterior frame by elastic strips,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8). In each of the elastic strips (10), the warp threads are less elastic than the weft threads.",JAMES PATRICK CONNOLLY,CONNOLLY JAMES PATRICK,,https://lens.org/197-117-091-407-141,Patent Application,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,DISCONTINUED
58,PT,E,PT 877590 E,001-822-239-685-734,2003-08-29,2003,PT 96945774 T,1996-12-17,IE 950950 A,1995-12-18,DISPOSITIVO TERAPEUTICO,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH,,https://lens.org/001-822-239-685-734,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
59,US,A,US 1259723 A,058-035-072-756-54X,1918-03-19,1918,US 16112717 A,1917-04-11,US 16112717 A,1917-04-11,MARKING-TICKET.,,A KIMBALL CO,CONNOLLY PATRICK J,,https://lens.org/058-035-072-756-54X,Granted Patent,no,0,0,1,1,0,G09F3/16;;G09F3/16,,,0,0,,,,EXPIRED
60,DK,T3,DK 1165404 T3,189-386-290-962-346,2006-08-21,2006,DK 00920862 T,2000-04-04,IE S990279 A,1999-04-06,Oplagringsbeholder,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/189-386-290-962-346,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
61,GB,B,GB 2127705 B,090-170-431-571-208,1986-10-08,1986,GB 8325841 A,1983-09-27,GB 8325841 A;;GB 8228177 A,1982-10-01,INVALID'S WALKING FRAME,,CONNOLLY LEO PATRICK,CONNOLLY LEO PATRICK,,https://lens.org/090-170-431-571-208,Granted Patent,no,0,0,3,3,0,A61H3/00;;A61H2003/005,A61H3/00,A6M21E,0,0,,,,EXPIRED
62,DK,T3,DK 0877590 T3,109-928-097-023-146,2003-07-28,2003,DK 96945774 T,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,Terapeutisk indretning,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,,https://lens.org/109-928-097-023-146,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
63,IE,A2,IE S990279 A2,053-437-477-455-77X,2000-10-18,2000,IE S990279 A,1999-04-06,IE S990279 A,1999-04-06,Storage container,"An improved portable storage container is described. This comprises an exterior support frame (1) defining an interior space having an upper periphery and including a plurality of upright members (3) spaced from one another around the periphery of the interior space and a plurality of substantially horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space, this flexible vessel (2) having a bottom wall (7) and an upstanding flexible perimetral wall (8) secured to the bottom wall (7). The container further comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each of which extends over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/053-437-477-455-77X,Patent Application,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,DISCONTINUED
64,GB,A,GB 2127705 A,056-058-027-990-889,1984-04-18,1984,GB 8325841 A,1983-09-27,GB 8325841 A;;GB 8228177 A,1982-10-01,Invalid's walking frame,"To enable an invalid, having active use of one leg only (or in certain instances defective use of both legs) to walk slowly, the walking frame, comprising main uprights 14 and converging secondary uprights 24 surmounted by handle units 16 including handles 20, includes a central beam 32 extending rearwardly and carrying a footrest 40 which can be adjusted front-to-rear and to project to one side or the other. This beam 32 couples to the walking frame a rest unit comprising a saddle 46 adjustable for height, upon which the user can sit or support at least part of his weight whilst moving his leg(s) between successive forward movements of the entire frame. <IMAGE>",CONNOLLY LEO PATRICK,CONNOLLY LEO PATRICK,,https://lens.org/056-058-027-990-889,Patent Application,no,8,9,3,3,0,A61H3/00;;A61H2003/005,A61H3/00,A6M MEA           MEA;;A6M M21E          M21E,0,0,,,,EXPIRED
65,GB,A,GB 2211726 A,070-862-057-934-911,1989-07-12,1989,GB 8825615 A,1988-11-02,IE 295087 A,1987-11-02,THERAPEUTIC BED,,ETHOS MEDICAL RESEARCH LIMITED,CONNOLLY PATRICK JOSEPH,,https://lens.org/070-862-057-934-911,Patent Application,no,1,0,8,8,0,A61G7/0507;;A61G7/0507;;A61G7/008;;A61G7/008;;A61G7/05;;A61G7/05;;A61G7/051;;A61G7/051;;A61G7/0513;;A61G7/0513;;A61G7/0519;;A61G7/0519;;A61G7/052;;A61G7/052,A61G7/008;;A61G7/05,A4L LBES          LBES;;A4L L101          LBES;;A4L L150          LBES;;A4L L702          LBES;;U1S S1030;;U1S S1044,0,0,,,,EXPIRED
66,US,A,US 3249974 A,136-063-911-976-638,1966-05-10,1966,US 33544464 A,1964-01-02,US 33544464 A,1964-01-02,Ornamental button,,CONNOLLY PATRICK J,CONNOLLY PATRICK J,,https://lens.org/136-063-911-976-638,Granted Patent,no,4,6,1,1,0,A44B1/04;;Y10T24/367;;Y10T24/3672;;Y10T24/367;;Y10T24/3672;;A44B1/04,A44B1/04,,0,0,,,,EXPIRED
67,EP,A3,EP 0248537 A3,141-372-850-860-585,1988-08-03,1988,EP 87304026 A,1987-05-05,IE 117086 A,1986-05-02,A THERAPEUTIC BED,"A therapeutic bed (1,60) comprising a patient support platform (2) rotatably and pivotally secured within a main bed frame (3) through pivot mountings (4), the main bed frame (3) being supported on a base frame (5) by two spaced-apart end uprights formed by a pair of hydraulic rams (6). Each ram (6) is individually height adjustable and one of the pairs of rams (6) is pivotally connected to the base frame (5) by a crankshaft (7) which in turn is pivotally connected to a pivot (8) to the base frame (5). The other pair of rams (6) is pivotally connected to the base frame (5) by a shaft (9). An electric motor (10) drives a belt (15) to rotate or oscillate the patient support platform (2). The arc of oscillation of the patient support platform (2) is controlled by a control unit (30) which includes a potentiometer (36). Weighing means for the patient support platform (2) is provided by a load cell (62) mounted between each of the pivot mountings (4) and the main bed frame (3).",ALLIANCE INVESTMENTS LTD,"CONNOLLY, PATRICK JOSEPH",,https://lens.org/141-372-850-860-585,Search Report,yes,3,0,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,,0,0,,,,EXPIRED
68,WO,A1,WO 1997/022323 A1,194-681-274-795-122,1997-06-26,1997,IE 9600087 W,1996-12-17,IE 950950 A,1995-12-18,A THERAPEUTIC DEVICE,"A therapeutic bed (1) comprises a castor support framework (2) and a Trendelenburg support frame (4) including curved arms (15) which are mounted on guide rollers (10) of the castor frame (2). The support frame (4) carries guide rollers (20) on which rings (26, 27) at opposite ends of the bed run. A patient support platform (5) is mounted on the rings (26, 27). A patient supine support including a mattress (30) and leg supports (31) are mounted on the patient support platform (5). Side rails (34) are engageable and lockable to the platform (5). Patient prone support means comprises a head support (35), an adjustable abdomen support (37) and support pad sections (36, 39, 40) which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails (34), engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings (26, 27) on the rollers (20) through 180°. The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVESTMENTS LTD;;CONNOLLY PATRICK J,CONNOLLY PATRICK J,,https://lens.org/194-681-274-795-122,Patent Application,yes,7,22,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,PATENTED
69,EP,B1,EP 0248537 B1,085-567-178-190-43X,1991-10-23,1991,EP 87304026 A,1987-05-05,IE 117086 A,1986-05-02,A THERAPEUTIC BED,"A therapeutic bed (1,60) comprising a patient support platform (2) rotatably and pivotally secured within a main bed frame (3) through pivot mountings (4), the main bed frame (3) being supported on a base frame (5) by two spaced-apart end uprights formed by a pair of hydraulic rams (6). Each ram (6) is individually height adjustable and one of the pairs of rams (6) is pivotally connected to the base frame (5) by a crankshaft (7) which in turn is pivotally connected to a pivot (8) to the base frame (5). The other pair of rams (6) is pivotally connected to the base frame (5) by a shaft (9). An electric motor (10) drives a belt (15) to rotate or oscillate the patient support platform (2). The arc of oscillation of the patient support platform (2) is controlled by a control unit (30) which includes a potentiometer (36). Weighing means for the patient support platform (2) is provided by a load cell (62) mounted between each of the pivot mountings (4) and the main bed frame (3).",ALLIANCE INVESTMENTS LTD,"CONNOLLY, PATRICK JOSEPH",,https://lens.org/085-567-178-190-43X,Granted Patent,yes,3,0,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,,0,0,,,,EXPIRED
70,US,A,US 3223231 A,147-604-390-857-42X,1965-12-14,1965,US 27988663 A,1963-05-13,US 27988663 A,1963-05-13,Rodenticide and feeding tray package,,PFIZER & CO C,CONNOLLY PATRICK J,,https://lens.org/147-604-390-857-42X,Granted Patent,no,7,6,1,1,0,B65D77/24;;B65D85/82;;B65D85/82;;B65D77/24,B65D77/24;;B65D85/82,,0,0,,,,EXPIRED
71,EP,B1,EP 0877590 B1,062-933-481-819-58X,2003-04-02,2003,EP 96945774 A,1996-12-17,IE 9600087 W;;IE 950950 A,1995-12-18,A THERAPEUTIC DEVICE,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,"KCI LICENSING, INC. (2005-12-01)",https://lens.org/062-933-481-819-58X,Granted Patent,yes,7,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
72,US,B1,US 6953374 B1,093-441-684-731-223,2005-10-11,2005,US 76735404 A,2004-01-28,US 76735404 A;;US 44349703 P,2003-01-29,Man overboard retrieval device,A man overboard retrieval device where a frame supports a net and rollers. The frame is secured to a handle. The frame includes a hinged arm.,CONNOLLY JOHN PATRICK,CONNOLLY JOHN PATRICK,,https://lens.org/093-441-684-731-223,Granted Patent,yes,6,6,1,1,0,B63C9/26;;B63C9/26;;B63C2009/265;;B63C2009/265,B63C9/00;;B63C9/26,441/80;;43/13,0,0,,,,EXPIRED
73,DE,D1,DE 69627196 D1,137-659-730-846-387,2003-05-08,2003,DE 69627196 T,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,THERAPEUTISCHE VORRICHTUNG,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,"KCI LICENSING, INC., SAN ANTONIO, TEX., US (2006-05-18)",https://lens.org/137-659-730-846-387,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
74,AT,T1,AT E235872 T1,163-391-089-429-585,2003-04-15,2003,AT 96945774 T,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,THERAPEUTISCHE VORRICHTUNG,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,,https://lens.org/163-391-089-429-585,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,PENDING
75,PH,A,PH 17016 A,027-731-172-986-080,1984-05-11,1984,PH 24419 A,1980-08-08,PH 24419 A,1980-08-08,IMPROVEMENTS IN OR RELATING TO TANKS OR LIKE CONTAINERS,,CONNOLLY JAMES PATRICK,PATRICK CONNOLLY JAMES,,https://lens.org/027-731-172-986-080,Granted Patent,no,0,0,1,1,0,,B65D90/00,,0,0,,,,EXPIRED
76,DE,D1,DE 3773999 D1,030-397-710-546-523,1991-11-28,1991,DE 3773999 T,1987-05-05,IE 117086 A,1986-05-02,THERAPEUTISCHES BETT.,"A therapeutic bed (1,60) comprising a patient support platform (2) rotatably and pivotally secured within a main bed frame (3) through pivot mountings (4), the main bed frame (3) being supported on a base frame (5) by two spaced-apart end uprights formed by a pair of hydraulic rams (6). Each ram (6) is individually height adjustable and one of the pairs of rams (6) is pivotally connected to the base frame (5) by a crankshaft (7) which in turn is pivotally connected to a pivot (8) to the base frame (5). The other pair of rams (6) is pivotally connected to the base frame (5) by a shaft (9). An electric motor (10) drives a belt (15) to rotate or oscillate the patient support platform (2). The arc of oscillation of the patient support platform (2) is controlled by a control unit (30) which includes a potentiometer (36). Weighing means for the patient support platform (2) is provided by a load cell (62) mounted between each of the pivot mountings (4) and the main bed frame (3).",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH,,https://lens.org/030-397-710-546-523,Granted Patent,no,0,0,8,8,0,A61G7/008;;A61G5/1078;;A61G7/0527;;A61G7/008;;A61G5/1078;;A61G7/0527,A61G5/10;;A61G7/00;;A61G7/008;;A61G7/05,,0,0,,,,EXPIRED
77,GB,B,GB 2363327 B,059-071-862-174-098,2003-04-02,2003,GB 0122845 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,Storage container,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/059-071-862-174-098,Granted Patent,no,7,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,A4N N2E           N2E,0,0,,,,EXPIRED
78,CA,A1,CA 2240732 A1,153-994-608-660-771,1997-06-26,1997,CA 2240732 A,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a castor support framework (2) and a Trendelenburg support frame (4) including curved arms (15) which are mounted on guide rollers (10) of the castor frame (2). The support frame (4) carries guide rollers (20) on which rings (26, 27) at opposite ends of the bed run. A patient support platform (5) is mounted on the rings (26, 27). A patient supine support including a mattress (30) and leg supports (31) are mounted on the patient support platform (5). Side rails (34) are engageable and lockable to the platform (5). Patient prone support means comprises a head support (35), an adjustable abdomen support (37) and support pad sections (36, 39, 40) which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails (34), engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings (26, 27) on the rollers (20) through 180~. The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK J,,https://lens.org/153-994-608-660-771,Patent Application,no,0,6,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
79,ES,T3,ES 2260007 T3,051-647-875-207-416,2006-11-01,2006,ES 00920862 T,2000-04-04,IE S990279 A,1999-04-06,CONTENEDOR DE ALMACENAMIENTO.,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/051-647-875-207-416,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
80,GB,B,GB 2211726 B,111-736-401-896-642,1991-08-21,1991,GB 8825615 A,1988-11-02,IE 295087 A,1987-11-02,A THERAPEUTIC BED,,ETHOS MEDICAL RESEARCH LIMITED,CONNOLLY PATRICK JOSEPH,,https://lens.org/111-736-401-896-642,Granted Patent,no,1,0,8,8,0,A61G7/0507;;A61G7/0507;;A61G7/008;;A61G7/008;;A61G7/05;;A61G7/05;;A61G7/051;;A61G7/051;;A61G7/0513;;A61G7/0513;;A61G7/0519;;A61G7/0519;;A61G7/052;;A61G7/052,A61G7/008;;A61G7/05,A4L LBES          LBES;;A4L L101          LBES;;A4L L150          LBES;;A4L L702          LBES;;U1S S1030;;U1S S1044,0,0,,,,EXPIRED
81,EP,A1,EP 0877590 A1,135-998-197-114-914,1998-11-18,1998,EP 96945774 A,1996-12-17,IE 9600087 W;;IE 950950 A,1995-12-18,A THERAPEUTIC DEVICE,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK J,"KCI LICENSING, INC. (2005-12-01)",https://lens.org/135-998-197-114-914,Patent Application,yes,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
82,EP,B9,EP 1165404 B9,001-457-367-525-468,2006-09-06,2006,EP 00920862 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,STORAGE CONTAINER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/001-457-367-525-468,Amended Patent,yes,6,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
83,CA,A,CA 791942 A,002-428-383-549-252,1968-08-13,1968,CA 791942D A,,CA 791942T A,,ANODIZED ALUMINUM CAP AND BRANCH OF SERVICE INSIGNIA,,US GOV SEC ARMY,CONNOLLY PATRICK J,,https://lens.org/002-428-383-549-252,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
84,JP,A,JP 2007111563 A,010-226-948-194-319,2007-05-10,2007,JP 2007025180 A,2007-02-05,IE 950950 A,1995-12-18,THERAPEUTIC BED,"<P>PROBLEM TO BE SOLVED: To help a patient become face-down to get various kinds of therapeutic exercises. <P>SOLUTION: This therapeutic bed includes a support framework 2, and a patient support platform. The patient support platform is rotatable from a face-up position to a face-down position. The treatment bed includes a means to support a patient face-down for supporting the patient on the bed as the patient support platform is at the face-down position, and a motor to move the patient support platform from the face-up position to the face-down position. The means to support the patient face-down includes a head support member, an abdomen part support member 37 that is adjustable, and support pad sections 36, 39, and 40. The motor is capable of rotating the patient support platform sideways to help the patient become face-down or face-up to get therapeutic exercises. <P>COPYRIGHT: (C)2007,JPO&INPIT",KCI LICENSING INC,CONNOLLY PATRICK J,,https://lens.org/010-226-948-194-319,Patent Application,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,INACTIVE
85,CA,C,CA 2240732 C,024-167-140-196-865,2006-09-12,2006,CA 2240732 A,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a castor support framework (2) and a Trendelenburg support frame (4) including curved arms (15) which are mounted on guide rollers (10) of the castor frame (2). The support frame (4) carries guide rollers (20) on which rings (26, 27) at opposite ends of the bed run. A patient support platform (5) is mounted on t he rings (26, 27). A patient supine support including a mattress (30) and leg supports (31) are mounted on the patient support platform (5). Side rails (34) are engageable and lockable to the platform (5). Patient prone support means comprises a head support (35), an adjustabl e abdomen support (37) and support pad sections (36, 39, 40) which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails (34), engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings (26, 27) on the rollers (20) through 180.degree.. The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,,https://lens.org/024-167-140-196-865,Granted Patent,no,0,1,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/008;;A61G7/00;;A61G7/005;;A61G13/00,,0,0,,,,EXPIRED
86,US,A,US 3434941 A,042-983-778-636-637,1969-03-25,1969,US 3434941D A,1965-05-03,US 45294665 A,1965-05-03,ANODIZED ALUMINUM CAP AND BRANCH OF SERVICE INSIGNIA,,US ARMY,CONNOLLY PATRICK J,,https://lens.org/042-983-778-636-637,Granted Patent,no,6,1,1,1,0,C25D11/04;;C25D11/04,C25D11/04,C7C CA199         -           -;;C7C CA253         -           -;;C7C CA308         -           -;;C7C CA327         -           -;;C7C CA541         -           -;;C7C CA613         -           -;;C7C CA614         -           -;;C7C CA618         -           -;;C7C CA62X         -           -;;C7C CA622         -           -;;C7C CA623         -           -;;C7C CA627         -           -;;C7C CB296         -           -;;C7C CB339         -           -;;C7C CC681         -           -;;C7C CC687         -           -;;C7C CC695         -           -;;C7C CC698         -           -;;C7C CC724         -           -;;C7C CC728         -           -;;C7C CC748         -           -;;C7C CC75X         -           -;;C7C CC755         -           -;;C7C CC762         -           -;;C7C CC766         -           -;;C7C CC767         -           -,0,0,,,,EXPIRED
87,AU,B2,AU 729921 B2,028-482-969-436-985,2001-02-15,2001,AU 1997/018089 A,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,A therapeutic device,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",ALLIANCE INVEST LTD,CONNOLLY PATRICK J,,https://lens.org/028-482-969-436-985,Granted Patent,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
88,GB,A,GB 2363327 A,105-351-695-997-144,2001-12-19,2001,GB 0122845 A,2000-04-04,GB 0001260 W;;IE S990279 A,1999-04-06,Storage container,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/105-351-695-997-144,Patent Application,no,7,1,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D90/20;;E04H4/00;;E04H4/14,A4N N2E           N2E,0,0,,,,EXPIRED
89,DE,D1,DE 60028019 D1,143-371-498-472-898,2006-06-22,2006,DE 60028019 T,2000-04-04,IE S990279 A;;GB 0001260 W,1999-04-06,AUFBEWAHRUNGSBEHÄLTER,"An improved portable storage container comprises an exterior support frame (1) defining an interior space having an upper periphery and including upright members (3) spaced around the periphery of the interior space and horizontal elongate members (6) disposed about the upper periphery of the interior space, the elongate members (6) each extending along a corresponding side of a polygon. A flexible vessel (2) is arranged within the interior space. The container comprises elastic support means for the upper perimetral portion of the perimetral wall (8) comprising a plurality of strips (10) of elastic material, each extending over a corresponding elongate member (6) of the supporting frame (1), a first end portion (11) of each strip (10) being bonded in a first region of bonding to an inner face of the perimetral wall (8), and a second end portion (12) being bonded in a second region of bonding to an outer face of perimetral wall (8).",CONNOLLY JAMES PATRICK,CONNOLLY JAMES PATRICK,,https://lens.org/143-371-498-472-898,Granted Patent,no,0,0,19,19,0,B65D90/205;;E04H4/0056;;E04H2004/146;;E04H4/0056;;E04H2004/146;;B65D90/205,B65D88/16;;B65D90/20;;E04H4/00;;E04H4/14,,0,0,,,,EXPIRED
90,AU,A,AU 1997/018089 A,193-983-970-125-090,1997-07-14,1997,AU 1997/018089 A,1996-12-17,IE 950950 A;;IE 9600087 W,1995-12-18,A therapeutic device,"A therapeutic bed includes a castor support framework and a Trendelenburg support frame including curved arms which are mounted on guide rollers of the castor frame. The Trendelenburg support frame carries guide rollers on which rings at opposite ends of the bed run. A patient support platform is mounted on the rings. A patient supine support including a mattress and leg supports are mounted on the patient support platform. Side rails are engagable and lockable to the platform. A patient prone support includes a head support, an adjustable abdomen support and support pad sections which are each split longitudinally to define adjustable support parts which are hingedly mounted to the corresponding opposite side rails, engaged and locked in position. The therapeutic bed provides for prone positioning of a patient by rotation of the rings on the rollers through 180 DEG . The bed may also be used for kinetic therapy and/or Trendelenburg motion when a patient is in the supine and/or prone position.",HUNTLEIGH TECHNOLOGY LTD,CONNOLLY PATRICK J,,https://lens.org/193-983-970-125-090,Patent Application,no,0,0,21,39,0,A61G7/001;;A61G7/008;;A61G7/001;;A61G7/001;;A61G7/008,A61G7/00;;A61G7/008;;A61G13/00,,0,0,,,,EXPIRED
91,CN,A,CN 113520524 A,001-286-411-022-531,2021-10-22,2021,CN 202110411696 A,2021-04-16,US 202016852099 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,"The invention relates to a clot retrieval device for removing clots from a blood vessel. The invention provides a clot removal device. The clot removal device including a first scaffolding section, a second scaffolding section distal of the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state configured to pinch at least a portion of a clot. A third scaffolding section is distal of the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/001-286-411-022-531,Patent Application,no,0,1,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221,,0,0,,,,PENDING
92,US,A1,US 2023/0346403 A1,053-152-742-089-362,2023-11-02,2023,US 202318217647 A,2023-07-03,US 202318217647 A;;US 202016852093 A,2020-04-17,FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"A clot removal device including an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/053-152-742-089-362,Patent Application,yes,0,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221,,0,0,,,,PENDING
93,US,B2,US 11717308 B2,158-872-329-586-755,2023-08-08,2023,US 202016852104 A,2020-04-17,US 202016852104 A,2020-04-17,Clot retrieval device for removing heterogeneous clots from a blood vessel,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/158-872-329-586-755,Granted Patent,yes,1035,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221;;A61B17/22,,3,0,,,"Britannica Dictionary, End Definition & Meaning, https://www.britannica.com/dictionary/end, accessed Dec. 15, 2022, copyright 2022 Encyclopaedia Britannica, Inc. (Year: 2022).;;US 6,348,062, 7/2003, Hopkins et al. (withdrawn);;Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only).",ACTIVE
94,US,A1,US 2022/0330951 A1,167-726-366-669-235,2022-10-20,2022,US 202017640982 A,2020-09-03,US 202017640982 A;;US 201962896056 P;;IB 2020058223 W,2019-09-05,Sleeve For Rotary Surgical Instrument,"An instrument sleeve is provided for use with a surgical rotary instrument having a tube extending to a distal tube end, and a cutting accessory having a head and a shank extending from the head adapted to be rotatably supported by the tube of the rotary instrument. The instrument sleeve comprises a sleeve body extending between proximal and distal sleeve portions, a first lumen for receiving at least a portion of the tube of the rotary instrument, and a shield extension coupled to the sleeve body. The shield extension extends between proximal and distal shield portions the proximal shield portion engaged with the distal sleeve portion and adapted to minimize tissue wrap about the cutting accessory shank.",STRYKER EUROPEAN OPERATIONS LTD,CUSHEN PATRICK;;CONNOLLY EOIN,STRYKER EUROPEAN OPERATIONS LIMITED (2020-10-01),https://lens.org/167-726-366-669-235,Patent Application,yes,0,0,6,6,0,A61B2090/0801;;A61B2217/007;;A61B17/32002;;A61B2017/3443;;A61B2090/062;;A61B17/1633;;A61B17/1644;;A61B2217/007,A61B17/16,,0,0,,,,PENDING
95,US,A1,US 2017/0296783 A1,070-813-877-009-704,2017-10-19,2017,US 201715479327 A,2017-04-05,US 201715479327 A;;US 201662322309 P,2016-04-14,Guide Extension Catheter With Helically-Shaped Entry Port,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,MEDTRONIC VASCLAR INC (2016-04-15),https://lens.org/070-813-877-009-704,Patent Application,yes,4,14,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/06;;A61M25/09,,0,0,,,,ACTIVE
96,KR,A,KR 20210129600 A,118-580-426-751-104,2021-10-28,2021,KR 20210048551 A,2021-04-14,US 202016852104 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include: a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a micro-catheter and a deployed configuration distal to the micro-catheter and operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, in which each pinching portion includes at least one pinching cell which can include a collapsed state and an expanded state distal of the micro-catheter operable to tweeze at least a portion of the clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/118-580-426-751-104,Patent Application,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
97,WO,A1,WO 2017/180398 A1,114-287-005-801-865,2017-10-19,2017,US 2017/0026213 W,2017-04-05,US 201662322309 P,2016-04-14,GUIDE EXTENSION CATHETER WITH HELICALLY-SHAPED ENTRY PORT,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,,https://lens.org/114-287-005-801-865,Patent Application,yes,8,1,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/06,,0,0,,,,PENDING
98,US,B2,US 10729884 B2,020-584-966-687-128,2020-08-04,2020,US 201715479327 A,2017-04-05,US 201715479327 A;;US 201662322309 P,2016-04-14,Guide extension catheter with helically-shaped entry port,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,MEDTRONIC VASCLAR INC (2016-04-15),https://lens.org/020-584-966-687-128,Granted Patent,yes,10,4,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/00;;A61M25/06;;A61M25/09,,1,0,,,"PCT/US2017/026213, The International Search Report and the Written Opinion of the International Searching Authority, dated Jun. 22, 2017.",ACTIVE
99,EP,A1,EP 4025139 A1,060-594-307-005-138,2022-07-13,2022,EP 20768714 A,2020-09-03,US 201962896056 P;;IB 2020058223 W,2019-09-05,SLEEVE FOR ROTARY SURGICAL INSTRUMENT,,STRYKER EUROPEAN OPERATIONS LTD,CUSHEN PATRICK;;CONNOLLY EOIN,,https://lens.org/060-594-307-005-138,Patent Application,yes,0,0,6,6,0,A61B2090/0801;;A61B2217/007;;A61B17/32002;;A61B2017/3443;;A61B2090/062;;A61B17/1633;;A61B17/1644;;A61B2217/007,A61B17/32,,0,0,,,,PENDING
100,AT,T1,AT E427206 T1,056-974-845-604-373,2009-04-15,2009,AT 06734377 T,2006-02-03,EP 05075290 A,2005-02-04,HERSTELLUNGSVERFAHREN FUR BEHALTER MIT EINGEBAUTEM GRIFF,,PROCTER & GAMBLE,ETESSE PATRICK;;CONNOLLY WILLIAM,,https://lens.org/056-974-845-604-373,Granted Patent,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,,,0,0,,,,INACTIVE
101,WO,A1,WO 2021/044347 A1,074-355-280-773-435,2021-03-11,2021,IB 2020058223 W,2020-09-03,US 201962896056 P,2019-09-05,SLEEVE FOR ROTARY SURGICAL INSTRUMENT,"An instrument sleeve is provided for use with a surgical rotary instrument having a tube extending to a distal tube end, and a cutting accessory having a head and a shank extending from the head adapted to be rotatably supported by the tube of the rotary instrument. The instrument sleeve comprises a sleeve body extending between proximal and distal sleeve portions, a first lumen for receiving at least a portion of the tube of the rotary instrument, and a shield extension coupled to the sleeve body. The shield extension extends between proximal and distal shield portions the proximal shield portion engaged with the distal sleeve portion and adapted to minimize tissue wrap about the cutting accessory shank.",STRYKER EUROPEAN OPERATIONS LTD,CUSHEN PATRICK;;CONNOLLY EOIN,,https://lens.org/074-355-280-773-435,Patent Application,yes,8,0,6,6,0,A61B2090/0801;;A61B2217/007;;A61B17/32002;;A61B2017/3443;;A61B2090/062;;A61B17/1633;;A61B17/1644;;A61B2217/007,A61B17/32002,,0,0,,,,PENDING
102,US,A1,US 2023/0277200 A1,135-029-195-956-402,2023-09-07,2023,US 202318197173 A,2023-05-15,US 202318197173 A;;US 202016852104 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/135-029-195-956-402,Patent Application,yes,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221,,0,0,,,,PENDING
103,CN,A,CN 108778389 A,172-497-700-492-581,2018-11-09,2018,CN 201780018271 A,2017-04-05,US 201662322309 P;;US 2017/0026213 W,2016-04-14,GUIDE EXTENSION CATHETER WITH HELICALLY-SHAPED ENTRY PORT,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,,https://lens.org/172-497-700-492-581,Patent Application,no,16,0,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/06,,0,0,,,,DISCONTINUED
104,CN,A,CN 111374648 A,141-766-770-472-701,2020-07-07,2020,CN 201911377736 A,2019-12-27,US 201862785543 P,2018-12-27,Method and apparatus for managing acute ischemic events,"A system for use with clots located in a target vessel for managing one or more acute ischemic events is disclosed. The system may include a guidewire extending in a longitudinal direction from a proximal end to a distal end, the distal end configured to control its orientation relative to the clot and the target vessel. The guidewire may include one or more sensors disposed on or adjacent to thedistal end, the one or more sensors configured to sense a characteristic of the in vivo clot and treat the clot based on the sensed characteristic.",NEURAVI LTD,VALE DAVID;;CONNOLLY PATRICK,,https://lens.org/141-766-770-472-701,Patent Application,no,0,0,4,20,0,A61B5/02007;;A61B17/22;;A61B17/221;;A61B5/0075;;A61B5/0075;;A61B5/0084;;A61B5/0086;;A61B5/0086;;A61B5/02007;;A61B5/0538;;A61B5/055;;A61B5/6851;;A61B5/7292;;A61B17/22;;A61B17/221;;A61B34/10;;A61B2017/00022;;A61B2017/00084;;A61B2017/00778;;A61B2017/22034;;A61B2017/22035;;A61B2017/22038;;A61B2017/22042;;A61B2017/22042;;A61B2017/22047;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2034/105;;A61B2090/3966;;A61M25/09;;A61M2025/0042,A61B5/02;;A61B17/22,,0,0,,,,DISCONTINUED
105,EP,A3,EP 3895634 A3,075-437-741-850-276,2021-11-10,2021,EP 21168823 A,2021-04-16,US 202016852104 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/075-437-741-850-276,Search Report,yes,1,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
106,US,B2,US 11547834 B2,077-568-185-946-842,2023-01-10,2023,US 202016934593 A,2020-07-21,US 202016934593 A;;US 201715479327 A;;US 201662322309 P,2016-04-14,Guide extension catheter with helically-shaped entry port,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,MEDTRONIC VASCULAR INC (2016-04-15),https://lens.org/077-568-185-946-842,Granted Patent,yes,23,0,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/00;;A61M25/06;;A61M25/09,,5,0,,,"Notice of Reasons for Rejection, and translation, from counterpad Japanese Patent Application No. 2018-547292 dated Feb. 22, 2021, 6 pp.;;Notice of the 1st Office Action, and translation, from counterpart Chinese Patent Application No. 201780018271.1, dated Aug. 28, 2020, 20 pp.;;International Search Report and the Written Opinion of the International Searching Authority, issued in PCT/US2017/026213, dated Jun. 22, 2017.;;Prosecution History from U.S. Appl. No. 15/479,327, dated Sep. 19, 2019 through Apr. 7, 2020, 39 pp.;;International Preliminary Report on Patentability from International Application No. PCT/US2017/026213, dated Oct. 16, 2018, 10 pp.",ACTIVE
107,JP,A,JP 2020103900 A,107-556-588-382-322,2020-07-09,2020,JP 2019233921 A,2019-12-25,US 201862785543 P,2018-12-27,APPARATUS AND METHOD FOR MANAGING ACUTE ISCHEMIC EVENTS,"To provide a system for use with a clot located in a target vessel for managing one or more acute ischemic events.SOLUTION: The system can include a guidewire 30 extending in a longitudinal direction from a proximal end to a distal end 40, the distal end being configured to control its orientation relative to the clot and the target vessel. The guidewire can include one or more sensors 60 disposed on or adjacently to the distal end, the one or more sensors configured for sensing properties of the clot in vivo and treating the clot based on the sensed properties.SELECTED DRAWING: Figure 15",NEURAVI LTD,DAVID VALE;;PATRICK CONNOLLY,,https://lens.org/107-556-588-382-322,Patent Application,no,0,0,4,20,0,A61B5/02007;;A61B5/7292;;A61B5/0084;;A61B5/0075;;A61B17/22;;A61B2017/22047;;A61B2017/22042;;A61B17/22;;A61B17/221;;A61B2017/00022;;A61B2017/00084;;A61B2017/22034;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B5/6851;;A61B5/02007;;A61B5/055;;A61B5/0086;;A61B2090/3966;;A61B17/221;;A61M25/09;;A61B5/0538;;A61B5/0075;;A61B5/0086;;A61B34/10;;A61B2017/22038;;A61B2017/22042;;A61B2017/22035;;A61M2025/0042;;A61B2034/105;;A61B2017/00778,A61B17/22;;A61M25/09,,0,0,,,,PENDING
108,KR,A,KR 20210129601 A,151-067-706-221-713,2021-10-28,2021,KR 20210048559 A,2021-04-14,US 202016852099 A,2020-04-17,PA PA CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,A clot removing device comprises: a first scaffolding section; and a second scaffolding section which is positioned at a distal of the first scaffolding section by passing through a first hinge type element comprising a pinching cell. The pinching cell has an expanded state and a collapsed state configured to pinch at least a part of a clot. A third scaffolding section is positioned at a distal of the second scaffolding section beside a second hinge type strut element comprising a pinching cell having an expanded state and a collapsed state configured to pinch at least a part of the clot. An outer diameter of the third scaffolding section is larger than an outer diameter of the second scaffolding section which is larger than the outer diameter of the first scaffolding section.,NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/151-067-706-221-713,Patent Application,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221;;A61B17/22,,0,0,,,,PENDING
109,EP,A3,EP 3895636 A3,171-439-360-137-716,2021-11-10,2021,EP 21168866 A,2021-04-16,US 202016852093 A,2020-04-17,A FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"A clot removal device including an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/171-439-360-137-716,Search Report,yes,2,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
110,EP,A1,EP 3442641 A1,192-459-075-236-045,2019-02-20,2019,EP 17718282 A,2017-04-05,US 201662322309 P;;US 2017/0026213 W,2016-04-14,GUIDE EXTENSION CATHETER WITH HELICALLY-SHAPED ENTRY PORT,,MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,,https://lens.org/192-459-075-236-045,Patent Application,yes,0,0,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/06,,0,0,,,,ACTIVE
111,EP,C0,EP 3895635 C0,111-870-625-268-765,2023-11-22,2023,EP 21168847 A,2021-04-16,US 202016852099 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,,NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/111-870-625-268-765,Unknown,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221;;A61B17/22,,0,0,,,,ACTIVE
112,EP,B1,EP 3895635 B1,099-341-509-364-120,2023-11-22,2023,EP 21168847 A,2021-04-16,US 202016852099 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,,NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/099-341-509-364-120,Granted Patent,yes,2,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221;;A61B17/22,,0,0,,,,ACTIVE
113,US,B2,US 11730501 B2,184-535-796-223-756,2023-08-22,2023,US 202016852093 A,2020-04-17,US 202016852093 A,2020-04-17,Floating clot retrieval device for removing clots from a blood vessel,"A clot removal device including an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/184-535-796-223-756,Granted Patent,yes,1026,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221;;A61B17/00;;A61B17/22,,2,0,,,"US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn);;Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only).",ACTIVE
114,KR,A,KR 20200083911 A,031-061-467-914-994,2020-07-09,2020,KR 20190172731 A,2019-12-23,US 201862785543 P,2018-12-27,METHOD AND APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,"Disclosed is a system for a thrombus positioned within a target blood vessel to manage one or more acute ischemic events. The system may include a guide wire extending longitudinally from a proximal end to a distal end, wherein the distal end is configured to control the orientation thereof relative to the thrombus and the target blood vessel. The guide wire may include one or more sensors disposed on or adjacent to the distal end, wherein the one or more sensors are configured to detect characteristics of the thrombus in vivo and treat the thrombus based on the detected characteristics.",NEURAVI LTD,VALE DAVID;;CONNOLLY PATRICK,,https://lens.org/031-061-467-914-994,Patent Application,no,0,0,4,20,0,A61B5/02007;;A61B17/22;;A61B17/221;;A61B5/0075;;A61B5/0075;;A61B5/0084;;A61B5/0086;;A61B5/0086;;A61B5/02007;;A61B5/0538;;A61B5/055;;A61B5/6851;;A61B5/7292;;A61B17/22;;A61B17/221;;A61B34/10;;A61B2017/00022;;A61B2017/00084;;A61B2017/00778;;A61B2017/22034;;A61B2017/22035;;A61B2017/22038;;A61B2017/22042;;A61B2017/22042;;A61B2017/22047;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2034/105;;A61B2090/3966;;A61M25/09;;A61M2025/0042,A61B17/221;;A61B5/00;;A61B5/053;;A61B17/00;;A61B17/22;;A61B34/10;;A61M25/00;;A61M25/09,,0,0,,,,PENDING
115,KR,A,KR 20210129604 A,147-237-891-810-839,2021-10-28,2021,KR 20210049065 A,2021-04-15,US 202016852093 A,2020-04-17,A FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"A thrombus removal device comprises: an elongate member including a distal end; and an expandable frame including a proximal end and one or more frame members. The one or more frame members include one or more pinching cells operable to be slidably and rotatably disposed thereon, wherein each of the pinching cells includes a folded state within a microcatheter and a distally expanded state of the microcatheter, configured to pick up at least a portion of a thrombus.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/147-237-891-810-839,Patent Application,no,0,3,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221;;A61B17/22;;A61B17/3207,,0,0,,,,PENDING
116,EP,A2,EP 3895636 A2,159-314-823-931-091,2021-10-20,2021,EP 21168866 A,2021-04-16,US 202016852093 A,2020-04-17,A FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"A clot removal device including an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/159-314-823-931-091,Patent Application,yes,0,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
117,EP,B1,EP 3442641 B1,096-403-868-432-609,2023-07-26,2023,EP 17718282 A,2017-04-05,US 201662322309 P;;US 2017/0026213 W,2016-04-14,GUIDE EXTENSION CATHETER WITH HELICALLY-SHAPED ENTRY PORT,,MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,,https://lens.org/096-403-868-432-609,Granted Patent,yes,8,0,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/06,,0,0,,,,ACTIVE
118,EP,A2,EP 3895635 A2,173-285-986-791-975,2021-10-20,2021,EP 21168847 A,2021-04-16,US 202016852099 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,"A clot removal device including a first scaffolding section, a second scaffolding section distal of the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state configured to pinch at least a portion of a clot. A third scaffolding section is distal of the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/173-285-986-791-975,Patent Application,yes,6,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221,,0,0,,,,ACTIVE
119,CN,A,CN 113520522 A,012-637-695-600-620,2021-10-22,2021,CN 202110411651 A,2021-04-16,US 202016852093 A,2020-04-17,FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"The invention relates to a floating clot retrieval device for removing clots from a blood vessel. The invention provides a clot removal device. The clot removal device includes an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/012-637-695-600-620,Patent Application,no,0,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221,,0,0,,,,PENDING
120,CN,A,CN 113520523 A,095-440-675-082-514,2021-10-22,2021,CN 202110411672 A,2021-04-16,US 202016852104 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"The invention relates to a clot retrieval device for removing clots from a blood vessel. The invention provides a clot removal device. The clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, and each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/095-440-675-082-514,Patent Application,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221,,0,0,,,,PENDING
121,US,A1,US 2021/0322036 A1,130-353-763-863-718,2021-10-21,2021,US 202016852093 A,2020-04-17,US 202016852093 A,2020-04-17,FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM A BLOOD VESSEL,"A clot removal device including an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal of the microcatheter configured to tweeze at least a portion of a clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/130-353-763-863-718,Patent Application,yes,0,1,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/221,,0,0,,,,ACTIVE
122,AU,A1,AU 2020/341178 A1,091-340-693-790-027,2022-04-21,2022,AU 2020/341178 A,2020-09-03,US 201962896056 P;;IB 2020058223 W,2019-09-05,Sleeve for rotary surgical instrument,"An instrument sleeve is provided for use with a surgical rotary instrument having a tube extending to a distal tube end, and a cutting accessory having a head and a shank extending from the head adapted to be rotatably supported by the tube of the rotary instrument. The instrument sleeve comprises a sleeve body extending between proximal and distal sleeve portions, a first lumen for receiving at least a portion of the tube of the rotary instrument, and a shield extension coupled to the sleeve body. The shield extension extends between proximal and distal shield portions the proximal shield portion engaged with the distal sleeve portion and adapted to minimize tissue wrap about the cutting accessory shank.",STRYKER EUROPEAN OPERATIONS LTD,CUSHEN PATRICK;;CONNOLLY EOIN,,https://lens.org/091-340-693-790-027,Patent Application,no,0,0,6,6,0,A61B2090/0801;;A61B2217/007;;A61B17/32002;;A61B2017/3443;;A61B2090/062;;A61B17/1633;;A61B17/1644;;A61B2217/007,A61B17/32,,0,0,,,,PENDING
123,JP,A,JP 2021171644 A,104-330-722-322-240,2021-11-01,2021,JP 2021069556 A,2021-04-16,US 202016852099 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM BLOOD VESSEL,"To provide a clot removal device.SOLUTION: A clot removal device includes a first scaffolding section, and a second scaffolding section distal to the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state that is configured to pinch at least a portion of a clot. A third scaffolding section is distal to the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state that is configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.SELECTED DRAWING: Figure 1",NEURAVI LTD,ANUSHREE DWIVEDI;;PATRICK CONNOLLY,,https://lens.org/104-330-722-322-240,Patent Application,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/22,,0,0,,,,PENDING
124,US,A1,US 2021/0322037 A1,136-553-223-328-700,2021-10-21,2021,US 202016852099 A,2020-04-17,US 202016852099 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,"A clot removal device including a first scaffolding section, a second scaffolding section distal of the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state configured to pinch at least a portion of a clot. A third scaffolding section is distal of the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/136-553-223-328-700,Patent Application,yes,0,1,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221,,1,0,,,"Comprise definition in the Cambridge English Dictionary, https://dictionary.cambridge/org/us/dictionary/english/comprise, accessed 4/21/23, copyright Cambridge University Press & Assessment 2023 (Year: 2023)",ACTIVE
125,GB,A,GB 190726613 A,160-960-375-807-856,1908-05-21,1908,GB 190726613D A,1907-12-02,GB 190726613T A,1907-12-02,Improvements in and relating to Odometers.,,BROWNE HARRY PATRICK CONNOLLY,BROWNE HARRY PATRICK CONNOLLY,,https://lens.org/160-960-375-807-856,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
126,JP,A,JP 2021171643 A,050-006-617-755-00X,2021-11-01,2021,JP 2021069546 A,2021-04-16,US 202016852104 A,2020-04-17,CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM BLOOD VESSEL,"To provide a clot removal device.SOLUTION: A clot removal device can include a caged portion which can include: a distal end; a proximal end; an inner cage having a network structure of inner struts; and an outer cage having a network structure of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal to the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximately to the distal end of the caged portion, and a proximal pinching portion located proximately to the proximal end of the caged portion, where each pinching portion can include at least one pinching cell which can include a collapsed state and an expanded state distal to the microcatheter operable to tweeze at least a portion of the clot.SELECTED DRAWING: Figure 1",NEURAVI LTD,ANUSHREE DWIVEDI;;PATRICK CONNOLLY,,https://lens.org/050-006-617-755-00X,Patent Application,no,0,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/22,,0,0,,,,PENDING
127,EP,A1,EP 4042956 A1,135-155-511-586-165,2022-08-17,2022,EP 22159094 A,2021-04-16,US 202016852104 A;;EP 21168823 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/135-155-511-586-165,Patent Application,yes,11,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
128,EP,A3,EP 3895635 A3,185-466-220-632-143,2021-11-10,2021,EP 21168847 A,2021-04-16,US 202016852099 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING CLOT FROM A BLOOD VESSEL,"A clot removal device including a first scaffolding section, a second scaffolding section distal of the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state configured to pinch at least a portion of a clot. A third scaffolding section is distal of the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/185-466-220-632-143,Search Report,yes,2,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221;;A61B17/22,,0,0,,,,ACTIVE
129,EP,A1,EP 3673840 A1,007-745-485-399-794,2020-07-01,2020,EP 19217869 A,2019-12-19,US 201862785543 P,2018-12-27,APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,"A system is disclosed for use with a clot located in a target vessel for managing one or more acute ischemic events. The system can include a guidewire extending in a longitudinal direction from a proximal end to a distal end, the distal end being configured to control its orientation relative to the clot and the target vessel. The guidewire can include one or more sensors disposed on or adjacent the distal end, the one or more sensors configured for sensing properties of the clot  in vivo  and treating the clot based on the sensed properties.
",NEURAVI LTD,VALE DAVID;;CONNOLLY PATRICK,,https://lens.org/007-745-485-399-794,Patent Application,yes,10,1,4,20,0,A61B5/02007;;A61B17/22;;A61B17/221;;A61B5/0075;;A61B5/0075;;A61B5/0084;;A61B5/0086;;A61B5/0086;;A61B5/02007;;A61B5/0538;;A61B5/055;;A61B5/6851;;A61B5/7292;;A61B17/22;;A61B17/221;;A61B34/10;;A61B2017/00022;;A61B2017/00084;;A61B2017/00778;;A61B2017/22034;;A61B2017/22035;;A61B2017/22038;;A61B2017/22042;;A61B2017/22042;;A61B2017/22047;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2034/105;;A61B2090/3966;;A61M25/09;;A61M2025/0042,A61B17/22;;A61B5/00;;A61B17/221;;A61B34/00;;A61B34/10;;A61M25/00;;A61M25/01;;A61M25/09,,0,0,,,,DISCONTINUED
130,US,A1,US 2021/0322038 A1,038-769-531-625-782,2021-10-21,2021,US 202016852104 A,2020-04-17,US 202016852104 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/038-769-531-625-782,Patent Application,yes,2,1,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221,,1,0,,,"Britannica Dictionary, End Definition & Meaning, https://www.britannica.com/dictionary/end, accessed 12/15/22, copyright 2022 Encyclopaedia Britannica, Inc. (Year: 2022)",ACTIVE
131,US,B2,US 11871946 B2,109-494-747-295-915,2024-01-16,2024,US 202016852099 A,2020-04-17,US 202016852099 A,2020-04-17,Clot retrieval device for removing clot from a blood vessel,"A clot removal device including a first scaffolding section, a second scaffolding section distal of the first scaffolding section by a first hinged element including a pinching cell. The pinching cell has a collapsed state and an expanded state configured to pinch at least a portion of a clot. A third scaffolding section is distal of the second scaffolding section by a second hinged strut element including a pinching cell that has a collapsed state and an expanded state configured to pinch at least a portion of the clot. An outer diameter of the third scaffolding section is greater than an outer diameter of the second scaffolding section, which is greater than an outer diameter of the first scaffolding section.",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-04-14),https://lens.org/109-494-747-295-915,Granted Patent,yes,1039,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/00867;;A61B2017/22079;;A61B2017/2215,A61B17/221;;A61B17/00;;A61B17/22,,5,0,,,"Notch definition & Meaning, Dictionary.com, https://www.dictionary.com/browse/notch, accessed May 5, 2022, copyright 2022 Dictionary.com, LLC (Year: 2022).;;Sinusoidal-Definition, Meaning &Synonyms, Vocabulary.com, https://www.vocabulary.com/dictionary/sinusoidal, accessed May 5, 2022, copyright 2022 Vocabulary.com, Inc., a division of IXL Learning (Year: 2022).;;Comprise definition in the Cambridge English Dictionary, https://dictionary.cambridge/org/US/dictionary/english/comprise, accessed Apr. 21, 2023, copyright Cambridge University Press & Assessment 2023 (Year: 2023).;;US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn);;Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only).",ACTIVE
132,CA,A1,CA 3153240 A1,145-267-757-173-650,2021-03-11,2021,CA 3153240 A,2020-09-03,US 201962896056 P;;IB 2020058223 W,2019-09-05,SLEEVE FOR ROTARY SURGICAL INSTRUMENT,"An instrument sleeve is provided for use with a surgical rotary instrument having a tube extending to a distal tube end, and a cutting accessory having a head and a shank extending from the head adapted to be rotatably supported by the tube of the rotary instrument. The instrument sleeve comprises a sleeve body extending between proximal and distal sleeve portions, a first lumen for receiving at least a portion of the tube of the rotary instrument, and a shield extension coupled to the sleeve body. The shield extension extends between proximal and distal shield portions the proximal shield portion engaged with the distal sleeve portion and adapted to minimize tissue wrap about the cutting accessory shank.",STRYKER EUROPEAN OPERATIONS LTD,CUSHEN PATRICK;;CONNOLLY EOIN,,https://lens.org/145-267-757-173-650,Patent Application,no,0,0,6,6,0,A61B2090/0801;;A61B2217/007;;A61B17/32002;;A61B2017/3443;;A61B2090/062;;A61B17/1633;;A61B17/1644;;A61B2217/007,A61B17/16;;A61B17/32;;A61M3/02,,0,0,,,,PENDING
133,US,A1,US 2020/0345984 A1,188-966-296-103-432,2020-11-05,2020,US 202016934593 A,2020-07-21,US 202016934593 A;;US 201715479327 A;;US 201662322309 P,2016-04-14,GUIDE EXTENSION CATHETER WITH HELICALLY-SHAPED ENTRY PORT,"A guide extension catheter includes a push member and a distal shaft coupled to and extending distally from the push member. The distal shaft includes a shaft wall and a passageway. The shaft wall includes a helically-shaped proximal end and a distal end. The helically-shaped proximal end coils helically about a first central longitudinal axis of the passageway of the distal shaft. The helically-shaped proximal end of the shaft wall defines a helically-shaped entry port of the distal shaft. The distal shaft may include a helically-shaped collar coupled to the helically-shaped proximal end of the distal shaft, the collar defining the helically-shaped entry port of the distal shaft.",MEDTRONIC VASCULAR INC,CONNOLLY COLM;;GRIFFIN PATRICK,MEDTRONIC VASCULAR INC (2016-04-15),https://lens.org/188-966-296-103-432,Patent Application,yes,0,0,10,10,0,A61M2025/0004;;A61M2025/0681;;A61M25/0052;;A61M25/0662;;A61M25/0052;;A61M2025/0681;;A61M2025/0004;;A61M25/0102;;A61M25/0662;;A61M25/09;;A61M2025/09191;;A61M2205/0266,A61M25/01;;A61M25/00;;A61M25/06;;A61M25/09,,0,0,,,,ACTIVE
134,JP,A,JP 2021171642 A,196-296-985-732-218,2021-11-01,2021,JP 2021069543 A,2021-04-16,US 202016852093 A,2020-04-17,FLOATING CLOT RETRIEVAL DEVICE FOR REMOVING CLOTS FROM BLOOD VESSEL,"To provide a clot removal device.SOLUTION: A clot removal device includes: an elongated member including a distal end; and an expandable frame including a proximal end, and one or more frame members including one or more pinching cells operable to be slidably and rotatably placed thereon, each of the pinching cells including a collapsed state within a microcatheter and an expanded state distal to the microcatheter configured to tweeze at least a portion of a clot.SELECTED DRAWING: Figure 1A",NEURAVI LTD,ANUSHREE DWIVEDI;;PATRICK CONNOLLY,,https://lens.org/196-296-985-732-218,Patent Application,no,0,0,8,8,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/3207;;A61B2017/2212;;A61B2017/22094;;A61B2017/22079;;A61B2017/320716;;A61B17/221;;A61B2017/00336;;A61B2017/22001,A61B17/22,,0,0,,,,PENDING
135,EP,A2,EP 3895634 A2,143-431-217-987-644,2021-10-20,2021,EP 21168823 A,2021-04-16,US 202016852104 A,2020-04-17,A CLOT RETRIEVAL DEVICE FOR REMOVING HETEROGENEOUS CLOTS FROM A BLOOD VESSEL,"A clot removal device can include a caged portion which can include a distal end; a proximal end; an inner cage having a network of inner struts; and an outer cage having a network of outer struts. The inner cage and the outer cage can include a delivery configuration within a microcatheter and a deployed configuration distal of the microcatheter operable to retrieve at least a portion of the clot. The device can include a distal pinching portion located proximate the distal end of the caged portion, and a proximal pinching portion located proximate the proximal end of the caged portion, each pinching portion can include at least one pinching cell can include a collapsed state and an expanded state distal of the microcatheter operable to tweeze at least a portion of the clot.
",NEURAVI LTD,DWIVEDI ANUSHREE;;CONNOLLY PATRICK,,https://lens.org/143-431-217-987-644,Patent Application,yes,10,0,9,9,0,A61B17/221;;A61B2017/2212;;A61B2017/22034;;A61B17/221;;A61B17/221;;A61B17/22031;;A61B2017/2215;;A61B2017/22094;;A61B2017/22079;;A61B17/221;;A61B2017/22001,A61B17/221;;A61B17/22,,0,0,,,,PENDING
136,US,B1,US 8636554 B1,077-342-172-841-134,2014-01-28,2014,US 81636410 A,2010-06-15,US 81636410 A,2010-06-15,Ice recovery device,"A buoyant rescue device for retrieval of drowning victims, particularly those that have fallen through floating ice, in the configuration of a catamaran with an opening in the bow to allow a ladder structure to rotate into the water. The ladder is pivotally mounted to the center of the craft and is lowered into the water the so the victim can climb the ladder onto the craft, or if the victim is injured or too weak to do so, a rescuer can provide a downward force at the top of the ladder and lift the victim out, such as a teeter totter would operate. The centrally located pivot point alleviates most of the listing or tilting and potential capsizing that would occur if a person were to climb onto the edge of the boat or if rescuers were reaching into the water to retrieve the person.",CONNOLLY JOHN PATRICK;;FARAIS JOSEPH PATRICK,CONNOLLY JOHN PATRICK;;FARAIS JOSEPH PATRICK,,https://lens.org/077-342-172-841-134,Granted Patent,yes,8,10,1,1,0,B60F3/0061;;B60F3/0061;;B63C9/32;;B63C9/32,B63C9/00;;B63C9/32,441/80;;441/82,0,0,,,,INACTIVE
137,IE,B2,IE S75064 B2,101-633-603-781-697,1997-08-27,1997,IE S970276 A,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 960166 A,1995-03-08,A therapeutic bed,,ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/101-633-603-781-697,Limited Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
138,HK,A1,HK 1036210 A1,124-526-797-963-034,2001-12-28,2001,HK 01106849 A,2001-09-27,IE 980415 A;;IE 9900049 W,1998-06-03,A therapeutic bed.,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",KCI LICENSING INC,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/124-526-797-963-034,Patent Application,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,DISCONTINUED
139,IE,A1,IE 960166 A1,138-908-806-437-653,1996-09-18,1996,IE 960166 A,1996-02-26,IE 960166 A;;IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,A therapeutic bed,"A therapeutic hospital bed (1) comprises a patient support platform (2) rotatably and pivotally secured within a main bed frame (3). The main bed frame (3) is supported on a base frame (5). An end board on the patient support platform (2) has an arcuate track (14) engaged by a drive belt (15) which is connected to a drive motor for oscillating the patient support platform (2) relative to the main bed frame (3). Opposite ends of the drive belt (15) are connected to disengagement arms (18,25) which are pivotally interconnected to form a scissors mechanism. The arms (18,25) are operable to tension or release the belt (15) to engage or disengage drive to the patient support platform (2). A spring (27) extends between the arms (18,25) to bias the arms (18,25) into a belt tensioning position. To disengage the drive for turning the patient support platform (2) manually the arms (18,25) are movable against spring bias to a disengaged position. When the arms (18,25) are subsequently released the spring (27) returns the arms (18,25) to the belt tensioning position to engage the drive. <Fig.1>",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/138-908-806-437-653,Patent Application,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,DISCONTINUED
140,PT,E,PT 814741 E,093-381-300-252-265,2001-10-30,2001,PT 96905981 T,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,CAMA TERAPEUTICA,,ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEEMAN EUGENE,,https://lens.org/093-381-300-252-265,Granted Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
141,FR,A1,FR 2800177 A1,193-273-480-448-210,2001-04-27,2001,FR 9913076 A,1999-10-20,FR 9913076 A,1999-10-20,SYSTEME DE DECLENCHEMENT SEQUENTIEL D'APPAREILS PHOTOGRAPHIQUES ET EQUIPEMENT DE PRISE DE VUES EQUIPE D'UN TEL SYSTEME,"<P>Système (10) de déclenchement séquentiel pour une pluralité d'appareils photographiques (42, 42a) équipés d'un mode de prise de vues en rafale, comprenant : - une horloge (12) et des moyens (14, 16) pour fixer une fréquence d'horloge,- des moyens (20) de mise en fonctionnement successif des appareils photographiques en mode rafale en réponse à un signal de déclenchement, les moyens étant pilotés par l'horloge de façon à mettre en fonctionnement les appareils selon une cadence de mise en fonctionnement supérieure à une cadence de prise de vues en mode rafale. Application à la photographie et à l'analyse d'événements rapides.</P>",AEROSPATIALE MATRA MISSILES,O CONNOLLY PATRICK;;TOINEAU MICHEL,,https://lens.org/193-273-480-448-210,Patent Application,no,4,0,14,14,0,G03B39/00;;G03B39/00,G03B15/00;;G03B17/38;;G03B39/00;;H04N5/225,,0,0,,,,EXPIRED
142,DK,T3,DK 0814741 T3,188-980-727-197-786,2001-08-13,2001,DK 96905981 T,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,Terapeutisk seng,,ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/188-980-727-197-786,Granted Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
143,GR,T3,GR 3036204 T3,138-212-927-960-197,2001-10-31,2001,GR 20010401055 T,2001-07-11,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,A THERAPEUTIC BED,,ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/138-212-927-960-197,Granted Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
144,EP,A1,EP 0814741 A1,176-300-218-062-229,1998-01-07,1998,EP 96905981 A,1996-02-26,IE 9600009 W;;IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,A THERAPEUTIC BED,,ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/176-300-218-062-229,Patent Application,yes,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
145,CA,C,CA 2331555 C,066-168-323-288-541,2007-12-04,2007,CA 2331555 A,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. T he base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the ba se frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patien t on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotation al axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient suppor t platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/066-168-323-288-541,Granted Patent,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
146,AT,T1,AT E200613 T1,114-904-772-308-941,2001-05-15,2001,AT 96905981 T,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,THERAPEUTISCHES BETT,,ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/114-904-772-308-941,Granted Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,PENDING
147,NZ,A,NZ 508673 A,004-520-472-681-284,2002-10-25,2002,NZ 50867399 A,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,A therapeutic bed,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,"KCI LICENSING, US (2004-05-28);;HUNTLEIGH TECHNOLOGY LIMITED, GB (2013-10-31)",https://lens.org/004-520-472-681-284,Patent Application,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,DISCONTINUED
148,ES,T3,ES 2158296 T3,152-482-606-281-772,2001-09-01,2001,ES 96905981 T,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,CAMA TERAPEUTICA.,"UNA CAMA TERAPEUTICA DE HOSPITAL (1) COMPRENDE UNA PLATAFORMA SOPORTE PARA EL PACIENTE (2), FIJADA DE FORMA GIRATORIA Y ARTICULADA DENTRO DE UNA ESTRUCTURA PRINCIPAL DE CAMA (3). LA ESTRUCTURA PRINCIPAL DE CAMA (3) SE SOSTIENE SOBRE UNA ESTRUCTURA DE CAMA (5). UN TABLERO EXTREMO SOBRE LA PLATAFORMA SOPORTE PARA EL PACIENTE (2), TIENE UN CANAL ARQUEADO (14) ACOPLADO POR UNA CORREA DE TRANSMISION (15) UNIDA A UN MOTOR DE ACCIONAMIENTO, PARA OSCILAR LA PLATAFORMA SOPORTE PARA EL PACIENTE (2) EN RELACION A LA ESTRUCTURA PRINCIPAL DE LA CAMA (3). SE UNEN LOS EXTREMOS OPUESTOS DE LA CORREA DE TRANSMISION (15), A BRAZOS DE DESACOPLAMIENTO (18, 25) QUE ESTAN ARTICULARMENTE INTERCONECTADOS PARA FORMAR UN MECANISMO DE TIJERA. LOS BRAZOS (18, 25) SON ACCIONABLES PARA TENSAR O SOLTAR LA CORREA (15), PARA ACOPLAR O DESACOPLAR EL ACCIONAMIENTO DE LA PLATAFORMA SOPORTE PARA EL PACIENTE (2). UN RESORTE (27) SE EXTIENDE ENTRE LOS BRAZOS (18, 25) PARA HACER TENDER A ESTOS A UNA POSICION DE TENSIONAMIENTO DELA CORREA. PARA DESACOPLAR EL ACCIONAMIENTO Y GIRAR LA PLATAFORMA SOPORTE PARA EL PACIENTE (2) DE FORMA MANUAL, LOS BRAZOS (18, 25) SON DESPLAZABLES CONTRA LA TENDENCIA DEL RESORTE A UNA POSICION DESACOPLADA. CUANDO A CONTINUACION SE SUELTAN LOS BRAZOS (18, 25), EL RESORTE (27) DEVUELVE LOS MISMOS A UNA POSICION DE TENSIONAMIENTO DE LA CORREA, PARA ACOPLAR EL ACCIONAMIENTO.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/152-482-606-281-772,Granted Patent,no,0,1,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
149,CA,C,CA 2214804 C,010-753-374-687-193,2009-11-17,2009,CA 2214804 A,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,A THERAPEUTIC BED,"A therapeutic hospital bed (1) comprises a patient support platform (2) rotatably and pivotally secured within a main bed frame (3). The main bed frame (3) is supported on a base frame (5). An end board on the patient support platform (2) has an arcuate track (14) engaged by a drive belt (15) which is connected to a drive motor for oscillating the patient support platform (2) relative to the main bed frame (3). Opposite ends of the drive belt (15) are connected to disengagement arms (18, 25) which are pivotally interconnected to form a scissors mechanism. The arms (18, 25) are operable to tension or release the belt (15) to engage or disengage drive to the patient support platform (2). A spring (27) extends between the arms (18, 25) to bias the arms (18, 25) into a belt tensioning position. To disengage the drive for turning the patient support platform (2) manually, the arms (18, 25) are movable against spring bias to a disengaged position. When the arms (18, 25) are subsequently released the spring (27) returns the arms (18, 25) to the belt tensioning position to engage the drive.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/010-753-374-687-193,Granted Patent,no,0,0,17,17,0,A61G7/008;;A61G7/008,A61G7/008;;A47C17/04;;A61G7/002,,0,0,,,,EXPIRED
150,GB,B,GB 2231314 B,138-949-681-822-494,1993-06-09,1993,GB 9007687 A,1990-04-05,GB 8907707 A,1989-04-05,FIRE ESCAPE,,MCCANN JOHN JOSEPH;;CONNOLLY PATRICK,MCCANN JOHN JOSEPH;;CONNOLLY PATRICK,,https://lens.org/138-949-681-822-494,Granted Patent,no,7,0,4,4,0,A62B1/20,A62B1/20,B7J J118          J118,0,0,,,,EXPIRED
151,AU,A,AU 1996/049525 A,174-603-682-514-722,1996-09-23,1996,AU 1996/049525 A,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,A therapeutic bed,,HUNTLEIGH TECHNOLOGY LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/174-603-682-514-722,Patent Application,no,0,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
152,CA,A1,CA 2214804 A1,152-576-846-377-519,1996-09-12,1996,CA 2214804 A,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,A THERAPEUTIC BED,"A therapeutic hospital bed (1) comprises a patient support platform (2) rotatably and pivotally secured within a main bed frame (3). The main bed frame (3) is supported on a base frame (5). An end board on the patient support platform (2) has an arcuate track (14) engaged by a drive belt (15) which is connected to a drive motor for oscillating the patient support platform (2) relative to the main bed frame (3). Opposite ends of the drive belt (15) are connected to disengagement arms (18, 25) which are pivotally interconnected to form a scissors mechanism. The arms (18, 25) are operable to tension or release the belt (15) to engage or disengage drive to the patient support platform (2). A spring (27) extends between the arms (18, 25) to bias the arms (18, 25) into a belt tensioning position. To disengage the drive for turning the patient support platform (2) manually, the arms (18, 25) are movable against spring bias to a disengaged position. When the arms (18, 25) are subsequently released the spring (27) returns the arms (18, 25) to the belt tensioning position to engage the drive.",ALLIANCE INVESTMENTS LTD,KEENAN EUGENE;;CONNOLLY PATRICK JOSEPH,,https://lens.org/152-576-846-377-519,Patent Application,no,0,7,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
153,WO,A1,WO 1999/062454 A1,158-312-445-860-170,1999-12-09,1999,IE 9900049 W,1999-06-03,IE 980415 A,1998-06-03,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVESTMENTS LTD;;CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/158-312-445-860-170,Patent Application,yes,6,23,16,39,0,A61G7/001,A61G7/00,,0,0,,,,PATENTED
154,FR,B1,FR 2800177 B1,177-776-420-980-904,2002-01-18,2002,FR 9913076 A,1999-10-20,FR 9913076 A,1999-10-20,SYSTEME DE DECLENCHEMENT SEQUENTIEL D'APPAREILS PHOTOGRAPHIQUES ET EQUIPEMENT DE PRISE DE VUES EQUIPE D'UN TEL SYSTEME,,AEROSPATIALE MATRA MISSILES,O CONNOLLY PATRICK;;TOINEAU MICHEL,,https://lens.org/177-776-420-980-904,Granted Patent,no,0,0,14,14,0,G03B39/00;;G03B39/00,G03B15/00;;G03B17/38;;G03B39/00;;H04N5/225,,0,0,,,,EXPIRED
155,EP,A1,EP 1083857 A1,185-321-887-422-737,2001-03-21,2001,EP 99955208 A,1999-06-03,IE 9900049 W;;IE 980415 A,1998-06-03,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/185-321-887-422-737,Patent Application,yes,0,1,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
156,AT,T1,AT E260629 T1,009-292-460-342-402,2004-03-15,2004,AT 99955208 T,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,THERAPEUTISCHES BETT,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/009-292-460-342-402,Granted Patent,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,PENDING
157,GB,A,GB 2231314 A,051-132-356-632-848,1990-11-14,1990,GB 9007687 A,1990-04-05,GB 8907707 A,1989-04-05,Fire escape,A fire escape (10) comprises a chute (12) made up of four or more telescopically nestable chute sections (14). The chute is stored in stowed form between the inner and outer walls of a house. <IMAGE>,MCCANN JOHN JOSEPH;;CONNOLLY PATRICK,MCCANN JOHN JOSEPH;;CONNOLLY PATRICK,,https://lens.org/051-132-356-632-848,Patent Application,no,6,8,4,4,0,A62B1/20,A62B1/20,B7J J118          J118,0,0,,,,EXPIRED
158,EP,B1,EP 1083857 B1,047-551-218-711-945,2004-03-03,2004,EP 99955208 A,1999-06-03,IE 9900049 W;;IE 980415 A,1998-06-03,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/047-551-218-711-945,Granted Patent,yes,5,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
159,AU,B2,AU 741477 B2,052-329-939-147-866,2001-11-29,2001,AU 1999/042862 A,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,A therapeutic bed,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/052-329-939-147-866,Granted Patent,no,3,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
160,AU,B2,AU 718876 B2,053-479-779-299-501,2000-04-20,2000,AU 1996/049525 A,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,A therapeutic bed,,ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/053-479-779-299-501,Granted Patent,no,3,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
161,IE,A1,IE 990459 A1,050-863-992-205-938,2001-03-21,2001,IE 990459 A,1999-06-03,IE 990459 A;;IE 980415 A,1998-06-03,A therapeutic bed,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates. <Figure 1>",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/050-863-992-205-938,Patent Application,no,0,2,1,39,0,,A61G7/008,,0,0,,,,DISCONTINUED
162,JP,A,JP 2001166374 A,144-549-187-752-202,2001-06-22,2001,JP 2000318503 A,2000-10-18,FR 9913076 A,1999-10-20,CONSECUTIVE TRIGGER SYSTEM FOR CAMERA AND PHOTOGRAPHING DEVICE EQUIPPED WITH THE SAME,"PROBLEM TO BE SOLVED: To provide a consecutive trigger system capable of being used with fluctuated number of cameras and used for photographing at various speeds in the respective cameras. SOLUTION: This consecutive trigger system 10 for triggering plural cameras 42 and 42a having a burst photographing mode is equipped with means 14 and 16 for deciding a clock 12 and clock frequency, and a means 20 for consecutively starting the operation of the camera in a burst mode in response to a trigger signal. The means 20 is controlled by the clock so as to operate the camera at operating speed higher than photographing speed in the burst mode.",AEROSPATIALE MATRA MISSILES,O CONNOLLY PATRICK;;TOINEAU MICHEL,,https://lens.org/144-549-187-752-202,Patent Application,no,0,4,14,14,0,G03B39/00;;G03B39/00,G03B15/00;;G03B17/38;;G03B39/00;;H04N5/225,,0,0,,,,DISCONTINUED
163,CA,A1,CA 2331555 A1,004-732-373-882-368,1999-12-09,1999,CA 2331555 A,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,A THERAPEUTIC BED,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/004-732-373-882-368,Patent Application,no,0,7,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
164,US,A,US 6108838 A,105-186-228-961-736,2000-08-29,2000,US 91315397 A,1997-09-08,IE 950172 A;;IE 950292 A;;IE 950860 A;;IE 9600009 W,1995-03-08,Therapeutic bed,"A therapeutic hospital bed (1) comprises a patient support platform (2) rotatably and pivotally secured within a main bed frame (3). The main bed frame (3) is supported on a base frame (5). An end board on the patient support platform (2) has an arcuate track (14) engaged by a drive belt (15) which is connected to a drive motor for oscillating the patient support platform (2) relative to the main bed frame (3). Opposite ends of the drive belt (15) are connected to disengagement arms (18, 25) which are pivotally interconnected to form a scissors mechanism. The arms (18, 25) are operable to tension or release the belt (15) to engage or disengage drive to the patient support platform (2). A spring (27) extends between the arms (18, 25) to bias the arms (18, 25) into a belt tensioning position. To disengage the drive for turning the patient support platform (2) manually, the arms (18, 25) are movable against spring bias to a disengaged position. When the arms (18, 25) are subsequently released the spring (27) returns the arms (18, 25) to the belt tensioning position to engage the drive.",ALLIANCE INVESTMENTS LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,ALLIANCE INVESTMENTS LIMITED (1997-11-09);;HUNTLEIGH TECHNOLOGY LIMITED (2012-11-08);;KCI LICENSING INC (2001-10-09),https://lens.org/105-186-228-961-736,Granted Patent,yes,5,41,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,5/609;;5/607,0,0,,,,EXPIRED
165,AU,A,AU 1999/042862 A,119-951-094-029-276,1999-12-20,1999,AU 1999/042862 A,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,A therapeutic bed,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",HUNTLEIGH TECHNOLOGY LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/119-951-094-029-276,Patent Application,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
166,DE,T2,DE 69915284 T2,007-803-600-620-275,2005-06-23,2005,DE 69915284 T,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,THERAPEUTISCHES BETT,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/007-803-600-620-275,Granted Patent,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
167,WO,A1,WO 1996/027356 A1,019-915-517-524-700,1996-09-12,1996,IE 9600009 W,1996-02-26,IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,A THERAPEUTIC BED,"A therapeutic hospital bed (1) comprises a patient support platform (2) rotatably and pivotally secured within a main bed frame (3). The main bed frame (3) is supported on a base frame (5). An end board on the patient support platform (2) has an arcuate track (14) engaged by a drive belt (15) which is connected to a drive motor for oscillating the patient support platform (2) relative to the main bed frame (3). Opposite ends of the drive belt (15) are connected to disengagement arms (18, 25) which are pivotally interconnected to form a scissors mechanism. The arms (18, 25) are operable to tension or release the belt (15) to engage or disengage drive to the patient support platform (2). A spring (27) extends between the arms (18, 25) to bias the arms (18, 25) into a belt tensioning position. To disengage the drive for turning the patient support platform (2) manually, the arms (18, 25) are movable against spring bias to a disengaged position. When the arms (18, 25) are subsequently released the spring (27) returns the arms (18, 25) to the belt tensioning position to engage the drive.",ALLIANCE INVESTMENTS LTD;;CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/019-915-517-524-700,Patent Application,yes,5,14,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,PATENTED
168,US,A1,US 2013/0000538 A1,138-891-311-009-034,2013-01-03,2013,US 201113174012 A,2011-06-30,US 201113174012 A,2011-06-30,EXTERIOR HULL PATCH,"An exterior hull patch and method of use for covering and containing leaks due to hull damage to ships, vessels and barges that has a flexible material center surrounded by an inflatable border or perimeter. The patch is positioned over the damaged area and then drawn tightly against the hull of the vessel via cables that are routed to both sides of the vessel and under its hull and attached to the patch perimeter as well as to winches or similar devices onboard the ship. Once the patch is relatively snug against the hull, the inflatable boarder is inflated with compressed gas to increase the pressure against the hull and leak, thus sealing the leak. This prevents the vessel from sinking as well as prevents liquid cargo to be lost.",CONNOLLY JOHN PATRICK;;FREEDLEY VINTON,CONNOLLY JOHN PATRICK;;FREEDLEY VINTON,,https://lens.org/138-891-311-009-034,Patent Application,yes,5,1,1,1,0,B63B43/16;;B63B43/16,B63B43/16,114/229,0,0,,,,DISCONTINUED
169,DE,D1,DE 69915284 D1,175-704-728-641-989,2004-04-08,2004,DE 69915284 T,1999-06-03,IE 980415 A;;IE 9900049 W,1998-06-03,THERAPEUTISCHES BETT,"A therapeutic bed (1) comprises a patient support platform (7) rotatably mounted on a base frame (4) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame (4) is in turn mounted on a wheeled chassis (2) by pivot linkages (5) which allow tilting and raising and lowering of the base frame (4) on the chassis (2). Drive interlocks prevent rotation of the patient support platform (7) unless side rails (25) are locked on the patient support platform (7) and patient support flaps (40, 41) extending between the side rails (25) are locked together to secure a patient on the patient support platform (7). Guides (51) are provided at each end of the patient support platform (7) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform (7) and associated devices externally of the patient support platform (7). This prevents entanglement of patient care lines as the patient support platform (7) rotates.",ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,,https://lens.org/175-704-728-641-989,Granted Patent,no,0,0,16,39,0,A61G7/001,A61G7/00,,0,0,,,,EXPIRED
170,EP,B1,EP 0814741 B1,183-614-370-029-445,2001-04-18,2001,EP 96905981 A,1996-02-26,IE 9600009 W;;IE 950172 A;;IE 950292 A;;IE 950860 A,1995-03-08,A THERAPEUTIC BED,,ALLIANCE INVEST LTD,CONNOLLY PATRICK JOSEPH;;KEENAN EUGENE,,https://lens.org/183-614-370-029-445,Granted Patent,yes,5,0,17,17,0,A61G7/008;;A61G7/008,A47C17/04;;A61G7/002;;A61G7/008,,0,0,,,,EXPIRED
171,US,B1,US 6874181 B1,044-743-766-028-861,2005-04-05,2005,US 70173901 A,2001-06-28,IE 950950 A;;IE 980415 A;;IE 9900049 W,1995-12-18,Therapeutic bed,"A therapeutic bed ( 1 ) comprises a patient support platform ( 7 ) rotatably mounted on a base frame ( 4 ) for rotation about a longitudinal pivot axis between a supine support position and a prone support position. The base frame ( 4 ) is in turn mounted on a wheeled chassis ( 2 ) by pivot linkages ( 5 ) which allow tilting and raising and lowering of the base frame ( 4 ) on the chassis ( 2 ). Drive interlocks prevent rotation of the patient support platform ( 7 ) unless side rails ( 25 ) are locked on the patient support platform ( 7 ) and patient support flaps ( 40, 41 ) extending between the side rails ( 25 ) are locked together to secure a patient on the patient support platform ( 7 ). Guides ( 51 ) are provided at each end of the patient support platform ( 7 ) at the longitudinal rotational axis to guide patient care lines between a patient on the patient support platform ( 7 ) and associated devices externally of the patient support platform ( 7 ). This prevents entanglement of patient care lines as the patient support platform ( 7 ) rotates.",KCI LICENSING INC,CONNOLLY PATRICK JOSEPH;;VIJAYENDRAN CHINNATHAMBY,ALLIANCE INVESTMENTS LIMITED (2001-06-25);;HUNTLEIGH TECHNOLOGY LIMITED (2012-11-08);;KCI LICENSING INC (2001-10-09),https://lens.org/044-743-766-028-861,Granted Patent,yes,36,81,1,39,0,A61G7/001;;A61G7/001,A61G7/00,5/609;;5/607;;5/429;;5/425;;5/503.1,0,0,,,,EXPIRED
172,US,A,US 3331107 A,197-561-612-140-392,1967-07-18,1967,US 50043765 A,1965-10-21,US 50043765 A,1965-10-21,Quick release mechanism for slide fasteners,,CONNOLLY PATRICK J;;ARSLANIAN MICHAEL M,CONNOLLY PATRICK J;;ARSLANIAN MICHAEL M,,https://lens.org/197-561-612-140-392,Granted Patent,no,5,2,1,1,0,A44B19/384;;A44B19/384;;Y10T24/2541;;Y10T24/2541;;Y10T24/2596;;Y10T24/2596,A44B19/38,,0,0,,,,EXPIRED
173,EP,A1,EP 3504650 A1,030-890-837-610-544,2019-07-03,2019,EP 17762310 A,2017-08-28,US 201662380635 P;;US 2017/0048940 W,2016-08-29,MANAGING CARE PATHWAYS,,CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;LANO TIMO HENRIK MATIAS,,https://lens.org/030-890-837-610-544,Patent Application,yes,0,0,4,4,0,G16H40/20;;G16H40/20;;G16H15/00,G06F19/00,,0,0,,,,DISCONTINUED
174,US,B1,US 6564515 B1,050-441-612-828-923,2003-05-20,2003,US 5056602 A,2002-01-15,US 5056602 A,2002-01-15,Land anchor,"
    A land anchor for use with a winch and cable assembly affixed to a vehicle to pull the vehicle when immobilized having a fluke formed by wings shaped to penetrate into the ground and shaped to keep the fluke level during penetration into the ground, and a removable stock assembly attachable to the fluke. The fluke is provided with a stock assembly mount having a tubular member provided with a parallel slot extending through one side of the tubular member. The tubular member is fixedly attached to the rear thrust end section of the fluke with the slot being positioned to permit the stock assembly to be received by the stock assembly mount. The stock assembly has an engaging member shaped to engage and fix the stock assembly to the stock assembly mount. The stock assembly has an elongated bar fixed at one end to the engaging member and with its opposite end extending upward at an angle from the top surface, an elongated tubular member having a bar attaching end and a cable attaching end, the bar attaching end being pivotally attached to the opposite end of the bar, and an extender pivotally attached at one end to the bar and pivotally attached at its opposite end to the tubular member to permit the bar and the tubular member to fold toward one another for compact storage. 
",FONTENOT STEVEN F;;CONNOLLY PATRICK J,FONTENOT STEVEN F;;CONNOLLY PATRICK J,CONNOLLY PATRICK J (2008-02-01),https://lens.org/050-441-612-828-923,Granted Patent,yes,3,14,1,1,0,B63B21/243;;B63B21/32;;E02D5/80;;E02D5/80;;B63B21/32;;B63B21/243,B63B21/24;;B63B21/32;;E02D5/80,52/155;;114/294;;114/304,0,0,,,,EXPIRED
175,US,A1,US 2018/0060521 A1,195-124-648-916-633,2018-03-01,2018,US 201715688689 A,2017-08-28,US 201715688689 A;;US 201662380635 P,2016-08-29,MANAGING CARE PATHWAYS,"A method of facilitating management of a care pathway includes receiving a care pathway definition, having a first care pathway step and a second care pathway step, where each care pathway step is identified by a unique identification (ID) code. The method includes determining a keyword associated with each care pathway step; and identifying, in patient information, care episodes. The method may include extracting, from the patient information, episode information corresponding to the care episodes; associating the care episodes with the corresponding care pathway steps; and determining, based on the care pathway definition and the episode information, a care metric. A display device may be used to present a representation of the care metric to a user.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;LANO TIMO HENRIK MATIAS,CARDIAC PACEMAKERS INC (2017-08-15),https://lens.org/195-124-648-916-633,Patent Application,yes,4,17,4,4,0,G16H40/20;;G16H40/20;;G16H15/00,G06F19/00,,0,0,,,,DISCONTINUED
176,AU,A1,AU 2003/219475 A1,168-161-796-280-159,2003-10-08,2003,AU 2003/219475 A,2003-03-24,IE 20020204 A;;IE 0300045 W,2002-03-22,"""A local area wireless network simulator""",,ROCOCO SOFTWARE LTD,CONNOLLY PATRICK;;CRANE STEPHEN;;SMART NIALL,,https://lens.org/168-161-796-280-159,Patent Application,no,0,0,5,5,0,G06F9/54;;G06F9/45537,G06F9/455;;G06F9/46;;G06F11/00;;G06F17/00;;H04L12/28,,0,0,,,,DISCONTINUED
177,WO,A1,WO 2002/089665 A1,171-958-110-581-851,2002-11-14,2002,US 0214214 W,2002-05-06,US 85025001 A,2001-05-07,IMPLANTABLE PARTICLE APPARATUS,"An implantable stent (10) which contains a tube, several optical emitters (30) located on the inner surface (26) of the tube, and several optical detectors (32) located on the inner surface (26) of the tube. The optical emitters (30) radiate energy with a wavelength of from about 30 nanometers to about 30 millimeters, and the optical detectors (32) receive energy with a wavelength of from about 30 nanometers to about 30 millimeters.",BIOPHAN LLC;;CONNOLLY PATRICK R;;FOSTER THOMAS H,CONNOLLY PATRICK R;;FOSTER THOMAS H,,https://lens.org/171-958-110-581-851,Patent Application,yes,5,0,2,38,0,A61F2/82;;A61F2/82;;A61B5/0002;;A61B5/0002;;A61B5/0071;;A61B5/0071;;A61B5/0084;;A61B5/0084;;A61B5/14503;;A61B5/14503,A61B5/00;;A61F2/82,,0,0,,,,PENDING
178,US,A1,US 2006/0175738 A1,046-409-636-331-036,2006-08-10,2006,US 34695806 A,2006-02-03,EP 05075290 A;;EP 05113085 A,2005-02-04,Process for blow-molding a container comprising a handle,"A process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a thermoplastic preform ( 2 ) into a mold cavity ( 6 ) and stretching the preform ( 2 ) with a stretch rod ( 3 );(ii) increasing the pressure within the preform ( 2 ) so that the preform ( 2 ) expands within the mold cavity ( 6 );(iii) displacing at least one moving mold section ( 4 ) within the mold and which deforms the thermoplastic material; wherein the displacement of the moving section ( 4 ) is in a direction which is substantially parallel to the direction of movement of the stretch rod ( 3 )",PROCTER & GAMBLE,CONNOLLY WILLIAM J;;ETESSE PATRICK J,PROCTER & GAMBLE COMPANY THE (2006-01-17),https://lens.org/046-409-636-331-036,Patent Application,yes,5,6,5,43,0,B29B11/08;;B29B11/10;;B29B11/12;;B29B11/14;;B29C43/36;;B29C49/04;;B29C49/06;;B29C49/12;;B29C49/4802;;B29C2043/3665;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29K2105/258;;B29L2031/463;;B29L2031/7158;;B29C2949/3024;;B29C2949/28;;B29C2949/26;;B29C2949/24;;B29C2949/22;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/072;;B29C49/071;;B29C2949/0715;;B29C49/4802;;B29B11/12;;B29B11/08;;B29L2031/463;;B29K2067/00;;B29C2049/4807;;B29C49/12;;B29C2043/3665;;B29K2105/258;;B29B11/10;;B29K2023/12;;B29C43/36;;B29L2031/7158;;B29K2023/06;;B29K2027/06;;B29C49/06;;B29B11/14;;B29K2067/046;;B29C49/04;;B29C2949/22;;B29C2949/24;;B29C2949/26;;B29C2949/28;;B29C2949/072;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/3024;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056,B29C49/12,264/532,0,0,,,,DISCONTINUED
179,CN,A,CN 109643586 A,085-857-819-333-249,2019-04-16,2019,CN 201780053591 A,2017-08-28,US 201662380635 P;;US 2017/0048940 W,2016-08-29,MANAGING CARE PATHWAYS,"A method of facilitating management of a care pathway includes the steps: receiving a care pathway definition, having a first care pathway step and a second care pathway step, where each care pathwaystep is identified by a unique identification (ID) code. The method includes determining a keyword associated with each care pathway step; and identifying, in patient information, care episodes. The method may include the steps: extracting, from the patient information, episode information corresponding to the care episodes; associating the care episodes with the corresponding care pathway steps;and determining, based on the care pathway definition and the episode information, a care metric. A display device may be used to present a representation of the care metric to a user.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;LANO TIMO HENRIK MATIAS,,https://lens.org/085-857-819-333-249,Patent Application,no,3,1,4,4,0,G16H40/20;;G16H40/20;;G16H15/00,G16H80/00,,0,0,,,,DISCONTINUED
180,WO,A2,WO 2003/081428 A2,061-323-154-080-330,2003-10-02,2003,IE 0300045 W,2003-03-24,IE 20020204 A,2002-03-22,"""A local area wireless network simulator""","A simulator (1) has virtual stacks (10, 23) which simulate entirely in software behaviour of actual stacks for hardware devices. Stubs (25) are provided for resource-poor applications (21) to communicate with virtual stacks (10). A discovery service (12) simulates in software hardware devices and has a discovery function to discover these simulated devices. It responds to application calls indicating the simulated devices as if they were the actual devices within range, i.e. within a piconet.",ROCOCO SOFTWARE LTD;;CONNOLLY PATRICK;;CRANE STEPHEN;;SMART NIALL,CONNOLLY PATRICK;;CRANE STEPHEN;;SMART NIALL,,https://lens.org/061-323-154-080-330,Patent Application,yes,0,0,5,5,0,G06F9/54;;G06F9/45537,G06F9/455;;G06F9/46;;G06F11/00;;G06F17/00;;H04L12/28,,0,0,,,,PENDING
181,EP,A2,EP 3950040 A2,094-664-774-274-665,2022-02-09,2022,EP 21188151 A,2021-07-28,US 202016942684 A,2020-07-29,BALLOON GUIDE CATHETER HAVING REDUCED OUTER DIAMETER DISTAL AND PROXIMAL BONDING INTERFACE AREAS WITH THE BALLOON,"A balloon guide catheter (100) including a balloon (145) and a catheter shaft (105) having a central lumen (107) defined axially therethrough, and an inflation lumen (135). An exterior surface of the catheter shaft has a distal reduced outer diameter recess area (120A) defined therein and a proximal reduced outer diameter recess area (120B) separated in an axial direction from the distal reduced outer diameter recess area with a discharge port (140) of the inflation lumen disposed therebetween. The balloon is secured to the catheter shaft by adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area; and the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.
",NEURAVI LTD,CONNOLLY PATRICK;;CONWAY SHANE;;CONLON RICHARD,,https://lens.org/094-664-774-274-665,Patent Application,yes,0,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10;;A61M25/00;;B29C65/00,,0,0,,,,PENDING
182,WO,A3,WO 2003/081428 A3,110-671-009-261-959,2004-04-29,2004,IE 0300045 W,2003-03-24,IE 20020204 A,2002-03-22,"""A local area wireless network simulator""","A simulator (1) has virtual stacks (10, 23) which simulate entirely in software behaviour of actual stacks for hardware devices. Stubs (25) are provided for resource-poor applications (21) to communicate with virtual stacks (10). A discovery service (12) simulates in software hardware devices and has a discovery function to discover these simulated devices. It responds to application calls indicating the simulated devices as if they were the actual devices within range, i.e. within a piconet.",ROCOCO SOFTWARE LTD;;CONNOLLY PATRICK;;CRANE STEPHEN;;SMART NIALL,CONNOLLY PATRICK;;CRANE STEPHEN;;SMART NIALL,,https://lens.org/110-671-009-261-959,Search Report,yes,0,0,5,5,0,G06F9/54;;G06F9/45537,G06F9/455;;G06F9/46;;G06F11/00;;G06F17/00;;H04L12/28,,5,0,,,"ANONYMOUS: ""Rococo datasheet"", ROCOCO SOFTWARE PRODUCTS PAGES, 7 February 2002 (2002-02-07), XP002269426, Retrieved from the Internet <URL:http://web.archive.org/web/20020207175709/http://www.rococosoft.com/products/data.html> [retrieved on 20040206];;GIGUÈRE E: ""Java 2 Micro Edition: The Ultimate Guide to Programming Handheld and Embedded Devices"", 17 November 2000, JOHN WILEY & SONS, ISBN: 0471390658, XP002269430;;WALDO J, THOMPSON K: ""The Jini Technology-Enabled Surrogate Architecture - TS-984"", JAVAONE 2000 - PRESENTATION SLIDES, 7 June 2000 (2000-06-07), pages 2 - 21, XP002269427, Retrieved from the Internet <URL:http://servlet.java.sun.com/javaone/javaone2000/pdfs/TS-984.pdf> [retrieved on 20040206];;SHARMA R: ""Java? API for XML-based RPC - JAX-RPC 1.0 - Proposed final draft v0.8"", JAVA COMMUNITY PROCESS SPECIFICATIONS - JSR-101, 5 March 2002 (2002-03-05), XP002269428;;BRODY STEVE: ""IBM develops Bluetooth network simulator"", IBM DEVELOPERWORKS, 1 February 2001 (2001-02-01), XP002269429, Retrieved from the Internet <URL:http://www-106.ibm.com/developerworks/library/l-blueh.html> [retrieved on 20040206]",PENDING
183,JP,A,JP 2022027585 A,168-100-753-357-399,2022-02-10,2022,JP 2021123091 A,2021-07-28,US 202016942684 A,2020-07-29,BALLOON GUIDE CATHETER HAVING REDUCED OUTER DIAMETER DISTAL AND PROXIMAL BONDING INTERFACE AREAS WITH BALLOON,"To provide a balloon guide catheter.SOLUTION: A balloon guide catheter includes a balloon and a catheter shaft having a central lumen defined axially therethrough, and an inflation lumen. An exterior surface of the catheter shaft has a distal reduced outer diameter recess area defined in the exterior surface and a proximal reduced outer diameter recess area separated in an axial direction from the distal reduced outer diameter recess area with a discharge port of the inflation lumen disposed therebetween. The balloon is secured to the catheter shaft by an adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area, and secured to the catheter shaft by an adhesive pooled in the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.SELECTED DRAWING: Figure 1B",NEURAVI LTD,PATRICK CONNOLLY;;SHANE CONWAY;;RICHARD CONLON,,https://lens.org/168-100-753-357-399,Patent Application,no,0,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10,,0,0,,,,PENDING
184,KR,A,KR 20220014840 A,139-907-605-451-311,2022-02-07,2022,KR 20210097790 A,2021-07-26,US 202016942684 A,2020-07-29,BALLOON GUIDE CATHETER HAVING REDUCED OUTER DIAMETER DISTAL AND PROXIMAL BONDING INTERFACE AREAS WITH THE BALLOON,"Provided is a balloon guide catheter including: a balloon; and a catheter shaft having a central lumen axially defined therethrough, and an inflation lumen. An exterior surface of the catheter shaft has a distal reduced outer diameter recess area defined therein and a proximal reduced outer diameter recess area separated in an axial direction from the distal reduced outer diameter recess area with a discharge port of the inflation lumen disposed therebetween. The balloon is fixed to the catheter shaft by an adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area, and is fixed to the catheter shaft by an adhesive pooled in the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.",NEURAVI LTD,CONNOLLY PATRICK;;CONWAY SHANE;;CONLON RICHARD,,https://lens.org/139-907-605-451-311,Patent Application,no,0,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10;;A61B17/22,,0,0,,,,PENDING
185,CA,A,CA 778059 A,017-040-901-408-85X,1968-02-13,1968,CA 778059D A,,CA 778059T A,,QUICK RELEASE MECHANISM FOR SLIDE FASTENERS,,US GOV SEC ARMY,ARSLANIAN MICHAEL M;;CONNOLLY PATRICK J,,https://lens.org/017-040-901-408-85X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
186,EP,A3,EP 3950040 A3,137-653-875-075-627,2022-04-27,2022,EP 21188151 A,2021-07-28,US 202016942684 A,2020-07-29,BALLOON GUIDE CATHETER HAVING REDUCED OUTER DIAMETER DISTAL AND PROXIMAL BONDING INTERFACE AREAS WITH THE BALLOON,"A balloon guide catheter (100) including a balloon (145) and a catheter shaft (105) having a central lumen (107) defined axially therethrough, and an inflation lumen (135). An exterior surface of the catheter shaft has a distal reduced outer diameter recess area (120A) defined therein and a proximal reduced outer diameter recess area (120B) separated in an axial direction from the distal reduced outer diameter recess area with a discharge port (140) of the inflation lumen disposed therebetween. The balloon is secured to the catheter shaft by adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area; and the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.
",NEURAVI LTD,CONNOLLY PATRICK;;CONWAY SHANE;;CONLON RICHARD,,https://lens.org/137-653-875-075-627,Search Report,yes,5,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10;;A61M25/00;;B29C65/00,,0,0,,,,PENDING
187,US,A1,US 2007/0048473 A1,124-539-563-594-70X,2007-03-01,2007,US 34696006 A,2006-02-03,EP 05447194 A,2005-08-29,Injection stretch blow-molded container,"An injection stretch blow-molded container 1 consisting essentially of polypropylene, wherein the container is provided with a decoration comprising label or sleeve 6 , and characterized in that the label or sleeve 6 consists essentially of polyolefin.",PROCTER & GAMBLE,CONNOLLY WILLIAM J;;ETESSE PATRICK J,PROCTER & GAMBLE COMPANY THE (2005-09-29),https://lens.org/124-539-563-594-70X,Patent Application,yes,8,5,1,43,0,B29C49/06;;B29K2023/12;;B29L2031/463;;B65D23/0842;;B65D51/00;;Y10T428/1352;;B29C2949/0715;;B29C2049/7831;;B29C2049/7832;;B29C2049/7862;;Y10T428/1352;;B65D51/00;;B29C49/06;;B65D23/0842;;B29K2023/12;;B29L2031/463,B32B27/08,428/35.7,0,0,,,,DISCONTINUED
188,WO,A1,WO 2018/044807 A1,107-968-365-656-067,2018-03-08,2018,US 2017/0048940 W,2017-08-28,US 201662380635 P,2016-08-29,MANAGING CARE PATHWAYS,"A method of facilitating management of a care pathway includes receiving a care pathway definition, having a first care pathway step and a second care pathway step, where each care pathway step is identified by a unique identification (ID) code. The method includes determining a keyword associated with each care pathway step; and identifying, in patient information, care episodes. The method may include extracting, from the patient information, episode information corresponding to the care episodes; associating the care episodes with the corresponding care pathway steps; and determining, based on the care pathway definition and the episode information, a care metric. A display device may be used to present a representation of the care metric to a user.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;LANO TIMO HENRIK MATIAS,,https://lens.org/107-968-365-656-067,Patent Application,yes,6,2,4,4,0,G16H40/20;;G16H40/20;;G16H15/00,G06F19/00,,0,0,,,,PENDING
189,US,A1,US 2022/0031342 A1,133-501-411-774-288,2022-02-03,2022,US 202016942684 A,2020-07-29,US 202016942684 A,2020-07-29,Balloon Guide Catheter Having Reduced Outer Diameter Distal and Proximal Bonding Interface Areas With the Balloon,"A balloon guide catheter including a balloon and a catheter shaft having a central lumen defined axially therethrough, and an inflation lumen. An exterior surface of the catheter shaft has a distal reduced outer diameter recess area defined therein and a proximal reduced outer diameter recess area separated in an axial direction from the distal reduced outer diameter recess area with a discharge port of the inflation lumen disposed therebetween. The balloon is secured to the catheter shaft by adhesive pooled in the distal reduced outer diameter recess area forming a distal bonding interface area; and the proximal reduced outer diameter recess area forming a proximal bonding interface area. Heat shrink tubing is positioned about the balloon at the distal and proximal bonding interface areas.",NEURAVI LTD,CONWAY SHANE;;CONLON RICHARD;;CONNOLLY PATRICK,NEURAVI LIMITED (2020-07-08),https://lens.org/133-501-411-774-288,Patent Application,yes,7,0,6,6,0,A61M25/1034;;A61M25/1002;;A61B17/22;;A61M2025/1052;;A61B2017/22067;;A61M25/1034;;A61M2025/1061;;A61M25/005;;A61M25/1006;;A61M25/1034;;A61M25/1036;;A61M25/104;;A61M25/1002;;A61M25/1025;;A61B17/22;;A61B2017/22067;;A61B2017/22094;;A61B2017/22079;;A61B17/22;;A61B2017/22051;;A61M25/0021;;A61M25/005;;A61M25/1034;;A61M2025/1061,A61M25/10;;A61B17/22,,0,0,,,,DISCONTINUED
190,US,A1,US 2006/0177615 A1,120-751-728-090-220,2006-08-10,2006,US 34695706 A,2006-02-03,EP 05075290 A;;EP 05113082 A,2005-02-04,Process for forming a container by stretch blow molding and container formed thereby,A process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; wherein the glass transition temperature (T g ) of the preform material is at least 10° C. below the temperature of the walls of the mold cavity.,PROCTER & GAMBLE,CONNOLLY WILLIAM J;;ETESSE PATRICK J,PROCTER & GABLE COMPANY THE (2006-01-17),https://lens.org/120-751-728-090-220,Patent Application,yes,4,9,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B32B27/08,428/35.7;;264/531,0,0,,,,DISCONTINUED
191,IE,B1,IE 64906 B1,166-080-703-997-859,1995-09-20,1995,IE 45989 A,1989-02-24,IE 45989 A,1989-02-24,Solar panel,,BQ TECHNOLOGY LIMITED,QUIGLEY WILLIAM;;FORKIN MARK PATRICK;;CONNOLLY PETER,,https://lens.org/166-080-703-997-859,Granted Patent,no,0,1,4,4,0,F24S70/10;;F24S70/10;;F24S10/80;;F24S10/80;;F24S20/67;;F24S20/67;;F24S80/45;;F24S80/45;;F24S2025/6003;;F24S2025/6003;;Y02A30/60;;Y02A30/60;;Y02B10/20;;Y02B10/20;;Y02E10/44;;Y02E10/44,F24J2/04;;F24J2/46;;F24J2/48;;F24S10/80,,0,0,,,,EXPIRED
192,WO,A2,WO 2006/084207 A2,179-731-508-596-740,2006-08-10,2006,US 2006/0003998 W,2006-02-03,EP 05075290 A;;EP 05447194 A,2005-02-04,INJECTION STRETCH BLOW-MOLDED CONTAINER,"The present invention relates to an injection stretch blow-molded container (1) consisting essentially of polypropylene, wherein the container is provided with a decoration comprising label or sleeve (6), and characterized in that the label or sleeve (6) consists essentially of polyolefin.",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/179-731-508-596-740,Patent Application,yes,0,4,5,43,0,B65D23/0842;;B65D51/00,B65D23/08;;B65D51/00,,0,0,,,,PENDING
193,WO,A2,WO 2006/084212 A2,057-783-023-936-357,2006-08-10,2006,US 2006/0004008 W,2006-02-03,EP 05075290 A;;EP 05113082 A,2005-02-04,A PROCESS FOR FORMING A CONTAINER BY STRETCH BLOW MOLDING AND CONTAINER FORMED THEREBY,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; wherein the glass transition temperature (Tg) of the preform material is at least 10&deg; C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30&deg;C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/057-783-023-936-357,Patent Application,yes,0,1,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,PENDING
194,CA,A1,CA 2593927 A1,066-535-214-556-238,2006-08-10,2006,CA 2593927 A,2006-02-03,EP 05075290 A;;EP 05113082 A;;US 2006/0004008 W,2005-02-04,A PROCESS FOR FORMING A CONTAINER BY STRETCH BLOW MOLDING AND CONTAINER FORMED THEREBY,,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/066-535-214-556-238,Patent Application,no,0,1,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,ACTIVE
195,US,B2,US 11340875 B2,144-867-696-334-58X,2022-05-24,2022,US 202016891024 A,2020-06-02,US 202016891024 A,2020-06-02,Searchable storage of sequential application programs,"A method, apparatus and system for enabling the searchable storage of sequential application programs includes normalizing the sequential application programs, canonicalizing the sequential application programs, determining a unique identifier for each of the sequential application programs, and storing the unique identifier for each of the sequential application programs. The stored, unique identifier for the canonicalized sequential application programs can then be searched to, for example, determine if a sequential application program is stored and/or to certify at least one of the stored, canonicalized sequential application programs.",STANFORD RES INST INT,CONNOLLY CHRISTOPHER;;YADAV MANEESH;;LINCOLN PATRICK D,SRI INTERNATIONAL (2020-05-29),https://lens.org/144-867-696-334-58X,Granted Patent,yes,10,0,2,2,0,G06F8/71;;H04L9/3239;;H04L9/50;;G06F8/4441;;G06F8/71;;H04L9/0643;;H04L9/50,G06F9/44;;G06F8/41;;G06F8/71;;H04L9/06,,0,0,,,,ACTIVE
196,TW,B,TW I625249 B,029-528-328-790-690,2018-06-01,2018,TW 105118956 A,2016-06-16,US 2015/0060006 W,2015-11-10,Printhead-integrated ink level sensor with clearing resistor,,HEWLETT PACKARD DEVELOPMENT CO LP,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/029-528-328-790-690,Granted Patent,no,2,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,,,0,0,,,,ACTIVE
197,US,A1,US 2021/0373864 A1,069-630-407-377-476,2021-12-02,2021,US 202016891024 A,2020-06-02,US 202016891024 A,2020-06-02,SEARCHABLE STORAGE OF SEQUENTIAL APPLICATION PROGRAMS,"A method, apparatus and system for enabling the searchable storage of sequential application programs includes normalizing the sequential application programs, canonicalizing the sequential application programs, determining a unique identifier for each of the sequential application programs, and storing the unique identifier for each of the sequential application programs. The stored, unique identifier for the canonicalized sequential application programs can then be searched to, for example, determine if a sequential application program is stored and/or to certify at least one of the stored, canonicalized sequential application programs.",STANFORD RES INST INT,CONNOLLY CHRISTOPHER;;YADAV MANEESH;;LINCOLN PATRICK D,SRI INTERNATIONAL (2020-05-29),https://lens.org/069-630-407-377-476,Patent Application,yes,0,0,2,2,0,G06F8/71;;H04L9/3239;;H04L9/50;;G06F8/4441;;G06F8/71;;H04L9/0643;;H04L9/50,G06F8/41;;G06F8/71;;H04L9/06,,0,0,,,,ACTIVE
198,BR,A2,BR PI0607113 A2,073-156-485-950-994,2009-08-11,2009,BR PI0607113 A,2006-02-03,EP 05075290 A;;EP 05113082 A;;US 2006/0004008 W,2005-02-04,"processo para formação de um recipiente mediante modelagem por sopro com estiramento, e um recipiente formado dessa maneira","PROCESSO PARA FORMAçãO DE UM RECIPIENTE MEDIANTE MODELAGEM POR SOPRO COM ESTIRAMENTO, E UM RECIPIENTE FORMADO DESSA MANEIRA. A presente invenção refere-se a um processo para formação de um recipiente mediante estiramento e modelagem por sopro de uma pré-forma no interior de uma cavidade do molde, compreendendo as etapas de: (i) introduzir uma pré-forma na cavidade de molde, e estirar a mesma com uma haste de extensão; (ii) aumentar a pressão no interior da pré-forma, de modo que a mesma se expanda no interior da cavidade do molde em uma etapa de sopro; (iii) mover para dentro ao menos uma seção móvel no interior da cavidade do molde, de modo que a pré-forma em expansão seja deformada pela seção móvel do molde, em que a temperatura de transição vítrea (T~ g~) do material da pré-forma situa-se ao menos 10°C abaixo da temperatura das paredes da cavidade do molde. A presente invenção refere-se, também, a um recipiente modelado a sopro com estiramento, compreendendo paredes de uma poliolefina termoplástica cuja temperatura de transição vítrea é menor que 30°C, sendo que o dito recipiente tem um grau de assimetria de ao menos 1,5.",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/073-156-485-950-994,Patent Application,no,0,0,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,PENDING
199,EP,A1,EP 0384787 A1,096-896-085-821-040,1990-08-29,1990,EP 90302032 A,1990-02-26,IE 45989 A,1989-02-24,Solar panel.,"A solar panel includes: a rectangular space frame constructed from timber members 1a, 1b, 1c and 1d; a sheet of plasterboard 2 beneath the timber frame; a foil backing 3 on the plasterboard; and a shaped bed 4 made of polyurethane foam which is moulded into position in the housing constituted by the timber frame and the sheet of plasterboard 2, and which adheres in an air-tight manner to the housing. A foil cover 5 is provided on top of the shaped bed 4. Above the foil cover 5 is a solar radiation absorber 6, comprising a matrix of glass fibre which is bonded by a phenol formaldehyde resin, seated in a recess 4a in the bed 4; and a housing cover 7 comprising a sheet of toughened glass. Cover retention means comprising aluminium extrusions 21 and silicone gaskets 22 secure the housing cover 7 in position. A series of air inlet ports 9 across one end of the panel, and a series of air outlet ports 10 across the other end of the panel enable air to circulate through the panel which can function as a solar panel and a heat exchanger for absorbing ambient heat from the atmosphere by circulating to the solar panel air at a temperature lower than the temperature of the ambient air.  ",CLAUDIUS ENTERPRISES LIMITED,QUIGLEY WILLIAM;;FORKIN MARK PATRICK;;CONNOLLY PETER,,https://lens.org/096-896-085-821-040,Patent Application,yes,8,5,4,4,0,F24S70/10;;F24S70/10;;F24S10/80;;F24S10/80;;F24S20/67;;F24S20/67;;F24S80/45;;F24S80/45;;F24S2025/6003;;F24S2025/6003;;Y02A30/60;;Y02A30/60;;Y02B10/20;;Y02B10/20;;Y02E10/44;;Y02E10/44,F24J2/04;;F24J2/46;;F24J2/48;;F24S10/80,,0,0,,,,DISCONTINUED
200,CN,B,CN 101115606 B,022-226-553-099-726,2011-01-12,2011,CN 200680004158 A,2006-02-03,US 2006/0004008 W;;EP 05075290 A;;EP 05113082 A,2005-02-04,Method for manufacturing containers through stretching and blow-molding and the containers manufactured thereof,"The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform (2) into a mold cavity and stretching the preform (2) with a stretch rod; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity in a first blowing step, the pressure inthe first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws (3, 4) within the mold cavity so that the expanding preform (2) is partially gripped between the jaws in the handle region; (iv)subsequently increasing the pressure within the preform (2) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform (2) expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws (3, 4) is completed within the first blowing step.",PROCTER & GAMBLE,JEAN-FRANCOIS ETESSE PATRICK;;JOHN CONNOLLY WILLIAM,,https://lens.org/022-226-553-099-726,Granted Patent,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,INACTIVE
201,EP,A1,EP 1688233 A1,151-632-821-115-528,2006-08-09,2006,EP 05075290 A,2005-02-04,EP 05075290 A,2005-02-04,"Process for the manufacture of containers which have an integral handle, and containers manufactured thereby","The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of:
 (i) introducing a preform (2) into a mold cavity and stretching the preform (2) with a stretch rod; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws (3, 4) within the mold cavity so that the expanding preform (2) is partially gripped and fused (10) between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform (2) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform (2) expands to the limits of the mold cavity in a second blowing step to form a container; 
and wherein the inward movement of the jaws (3, 4) is completed within the first blowing step. The present invention further relates to a blow-molded container (20) comprising biorientated polypropylene comprising a main bottle cavity (21) and an integrally molded, hollow handle cavity (22), and wherein the main bottle cavity (21) and the hollow handle cavity (22) are interconnected such that fluid can flow freely between the two cavities (21, 22).
",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/151-632-821-115-528,Patent Application,yes,6,6,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,DISCONTINUED
202,WO,A1,WO 2006/084213 A1,196-765-614-998-606,2006-08-10,2006,US 2006/0004009 W,2006-02-03,EP 05075290 A;;EP 05113085 A,2005-02-04,PROCESS FOR BLOW-MOLDING A CONTAINER COMPRISING A HANDLE,"he present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of : (i) introducing a thermoplastic preform (2) into a mold cavity (6) and stretching the preform (2) with a stretch rod (3) ; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity (6) ; (iii) displacing at least one moving mold section within the mold and which deforms the thermoplastic material; wherein the displacement of the moving section is in a direction which is substantially parallel to the direction of movement of the stretch rod (3) . T:",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/196-765-614-998-606,Patent Application,yes,2,0,5,43,0,B29B11/08;;B29B11/10;;B29B11/12;;B29B11/14;;B29C43/36;;B29C49/04;;B29C49/06;;B29C49/12;;B29C49/4802;;B29C2043/3665;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29K2105/258;;B29L2031/463;;B29L2031/7158;;B29C2949/3024;;B29C2949/28;;B29C2949/26;;B29C2949/24;;B29C2949/22;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/072;;B29C49/071;;B29C2949/0715;;B29C49/4802;;B29B11/12;;B29B11/08;;B29L2031/463;;B29K2067/00;;B29C2049/4807;;B29C49/12;;B29C2043/3665;;B29K2105/258;;B29B11/10;;B29K2023/12;;B29C43/36;;B29L2031/7158;;B29K2023/06;;B29K2027/06;;B29C49/06;;B29B11/14;;B29K2067/046;;B29C49/04;;B29C2949/22;;B29C2949/24;;B29C2949/26;;B29C2949/28;;B29C2949/072;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/3024;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056,B29C49/48;;B29C49/12,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1997, no. 01 31 January 1997 (1997-01-31);;PATENT ABSTRACTS OF JAPAN vol. 016, no. 087 (M - 1217) 3 March 1992 (1992-03-03)",PENDING
203,US,A1,US 2006/0186581 A1,064-077-754-977-465,2006-08-24,2006,US 34695906 A,2006-02-03,EP 05075290 A,2005-02-04,"Process for the manufacture of containers which have an integral handle, and containers manufactured thereby","A process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform ( 2 ) into a mold cavity and stretching the preform ( 2 ) with a stretch rod; (ii) increasing the pressure within the preform ( 2 ) so that the preform ( 2 ) expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws ( 3, 4 ) within the mold cavity so that the expanding preform ( 2 ) is partially gripped between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform ( 2 ) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform ( 2 ) expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws ( 3, 4 ) is completed within the first blowing step.",PROCTER & GAMBLE,ETESSE PATRICK J;;CONNOLLY WILLIAM J C,PROCTER & GAMBLE COMPANY THE (2006-01-24),https://lens.org/064-077-754-977-465,Patent Application,yes,10,3,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/00;;B29C49/08,264/531;;264/532,0,0,,,,ACTIVE
204,ES,T3,ES 2321976 T3,082-296-079-863-909,2009-06-15,2009,ES 06734377 T,2006-02-03,EP 05075290 A,2005-02-04,PROCEDIMIENTO PARA LA FABRICACION DE RECIPIENTES QUE TIENEN UN ASA INTEGRADA.,"Un proceso para moldear por soplado un recipiente, comprendiendo el recipiente un asa y en donde el proceso comprende las etapas de: (i) introducir una preforma (2) en una cavidad de molde y estirar la preforma (2) con una varilla estirable; (ii) aumentar la presión dentro de la preforma (2) de manera que la preforma (2) se expanda dentro de la cavidad de molde en una primera etapa de soplado; (iii) mover hacia dentro las mordazas (3, 4) dentro de la cavidad de molde de manera que la preforma (2) en expansión quede parcialmente sujeta entre las mordazas en la región de asa; (iv) a continuación aumentar la presión dentro de la preforma (2) de manera que la preforma (2) se expanda hasta los límites de la cavidad de molde en una segunda etapa de soplado para formar un recipiente; en donde el movimiento hacia el interior de las mordazas (3, 4) se completa en la primera etapa de soplado, que se caracteriza por que la presión en la primera etapa de soplado es de 0,1 MPa (1 bar) a 1 MPa (10 bar), y la presión máxima en la segunda etapa de soplado es mayor que 1 MPa (10 bar).",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/082-296-079-863-909,Granted Patent,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,ACTIVE
205,EP,A4,EP 3337663 A4,143-342-327-518-270,2019-03-27,2019,EP 15908431 A,2015-11-10,US 2015/0060006 W,2015-11-10,PRINTHEAD-INTEGRATED INK LEVEL SENSOR WITH CENTRAL CLEARING RESISTOR,,HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/143-342-327-518-270,Search Report,no,3,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,1,0,,,See also references of WO 2017082886A1,ACTIVE
206,CA,C,CA 2593927 C,153-458-537-280-798,2011-01-11,2011,CA 2593927 A,2006-02-03,EP 05075290 A;;EP 05113082 A;;US 2006/0004008 W,2005-02-04,A PROCESS FOR FORMING A CONTAINER BY STRETCH BLOW MOLDING AND CONTAINER FORMED THEREBY,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; wherein the glass transition temperature (Tg) of the preform material is at least 10~ C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30~C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/153-458-537-280-798,Granted Patent,no,0,0,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,ACTIVE
207,DE,D1,DE 602006006035 D1,146-696-252-291-995,2009-05-14,2009,DE 602006006035 T,2006-02-03,EP 05075290 A;;US 2006/0004010 W,2005-02-04,HERSTELLUNGSVERFAHREN FÜR BEHÄLTER MIT EINGEBAUTEM GRIFF,,PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/146-696-252-291-995,Granted Patent,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,ACTIVE
208,MX,A,MX 2007009419 A,039-128-567-997-349,2007-08-17,2007,MX 2007009419 A,2006-02-03,EP 05075290 A;;EP 05113082 A;;US 2006/0004008 W,2005-02-04,A PROCESS FOR FORMING A CONTAINER BY STRETCH BLOW MOLDING AND CONTAINER FORMED THEREBY.,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; wherein the glass transition temperature (T<sub>g</sub>) of the preform material is at least 10 degree C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30 degree C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/039-128-567-997-349,Patent Application,no,0,0,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,ACTIVE
209,TW,A,TW 201716249 A,103-190-930-655-877,2017-05-16,2017,TW 105118956 A,2016-06-16,US 2015/0060006 W,2015-11-10,Printhead integrated ink level snesor with clearing resistor,"The present subject matter relates to printhead-integrated ink level sensor (PILS) system. In an example implementation, the PILS system includes a sense capacitor plate in a fluid sensing chamber to sense a level of fluid in the fluid sensing chamber. The fluid sensing chamber is in fluid communication with a fluid reservoir of the printhead to receive fluid from the fluid reservoir. The sense capacitor plate includes at least one slot. The PILS system further includes at least one central clearing resistor and at least one peripheral clearing resistor to clear the fluid sensing chamber of the fluid. The central clearing resistor is provided in the at least one slot of the sense capacitor plate. The at least one peripheral resistor is provided in the fluid sensing chamber surrounding the sense capacitor plate.",HEWLETT PACKARD DEVELOPMENT CO LP,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/103-190-930-655-877,Patent of Addition,no,0,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/195;;G01F23/26,,0,0,,,,ACTIVE
210,EP,A2,EP 1688356 A2,121-439-518-004-195,2006-08-09,2006,EP 05447194 A,2005-08-29,EP 05075290 A;;EP 05447194 A,2005-02-04,Injection stretch blow-molded container,"The present invention relates to an injection stretch blow-molded container 1 consisting essentially of polypropylene, wherein the container is provided with a decoration comprising label or sleeve 6, and characterized in that the label or sleeve 6 consists essentially of polyolefin.
",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/121-439-518-004-195,Patent Application,yes,0,2,5,43,0,B65D23/0842;;B65D51/00,B65D23/08;;B65D51/00,,0,0,,,,DISCONTINUED
211,EP,A3,EP 1688356 A3,188-819-084-802-725,2006-08-16,2006,EP 05447194 A,2005-08-29,EP 05075290 A;;EP 05447194 A,2005-02-04,Injection stretch blow-molded container,"The present invention relates to an injection stretch blow-molded container 1 consisting essentially of polypropylene, wherein the container is provided with a decoration comprising label or sleeve 6, and characterized in that the label or sleeve 6 consists essentially of polyolefin.
",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/188-819-084-802-725,Search Report,yes,8,0,5,43,0,B65D23/0842;;B65D51/00,B65D51/00;;B65D23/08,,0,0,,,,DISCONTINUED
212,GB,A,GB 190719888 A,165-148-492-996-128,1908-03-12,1908,GB 190719888D A,1907-09-05,GB 190719888T A,1907-09-05,Improved Transmission Gear for Rotation Indicating Instruments,"19,888. Browne, H. P. C., and Palmer, W. H. Sept. 5. Speed indicators; odometers.-Various forms of transmission gearing are described for operating a distance or speed indicator from the shaft of the vehicle. (1) A cogged wheel D is fixed to the hub of the wheel by screws through lugs d ; gearing with this wheel is a pinion the axle f of which is flattened at one side to receive the end of the flexible shaft connecting it to the odometer. The casing A in which the pinion is journaled is carried by, and fits closely upon the wheel D, and is prevented from rotating with the wheel by means of an arm secured: to some fixed part of the vehicle engaging with lugs a projecting from the casing. The faces of the wheel D are grooved to permit the insertion of packing E. Variation in the speed ratio may be obtained by the introduction of further bevelled pinions. (2) The gear wheel D may take the form of a bevel-wheel gearing with a smaller bevelled pinion, or may be a plain annular ring D<2>, Fig. 8, upon which the tyre of a smaller wheel F<6> travels. The housing of the wheel is adjustable through a small angle, thus allowing for wear &c. of the tyre. (3) A further modification consists in replacing the pinion by a starwheel which is rotated by a spiral race on the ring D. (4) In another modification, the gearwheel D is supported from the hub by means of a projecting piece screwed to the outside of the hub. In this form the casing is prevented from rotating by the casing of the flexible shaft. (5) In another form, the casing is fixed to the pivot of the axle, and the gear is rotated by pins projecting from the hub and engaging notches in the lugs d of the wheel D. The packing in the wheel serves the double purpose of retaining oil in, and excluding dust from the casing.",BROWNE HARRY PATRICK CONNOLLY;;PALMER WILLIAM HENRY,BROWNE HARRY PATRICK CONNOLLY;;PALMER WILLIAM HENRY,,https://lens.org/165-148-492-996-128,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
213,EP,A1,EP 3337663 A1,189-858-681-219-51X,2018-06-27,2018,EP 15908431 A,2015-11-10,US 2015/0060006 W,2015-11-10,PRINTHEAD-INTEGRATED INK LEVEL SENSOR WITH CENTRAL CLEARING RESISTOR,,HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/189-858-681-219-51X,Patent Application,yes,0,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,0,0,,,,ACTIVE
214,WO,A3,WO 2006/084212 A3,193-407-396-729-440,2006-12-21,2006,US 2006/0004008 W,2006-02-03,EP 05075290 A;;EP 05113082 A,2005-02-04,A PROCESS FOR FORMING A CONTAINER BY STRETCH BLOW MOLDING AND CONTAINER FORMED THEREBY,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; wherein the glass transition temperature (Tg) of the preform material is at least 10&deg; C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30&deg;C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/193-407-396-729-440,Search Report,yes,3,0,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,PENDING
215,WO,A1,WO 2017/082886 A1,040-566-817-839-737,2017-05-18,2017,US 2015/0060006 W,2015-11-10,US 2015/0060006 W,2015-11-10,PRINTHEAD-INTEGRATED INK LEVEL SENSOR WITH CENTRAL CLEARING RESISTOR,"The present subject matter relates to printhead-integrated ink level sensor (PILS) system. In an example implementation, the PILS system includes a sense capacitor plate in a fluid sensing chamber to sense a level of fluid in the fluid sensing chamber. The fluid sensing chamber is in fluid communication with a fluid reservoir of the printhead to receive fluid from the fluid reservoir. The sense capacitor plate includes at least one slot. The PILS system further includes at least one central clearing resistor and at least one peripheral clearing resistor to clear the fluid sensing chamber of the fluid. The central clearing resistor is provided in the at least one slot of the sense capacitor plate. The at least one peripheral resistor is provided in the fluid sensing chamber surrounding the sense capacitor plate.",HEWLETT PACKARD DEVELOPMENT CO LP,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/040-566-817-839-737,Patent Application,yes,5,1,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,0,0,,,,PENDING
216,EP,B1,EP 3337663 B1,125-558-483-483-700,2020-05-06,2020,EP 15908431 A,2015-11-10,US 2015/0060006 W,2015-11-10,PRINTHEAD-INTEGRATED INK LEVEL SENSOR WITH CENTRAL CLEARING RESISTOR,,HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/125-558-483-483-700,Granted Patent,yes,8,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,0,0,,,,ACTIVE
217,US,A1,US 2018/0354271 A1,041-667-846-486-079,2018-12-13,2018,US 201515761621 A,2015-11-10,US 2015/0060006 W,2015-11-10,PRINTHEAD-INTEGRATED INK LEVEL SENSOR WITH CENTRAL CLEARING RESISTOR,"The present subject matter relates to printhead-integrated ink level sensor (PILS) system. In an example implementation, the PILS system includes a sense capacitor plate in a fluid sensing chamber to sense a level of fluid in the fluid sensing chamber. The fluid sensing chamber is in fluid communication with a fluid reservoir of the printhead to receive fluid from the fluid reservoir. The sense capacitor plate includes at least one slot. The PILS system further includes at least one central clearing resistor and at least one peripheral clearing resistor to clear the fluid sensing chamber of the fluid. The central clearing resistor is provided in the at least one slot of the sense capacitor plate. The at least one peripheral resistor is provided in the fluid sensing chamber surrounding the sense capacitor plate.",HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2015-10-27),https://lens.org/041-667-846-486-079,Patent Application,yes,7,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;G01F23/26,,0,0,,,,INACTIVE
218,EP,A1,EP 1688235 A1,079-216-677-418-003,2006-08-09,2006,EP 05113085 A,2005-12-30,EP 05075290 A;;EP 05113085 A,2005-02-04,Process for blow-molding a container comprising a handle,"The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of:
 (i) introducing a thermoplastic preform (2) into a mold cavity (6) and stretching the preform (2) with a stretch rod (3); (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity (6); (iii) displacing at least one moving mold section within the mold and which deforms the thermoplastic material; 
wherein the displacement of the moving section is in a direction which is substantially parallel to the direction of movement of the stretch rod (3).
",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/079-216-677-418-003,Patent Application,yes,2,4,5,43,0,B29B11/08;;B29B11/10;;B29B11/12;;B29B11/14;;B29C43/36;;B29C49/04;;B29C49/06;;B29C49/12;;B29C49/4802;;B29C2043/3665;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29K2105/258;;B29L2031/463;;B29L2031/7158;;B29C2949/3024;;B29C2949/28;;B29C2949/26;;B29C2949/24;;B29C2949/22;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/072;;B29C49/071;;B29C2949/0715;;B29C49/4802;;B29B11/12;;B29B11/08;;B29L2031/463;;B29K2067/00;;B29C2049/4807;;B29C49/12;;B29C2043/3665;;B29K2105/258;;B29B11/10;;B29K2023/12;;B29C43/36;;B29L2031/7158;;B29K2023/06;;B29K2027/06;;B29C49/06;;B29B11/14;;B29K2067/046;;B29C49/04;;B29C2949/22;;B29C2949/24;;B29C2949/26;;B29C2949/28;;B29C2949/072;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/3024;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056,B29C49/48;;B29C49/06;;B29C49/12,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1997, no. 01 31 January 1997 (1997-01-31);;PATENT ABSTRACTS OF JAPAN vol. 016, no. 087 (M - 1217) 3 March 1992 (1992-03-03)",DISCONTINUED
219,EP,A2,EP 1688234 A2,071-450-138-603-562,2006-08-09,2006,EP 05113082 A,2005-12-30,EP 05075290 A;;EP 05113082 A,2005-02-04,A process for forming a container by stretch blow molding and container formed thereby,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of:
 (i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; (iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; 
wherein the glass transition temperature (Tg) of the preform material is at least 10°C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30°C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/071-450-138-603-562,Patent Application,yes,0,38,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,DISCONTINUED
220,BR,A2,BR PI0607118 A2,061-511-906-907-184,2009-08-11,2009,BR PI0607118 A,2006-02-03,EP 05075290 A;;EP 05113085 A;;US 2006/0004009 W,2005-02-04,processo para modelagem por sopro de um recipiente compreendendo uma empunhadura,"PROCESSO PARA MODELAGEM POR SOPRO DE UM RECIPIENTE COMPREENDENDO UMA EMPUNHADURA. A presente invenção refere-se a um processo para a modelagem por sopro de um recipiente que compreende uma empunhadura, sendo que o dito processo compreende as etapas de: (i) introduzir uma pré-forma (2) de termoplástico em uma cavidade de molde (6), e estirar a mesma com uma haste de extensão (3); (ii) aumentar a pressão no interior da pré-forma (2) de modo que a mesma se expanda no interior da cavidade do molde (6); (iii) deslocar ao menos uma seção móvel do molde no interior do mesmo, a qual deforma o material termoplástico; sendo que o deslocamento da seção móvel se dá em uma direção que é substancialmente paralela à direção de movimento da haste de extensão (3).",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/061-511-906-907-184,Patent Application,no,0,0,5,43,0,B29B11/08;;B29B11/10;;B29B11/12;;B29B11/14;;B29C43/36;;B29C49/04;;B29C49/06;;B29C49/12;;B29C49/4802;;B29C2043/3665;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29K2105/258;;B29L2031/463;;B29L2031/7158;;B29C2949/3024;;B29C2949/28;;B29C2949/26;;B29C2949/24;;B29C2949/22;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/072;;B29C49/071;;B29C2949/0715;;B29C49/4802;;B29B11/12;;B29B11/08;;B29L2031/463;;B29K2067/00;;B29C2049/4807;;B29C49/12;;B29C2043/3665;;B29K2105/258;;B29B11/10;;B29K2023/12;;B29C43/36;;B29L2031/7158;;B29K2023/06;;B29K2027/06;;B29C49/06;;B29B11/14;;B29K2067/046;;B29C49/04;;B29C2949/22;;B29C2949/24;;B29C2949/26;;B29C2949/28;;B29C2949/072;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/3024;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056,B29C49/48;;B29C49/12,,0,0,,,,DISCONTINUED
221,CA,A1,CA 2593932 A1,087-937-166-168-313,2006-08-10,2006,CA 2593932 A,2006-02-03,EP 05075290 A;;EP 05113085 A;;US 2006/0004009 W,2005-02-04,PROCESS FOR BLOW-MOLDING A CONTAINER COMPRISING A HANDLE,,PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/087-937-166-168-313,Patent Application,no,0,0,5,43,0,B29B11/08;;B29B11/10;;B29B11/12;;B29B11/14;;B29C43/36;;B29C49/04;;B29C49/06;;B29C49/12;;B29C49/4802;;B29C2043/3665;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29K2105/258;;B29L2031/463;;B29L2031/7158;;B29C2949/3024;;B29C2949/28;;B29C2949/26;;B29C2949/24;;B29C2949/22;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/072;;B29C49/071;;B29C2949/0715;;B29C49/4802;;B29B11/12;;B29B11/08;;B29L2031/463;;B29K2067/00;;B29C2049/4807;;B29C49/12;;B29C2043/3665;;B29K2105/258;;B29B11/10;;B29K2023/12;;B29C43/36;;B29L2031/7158;;B29K2023/06;;B29K2027/06;;B29C49/06;;B29B11/14;;B29K2067/046;;B29C49/04;;B29C2949/22;;B29C2949/24;;B29C2949/26;;B29C2949/28;;B29C2949/072;;B29C2949/073;;B29C2949/0762;;B29C2949/0763;;B29C2949/0767;;B29C2949/3024;;B29C2949/3032;;B29C2949/3041;;B29C2949/3056,B29C49/48;;B29C49/12,,0,0,,,,DISCONTINUED
222,EP,A3,EP 1688234 A3,162-652-482-238-685,2006-10-11,2006,EP 05113082 A,2005-12-30,EP 05075290 A;;EP 05113082 A,2005-02-04,A process for forming a container by stretch blow molding and container formed thereby,"The present invention relates to process for forming a container by stretching and blow-molding a preform within a mold cavity comprising the steps of: 
(i) introducing a preform into the mold cavity and stretching the preform with a stretch rod; 
(ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a blowing step; 
(iii) at least one inwardly moving mold section within the mold cavity so that the expanding preform is deformed by the inwardly moving mold section; 
wherein the glass transition temperature (Tg) of the preform material is at least 10°C below the temperature of the walls of the mold cavity. The present invention further relates to a stretch blow molded container comprising walls of a thermoplastic polyolefin, the thermoplastic polyolefin having a glass transition temperature of less than 30°C and wherein the container has a degree of asymmetry of at least 1.5.",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/162-652-482-238-685,Search Report,yes,7,0,11,43,0,B29C49/06;;B29C49/12;;B29C49/18;;B29C49/4802;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2027/06;;B29L2031/7158;;Y10T428/1352;;B29C2949/0764;;B29C2949/0715;;B29C2049/7831;;B29C2049/78645;;Y10T428/1352;;B29C49/4802;;B29K2027/06;;B29K2023/06;;B29K2023/12;;B29L2031/7158;;B29C49/12;;B29C49/18;;B29C49/06;;B29C2049/4807;;B29C2949/0764,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/18;;B29C49/64,,0,0,,,,DISCONTINUED
223,CN,A,CN 108472960 A,165-954-030-992-137,2018-08-31,2018,CN 201580083525 A,2015-11-10,US 2015/0060006 W,2015-11-10,Printhead-integrated ink level sensor with central clearing resistor,"The present subject matter relates to printhead-integrated ink level sensor (PILS) system. In an example implementation, the PILS system includes a sense capacitor plate in a fluid sensing chamber tosense a level of fluid in the fluid sensing chamber. The fluid sensing chamber is in fluid communication with a fluid reservoir of the printhead to receive fluid from the fluid reservoir. The sense capacitor plate includes at least one slot. The PILS system further includes at least one central clearing resistor and at least one peripheral clearing resistor to clear the fluid sensing chamber of the fluid. The central clearing resistor is provided in the at least one slot of the sense capacitor plate. The at least one peripheral resistor is provided in the fluid sensing chamber surrounding thesense capacitor plate.",HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/165-954-030-992-137,Patent Application,no,12,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,0,0,,,,ACTIVE
224,WO,A3,WO 2006/084207 A3,170-114-864-648-323,2006-12-14,2006,US 2006/0003998 W,2006-02-03,EP 05075290 A;;EP 05447194 A,2005-02-04,INJECTION STRETCH BLOW-MOLDED CONTAINER,"The present invention relates to an injection stretch blow-molded container (1) consisting essentially of polypropylene, wherein the container is provided with a decoration comprising label or sleeve (6), and characterized in that the label or sleeve (6) consists essentially of polyolefin.",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,CONNOLLY WILLIAM JOHN;;ETESSE PATRICK JEAN-FRANCOIS,,https://lens.org/170-114-864-648-323,Search Report,yes,4,0,5,43,0,B65D23/0842;;B65D51/00,B65D23/08;;B65D51/00,,0,0,,,,PENDING
225,US,B2,US 10532579 B2,197-647-766-885-087,2020-01-14,2020,US 201515761621 A,2015-11-10,US 2015/0060006 W,2015-11-10,Printhead-integrated ink level sensor with central clearing resistor,"The present subject matter relates to printhead-integrated ink level sensor (PILS) system. In an example implementation, the PILS system includes a sense capacitor plate in a fluid sensing chamber to sense a level of fluid in the fluid sensing chamber. The fluid sensing chamber is in fluid communication with a fluid reservoir of the printhead to receive fluid from the fluid reservoir. The sense capacitor plate includes at least one slot. The PILS system further includes at least one central clearing resistor and at least one peripheral clearing resistor to clear the fluid sensing chamber of the fluid. The central clearing resistor is provided in the at least one slot of the sense capacitor plate. The at least one peripheral resistor is provided in the fluid sensing chamber surrounding the sense capacitor plate.",HEWLETT PACKARD DEVELOPMENT CO,NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2015-10-27),https://lens.org/197-647-766-885-087,Granted Patent,yes,22,0,10,10,0,B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;G01F23/263;;G01F23/268;;G01F23/26;;B41J2/175;;B41J2/14129;;B41J2/14153;;B41J2/17566;;B41J2/1753;;B41J2/17596;;B41J2002/14354;;B41J2002/17579;;B41J2202/13;;G01F23/263,B41J2/175;;B41J2/14;;G01F23/26,,0,0,,,,INACTIVE
226,BR,A2,BR PI0606785 A2,130-313-234-688-460,2009-07-14,2009,BR PI0606785 A,2006-02-03,EP 05075290 A;;US 2006/0004010 W,2005-02-04,"processo para a fabricação de recipientes dotados de uma empunhadura intregal, e recipientes fabricados dessa maneira","PROCESSO PARA A FABRICAçãO DE RECIPIENTES DOTADOS DE UMA EMPUNHADURA INTEGRAL, E RECIPIENTES FABRICADOS DESSA MANEIRA. A presente invenção refere-se a um processo para a modelagem por sopro de um recipiente que compreende uma empunhadura, sendo que o dito processo compreende as etapas de: (i) introduzir uma pré-forma (2) em uma cavidade de molde, e estirar a mesma com uma haste de extensão; (ii) aumentar a pressão no interior da pré-forma (2) de modo que a mesma se expanda no interior da cavidade do molde em uma primeira etapa de sopro, durante a qual a pressão situa-se na faixa de 0,1 MPa (1 bar) a 1 MPa (10 bar); (iii) mover para dentro as mandíbulas (3, 4) no interior da cavidade do molde, de modo que a pré-forma (2) em expansão fique parcialmente presa entre as mesmas na região da empunhadura; (iv) subseqúentemente, aumentar a pressão no interior da pré-forma (2), sendo que a pressão máxima na segunda etapa de sopro é maior que 1 MPa (10 bar), de modo que a pré-forma (2) se expanda até os limites da cavidade do molde para formar um recipiente; e sendo que o movimento das mandíbulas (3, 4) para dentro é completado durante a primeira etapa de sopro.",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN,,https://lens.org/130-313-234-688-460,Patent Application,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,DISCONTINUED
227,EP,A1,EP 1853416 A1,016-630-027-485-376,2007-11-14,2007,EP 06734377 A,2006-02-03,US 2006/0004010 W;;EP 05075290 A;;EP 06734377 A,2005-02-04,PROCESS FOR THE MANUFACTURE OF CONTAINERS WHICH HAVE AN INTEGRAL HANDLE,,PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAN,,https://lens.org/016-630-027-485-376,Patent Application,yes,0,4,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,ACTIVE
228,US,A1,US 2022/0335362 A1,007-742-522-117-597,2022-10-20,2022,US 202117235294 A,2021-04-20,US 202117235294 A,2021-04-20,"ARTIFICIAL INTELLIGENCE-BASED BUSINESS PROCESS MANAGEMENT VISUALIZATION, DEVELOPMENT AND MONITORING","Aspects of the subject disclosure may include, for example, providing a graphical user interface on a display device for interaction with operations personnel associated with a process to be performed; receiving, from the operations personnel, information defining one or more tasks to perform the process; receiving, from technical personnel associated with respective task of the one or more tasks, respective rulesets associated with the respective tasks, each respective ruleset defining procedures to complete a respective task, one or more of the respective rulesets implementing a machine learning algorithm to complete the respective task; displaying information about the one or more tasks on the graphical user interface during performance of the process; estimating, with an artificial intelligence process, a current status of the process, producing a current status estimate, wherein the estimating comprises estimating a status of the machine learning algorithm; and displaying process status information on the graphical user interface wherein the process status information is based on the current status estimate. Other embodiments are disclosed.",AT & T IP I LP,NIKAIN MOHAMMAD;;CONNOLLY DANIEL;;WANG JIYUAN;;TAGATSI PATRICK,AT&T INTELLECTUAL PROPERTY I L.P (2021-04-15),https://lens.org/007-742-522-117-597,Patent Application,yes,4,1,1,1,0,G06Q10/063114;;G06Q10/06316;;G06Q10/063118;;G06Q10/0633;;G06Q10/06312;;G06Q10/06313;;G06N20/00;;G06Q10/063114;;G06Q10/06313;;G06Q10/0633;;G06N20/00;;G06Q10/06312;;G06Q10/063118;;G06F3/04817;;G06Q10/06316,G06Q10/06;;G06F3/0481;;G06N20/00,,0,0,,,,PENDING
229,US,B2,US 8663543 B2,123-955-409-893-775,2014-03-04,2014,US 201313924009 A,2013-06-21,US 201313924009 A;;EP 05075290 A;;US 34695906 A,2005-02-04,Process for the manufacture of a container having an integral handle,"A process for blow-molding a container, the container having a handle, whereby the process includes the steps of: (i) introducing a preform into a mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws within the mold cavity so that the expanding preform is partially gripped between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws is completed within the first blowing step.",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND,,https://lens.org/123-955-409-893-775,Granted Patent,yes,15,1,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/00;;B29C49/12;;B29C49/16;;B29C49/30;;B29D22/00,264/529;;264/531;;264/532;;264/534;;425/525,11,0,,,"Partial European Search Report for EP Application No. 05075290.6, dated Aug. 5, 2005, 13 pages.;;International Search Report for International Application Serial No. PCT/US2006/004010, mailed May 24, 2006, 11 pages.;;Non-Final Office Action for U.S. Appl. No. 11/346,959, mailed Jan. 16, 2007, 9 pages.;;Final Office Action for U.S. Appl. No. 11/346,959, mailed Aug. 22, 2007, 7 pages.;;Non-Final Office Action for U.S. Appl. No. 11/346,959, mailed Sep. 5, 2008, 8 pages.;;Final Office Action for U.S. Appl. No. 11/346,959, mailed Mar. 5, 2009, 7 pages.;;Non-Final Office Action for U.S. Appl. No. 11/346,959, mailed Jun. 22, 2009, 9 pages.;;Final Office Action for U.S. Appl. No. 11/346,959, mailed Nov. 25, 2009, 9, pages.;;Examiner's Answer for U.S. Appl. No. 11/346,959, mailed Jun. 28, 2010, 10 pages.;;Decision on Appeal for U.S. Appl. No. 11/346,959, mailed Jan. 17, 2013, 5 pages.;;Notice of Allowance for U.S. Appl. No. 11/346,959, mailed Apr. 11, 2013, 6 pages.",ACTIVE
230,FR,A,FR 382330 A,033-583-166-116-690,1908-02-04,1908,FR 382330D A,1907-09-14,FR 382330T A,1907-09-14,Dispositif de transmission pour indicateurs de vitesse,,HARRY PATRICK CONNOLLY BROWNE;;WILLIAM HENRY PALMER JR,BROWNE HARRY PATRICK CONNOLLY;;JR WILLIAM HENRY PALMER,,https://lens.org/033-583-166-116-690,Granted Patent,no,0,0,1,1,0,G01P1/04,G01P1/04,"XII, 3",0,0,,,,EXPIRED
231,US,A1,US 2010/0100001 A1,089-830-844-256-682,2010-04-22,2010,US 64566309 A,2009-12-23,US 64566309 A;;US 96532507 A;;US 35668109 A,2007-12-27,FIXATION-LOCKED MEASUREMENT OF BRAIN RESPONSES TO STIMULI,Fixation-locked measurement of brain activity generates time-coded cues indicative of whether an operator exhibited a significant cognitive response to task-relevant stimuli. The free-viewing environment is one in which the presentation of stimuli is natural to the task encompassing both pre- and post-fixation stimuli and the operator is allowed to move his or her eyes naturally to perform the task.,TELEDYNE SCIENT & IMAGING LLC,AGUILAR MARIO;;HAWKINS AARON;;CONNOLLY PATRICK;;QIAN MING,TELEDYNE LICENSING LLC (2009-12-17),https://lens.org/089-830-844-256-682,Patent Application,yes,1,64,2,7,0,A61B3/113;;A61B5/378;;A61B3/113;;A61B5/16;;A61B5/378;;A61B5/38;;A61B5/38;;A61B5/7267;;A61B5/7267;;G16H50/70,A61B5/0476;;A61B5/11,600/544;;600/595,1,1,136-547-899-436-137,10.1007/978-3-540-73110-8_65,"Daimoto et al. ""Effects of a Dual-Task Tracking on Eye Fixation Related Potentials (EFRP)"" Human-Computer Interaction, Part III, HCII 2007, LNCS 4552, pp. 599-604.",ACTIVE
232,US,B2,US 8265743 B2,117-266-692-158-408,2012-09-11,2012,US 64566309 A,2009-12-23,US 64566309 A;;US 96532507 A;;US 35668109 A,2007-12-27,Fixation-locked measurement of brain responses to stimuli,Fixation-locked measurement of brain activity generates time-coded cues indicative of whether an operator exhibited a significant cognitive response to task-relevant stimuli. The free-viewing environment is one in which the presentation of stimuli is natural to the task encompassing both pre- and post-fixation stimuli and the operator is allowed to move his or her eyes naturally to perform the task.,AGUILAR MARIO;;HAWKINS AARON;;CONNOLLY PATRICK;;QIAN MING;;TELEDYNE SCIENT & IMAGING LLC,AGUILAR MARIO;;HAWKINS AARON;;CONNOLLY PATRICK;;QIAN MING,TELEDYNE LICENSING LLC (2009-12-17),https://lens.org/117-266-692-158-408,Granted Patent,yes,28,19,2,7,0,A61B3/113;;A61B5/378;;A61B3/113;;A61B5/16;;A61B5/378;;A61B5/38;;A61B5/38;;A61B5/7267;;A61B5/7267;;G16H50/70,A61B5/04,600/544,14,11,136-547-899-436-137;;006-976-786-871-724;;005-861-492-610-995;;019-355-099-151-928;;090-770-432-294-248;;106-975-985-948-422;;094-065-356-249-630;;048-054-797-340-892;;013-672-340-621-57X;;087-178-362-318-214;;089-101-731-046-881,10.1007/978-3-540-73110-8_65;;16792287;;10.1109/tnsre.2006.875550;;8632824;;10.1038/381520a0;;10.1016/j.tics.2003.10.012;;14643372;;1399755;;10.1016/0167-8760(92)90055-g;;9572588;;10.1016/s0304-3940(98)00122-0;;15003368;;10.1016/j.ijpsycho.2003.12.001;;10.1016/j.neuroimage.2005.05.032;;16084117;;10.1523/jneurosci.1655-06.2006;;16943552;;pmc6675324;;10.1109/tnsre.2003.814446;;12899266;;10.1016/s0925-2312(02)00821-4,"Daimoto et al. ""Effects of a Dual-Task Tracking on Eye Fixation Related Potentials (EFRP)"" Human-Computer Interaction, Part III, HCII 2007, LNCS 4552, pp. 599-604.;;Adam D. Gerson, Cortically coupled computer vision for rapid image serach, IEEE Trans on Neural Systems and Rehabilitation Engineering, vol. 14, No. 2, pp. 174-179, Jun. 2006.;;Simon Thorpe, Speed of processing in the human visual system, Nature, vol. 381, Jun. 6, 1006, pp. 520-522.;;Lawrence M. Ward, Synchronous neural oscillations and cognitive processes, Trends in Cognitive Science, vol. 7, No. 12, Dec. 2003, pp. 553-559.;;Canan Basar-Eroglu, P300-response: possible psychophysiological correlates in delta and theta frequency channels, A Review, International Journal of Psychophysiology 13, (1992).;;W.Klimesh, Induced alpha band power changes in the human EEG and attention, Neuroscience Letters 244, (1998), pp. 73-76.;;Eric Granholm, Pupillometric measures of cognitive and emotional processes, Internatinal Journal of Psychophysiology 42 (2004), pp. 1-6.;;Lucas C. Parra, Recipes for the linear analysis of EEG, NeuroImage 28 (2005) pp. 326-341.;;Marios G. Philiastides, Neural representation of task difficulty and decision making during perceptual categorization: a timing diagram, The Journal of Neuroscience, Aug. 30.;;Lucas C. Parra, Response error correction-a demonstration of improved human machine performance using real-time EEG monitoring, IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. XX, No. Y, Month 2003.;;German Gomez-Herrero, Automatic removal of ocular artifacts in the EEG without an EOG reference channel, Tampere University of Technology, Finland, 2006.;;Olaf Dimingen, Long reading regressions are accompanied by a P600-like brain potential, Evidence from simultaneous recordings of eye movements and ERPs Department of Psychology, University of Pottsdam, Germany.;;Olaf Dimingen, Measuring ERP effects of word predictability during left-to-right reading, Department of Psychology, University of Pottsdam, Germany.;;Lucas C. Parra, Single trial detection in EEG and MEG; keeping it linear, Neurocomputing 52-54 (2003) pp. 177-183.",ACTIVE
233,EP,B1,EP 1853416 B1,013-393-864-526-838,2009-04-01,2009,EP 06734377 A,2006-02-03,US 2006/0004010 W;;EP 05075290 A;;EP 06734377 A,2005-02-04,PROCESS FOR THE MANUFACTURE OF CONTAINERS WHICH HAVE AN INTEGRAL HANDLE,,PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND,,https://lens.org/013-393-864-526-838,Granted Patent,yes,6,3,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,ACTIVE
234,CA,A1,CA 2593938 A1,051-780-459-503-649,2006-08-10,2006,CA 2593938 A,2006-02-03,EP 05075290 A;;US 2006/0004010 W,2005-02-04,"PROCESS FOR THE MANUFACTURE OF CONTAINERS WHICH HAVE AN INTEGRAL HANDLE, AND CONTAINERS MANUFACTURED THEREBY",,PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAN,,https://lens.org/051-780-459-503-649,Patent Application,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,DISCONTINUED
235,NZ,A,NZ 195984 A,070-752-997-494-170,1983-07-29,1983,NZ 19598481 A,1981-01-08,US 11393080 A,1980-01-21,MEDICAL LIQUID BAG PLUG RETAINER SEALED TO PUNCTURE TUBE OF ADDITIVE PORT,,AMERICAN HOSPITAL SUPPLY CORP,CONNOLLY T;;PATRICK M;;RUDOLPH T;;STANELY A,,https://lens.org/070-752-997-494-170,Patent Application,no,0,0,5,5,0,A61F5/44;;A61J1/10;;A61J1/10;;A61J1/1406;;A61J1/1406;;A61J2200/76;;A61J2200/76;;Y10S128/24;;Y10S128/24,A61J1/10;;A61J1/00;;A61J1/05;;A61J1/14,,0,0,,,,DISCONTINUED
236,WO,A1,WO 2011/029055 A1,144-435-262-747-812,2011-03-10,2011,US 2010/0047897 W,2010-09-03,US 55396609 A;;US 55396109 A;;US 55395909 A;;US 55396209 A,2009-09-03,"APPARATUSES, METHODS AND SYSTEMS FOR A VISUAL QUERY BUILDER","Taking user gesture inputs on displayed objects, and transforming them via VQB components into search results display objects arranged by search relevance in proximity to the displayed objects is disclosed In one embodiment, the VQB obtains an object- manipulating gesture input, and correlates the object-manipulating gesture input to a display object. The VQB then classifies the object- manipulating gesture input as a specified type of search request. The VQB generates a search query according to the specified type of search request using metadata associated with the display object, and provides the search query to search engine(s) and/or database(s). The VQB obtains, in response to providing the search query, search result display objects and associated search result display object relevance vajues. The VQB displays the search result display objects arranged in proximity to the display object such that search result display objects are arranged according to their associated search result display object relevance values.",OBSCURA DIGITAL INC;;MASON STEVE;;HAGGERTY AMMON;;HARVILLE MICHAEL;;CONNOLLY PATRICK,MASON STEVE;;HAGGERTY AMMON;;HARVILLE MICHAEL;;CONNOLLY PATRICK,,https://lens.org/144-435-262-747-812,Patent Application,yes,5,2,3,10,0,G06F3/017;;G06F3/04883;;G06F16/90328;;G06F2203/04104,G06F3/033;;G06F3/048;;G06F3/0488,,0,0,,,,PENDING
237,US,A1,US 2013/0285295 A1,195-331-287-873-966,2013-10-31,2013,US 201313924009 A,2013-06-21,US 201313924009 A;;EP 05075290 A;;US 34695906 A,2005-02-04,PROCESS FOR THE MANUFACTURE OF A CONTAINER HAVING AN INTEGRAL HANDLE,"A process for blow-molding a container, the container having a handle, whereby the process includes the steps of: (i) introducing a preform into a mold cavity and stretching the preform with a stretch rod; (ii) increasing the pressure within the preform so that the preform expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws within the mold cavity so that the expanding preform is partially gripped between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws is completed within the first blowing step.",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND,,https://lens.org/195-331-287-873-966,Patent Application,yes,0,1,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29D22/00,264/529,0,0,,,,ACTIVE
238,US,A1,US 2011/0196864 A1,048-967-004-364-752,2011-08-11,2011,US 87597910 A,2010-09-03,US 87597910 A;;US 55396609 A;;US 55396109 A;;US 55395909 A;;US 55396209 A,2009-09-03,"APPARATUSES, METHODS AND SYSTEMS FOR A VISUAL QUERY BUILDER","The APPARATUSES, METHODS AND SYSTEMS FOR A VISUAL QUERY BUILDER (“VQB”) take user gesture inputs on displayed objects, and transform them via VQB components into search results display objects arranged by search relevance in proximity to the displayed objects. In one embodiment, the VQB obtains an object-manipulating gesture input, and correlates the object-manipulating gesture input to a display object. The VQB then classifies the object-manipulating gesture input as a specified type of search request. The VQB generates a search query according to the specified type of search request using metadata associated with the display object, and provides the search query to search engine(s) and/or database(s). The VQB obtains, in response to providing the search query, search result display objects and associated search result display object relevance values. The VQB displays the search result display objects arranged in proximity to the display object such that search result display objects are arranged according to their associated search result display object relevance values.",MASON STEVE;;HAGGERTY AMMON;;HARVILLE MICHAEL;;CONNOLLY PATRICK,MASON STEVE;;HAGGERTY AMMON;;HARVILLE MICHAEL;;CONNOLLY PATRICK,,https://lens.org/048-967-004-364-752,Patent Application,yes,5,147,1,10,0,G06F3/0416;;G06F3/0488;;G06F2203/04808;;G06F16/436;;G06F16/438;;G06F16/4393;;G06F16/48;;G06F16/41;;G06F16/44;;G06F3/0416;;G06F2203/04808;;G06F3/0488;;G06F16/4393;;G06F16/436;;G06F16/41;;G06F16/48;;G06F16/438;;G06F16/44,G06F17/30,707/728;;X707E17014,0,0,,,,DISCONTINUED
239,WO,A1,WO 2006/084214 A1,043-504-897-216-243,2006-08-10,2006,US 2006/0004010 W,2006-02-03,EP 05075290 A,2005-02-04,"PROCESS FOR THE MANUFACTURE OF CONTAINERS WHICH HAVE AN INTEGRAL HANDLE, AND CONTAINERS MANUFACTURED THEREBY","The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform (2) into a mold cavity and stretching the preform (2) with a stretch rod; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws (3, 4) within the mold cavity so that the expanding preform (2) is partially gripped between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform (2) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform (2) expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws (3, 4) is completed within the first blowing step.",PROCTER & GAMBLE;;ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAN,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAN,,https://lens.org/043-504-897-216-243,Patent Application,yes,6,5,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,PENDING
240,MX,A,MX 2007009421 A,045-955-787-893-230,2007-08-16,2007,MX 2007009421 A,2006-02-03,EP 05075290 A;;US 2006/0004010 W,2005-02-04,"PROCESS FOR THE MANUFACTURE OF CONTAINERS WHICH HAVE AN INTEGRAL HANDLE, AND CONTAINERS MANUFACTURED THEREBY.","The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform (2) into a mold cavity and stretching the preform (2) with a stretch rod; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws (3, 4) within the mold cavity so that the expanding preform (2) is partially gripped between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform (2) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform (2) expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws (3, 4) is completed within the first blowing step.",PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND,,https://lens.org/045-955-787-893-230,Patent Application,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48;;B29C49/06;;B29C49/18;;B29C49/78,,0,0,,,,PENDING
241,US,B2,US 8540928 B2,118-763-903-466-421,2013-09-24,2013,US 34695906 A,2006-02-03,EP 05075290 A,2005-02-04,"Process for the manufacture of containers which have an integral handle, and containers manufactured thereby","A process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform ( 2 ) into a mold cavity and stretching the preform ( 2 ) with a stretch rod;(ii) increasing the pressure within the preform ( 2 ) so that the preform ( 2 ) expands within the mold cavity in a first blowing step, the pressure in the first blowing step is from 1 to 10 bar;(iii) inwardly moving jaws ( 3, 4 ) within the mold cavity so that the expanding preform ( 2 ) is partially gripped between the jaws in the handle region;(iv) subsequently increasing the pressure within the preform ( 2 ) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform ( 2 ) expands to the limits of the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws ( 3, 4 ) is completed within the first blowing step.",ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND;;PROCTER & GAMBLE,ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND,PROCTER & GAMBLE COMPANY THE (2006-01-24),https://lens.org/118-763-903-466-421,Granted Patent,yes,11,3,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/00;;B29C49/12;;B29C49/16;;B29C49/30;;B29D22/00,264/529;;264/531;;264/532;;264/534;;425/525,1,0,,,"PCT International Search Report, 4 pages, Mailed May 24, 2006.",ACTIVE
242,FR,A,FR 384688 A,082-868-188-141-48X,1908-04-17,1908,FR 384688D A,1907-12-05,FR 384688T A,1907-12-05,Odomètre de moyeu,,HARRY PATRICK CONNOLLY BROWNE;;WILLIAM HENRY PALMER JUNIOR,BROWNE HARRY PATRICK CONNOLLY;;JUNIOR WILLIAM HENRY PALMER,,https://lens.org/082-868-188-141-48X,Granted Patent,no,0,0,1,1,0,G01C22/00,G01C22/00,"XII, 3",0,0,,,,EXPIRED
243,CN,C,CN 100591511 C,144-299-514-062-745,2010-02-24,2010,CN 200680004185 A,2006-02-03,EP 05075290 A,2005-02-04,"Process for the manufacture of containers which have an integral handle, and containers manufactured thereby","The present invention relates to a process for blow-molding a container, the container comprising a handle, whereby the process comprises the steps of: (i) introducing a preform (2) into a mold cavityand stretching the preform (2) with a stretch rod; (ii) increasing the pressure within the preform (2) so that the preform (2) expands within the mold cavity in a first blowing step, the pressure inthe first blowing step is from 1 to 10 bar; (iii) inwardly moving jaws (3, 4) within the mold cavity so that the expanding preform (2) is partially gripped and fused (10) between the jaws in the handle region; (iv) subsequently increasing the pressure within the preform (2) wherein the maximum pressure in the second blowing step is greater than 10 bar, so that the preform (2) expands to the limitsof the mold cavity in a second blowing step to form a container; and wherein the inward movement of the jaws (3, 4) is completed within the first blowing step. The present invention further relates to a blow-molded container (20) comprising biorientated polypropylene comprising a main bottle cavity (21) and an integrally molded, hollow handle cavity (22), and wherein the main bottle cavity (21) and the hollow handle cavity (22) are interconnected such that fluid can flow freely between the two cavities (21, 22).",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN C;;JEAN-FRANCOIS ETESSE PATRICK,,https://lens.org/144-299-514-062-745,Granted Patent,no,0,0,21,43,0,B29C49/4802;;B29L2031/463;;B65D23/0842;;B65D51/00;;B29C2949/079;;B65D23/0842;;B65D51/00;;B29C49/4802;;B29L2031/463;;B29C2949/079;;B29D22/003,B29C49/48,,0,0,,,,INACTIVE
244,EP,A1,EP 3545291 A1,048-314-684-833-111,2019-10-02,2019,EP 17873104 A,2017-11-27,US 201662426394 P;;CA 2017051425 W,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,,ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY BECCA,SENTRY: WATER MONITORING AND CONTROL INC. (2021-05-19),https://lens.org/048-314-684-833-111,Patent Application,yes,0,0,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N27/416;;C02F1/00;;C02F3/00;;C02F3/28;;C12M1/34;;G01N27/49;;G01N33/18,,0,0,,,,PENDING
245,EP,B1,EP 3328296 B1,083-787-794-996-113,2020-06-10,2020,EP 16747672 A,2016-07-21,US 201562198436 P;;US 201615213999 A;;US 2016/0043363 W,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,,CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,,https://lens.org/083-787-794-996-113,Granted Patent,yes,3,0,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/12;;A61B17/04,,0,0,,,,ACTIVE
246,EP,A1,EP 3733095 A1,132-429-617-140-168,2020-11-04,2020,EP 20177166 A,2016-07-21,US 201562198436 P;;US 2016/0043363 W;;US 201615213999 A;;EP 16747672 A,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,"A medical implant for a left atrial appendage may include a central member having an anchor at a distal end and a plurality of legs joined together at a joint coupled to the central member. The plurality of legs may be configured to expand from a delivery configuration to a deployed configuration. A medical implant may include a central shaft having an anchor at a distal end and a cup-shaped occluder fixed to a proximal end of the central shaft, the occluder being configured to expand from a delivery configuration to a deployed configuration and retard tissue ingrowth thereon. A medical implant system may include a delivery sheath, an implant having an expandable frame including a plurality of legs each having an anchor and a mesh having a plurality of openings therethrough attached to the frame, and a plurality of particles disposed within the delivery sheath.
",CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,"CARDIAC PACEMAKERS, INC. (2023-09-13)",https://lens.org/132-429-617-140-168,Patent Application,yes,2,1,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/12,,0,0,,,,ACTIVE
247,CA,C,CA 3044272 C,166-540-769-291-087,2022-12-06,2022,CA 3044272 A,2017-11-27,US 201662426394 P;;CA 2017051425 W,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY BECCA,,https://lens.org/166-540-769-291-087,Granted Patent,no,0,0,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N27/416;;C02F1/00;;C02F3/00;;C02F3/28;;C12M1/34;;G01N27/49;;G01N33/18,,0,0,,,,PENDING
248,US,B2,US 10349947 B2,141-286-576-729-056,2019-07-16,2019,US 201615047217 A,2016-02-18,US 201615047217 A;;US 201562117503 P,2015-02-18,Vascular occlusion devices,"The present disclosure provides occlusion devices which comprise (a) a self-expanding support frame having a longitudinal axis comprising a plurality of loops each having an orifice, the support frame being self-expandable from a constrained shape to an unconstrained shape, and (b) a covering material covering an orifice of at least one of the loops. Also provided are assemblies and kits that contain such occlusion devices, and methods of delivering such occlusion devices to a patient.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,BOSTON SCIENTIFIC SCIMED INC (2016-09-15),https://lens.org/141-286-576-729-056,Granted Patent,yes,16,0,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12,,1,1,025-290-949-810-620,24722897;;10.1007/s00270-014-0889-y,"O. Pellerin et al., “Microvascular plug: a new embolic material for hepatic arterial skeletonization,” Cardiovasc Intervent Radiol. Dec. 2014;37(6):1597-601. doi: 10.1007/s00270-014-0889-y. Epub Apr. 11, 2014.",ACTIVE
249,US,B2,US 10548579 B2,005-205-684-445-327,2020-02-04,2020,US 201615213999 A,2016-07-19,US 201615213999 A;;US 201562198436 P,2015-07-29,Left atrial appendage implant,"A medical implant for a left atrial appendage may include a central member having an anchor at a distal end and a plurality of legs joined together at a joint coupled to the central member. The plurality of legs may be configured to expand from a delivery configuration to a deployed configuration. A medical implant may include a central shaft having an anchor at a distal end and a cup-shaped occluder fixed to a proximal end of the central shaft, the occluder being configured to expand from a delivery configuration to a deployed configuration and retard tissue ingrowth thereon. A medical implant system may include a delivery sheath, an implant having an expandable frame including a plurality of legs each having an anchor and a mesh having a plurality of openings therethrough attached to the frame, and a plurality of particles disposed within the delivery sheath.",CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,CARDIAC PACEMAKERS INC (2016-08-03),https://lens.org/005-205-684-445-327,Granted Patent,yes,46,0,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61M29/00;;A61B17/00;;A61B17/12;;A61F2/01,,2,1,041-861-807-315-604,10.4137/cmc.s14043;;pmc4064949;;24963274,"Romero et al., “Left Atrial Appendage Closure Devices,” Clinical Medicine Insights: Cardiology, vol. 8, pp. 45-52, 2014.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, dated Oct. 13, 2016.",ACTIVE
250,US,A1,US 2019/0389751 A1,061-766-548-631-791,2019-12-26,2019,US 201716463751 A,2017-11-27,US 201716463751 A;;US 201662426394 P;;CA 2017051425 W,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY REBECCA,SENTRY: WATER MONITORING AND CONTROL INC (2021-01-21);;ISLAND WATER TECHNOLOGIES INC (2021-05-04),https://lens.org/061-766-548-631-791,Patent Application,yes,0,3,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,C02F1/52;;C02F3/28;;G01N33/18,,0,0,,,,ACTIVE
251,EP,B1,EP 3733095 B1,068-783-787-290-110,2024-01-24,2024,EP 20177166 A,2016-07-21,US 201562198436 P;;US 2016/0043363 W;;US 201615213999 A;;EP 16747672 A,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,,CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,"CARDIAC PACEMAKERS, INC. (2023-09-13)",https://lens.org/068-783-787-290-110,Granted Patent,yes,2,0,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/12,,0,0,,,,ACTIVE
252,EP,A1,EP 3258857 A1,159-900-511-601-212,2017-12-27,2017,EP 16707338 A,2016-02-18,US 201562117503 P;;US 2016/0018478 W,2015-02-18,VASCULAR OCCLUSION DEVICES,,BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,,https://lens.org/159-900-511-601-212,Patent Application,yes,0,0,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12;;A61B17/00,,0,0,,,,ACTIVE
253,US,A1,US 2016/0235413 A1,195-841-257-820-169,2016-08-18,2016,US 201615047217 A,2016-02-18,US 201615047217 A;;US 201562117503 P,2015-02-18,VASCULAR OCCLUSION DEVICES,"The present disclosure provides occlusion devices which comprise (a) a self-expanding support frame having a longitudinal axis comprising a plurality of loops each having an orifice, the support frame being self-expandable from a constrained shape to an unconstrained shape, and (b) a covering material covering an orifice of at least one of the loops. Also provided are assemblies and kits that contain such occlusion devices, and methods of delivering such occlusion devices to a patient.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,BOSTON SCIENTIFIC SCIMED INC (2016-09-15),https://lens.org/195-841-257-820-169,Patent Application,yes,4,1,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
254,WO,A1,WO 2017/019452 A1,185-064-765-280-211,2017-02-02,2017,US 2016/0043363 W,2016-07-21,US 201562198436 P;;US 201615213999 A,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,"A medical implant for a left atrial appendage may include a central member having an anchor at a distal end and a plurality of legs joined together at a joint coupled to the central member. The plurality of legs may be configured to expand from a delivery configuration to a deployed configuration. A medical implant may include a central shaft having an anchor at a distal end and a cup-shaped occluder fixed to a proximal end of the central shaft, the occluder being configured to expand from a delivery configuration to a deployed configuration and retard tissue ingrowth thereon. A medical implant system may include a delivery sheath, an implant having an expandable frame including a plurality of legs each having an anchor and a mesh having a plurality of openings therethrough attached to the frame, and a plurality of particles disposed within the delivery sheath.",CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,,https://lens.org/185-064-765-280-211,Patent Application,yes,4,0,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/12;;A61B17/04,,0,0,,,,PENDING
255,EP,A4,EP 3545291 A4,039-326-152-490-789,2020-08-26,2020,EP 17873104 A,2017-11-27,US 201662426394 P;;CA 2017051425 W,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,,ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY BECCA,SENTRY: WATER MONITORING AND CONTROL INC. (2021-05-19),https://lens.org/039-326-152-490-789,Search Report,no,3,0,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N33/18;;C02F1/52;;C02F3/00;;C02F3/28;;C12M1/34,,1,0,,,See also references of WO 2018094537A1,PENDING
256,US,A,US 4103230 A,145-654-205-953-050,1978-07-25,1978,US 70337576 A,1976-07-08,FR 7521355 A,1975-07-08,APPARATUS FOR ANALYZING ELECTRICAL SIGNALS OF VARIABLE AMPLITUDE,An electrical signal analyzing circuit for manually controlling the durational sequencing of an integrator circuit for providing visual readout of test signal divergence and maximum peak voltage levels. The integrator circuit is first time delay activatable for a predetermined duration according to a counter circuitry having a preselectable end of time count. The admittance of a variable amplitude test signal to the analyzing circuit is controllable according to a second time delay for a duration determined by the end of time count.,AEROSPATIALE,DUBERNET ROBERT;;JANVIER LUCIEN;;TIRILLY ROGER;;O CONNOLLY PATRICK,,https://lens.org/145-654-205-953-050,Granted Patent,yes,3,0,7,7,0,G01R19/04;;G01R29/02;;G01R29/02;;G01R19/04,G01R19/04;;G01R29/02,324 77H,0,0,,,,EXPIRED
257,WO,A1,WO 2016/134149 A1,155-125-634-950-762,2016-08-25,2016,US 2016/0018478 W,2016-02-18,US 201562117503 P,2015-02-18,VASCULAR OCCLUSION DEVICES,"The present disclosure provides occlusion devices which comprise (a) a self-expanding support frame having a longitudinal axis comprising a plurality of loops each having an orifice, the support frame being self-expandable from a constrained shape to an unconstrained shape, and (b) a covering material covering an orifice of at least one of the loops. Also provided are assemblies and kits that contain such occlusion devices, and methods of delivering such occlusion devices to a patient.",BOSTON SCIENT SCIMED INC;;HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,,https://lens.org/155-125-634-950-762,Patent Application,yes,3,0,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12;;A61B17/00,,0,0,,,,PENDING
258,CN,A,CN 107427303 A,168-987-396-926-652,2017-12-01,2017,CN 201680010819 A,2016-02-18,US 201562117503 P;;US 2016/0018478 W,2015-02-18,Vascular occlusion devices,"The present disclosure provides occlusion devices which comprise (a) a self-expanding support frame having a longitudinal axis comprising a plurality of loops each having an orifice, the support frame being self-expandable from a constrained shape to an unconstrained shape, and (b) a covering material covering an orifice of at least one of the loops. Also provided are assemblies and kits that contain such occlusion devices, and methods of delivering such occlusion devices to a patient.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,,https://lens.org/168-987-396-926-652,Patent Application,no,2,0,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12,,0,0,,,,DISCONTINUED
259,US,A1,US 2017/0357771 A1,166-258-440-509-74X,2017-12-14,2017,US 201715619344 A,2017-06-09,US 201715619344 A;;US 201662348649 P,2016-06-10,PATIENT RISK SCORING & EVALUATION SYSTEM,"A method of facilitating health of a patient includes determining, based on patient information, a risk score. The patient information includes clinical information and at least one of psychosocial information, experiential information, relational information, preferential information, demographic information, barrier information, and compliance information. The method further includes identifying a number of risk factors that influence the risk score; determining a level of influence that each risk factor has on the risk score; and causing a display device to present a representation of the risk score.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;CAVALERIE MAUREEN C;;WILSON NICOLAUS;;O'GRADY BARRY,CARDIAC PACEMAKERS INC (2017-05-02),https://lens.org/166-258-440-509-74X,Patent Application,yes,0,15,4,4,0,G16H50/30;;G16H50/30,G06F19/00,,0,0,,,,DISCONTINUED
260,CN,A,CN 109219854 A,184-984-421-359-730,2019-01-15,2019,CN 201780034421 A,2017-06-09,US 201662348649 P;;US 2017/0036887 W,2016-06-10,PATIENT RISK SCORING & EVALUATION SYSTEM,"A method of facilitating health of a patient includes determining, based on patient information, a risk score. The patient information includes clinical information and at least one of psychosocial information, experiential information, relational information, preferential information, demographic information, barrier information, and compliance information. The method further includes identifyinga number of risk factors that influence the risk score; determining a level of influence that each risk factor has on the risk score; and causing a display device to present a representation of the risk score.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;CAVALERIE MAUREEN C;;WILSON NICOLAUS;;O'GRADY BARRY,,https://lens.org/184-984-421-359-730,Patent Application,no,6,3,4,4,0,G16H50/30;;G16H50/30,G16H50/30,,0,0,,,,DISCONTINUED
261,CA,A1,CA 3044272 A1,074-567-752-191-711,2018-05-31,2018,CA 3044272 A,2017-11-27,US 201662426394 P;;CA 2017051425 W,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY BECCA,,https://lens.org/074-567-752-191-711,Patent Application,no,0,0,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N27/416;;C02F1/00;;C02F3/00;;C02F3/28;;C12M1/34;;G01N27/49;;G01N33/18,,0,0,,,,PENDING
262,WO,A1,WO 2017/214586 A1,026-758-025-963-341,2017-12-14,2017,US 2017/0036887 W,2017-06-09,US 201662348649 P,2016-06-10,PATIENT RISK SCORING & EVALUATION SYSTEM,"A method of facilitating health of a patient includes determining, based on patient information, a risk score. The patient information includes clinical information and at least one of psychosocial information, experiential information, relational information, preferential information, demographic information, barrier information, and compliance information. The method further includes identifying a number of risk factors that influence the risk score; determining a level of influence that each risk factor has on the risk score; and causing a display device to present a representation of the risk score.",CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;CAVALERIE MAUREEN C;;WILSON NICOLAUS;;O'GRADY BARRY,,https://lens.org/026-758-025-963-341,Patent Application,yes,2,0,4,4,0,G16H50/30;;G16H50/30,G06F19/00,,0,0,,,,PENDING
263,EP,A1,EP 3469501 A1,038-840-630-868-295,2019-04-17,2019,EP 17731734 A,2017-06-09,US 201662348649 P;;US 2017/0036887 W,2016-06-10,PATIENT RISK SCORING & EVALUATION SYSTEM,,CARDIAC PACEMAKERS INC,CONNOLLY PATRICK;;CAVALERIE MAUREEN C;;WILSON NICOLAUS;;O'GRADY BARRY,,https://lens.org/038-840-630-868-295,Patent Application,yes,0,0,4,4,0,G16H50/30;;G16H50/30,G06F19/00,,0,0,,,,DISCONTINUED
264,US,A1,US 2022/0348483 A1,109-519-893-859-617,2022-11-03,2022,US 202217747846 A,2022-05-18,US 202217747846 A;;US 201916463751 A;;CA 2017051425 W;;US 201662426394 P,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",SENTRY WATER MONITORING AND CONTROL INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY REBECCA,SENTRY: WATER MONITORING AND CONTROL INC (2021-01-21);;ISLAND WATER TECHNOLOGIES INC (2021-05-04),https://lens.org/109-519-893-859-617,Patent Application,yes,1,0,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,C02F1/52;;C02F3/28;;G01N33/18,,0,0,,,,PENDING
265,EP,A1,EP 3328296 A1,117-109-638-961-022,2018-06-06,2018,EP 16747672 A,2016-07-21,US 201562198436 P;;US 201615213999 A;;US 2016/0043363 W,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,,CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,,https://lens.org/117-109-638-961-022,Patent Application,yes,0,1,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/12;;A61B17/04,,0,0,,,,ACTIVE
266,US,A,US 1011584 A,190-573-515-793-096,1911-12-12,1911,US 1910/0581685 A,1910-09-12,US 1910/0581685 A,1910-09-12,FOLDING SHIPPING-CASE.,,CONNOLLY PAPKE FISHER COMPANY,CONNOLLY MARTIN PATRICK;;FISHER WILLIAM HENRY;;PAPKE CHARLES OTTO,,https://lens.org/190-573-515-793-096,Granted Patent,no,0,3,1,1,0,B65D9/14;;B65D9/14,B65D6/18,,0,0,,,,EXPIRED
267,US,A1,US 2019/0282812 A1,090-576-167-344-486,2019-09-19,2019,US 201916354029 A,2019-03-14,US 201916354029 A;;US 201862642871 P,2018-03-14,METHOD FOR NON-INVASIVE ENHANCEMENT OF DEEP SLEEP,"Provided is an apparatus, system, and method for targeted sleep enhancement. A computer processing circuit receives a plurality of EEG signals from a plurality of spatially separated EEG sensors configured to be located on the head of a subject. The computer processing circuit executes machine executable instructions to: receive and process the plurality of EEG signals; determine that the subject is in sleep stage 3 based on a specific EEG signal of the processed plurality of EEG signals; determine a period of at least one of quiescent and asynchronous brain activity of the subject, wherein the period is determined based on the processed plurality of EEG signals; and deliver a transcranial electrical stimulation through the plurality of stimulation electrodes during the period of quiescent brain activity.",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;CONNOLLY PATRICK;;SHIMIZU RENEE;;AGUILAR-SIMON MARIO,TELEDYNE SCIENTIFIC & IMAGING LLC (2018-05-15),https://lens.org/090-576-167-344-486,Patent Application,yes,0,13,1,1,0,A61M21/02;;A61N1/36031;;A61B5/282;;A61B5/291;;A61B5/374;;A61B5/398;;A61B5/4812;;A61B5/4812;;A61B5/4836;;A61B5/6803;;A61M21/02;;A61M2021/0072;;A61M2021/0072;;A61M2205/3592;;A61M2205/50;;A61M2205/8206;;A61M2209/088;;A61M2230/04;;A61M2230/10;;A61M2230/14;;A61M2230/40;;A61M2230/60;;A61N1/0456;;A61N1/20;;A61N1/36025;;A61N1/36025;;A61N1/36031,A61N1/36;;A61B5/00;;A61B5/0408;;A61B5/0478;;A61B5/0496;;A61M21/02;;A61N1/20,,0,0,,,,DISCONTINUED
268,US,A1,US 2017/0027552 A1,036-588-672-652-199,2017-02-02,2017,US 201615213999 A,2016-07-19,US 201615213999 A;;US 201562198436 P,2015-07-29,LEFT ATRIAL APPENDAGE IMPLANT,"A medical implant for a left atrial appendage may include a central member having an anchor at a distal end and a plurality of legs joined together at a joint coupled to the central member. The plurality of legs may be configured to expand from a delivery configuration to a deployed configuration. A medical implant may include a central shaft having an anchor at a distal end and a cup-shaped occluder fixed to a proximal end of the central shaft, the occluder being configured to expand from a delivery configuration to a deployed configuration and retard tissue ingrowth thereon. A medical implant system may include a delivery sheath, an implant having an expandable frame including a plurality of legs each having an anchor and a mesh having a plurality of openings therethrough attached to the frame, and a plurality of particles disposed within the delivery sheath.",CARDIAC PACEMAKERS INC,TURKINGTON MARIE;;CONNOLLY PATRICK;;FOLAN MARTYN G;;HORGAN FERGAL,CARDIAC PACEMAKERS INC (2016-08-03),https://lens.org/036-588-672-652-199,Patent Application,yes,18,10,7,7,0,A61B17/12172;;A61B17/12177;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12122;;A61B17/12172;;A61B2017/12054;;A61B17/12186;;A61B17/1219;;A61B17/12177;;A61B17/0057;;A61B17/12122;;A61B17/1214;;A61B2017/00588;;A61B2017/00597;;A61B2017/00623;;A61B2017/00628;;A61B2017/00632,A61B17/00;;A61B17/12;;A61F2/01,,0,0,,,,ACTIVE
269,US,B2,US 11352272 B2,056-412-285-841-48X,2022-06-07,2022,US 201716463751 A,2017-11-27,US 201716463751 A;;US 201662426394 P;;CA 2017051425 W,2016-11-25,Bio-electrochemical sensor and method for optimizing performance of a wastewater treatment system,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",SENTRY WATER MONITORING AND CONTROL INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY REBECCA,SENTRY: WATER MONITORING AND CONTROL INC (2021-01-21);;ISLAND WATER TECHNOLOGIES INC (2021-05-04),https://lens.org/056-412-285-841-48X,Granted Patent,yes,34,2,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N33/18;;C02F1/52;;C02F3/00;;C02F3/28,,10,2,093-791-504-756-221;;069-830-645-639-714,27179564;;10.1016/j.bios.2016.05.018;;pmc3715250;;23708274;;10.3390/s130606936,"Xu et al. Biosensors and Bioelectronics, 85, 2016, 232 (Year: 2016).;;European Patent Application No. 17873104.8, Extended European Search Report dated Jul. 27, 2020.;;U.S. Appl. No. 14/126,264, Final Office Action dated Sep. 25, 2017.;;U.S. Appl. No. 14/126,264, Non-Final Office Action dated Dec. 22, 2017.;;U.S. Appl. No. 14/126,264, Non-Final Office Action dated Mar. 10, 2017.;;U.S. Appl. No. 14/126,264, Non-Final Office Action dated Apr. 2, 2019.;;U.S. Appl. No. 14/126,264, Non-Final Office Action dated Sep. 14, 2018.;;International Patent Application No. PCT/CA2017/051425, International Preliminary Report of Patentability dated Feb. 22, 2019.;;International Patent Application No. PCT/CA2017/051425, International Search Report and Written Opinion dated Feb. 26, 2018.;;Zhang et al., “A Potentiometric Flow Biosensor Based on Ammonia-Oxidizing Bacteria for the Detection of Toxicity in Water”, Sensors, May 2013, vol. 13(6), pp. 6937-6945, ISSN 1424-8220.",ACTIVE
270,EP,B1,EP 3258857 B1,057-138-381-525-791,2023-07-26,2023,EP 16707338 A,2016-02-18,US 201562117503 P;;US 2016/0018478 W,2015-02-18,VASCULAR OCCLUSION DEVICES,,BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;CONNOLLY JOSEPH MICHAEL;;GROFF JOEL N,,https://lens.org/057-138-381-525-791,Granted Patent,yes,3,0,8,8,0,A61B17/12031;;A61B17/12109;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054;;A61B17/12109;;A61B17/12109;;A61B17/12145;;A61B2017/1205;;A61B17/12031;;A61B17/12163;;A61B17/12172;;A61B2017/12054,A61B17/12;;A61B17/00,,0,0,,,,ACTIVE
271,WO,A1,WO 2018/094537 A1,062-510-533-882-421,2018-05-31,2018,CA 2017051425 W,2017-11-27,US 201662426394 P,2016-11-25,BIO-ELECTROCHEMICAL SENSOR AND METHOD FOR OPTIMIZING PERFORMANCE OF A WASTEWATER TREATMENT SYSTEM,"The present disclosure generally relates to a system for monitoring and/or controlling one or more agents, such as cleaning agents, in a wastewater treatment system. The system comprises a bio-electrochemical sensor for monitoring metabolic activity of a population of exo-electrogenic bacteria and providing an electrical output corresponding with the metabolic activity, where the bio-electrochemical sensor comprises an electrode pair and a power source for delivering a voltage across the electrode pair, and an electrical output analyzer for analyzing the electrical output and correlating the electrical output with the one or more agents in the wastewater treatment system. a change in electrical output beyond a threshold indicates that an adjustment in the delivery of the one or more agents is needed. a method and sensor for monitoring and/or controlling a cleaning process in a wastewater treatment system are also provided. The system, method, and sensor disclosed herein are particularly useful for cleaning membranes incorporated in a wastewater treatment process.",ISLAND WATER TECH INC,KIELY PATRICK DESMOND;;CELLA MONICA;;AMBLER JACK;;CONNOLLY BECCA,,https://lens.org/062-510-533-882-421,Patent Application,yes,7,4,8,8,0,G01N33/1886;;C02F1/5236;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/00;;C02F2209/03;;C02F2303/16;;Y02W10/10;;C02F1/5245;;C02F3/005;;C02F3/2853;;C02F2209/03;;C02F2303/16;;G01N33/1806;;G01N33/1886,G01N27/416;;C02F1/00;;C02F3/00;;C02F3/28;;C12M1/34;;G01N27/49;;G01N33/18,,1,0,,,See also references of EP 3545291A4,PENDING
272,US,A,US 4303067 A,084-704-921-164-927,1981-12-01,1981,US 11393080 A,1980-01-21,US 11393080 A,1980-01-21,Medical liquid bag having an improved additive port,"A flexible bag for dispensing medical liquid, such as intravenous solutions, to a patient. The bag has an improved additive port for periodically injecting medication or other liquid into the bag through a puncturable, resealable plug. The additive port includes a flexible support tube segment sealed between opposed walls of the bag and a substantially stiffer puncture tube sealed to an outer end of a port tube segment, which substantially stiffer puncture tube is in turn sealed to a tear-off closure. A puncturable, resealable plug is held against an integral puncturable (nonresealable) diaphragm of the puncture tube by the retaining member sealed within the puncture tube. This construction provides more reliable, leak proof sealing between components of an additive port of a medical liquid bag.",AMERICAN HOSPITAL SUPPLY CORP,CONNOLLY TERRY;;PATRICK MILTON L;;RUDOLPH THOMAS E;;STANLEY ALAN,B. BRAUN MEDICAL INC. (PA CORPORATION) (1997-12-18);;MCGAW INC. MORAINE MONTGOMERY COUNTY A CORP. OF OH (1991-02-05);;KENDALL MCGAW LABORATORIES INC. A CORP OF OH (1985-11-26);;GENERAL ELECTRIC CAPITAL CORPORATION A NEW YORK CORP (1992-04-01),https://lens.org/084-704-921-164-927,Granted Patent,yes,11,106,5,5,0,A61F5/44;;A61J1/10;;A61J1/10;;A61J1/1406;;A61J1/1406;;A61J2200/76;;A61J2200/76;;Y10S128/24;;Y10S128/24,A61J1/10;;A61J1/00;;A61J1/05;;A61J1/14,128/272,0,0,,,,EXPIRED
273,WO,A1,WO 2020/039258 A1,193-248-767-687-687,2020-02-27,2020,IB 2019000942 W,2019-08-23,US 201862722648 P;;US 201862782217 P;;US 201862785543 P;;US 201862785566 P;;US 201962844559 P,2018-08-24,APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,"A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and/or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.",NEURAVI LTD,VALE DAVID;;CASEY BRENDAN;;MIRZA MAHMOOD;;MCCARTHY RAY;;CONNOLLY PATRICK,,https://lens.org/193-248-767-687-687,Patent Application,yes,12,0,7,20,0,A61B17/221;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B2017/22079;;A61B5/055;;A61B5/02007;;A61B5/14546;;A61B17/221;;A61B17/22031;;A61B5/02007;;A61B5/055;;A61B5/0036;;A61B5/14546;;A61B5/7264;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B5/0036;;A61B5/0035;;A61B5/02007;;A61B5/14546;;A61B5/7264;;A61B17/221;;A61B2017/00084;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2217/005,A61B17/22;;A61B17/221;;A61M25/01,,0,0,,,,PENDING
274,US,A1,US 2021/0315599 A1,125-022-195-366-133,2021-10-14,2021,US 201917268209 A,2019-08-23,US 201917268209 A;;US 201862722648 P;;US 201862782217 P;;US 201862785566 P;;US 201862785543 P;;US 201962844559 P;;IB 2019000942 W,2018-08-24,METHOD AND APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,"A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and/or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.",NEURAVI LTD,VALE DAVID;;CASEY BRENDAN;;MIRZA MAHMOOD;;MCCARTHY RAY;;CONNOLLY PATRICK,NEURAVI LIMITED (2021-02-05),https://lens.org/125-022-195-366-133,Patent Application,yes,3,3,7,20,0,A61B17/221;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B2017/22079;;A61B5/055;;A61B5/02007;;A61B5/14546;;A61B17/221;;A61B17/22031;;A61B5/02007;;A61B5/055;;A61B5/0036;;A61B5/14546;;A61B5/7264;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B5/0036;;A61B5/0035;;A61B5/02007;;A61B5/14546;;A61B5/7264;;A61B17/221;;A61B2017/00084;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2217/005,A61B17/221;;A61B5/00;;A61B5/02;;A61B5/055;;A61B5/145,,0,0,,,,PENDING
275,KR,A,KR 20210052484 A,101-377-017-854-953,2021-05-10,2021,KR 20217008757 A,2019-08-23,US 201862782217 P;;US 201862785566 P;;US 201962844559 P;;US 201862785543 P;;US 201862722648 P;;IB 2019000942 W,2018-08-24,급성 허혈성 이벤트를 관리하기 위한 장치,"하나 이상의 급성 허혈성 이벤트를 관리하기 위한 방법 또는 사용 방법. 본 방법은 혈전의 기준을 결정하는 단계; 기준에 기초하여 혈전을 분류하고 분류를 생성하는 단계; 분류에 기초하여 혈전에 대한 개별화된 치료 프로토콜을 결정하는 단계로서, 개별화된 치료 프로토콜은 흡인을 사용하는 것, 제1 재관류 장치를 사용하여 관류를 복구하는 것, 및/또는 제2 재관류 장치를 사용하여 관류를 복구하는 것으로부터 선택된 하나 이상의 기술을 포함하는, 상기 개별화된 치료 프로토콜을 결정하는 단계; 및 개별화된 치료 프로토콜에 기초하여 혈전을 치료하는 단계를 포함할 수 있다.",NEURAVI LTD,VALE DAVID;;CASEY BRENDAN;;MIRZA MAHMOOD;;MCCARTHY RAY;;CONNOLLY PATRICK,,https://lens.org/101-377-017-854-953,Patent Application,no,0,0,7,20,0,A61B17/221;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B2017/22079;;A61B5/055;;A61B5/02007;;A61B5/14546;;A61B17/221;;A61B17/22031;;A61B5/02007;;A61B5/055;;A61B5/0036;;A61B5/14546;;A61B5/7264;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B5/0036;;A61B5/0035;;A61B5/02007;;A61B5/14546;;A61B5/7264;;A61B17/221;;A61B2017/00084;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2217/005,A61B17/221;;A61B5/00;;A61B5/02;;A61B5/055;;A61B5/145;;A61B17/00;;A61B17/22,,0,0,,,,PENDING
276,US,B2,US 11752339 B2,070-056-157-199-815,2023-09-12,2023,US 201715608872 A,2017-05-30,US 201715608872 A;;US 2017/0034863 W;;US 201662342402 P;;US 201762450478 P,2016-05-27,Methods and systems for stimulating nerve signals,"Systems and methods of generating and applying a synthetic neuromodulatory signal are described. A subject may be put under a particular condition that causes an effect in the subject. While the subject is under the condition, a recording of neurogram signals derived from the condition can be made from the subject. For example, neuronal signals traveling on the vagus nerve of the subject may be monitored and recorded. The neurogram may then be used to create a synthetic neuromodulatory signal that can be administered to a user. When the synthetic neuromodulatory signal is administered to the user, the user may experience the same effect as the subject that had been placed in the condition, even though the user was never put under the same condition.",STANFORD RES INST INT,CONNOLLY CHRISTOPHER;;LINCOLN PATRICK;;YADAV MANEESH;;CORNWELL JOHN;;RAMAMURTHY BHASKAR,SRI INTERNATIONAL (2017-05-29),https://lens.org/070-056-157-199-815,Granted Patent,yes,18,0,7,7,0,A61B5/4029;;A61B5/4836;;A61N1/36053;;A61B2503/40;;G16H40/63;;G16H40/67;;G16H50/50;;A61F2/72;;A61N1/3605;;G16H20/10;;G16H20/70;;A61B5/24;;A61B5/4029;;A61B5/4836;;A61B2503/40;;A61N1/36053;;G16H50/50;;G16H40/63;;G16H40/67;;G16H20/10;;G16H20/70;;A61B5/24;;A61F2/72;;A61N1/3605;;A61N1/3606,A61N1/36;;A61B5/00;;A61B5/24;;A61F2/72;;G16H20/10;;G16H20/70;;G16H40/63;;G16H40/67;;G16H50/50,,4,1,085-928-192-998-225,10.1515/bmt.2008.022;;18601618,"Dietrich S, Smith J, Scherzinger C, et al. A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI. Biomed Tech (Berl) 2008;53: 104-111.;;Kevin J. Tracey, “Shock Medicine—Stimulation of the nervous system could replace drugs for inflammatory and autoimmune conditions,” Scientific American (Mar. 2015).;;Japanese Patent Office, Notice of Refusal dated Apr. 2, 2021, 6 pp.;;European Patent Office, European Search Report and Written Opinion, PCT/US2017/046314, dated Jan. 8, 2020, 8 pp.",ACTIVE
277,US,A1,US 2016/0248867 A1,039-808-806-379-476,2016-08-25,2016,US 201615052322 A,2016-02-24,US 201615052322 A;;US 201562119890 P,2015-02-24,OPTIMIZATION OF ASYNCHRONOUS PUSHING OF WEB RESOURCES,"A system and method for optimization of resource pushing are presented. The method includes intercepting a current request for web content from a client device; determining a current PUSH list from at least one generated PUSH list based on the current request, wherein each generated PUSH list ensures availability of resources to the client device prior to receiving of a response, from an origin server, corresponding to the request; and pushing, in real-time, resources to the client device based on the determined PUSH list. Some embodiments also include a method and system for generating PUSH lists for optimizing asynchronous resource pushing.",RADWARE LTD,ALSTAD KENT DOUGLAS;;BISSELL SHAWN DAVID;;CONNOLLY JARROD PATRICK THOMAS,RADWARE LTD (2016-02-23),https://lens.org/039-808-806-379-476,Patent Application,yes,8,9,2,2,0,H04L67/02;;H04L67/5682;;H04L67/55;;H04L67/02;;H04L67/55;;H04L67/5682,H04L29/06;;H04L29/08,,0,0,,,,ACTIVE
278,CN,A,CN 113164181 A,078-211-445-943-15X,2021-07-23,2021,CN 201980070399 A,2019-08-23,US 201862722648 P;;US 201862782217 P;;US 201862785566 P;;US 201862785543 P;;US 201962844559 P;;IB 2019000942 W,2018-08-24,APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,"A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and/or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.",NEURAVI LTD,VALE DAVID;;CASEY BRENDAN;;MIRZA MAHMOOD;;MCCARTHY RAY;;CONNOLLY PATRICK,,https://lens.org/078-211-445-943-15X,Patent Application,no,0,1,7,20,0,A61B17/221;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B2017/22079;;A61B5/055;;A61B5/02007;;A61B5/14546;;A61B17/221;;A61B17/22031;;A61B5/02007;;A61B5/055;;A61B5/0036;;A61B5/14546;;A61B5/7264;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B5/0036;;A61B5/0035;;A61B5/02007;;A61B5/14546;;A61B5/7264;;A61B17/221;;A61B2017/00084;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2217/005,A61B17/22;;A61B17/221;;A61M25/01,,0,0,,,,PENDING
279,EP,A1,EP 3840674 A1,152-996-845-452-012,2021-06-30,2021,EP 19805728 A,2019-08-23,US 201862722648 P;;US 201862782217 P;;US 201862785566 P;;US 201862785543 P;;US 201962844559 P;;IB 2019000942 W,2018-08-24,APPARATUS FOR MANAGING ACUTE ISCHEMIC EVENTS,,NEURAVI LTD,VALE DAVID;;CASEY BRENDAN;;MIRZA MAHMOOD;;MCCARTHY RAY;;CONNOLLY PATRICK,,https://lens.org/152-996-845-452-012,Patent Application,yes,0,0,7,20,0,A61B17/221;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B2017/22079;;A61B5/055;;A61B5/02007;;A61B5/14546;;A61B17/221;;A61B17/22031;;A61B5/02007;;A61B5/055;;A61B5/0036;;A61B5/14546;;A61B5/7264;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2017/22034;;A61B2017/00022;;A61B2017/00084;;A61B5/0036;;A61B5/0035;;A61B5/02007;;A61B5/14546;;A61B5/7264;;A61B17/221;;A61B2017/00084;;A61B2017/22079;;A61B2017/2212;;A61B2017/2215;;A61B2217/005,A61B17/22;;A61B17/221;;A61M25/01,,0,0,,,,PENDING
280,BR,A,BR 8101700 A,014-691-747-374-03X,1982-11-03,1982,BR 8101700 A,1981-03-23,BR 8101700 A,1981-03-23,BOLSA PARA LIQUIDO DE TRATAMENTO MEDICO,,AMERICAN HOSPITAL SUPPLY CORP,CONNOLLY TERRY;;STANLEY ALAN;;PATRICK MILTON L;;RUDOLPH THOMAS E,,https://lens.org/014-691-747-374-03X,Patent Application,no,0,0,1,1,0,,A61M5/14;;B65B3/04;;B65B3/26,,0,0,,,,DISCONTINUED
281,AT,T1,AT E367843 T1,071-798-613-761-699,2007-08-15,2007,AT 02737471 T,2002-06-12,US 88108001 A,2001-06-12,SPITZENDICHTUNG SPITZE BEFESTIGUNG,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC VASCULAR INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/071-798-613-761-699,Granted Patent,no,0,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,EXPIRED
282,US,A1,US 2017/0340881 A1,045-487-059-191-105,2017-11-30,2017,US 201715608872 A,2017-05-30,US 201715608872 A;;US 2017/0034863 W;;US 201662342402 P;;US 201762450478 P,2016-05-27,METHODS AND SYSTEMS FOR STIMULATING NERVE SIGNALS,"Systems and methods of generating and applying a synthetic neuromodulatory signal are described. A subject may be put under a particular condition that causes an effect in the subject. While the subject is under the condition, a recording of neurogram signals derived from the condition can be made from the subject. For example, neuronal signals traveling on the vagus nerve of the subject may be monitored and recorded. The neurogram may then be used to create a synthetic neuromodulatory signal that can be administered to a user. When the synthetic neuromodulatory signal is administered to the user, the user may experience the same effect as the subject that had been placed in the condition, even though the user was never put under the same condition.",STANFORD RES INST INT,CONNOLLY CHRISTOPHER;;LINCOLN PATRICK;;YADAV MANEESH;;CORNWELL JOHN;;RAMAMURTHY BHASKAR,SRI INTERNATIONAL (2017-05-29),https://lens.org/045-487-059-191-105,Patent Application,yes,2,1,7,7,0,A61B5/4029;;A61B5/4836;;A61N1/36053;;A61B2503/40;;G16H40/63;;G16H40/67;;G16H50/50;;A61F2/72;;A61N1/3605;;G16H20/10;;G16H20/70;;A61B5/24;;A61B5/4029;;A61B5/4836;;A61B2503/40;;A61N1/36053;;G16H50/50;;G16H40/63;;G16H40/67;;G16H20/10;;G16H20/70;;A61B5/24;;A61F2/72;;A61N1/3605;;A61N1/3606,A61B5/04;;A61N1/36;;A61F2/72;;G16H20/10;;G16H20/70,,0,0,,,,ACTIVE
283,EP,A4,EP 3463561 A4,051-595-286-244-559,2020-01-29,2020,EP 17803734 A,2017-05-26,US 201662342402 P;;US 201762450478 P;;US 2017/0034863 W,2016-05-27,METHODS AND SYSTEMS FOR STIMULATING NERVE SIGNALS,,SRI INT INC,CONNOLLY CHRISTOPHER;;LINCOLN PATRICK;;YADAV MANEESH;;CORNWELL JOHN;;RAMAMURTHY BHASKAR,,https://lens.org/051-595-286-244-559,Search Report,no,2,0,7,7,0,A61B5/4029;;A61B5/4836;;A61N1/36053;;A61B2503/40;;G16H40/63;;G16H40/67;;G16H50/50;;A61F2/72;;A61N1/3605;;G16H20/10;;G16H20/70;;A61B5/24;;A61B5/4029;;A61B5/4836;;A61B2503/40;;A61N1/36053;;G16H50/50;;G16H40/63;;G16H40/67;;G16H20/10;;G16H20/70;;A61B5/24;;A61F2/72;;A61N1/3605;;A61N1/3606,A61N1/36;;A61B5/00;;A61B5/04;;A61F2/72;;G16H20/10;;G16H20/70;;G16H40/63;;G16H40/67;;G16H50/50,,0,0,,,,PENDING
284,EP,A1,EP 3463561 A1,178-717-498-701-502,2019-04-10,2019,EP 17803734 A,2017-05-26,US 201662342402 P;;US 201762450478 P;;US 2017/0034863 W,2016-05-27,METHODS AND SYSTEMS FOR STIMULATING NERVE SIGNALS,,SRI INT INC,CONNOLLY CHRISTOPHER;;LINCOLN PATRICK;;YADAV MANEESH;;CORNWELL JOHN;;RAMAMURTHY BHASKAR,,https://lens.org/178-717-498-701-502,Patent Application,yes,0,0,7,7,0,A61B5/4029;;A61B5/4836;;A61N1/36053;;A61B2503/40;;G16H40/63;;G16H40/67;;G16H50/50;;A61F2/72;;A61N1/3605;;G16H20/10;;G16H20/70;;A61B5/24;;A61B5/4029;;A61B5/4836;;A61B2503/40;;A61N1/36053;;G16H50/50;;G16H40/63;;G16H40/67;;G16H20/10;;G16H20/70;;A61B5/24;;A61F2/72;;A61N1/3605;;A61N1/3606,A61N1/04;;A61N1/36;;A61N1/05;;A61N1/08;;A61N1/18;;G16H20/10;;G16H20/70,,0,0,,,,PENDING
285,US,B2,US 10616356 B2,120-622-471-828-494,2020-04-07,2020,US 201615052322 A,2016-02-24,US 201615052322 A;;US 201562119890 P,2015-02-24,Optimization of asynchronous pushing of web resources,"A system and method for optimization of resource pushing are presented. The method includes intercepting a current request for web content from a client device; determining a current PUSH list from at least one generated PUSH list based on the current request, wherein each generated PUSH list ensures availability of resources to the client device prior to receiving of a response, from an origin server, corresponding to the request; and pushing, in real-time, resources to the client device based on the determined PUSH list. Some embodiments also include a method and system for generating PUSH lists for optimizing asynchronous resource pushing.",RADWARE LTD,ALSTAD KENT DOUGLAS;;BISSELL SHAWN DAVID;;CONNOLLY JARROD PATRICK THOMAS,RADWARE LTD (2016-02-23),https://lens.org/120-622-471-828-494,Granted Patent,yes,11,0,2,2,0,H04L67/02;;H04L67/5682;;H04L67/55;;H04L67/02;;H04L67/55;;H04L67/5682,H04L29/08;;H04L29/06,,0,0,,,,ACTIVE
286,US,A1,US 2016/0143739 A1,088-304-827-420-229,2016-05-26,2016,US 201514950637 A,2015-11-24,US 201514950637 A;;US 201462084215 P,2014-11-25,PROSTHETIC VENTRICULAR HEART SYSTEM,"An implantable heart system for the treatment of a heart with impaired function. The implantable heart system includes a prosthetic heart chamber assembly and a cooperative mechanism. The prosthetic heart chamber assembly comprises a first prosthesis, a second prosthesis, and a prosthetic heart chamber interconnecting the first and second prostheses. One of the prostheses is a valve and the other prosthesis is either a valve or a tubular prosthesis. The cooperative mechanism is selected from the group consisting of an adhesive; an anchor; a filler material; a shape memory element; an expandable member; a pumping agent; material attached to, or forming a part of, the wall of the prosthetic heart chamber; and combinations thereof.",BOSTON SCIENT SCIMED INC,HORGAN FERGAL;;FOLAN MARTYN G MR;;CONNOLLY PATRICK;;TURKINGTON MARIE,BOSTON SCIENTIFIC SCIMED INC (2016-04-11),https://lens.org/088-304-827-420-229,Patent Application,yes,4,28,1,1,0,A61F2/2412;;A61F2/2418;;A61F2/2487;;A61F2220/0008;;A61M2205/0283;;A61M60/896;;A61M60/148;;A61M60/454;;A61M60/427;;A61M60/497;;A61M60/187;;A61M60/289;;A61M60/295;;A61M60/17;;A61M60/117;;A61M60/486;;A61M60/861;;A61F2/2487;;A61F2220/0008;;A61F2/2418;;A61F2/2412;;A61M60/148;;A61M60/896;;A61M60/497;;A61M60/486;;A61M60/17;;A61M60/187;;A61M60/289;;A61M60/861;;A61M60/295;;A61M60/117,A61F2/24;;A61M60/117;;A61M60/17;;A61M60/187;;A61M60/289;;A61M60/295;;A61M60/486;;A61M60/497;;A61M60/861;;A61M60/896,,0,0,,,,DISCONTINUED
287,WO,A1,WO 2017/205847 A1,156-481-737-663-472,2017-11-30,2017,US 2017/0034863 W,2017-05-26,US 201662342402 P;;US 201762450478 P,2016-05-27,METHODS AND SYSTEMS FOR STIMULATING NERVE SIGNALS,"Systems and methods of generating and applying a synthetic neuromodulatory signal are described. A subject may be put under a particular condition that causes an effect in the subject. While the subject is under the condition, a recording of neurogram signals derived from the condition can be made from the subject. For example, neuronal signals traveling on the vagus nerve of the subject may be monitored and recorded. The neurogram may then be used to create a synthetic neuromodulatory signal that can be administered to a user. When the synthetic neuromodulatory signal is administered to the user, the user may experience the same effect as the subject that had been placed in the condition, even though the user was never put under the same condition.",STANFORD RES INST INT,CONNOLLY CHRISTOPHER;;LINCOLN PATRICK;;YADAV MANEESH;;CORNWELL JOHN;;RAMAMURTHY BHASKAR,,https://lens.org/156-481-737-663-472,Patent Application,yes,11,0,7,7,0,A61B5/4029;;A61B5/4836;;A61N1/36053;;A61B2503/40;;G16H40/63;;G16H40/67;;G16H50/50;;A61F2/72;;A61N1/3605;;G16H20/10;;G16H20/70;;A61B5/24;;A61B5/4029;;A61B5/4836;;A61B2503/40;;A61N1/36053;;G16H50/50;;G16H40/63;;G16H40/67;;G16H20/10;;G16H20/70;;A61B5/24;;A61F2/72;;A61N1/3605;;A61N1/3606,A61N1/36;;A61N1/04;;A61N1/05;;A61N1/08;;A61N1/18;;G16H20/10;;G16H20/70,,1,1,085-928-192-998-225,10.1515/bmt.2008.022;;18601618,"DIETRICH SSMITH JSCHERZINGER C ET AL.: ""A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI"", BIOMED TECH (BERL, vol. 53, 2008, pages 104 - 111",PENDING
288,WO,A2,WO 2002/100472 A2,042-533-716-020-302,2002-12-19,2002,US 0218561 W,2002-06-12,US 88108001 A,2001-06-12,TIP SEAL TIP ATTACH,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC AVE INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/042-533-716-020-302,Patent Application,yes,0,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,PATENTED
289,CN,A,CN 116879818 A,153-470-093-141-261,2023-10-13,2023,CN 202310859434 A,2018-08-16,US 201762546395 P;;CN 201880064884 A;;US 2018/0000231 W,2017-08-16,Pulse magnetic particle imaging system and method,"A pulsed magnetic particle imaging system includes a magnetic field generation system including at least one magnet, the magnetic field generation system providing a spatially structured magnetic field within an observation region of the magnetic particle imaging system, such that the spatially structured magnetic field will have a field-free region (FFR) for an object to be observed having a magnetic nanoparticle tracer distribution therein. The pulsed magnetic particle imaging system also includes a pulsed excitation system disposed near the observation area, the pulsed excitation system including an electromagnet and a pulse sequence generator electrically connected to the electromagnet to provide an excitation waveform to the electromagnet, wherein the electromagnet, when provided with the excitation waveform, generates an excitation magnetic field within the observation region to induce an excitation signal therefrom by shifting at least one of a position or a condition of the FFR. The pulsed magnetic particle imaging system also includes a detection system disposed near the observation region, the detection system configured to detect the excitation signal to provide a detection signal. The excitation waveform includes a transient portion and a substantially constant portion.",UNIV CALIFORNIA,CONNOLLY STEVEN M;;GOODWILL PATRICK;;HENSLEY DANIEL;;ZHENG ZHIWEI;;ZHENG BO,,https://lens.org/153-470-093-141-261,Patent Application,no,0,0,14,14,0,G01R33/1276;;G01R33/10;;G01R33/1276;;A61B5/0515;;G01R33/10;;G01R33/1276,G01R33/12,,0,0,,,,PENDING
290,DE,D1,DE 60221388 D1,060-188-992-443-326,2007-09-06,2007,DE 60221388 T,2002-06-12,US 88108001 A;;US 0218561 W,2001-06-12,SPITZENDICHTUNG SPITZE BEFESTIGUNG,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC VASCULAR INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/060-188-992-443-326,Granted Patent,no,0,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,EXPIRED
291,WO,A3,WO 2002/100472 A3,148-866-940-393-137,2003-02-20,2003,US 0218561 W,2002-06-12,US 88108001 A,2001-06-12,TIP SEAL TIP ATTACH,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC AVE INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/148-866-940-393-137,Search Report,yes,3,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,PATENTED
292,EP,A2,EP 1395325 A2,134-465-748-363-346,2004-03-10,2004,EP 02737471 A,2002-06-12,US 0218561 W;;US 88108001 A,2001-06-12,TIP SEAL TIP ATTACH,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC VASCULAR INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/134-465-748-363-346,Patent Application,yes,0,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,EXPIRED
293,EP,B1,EP 1395325 B1,148-117-236-244-72X,2007-07-25,2007,EP 02737471 A,2002-06-12,US 0218561 W;;US 88108001 A,2001-06-12,TIP SEAL TIP ATTACH,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC VASCULAR INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/148-117-236-244-72X,Granted Patent,yes,3,0,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,EXPIRED
294,DE,T2,DE 60221388 T2,010-093-542-159-71X,2008-04-10,2008,DE 60221388 T,2002-06-12,US 88108001 A;;US 0218561 W,2001-06-12,SPITZENDICHTUNG SPITZE BEFESTIGUNG,"The present invention is a catheter having an elongated tubular member having a proximal and a distal end. A balloon is positioned at the distal end of the tubular member. A guidewire tubular member extends from a position proximal the balloon through the balloon to a position distal the balloon, the guidewire tubular member has a proximal segment having a first flexibility and a distal segment having a second flexibility. The distal segment is more flexible than the proximal segment. A bond joins the balloon distal end to the proximal segment and the distal segment.",MEDTRONIC VASCULAR INC,GUINAN TERRY;;CONNOLLY JOHN;;DUANE PATRICK J;;O'SHAUGHNESSY DONAGH;;BANNON MICHAEL,,https://lens.org/010-093-542-159-71X,Granted Patent,no,0,2,10,10,0,A61M25/1006;;A61M2025/0081;;A61M2025/0183;;A61M2025/1013;;A61M25/1006;;A61M2025/0183;;A61M2025/0081;;A61M2025/1013,A61M25/00;;A61F2/958,,0,0,,,,EXPIRED
295,WO,A1,WO 2016/068954 A1,116-916-112-556-481,2016-05-06,2016,US 2014/0063214 W,2014-10-30,US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,A print head has an ink slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A recirculation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the recirculation passage.,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/116-916-112-556-481,Patent Application,yes,5,3,10,10,0,B41J2/175;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2002/14467;;B41J2/17566;;B41J2/18;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2/175;;B41J2002/14467;;B41J2/17566;;B41J2/18,B41J2/175;;B41J2/135,,0,0,,,,PENDING
296,ZA,B,ZA 81170 B,184-881-688-785-294,1982-01-27,1982,ZA 81170 A,1981-01-12,US 11393080 A,1980-01-21,MEDICAL LIQUID BAG,,AMERICAN HOSPITAL SUPPLY CORP,PATRICK M;;STANLEY A;;CONNOLLY T;;RUDOLPH THOMAS E;;THOMAS E RUDOLPH,,https://lens.org/184-881-688-785-294,Granted Patent,no,0,0,5,5,0,A61F5/44;;A61J1/10;;A61J1/10;;A61J1/1406;;A61J1/1406;;A61J2200/76;;A61J2200/76;;Y10S128/24;;Y10S128/24,A61J1/10;;A61J1/00;;A61J1/05;;A61J1/14,,0,0,,,,EXPIRED
297,CA,A,CA 768351 A,065-397-991-447-221,1967-10-03,1967,CA 768351D A,,CA 768351T A,,SNAP HOOK FOR LOAD-CARRYING EQUIPMENT,,US GOV SEC ARMY,METZGER ELDON C;;BROWN JOHN S;;ARSLANIAN MICHAEL M;;CONNOLLY PATRICK J,,https://lens.org/065-397-991-447-221,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
298,WO,A1,WO 2015/105490 A1,038-208-326-525-061,2015-07-16,2015,US 2014/0010793 W,2014-01-09,US 2014/0010793 W,2014-01-09,METHOD FOR ANALYZING DEFECTS IN THERMOPLASTIC ARTICLES,"This invention relates to methods method for analyzing defects in a thermoplastic article containing filler particles. In certain aspects, the method comprises providing a thermoplastic article sample, wherein the thermoplastic article sample comprises a thermoplastic base material with filler particles dispersed therein; providing an optical scanning/capture device capable of scanning and capturing images of light transmitted through said article in the visible wavelengths; providing computer executable code comprising an image analysis algorithm; scanning the thermoplastic article sample with the optical scanning device to produce a two-dimensional digital image of transmitted light in the visible wavelengths; analyzing the digital image using the programmable image analysis algorithm; and determining whether the thermoplastic article sample is of acceptable quality based upon the output of the image analysis algorithm.",DU PONT,BLOOM JOY SAWYER;;CONNOLLY JOHN D JR;;MILONE MICHAEL PATRICK;;RUBIN BARRY,,https://lens.org/038-208-326-525-061,Patent Application,yes,4,0,1,1,0,G01N21/95;;G01N21/894;;G06T7/0006,G01N21/88;;G01N21/95;;G06T7/00,,1,1,079-963-453-633-352,10.1016/0142-9418(86)90063-2,"ESS J W ET AL: ""Characterisation of distributive mixing in thermoplastics compositions"", POLYMER TESTING, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 3, 1 January 1986 (1986-01-01), pages 205 - 218, XP022835617, ISSN: 0142-9418, [retrieved on 19860101], DOI: 10.1016/0142-9418(86)90063-2",PENDING
299,US,B2,US 10099484 B2,055-001-483-561-400,2018-10-16,2018,US 201415520338 A,2014-10-30,US 2014/0063214 W,2014-10-30,Print head sensing chamber circulation,A print head has an ink slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A recirculation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the recirculation passage.,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-10-27),https://lens.org/055-001-483-561-400,Granted Patent,yes,16,0,10,10,0,B41J2/17566;;B41J2/17566;;B41J2/04541;;B41J2/04541;;B41J2/0458;;B41J2/0458;;B41J2/1404;;B41J2/1404;;B41J2/14072;;B41J2/14072;;B41J2/14153;;B41J2/14153;;B41J2/175;;B41J2/175;;B41J2/18;;B41J2/18;;B41J2002/14467;;B41J2002/14467;;B41J2202/11;;B41J2202/11;;B41J2202/12;;B41J2202/12,B41J2/175;;B41J2/18,,1,1,086-440-742-650-790,10.1016/j.sna.2007.04.027,"Reverter, et al. “Liquid-level Measurement System Based on a Remote Grounded Capacitive Sensor” Mar. 21, 2007.",ACTIVE
300,US,A1,US 2019/0001695 A1,099-784-413-727-137,2019-01-03,2019,US 201816125701 A,2018-09-08,US 201816125701 A;;US 201715520338 A;;US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,A print head has a fluid slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A circulation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the circulation passage.,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-10-27),https://lens.org/099-784-413-727-137,Patent Application,yes,0,0,10,10,0,B41J2/17566;;B41J2/17566;;B41J2/04541;;B41J2/04541;;B41J2/0458;;B41J2/0458;;B41J2/1404;;B41J2/1404;;B41J2/14072;;B41J2/14072;;B41J2/14153;;B41J2/14153;;B41J2/175;;B41J2/175;;B41J2/18;;B41J2/18;;B41J2002/14467;;B41J2002/14467;;B41J2202/11;;B41J2202/11;;B41J2202/12;;B41J2202/12,B41J2/175;;B41J2/045;;B41J2/14;;B41J2/18,,0,0,,,,ACTIVE
301,CN,A,CN 107073949 A,165-416-473-751-73X,2017-08-18,2017,CN 201480083094 A,2014-10-30,US 2014/0063214 W,2014-10-30,Print head sensing chamber circulation,A print head has an ink slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A recirculation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the recirculation passage.,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,,https://lens.org/165-416-473-751-73X,Patent Application,no,9,13,10,10,0,B41J2/17566;;B41J2/17566;;B41J2/04541;;B41J2/04541;;B41J2/0458;;B41J2/0458;;B41J2/1404;;B41J2/1404;;B41J2/14072;;B41J2/14072;;B41J2/14153;;B41J2/14153;;B41J2/175;;B41J2/175;;B41J2/18;;B41J2/18;;B41J2002/14467;;B41J2002/14467;;B41J2202/11;;B41J2202/11;;B41J2202/12;;B41J2202/12,B41J2/175;;B41J2/135,,0,0,,,,ACTIVE
302,EP,A1,EP 3212408 A1,059-002-375-513-911,2017-09-06,2017,EP 14904635 A,2014-10-30,US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,,HEWLETT PACKARD DEVELOPMENT CO LP,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/059-002-375-513-911,Patent Application,yes,0,0,10,10,0,B41J2/175;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2002/14467;;B41J2/17566;;B41J2/18;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2/175;;B41J2002/14467;;B41J2/17566;;B41J2/18,B41J2/175;;B41J2/135,,0,0,,,,ACTIVE
303,US,B2,US 11790275 B2,174-922-271-265-758,2023-10-17,2023,US 202016851426 A,2020-04-17,US 202016851426 A;;US 201962835777 P,2019-04-18,Adaptive continuous machine learning by uncertainty tracking,"Systems and methods for a machine learning system to learn a new skill without catastrophically forgetting an existing skill and to continually learn in a self-supervised manner during operation, without human intervention.",TELEDYNE SCIENT & IMAGING LLC,AGUILAR-SIMON MARIO;;BRNA ANDREW PAUL;;BROWN RYAN CHARLES;;CONNOLLY PATRICK MARTIN,TELEDYNE SCIENTIFIC & IMAGING LLC (2019-04-18),https://lens.org/174-922-271-265-758,Granted Patent,yes,11,0,2,2,0,G06N20/10;;G06N3/088;;G06N3/049;;G06V10/7788;;G06N3/047;;G06N3/044;;G06N3/045;;G06N20/10;;G06N3/04;;G06F18/22;;G06F18/2413;;G06V10/7788;;G10L15/30;;G06V10/70;;G10L17/08;;G06V10/761;;G06F18/24317;;G06F18/254;;G10L15/10,G06F18/22;;G06F18/2413;;G06F18/243;;G06F18/25;;G06N3/04;;G06N20/10;;G06V10/70;;G06V10/74;;G06V10/778;;G10L15/10;;G10L15/30;;G10L17/08,,3,3,023-795-887-537-788;;116-807-675-788-689;;024-222-102-912-700,10.1016/s0734-189x(87)80014-2;;10.1016/0166-2236(93)90118-6;;7682344;;10.1117/12.942747,"Carpenter et al., “A Massively Parallel Architecture for a Self-Organizing Neural Pattern Recognition Machine,” Computer Vision, Graphics, and Image Processing, vol. 37, 1987, pp. 54-115.;;Carpenter et al., “Normal and Amnesic Learning, Recognition and Memory by a Neural Model of Cortico-Hippocampal Interactions,” Trends in Neurosciences, vol. 16, No. 4, 1993, pp. 131-137.;;Carpenter et al., “Art 2: Self-Organization Of Stable Category Recognition Codes For Analog Input Patterns”, Proc. SPIE vol. 848, Intelligent Robots and Computer Vision VI, 1987, pp. 272-280.",ACTIVE
304,EP,B1,EP 3212408 B1,175-374-558-524-296,2020-08-26,2020,EP 14904635 A,2014-10-30,US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/175-374-558-524-296,Granted Patent,yes,10,0,10,10,0,B41J2/175;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2002/14467;;B41J2/17566;;B41J2/18;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2/175;;B41J2002/14467;;B41J2/17566;;B41J2/18,B41J2/045;;B41J2/175;;B41J2/135;;B41J2/14;;B41J2/18,,0,0,,,,ACTIVE
305,EP,A1,EP 3862047 A1,037-197-938-062-830,2021-08-11,2021,EP 21153958 A,2021-01-28,US 202062969835 P,2020-02-04,SYSTEM AND METHOD OF SLEEP INDUCTION,"A sleep induction device includes a headband, multiple transcranial stimulation electrodes, and control electronics to drive the electrodes. The sleep induction device may be worn by an awake user prior to attempting sleep. The control electronics are configured to cause the stimulation electrodes to emit a sequence of stimulation waveforms separated by interstimulus periods. The stimulation waveforms may have the characteristics of low-delta waveforms that may characterize non-REM stage 3 sleep. The stimulation period may last from about 4-8 seconds and the interstimulus period may last from about 10 to 30 seconds. A sleep induction session may include multiple alternating stimulation and non-stimulation periods. The sleep induction session may last for about 5 minutes to about 30 minutes.
",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;CONNOLLY PATRICK;;SHIMIZU RENEE;;YANOSCHAK ALEXANDRA;;SCHMIDT CALVIN;;WEISEND MICHAEL,,https://lens.org/037-197-938-062-830,Patent Application,yes,5,0,3,3,0,A61M21/02;;A61M2021/0072;;A61M2021/0027;;A61M2021/0044;;A61N1/36025;;A61N1/36034;;A61M21/02;;A61N1/0456;;A61N1/0484;;A61M2021/0027;;A61M2021/0044;;A61B5/6803;;A61M2209/088;;A61M2210/06;;A61M2205/3569;;A61M2205/3592;;A61M2205/0216;;A61M2021/0072;;A61M2230/10;;A61M2205/587;;A61M2205/583;;A61M2205/52;;A61M2205/505;;A61M2205/80;;A61M2205/3375;;A61M2205/581;;A61B5/374;;A61B5/4812;;A61B5/4836;;A61N1/36031;;A61M21/02;;A61M2021/0027;;A61M2021/0044;;A61M2021/0072;;A61M2021/0083;;A61N1/0456;;A61N1/0484;;A61N1/08,A61N1/36;;A61B5/00;;A61M21/00;;A61M21/02;;A61N1/04,,0,0,,,,PENDING
306,US,A1,US 2017/0313093 A1,107-947-196-287-367,2017-11-02,2017,US 201415520338 A,2014-10-30,US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,A print head has an ink slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A recirculation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the recirculation passage.,HEWLETT PACKARD DEVELOPMENT CO LP,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-10-27),https://lens.org/107-947-196-287-367,Patent Application,yes,2,1,10,10,0,B41J2/175;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2002/14467;;B41J2/17566;;B41J2/18;;B41J2/04541;;B41J2/0458;;B41J2/1404;;B41J2/14072;;B41J2/14153;;B41J2202/11;;B41J2202/12;;B41J2/175;;B41J2002/14467;;B41J2/17566;;B41J2/18,B41J2/18;;B41J2/175,,0,0,,,,ACTIVE
307,US,A1,US 2020/0334579 A1,112-899-530-476-858,2020-10-22,2020,US 202016851426 A,2020-04-17,US 202016851426 A;;US 201962835777 P,2019-04-18,ADAPTIVE CONTINUOUS MACHINE LEARNING BY UNCERTAINTY TRACKING,"Systems and methods for a machine learning system to learn a new skill without catastrophically forgetting an existing skill and to continually learn in a self-supervised manner during operation, without human intervention.",TELEDYNE SCIENT & IMAGING LLC,AGUILAR-SIMON MARIO;;BRNA ANDREW PAUL;;BROWN RYAN CHARLES;;CONNOLLY PATRICK MARTIN,TELEDYNE SCIENTIFIC & IMAGING LLC (2019-04-18),https://lens.org/112-899-530-476-858,Patent Application,yes,2,0,2,2,0,G06N20/10;;G06N3/088;;G06N3/049;;G06V10/7788;;G06N3/047;;G06N3/044;;G06N3/045;;G06N20/10;;G06N3/04;;G06F18/22;;G06F18/2413;;G06V10/7788;;G10L15/30;;G06V10/70;;G10L17/08;;G06V10/761;;G06F18/24317;;G06F18/254;;G10L15/10,G06N20/10;;G06K9/62;;G06N3/04,,0,0,,,,ACTIVE
308,EP,A4,EP 3212408 A4,046-815-635-115-394,2018-06-20,2018,EP 14904635 A,2014-10-30,US 2014/0063214 W,2014-10-30,PRINT HEAD SENSING CHAMBER CIRCULATION,,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/046-815-635-115-394,Search Report,no,5,0,10,10,0,B41J2/17566;;B41J2/17566;;B41J2/04541;;B41J2/04541;;B41J2/0458;;B41J2/0458;;B41J2/1404;;B41J2/1404;;B41J2/14072;;B41J2/14072;;B41J2/14153;;B41J2/14153;;B41J2/175;;B41J2/175;;B41J2/18;;B41J2/18;;B41J2002/14467;;B41J2002/14467;;B41J2202/11;;B41J2202/11;;B41J2202/12;;B41J2202/12,B41J2/175;;B41J2/045;;B41J2/135;;B41J2/14;;B41J2/18,,1,0,,,See also references of WO 2016068954A1,ACTIVE
309,US,A,US 3328858 A,059-490-212-846-004,1967-07-04,1967,US 46459065 A,1965-06-16,US 46459065 A,1965-06-16,Snap hook for load-carrying equipment,,CONNOLLY PATRICK J;;BROWN JOHN S;;ARSLANIAN MICHAEL M;;METZGER ELDON C,CONNOLLY PATRICK J;;BROWN JOHN S;;ARSLANIAN MICHAEL M;;METZGER ELDON C,,https://lens.org/059-490-212-846-004,Granted Patent,no,4,2,1,1,0,Y10T24/45335;;F16B45/04;;F16B45/036;;F16B45/024,F16B45/04,,0,0,,,,EXPIRED
310,US,B2,US 10449776 B2,125-447-213-608-145,2019-10-22,2019,US 201816125701 A,2018-09-08,US 201816125701 A;;US 201715520338 A;;US 2014/0063214 W,2014-10-30,Print head sensing chamber circulation,A print head has a fluid slot and a sensing chamber having a first port connected to the fluid slot and a second port. The sensing chamber contains an ink level sensor. A circulation passage extends from the fluid slot and is fluidly coupled to the second port. A fluid pump circulates fluid through the circulation passage.,HEWLETT PACKARD DEVELOPMENT CO,GOVYADINOV ALEXANDER;;GHOZEIL ADAM L;;NG BOON BING;;LEONARD PATRICK;;CONNOLLY RAYMOND,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2014-10-27),https://lens.org/125-447-213-608-145,Granted Patent,yes,16,0,10,10,0,B41J2/17566;;B41J2/17566;;B41J2/04541;;B41J2/04541;;B41J2/0458;;B41J2/0458;;B41J2/1404;;B41J2/1404;;B41J2/14072;;B41J2/14072;;B41J2/14153;;B41J2/14153;;B41J2/175;;B41J2/175;;B41J2/18;;B41J2/18;;B41J2002/14467;;B41J2002/14467;;B41J2202/11;;B41J2202/11;;B41J2202/12;;B41J2202/12,B41J2/175;;B41J2/045;;B41J2/14;;B41J2/18,,1,1,086-440-742-650-790,10.1016/j.sna.2007.04.027,"Reverter, et al. Liquid-Level Measurement System Based on a Remote Grounded Capacitive Sensor. Jul. 2007.",ACTIVE
311,EP,A1,EP 3305189 A1,020-471-717-052-243,2018-04-11,2018,EP 17194233 A,2017-09-29,US 201662403318 P,2016-10-03,"APPARATUS, SYSTEM, AND METHODS FOR TARGETED MEMORY ENHANCEMENT DURING SLEEP","Provided is an apparatus, system, and method for targeted memory enhancement. A computer processing circuit receives a plurality of electroencephalography (EEG) signals from a plurality of spatially separated EEG sensors located on the head of a subject that is asleep. A first process of the computer processing system determines a sleep state of the subject and upon determining that the subject is in sleep stage 2 or 3 based on a specific EEG signal, the processing system triggers a second process of the computer processing system that determines a transition event in the specific EEG signal, and upon detecting the transition event delivers an intervention to the subject designed to evoke a specific neurophysiological change to the subject.
",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;AGUILAR-SIMON MARIO;;CONNOLLY PATRICK;;ESTRADA ROLANDO;;SHIMIZU RENEE;;WHATLEY MARY,,https://lens.org/020-471-717-052-243,Patent Application,yes,3,2,4,4,0,A61B5/7282;;A61B5/4812;;A61B5/369;;A61B5/375;;A61N1/36031;;A61N1/36025;;A61N1/0456;;A61B5/7282;;A61B5/369;;A61B5/375;;A61N1/36031;;A61B5/4812;;A61B5/6803;;A61M21/02;;A61M2230/04,A61B5/00;;A61B5/375,,0,0,,,,ACTIVE
312,US,A1,US 2020/0259907 A1,027-259-726-141-033,2020-08-13,2020,US 202016806884 A,2020-03-02,US 202016806884 A;;US 201815996331 A;;US 201762513688 P,2017-06-01,DYNAMIC DETERMINATION OF PUBLIC SPACES AND THIRD PARTY DATA INCORPORATION FOR LOCATION-BASED MAPPING SYSTEMS AND METHODS,"A system that allows participating users to find other users with similar interests or characteristics based on a map area on a requesting device and the characteristics of each user. The system only reports a counter so as to preserve user anonymity and safety. The system preserves the user anonymity and safety in even granular searches using zoomed-in map views by comparing a map elevation level with a threshold and then a counted number of matched devices against a number of devices threshold. If the map is too zoomed in and there are not enough devices within the zoomed in area, the system does not provide a counter.",TURNOUTT INC,TASDEMIROGLU SEAN;;PUCCINI JAMES RICHARD;;CONNOLLY JASON;;FIROVED ANDREW;;MACDOWELL PATRICK;;EOM NOEL,,https://lens.org/027-259-726-141-033,Patent Application,yes,0,0,3,3,0,G06Q50/01;;H04W12/02;;H04W4/21;;H04W4/021;;H04L67/52;;H04W4/21;;H04W4/021;;G06F16/29;;H04W4/02;;H04W12/02;;G06Q50/01;;H04L67/52,G06F16/29;;H04L29/08;;G06Q50/00;;H04W4/02;;H04W4/021;;H04W4/21;;H04W12/02,,0,0,,,,DISCONTINUED
313,US,B2,US 10660569 B2,125-967-625-307-188,2020-05-26,2020,US 201715720621 A,2017-09-29,US 201715720621 A;;US 201662403318 P,2016-10-03,"Apparatus, system, and methods for targeted memory enhancement during sleep","Provided is an apparatus, system, and method for targeted memory enhancement. A computer processing circuit receives a plurality of electroencephalography (EEG) signals from a plurality of spatially separated EEG sensors located on the head of a subject that is asleep. A first process of the computer processing system determines a sleep state of the subject and upon determining that the subject is in sleep stage 2 or 3 based on a specific EEG signal, the processing system triggers a second process of the computer processing system that determines a transition event in the specific EEG signal, and upon detecting the transition event delivers an intervention to the subject designed to evoke a specific neurophysiological change to the subject.",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;AGUILAR-SIMON MARIO;;CONNOLLY PATRICK;;ESTRADA ROLANDO;;SHIMIZU RENEE;;WHATLEY MARY,TELEDYNE SCIENTIFIC & IMAGING LLC (2017-09-28),https://lens.org/125-967-625-307-188,Granted Patent,yes,5,1,4,4,0,A61B5/7282;;A61B5/4812;;A61B5/369;;A61B5/375;;A61N1/36031;;A61N1/36025;;A61N1/0456;;A61B5/7282;;A61B5/369;;A61B5/375;;A61N1/36031;;A61B5/4812;;A61B5/6803;;A61M21/02;;A61M2230/04,A61B5/00;;A61B5/375;;A61M21/02;;A61N1/36,,2,1,122-981-010-145-751,10.1515/cdbme-2015-0022,"Wilde et al., “Closed-loop transcranial alternating current stimulation of slow oscillations”, Current Directions in Biomedical Engineering, 2015; 1, pp. 85-88.;;Extended European Search Report for European Application No. 17194233.7 dated Mar. 8, 2018.",ACTIVE
314,CN,A,CN 114901162 A,063-919-793-805-297,2022-08-12,2022,CN 202080089769 A,2020-11-06,EP 2019080449 W;;GB 202006665 A;;EP 2020081399 W,2019-11-06,Wire for intravascular devices,"An elongate intravascular element for passing through an obstruction in a blood vessel comprises: a proximal section; a distal tip section, the diameter of the distal tip section being smaller than the diameter of the proximal section; and a distally tapering intermediate section, the distally tapering intermediate section extending between the proximal section and the distal tip section; wherein the length of the tapered intermediate section is substantially lambda/2 or a multiple of lambda/2, where lambda is the wavelength of the drive frequency that will produce longitudinal resonance in the element.",VERSONO MEDICAL LLC,DOLAN FRANCIS;;O 'DONOGHUE HEATHER;;MOONEY IAIN;;CONNOLLY PATRICK;;SMEDLEY JOHN;;TRAPPE BORIS,,https://lens.org/063-919-793-805-297,Patent Application,no,0,0,30,30,0,A61B17/22012;;A61B2017/00469;;A61B2017/22014;;A61B2017/22038;;A61B2017/22094;;A61B2017/320088;;A61B17/320708;;A61B2017/22039;;A61B2017/22044;;A61B2017/22049;;A61B2090/0807;;A61B2090/3966;;A61B17/22012;;A61B2017/22015;;A61B2090/0808;;A61B90/39;;A61B17/2202;;A61B2017/00477;;A61B2017/22094;;A61B2017/22027;;A61B2017/22049;;A61B2090/3966;;A61B2017/22017;;A61B2017/22041;;A61B2217/007;;A61B2017/22014;;A61B2017/22044,A61B17/22,,0,0,,,,PENDING
315,US,A1,US 2018/0352041 A1,195-817-418-272-221,2018-12-06,2018,US 201815996331 A,2018-06-01,US 201815996331 A;;US 201762513688 P,2017-06-01,DYNAMIC DETERMINATION OF PUBLIC SPACES AND THIRD PARTY DATA INCORPORATION FOR LOCATION-BASED MAPPING SYSTEMS AND METHODS,"A system that allows participating users to find other users with similar interests or characteristics based on a map area on a requesting device and the characteristics of each user. The system only reports a counter so as to preserve user anonymity and safety. The system preserves the user anonymity and safety in even granular searches using zoomed-in map views by comparing a map elevation level with a threshold and then a counted number of matched devices against a number of devices threshold. If the map is too zoomed in and there are not enough devices within the zoomed in area, the system does not provide a counter.",TURNOUTT INC,TASDEMIROGLU SEAN;;PUCCINI JAMES RICHARD;;CONNOLLY JASON;;FIROVED ANDREW;;MACDOWELL PATRICK;;EOM NOEL,TURNOUTT INC (2019-12-19),https://lens.org/195-817-418-272-221,Patent Application,yes,0,6,3,3,0,G06Q50/01;;H04W12/02;;H04W4/21;;H04W4/021;;H04L67/52;;H04W4/21;;H04W4/021;;G06F16/29;;H04W4/02;;H04W12/02;;G06Q50/01;;H04L67/52,G06F17/30;;H04L29/08;;H04W4/021;;H04W4/21,,0,0,,,,ACTIVE
316,US,A1,US 2014/0078061 A1,198-505-859-194-325,2014-03-20,2014,US 201314011351 A,2013-08-27,US 201314011351 A;;US 201261703694 P,2012-09-20,COGNITIVE BIOMETRICS USING MOUSE PERTURBATION,"Cognitive biometrics comprises augmenting the richness of biometric signatures that can be extracted from mouse dynamics by introducing perturbations in the response of the computer mouse and measuring the motor responses of the individual user. User responses to unexpected and subtle perturbations (e.g., small changes in mouse velocity, position and/or acceleration) reveal new unique sources of information in the mouse movement signal that reflect the user's cognitive strategies and are inaccessible via existing mouse biometric technologies. A user's response to these perturbations contains information about intrinsic cognitive qualities that can be used as a robust biometric for personal authentication and to support profiling of the individual (e.g., gender, cultural background, cognitive or emotional state, cognitive quality etc.).",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;ZHOU JIANGYING;;LIAO YUWEI;;BRADWAY LAURA;;AGUILAR MARIO;;CONNOLLY PATRICK M,TELEDYNE SCIENTIFIC & IMAGING LLC (2013-08-22),https://lens.org/198-505-859-194-325,Patent Application,yes,3,72,1,1,0,G06F21/32;;G06F3/03543;;G06F21/32,G06F3/0354,345/163,0,0,,,,DISCONTINUED
317,EP,B1,EP 3305189 B1,095-042-454-097-225,2022-09-21,2022,EP 17194233 A,2017-09-29,US 201662403318 P,2016-10-03,SYSTEM AND METHOD FOR TARGETED MEMORY ENHANCEMENT DURING SLEEP,,TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;AGUILAR-SIMON MARIO;;CONNOLLY PATRICK;;ESTRADA ROLANDO;;SHIMIZU RENEE;;WHATLEY MARY,,https://lens.org/095-042-454-097-225,Granted Patent,yes,2,0,4,4,0,A61B5/7282;;A61B5/4812;;A61B5/369;;A61B5/375;;A61N1/36031;;A61N1/36025;;A61N1/0456;;A61B5/7282;;A61B5/369;;A61B5/375;;A61N1/36031;;A61B5/4812;;A61B5/6803;;A61M21/02;;A61M2230/04,A61B5/369;;A61B5/00;;A61B5/375,,1,1,014-873-254-224-874,10.1016/j.artmed.2008.07.005;;18804982,"SUSMAKOVA K ET AL: ""Discrimination ability of individual measures used in sleep stages classification"", ARTIFICIAL INTELLIGENCE IN MEDICINE, ELSEVIER, NL, vol. 44, no. 3, 1 November 2008 (2008-11-01), pages 261 - 277, XP025654975, ISSN: 0933-3657, [retrieved on 20080919], DOI: 10.1016/J.ARTMED.2008.07.005",ACTIVE
318,US,B2,US 10581986 B2,125-247-923-121-802,2020-03-03,2020,US 201815996331 A,2018-06-01,US 201815996331 A;;US 201762513688 P,2017-06-01,Dynamic determination of public spaces and third party data incorporation for location-based mapping systems and methods,"A system that allows participating users to find other users with similar interests or characteristics based on a map area on a requesting device and the characteristics of each user. The system only reports a counter so as to preserve user anonymity and safety. The system preserves the user anonymity and safety in even granular searches using zoomed-in map views by comparing a map elevation level with a threshold and then a counted number of matched devices against a number of devices threshold. If the map is too zoomed in and there are not enough devices within the zoomed in area, the system does not provide a counter.",TURNOUTT INC,TASDEMIROGLU SEAN;;PUCCINI JAMES RICHARD;;CONNOLLY JASON;;FIROVED ANDREW;;MACDOWELL PATRICK;;EOM NOEL,TURNOUTT INC (2019-12-19),https://lens.org/125-247-923-121-802,Granted Patent,yes,6,0,3,3,0,G06Q50/01;;H04W12/02;;H04W4/21;;H04W4/021;;H04L67/52;;H04W4/21;;H04W4/021;;G06F16/29;;H04W4/02;;H04W12/02;;G06Q50/01;;H04L67/52,H04W4/02;;G06F16/29;;H04L29/08;;H04W4/021;;H04W4/21,,1,0,,,"Google, Captured May 31, 2018, Stack Overflow, 3 pages.",ACTIVE
319,US,A1,US 2018/0092600 A1,132-212-498-667-84X,2018-04-05,2018,US 201715720621 A,2017-09-29,US 201715720621 A;;US 201662403318 P,2016-10-03,"APPARATUS, SYSTEM, AND METHODS FOR TARGETED MEMORY ENHANCEMENT DURING SLEEP","Provided is an apparatus, system, and method for targeted memory enhancement. A computer processing circuit receives a plurality of electroencephalography (EEG) signals from a plurality of spatially separated EEG sensors located on the head of a subject that is asleep. A first process of the computer processing system determines a sleep state of the subject and upon determining that the subject is in sleep stage 2 or 3 based on a specific EEG signal, the processing system triggers a second process of the computer processing system that determines a transition event in the specific EEG signal, and upon detecting the transition event delivers an intervention to the subject designed to evoke a specific neurophysiological change to the subject.",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN;;AGUILAR-SIMON MARIO;;CONNOLLY PATRICK;;ESTRADA ROLANDO;;SHIMIZU RENEE;;WHATLEY MARY,TELEDYNE SCIENTIFIC & IMAGING LLC (2017-09-28),https://lens.org/132-212-498-667-84X,Patent Application,yes,2,14,4,4,0,A61B5/7282;;A61B5/4812;;A61B5/369;;A61B5/375;;A61N1/36031;;A61N1/36025;;A61N1/0456;;A61B5/7282;;A61B5/369;;A61B5/375;;A61N1/36031;;A61B5/4812;;A61B5/6803;;A61M21/02;;A61M2230/04,A61B5/00;;A61B5/375;;A61N1/36,,0,0,,,,ACTIVE
320,US,A1,US 2022/0039801 A1,163-886-018-022-686,2022-02-10,2022,US 202117376769 A,2021-07-15,US 202117376769 A;;US 201916292621 A;;US 201615089084 A;;US 201562141536 P,2015-04-01,SYSTEMS AND METHODS FOR DELIVERY OF GEL EMBOLICS,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/163-886-018-022-686,Patent Application,yes,8,0,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
321,CN,A,CN 114901161 A,175-249-568-068-498,2022-08-12,2022,CN 202080087139 A,2020-11-06,EP 2019080449 W;;GB 202006665 A;;EP 2020081386 W,2019-11-06,Intravascular device,"An intravascular device for passing through an obstruction in a blood vessel comprises: an elongate intravascular element, such as a lead; an ultrasound transducer mechanically coupled to the endovascular element to ultrasonically excite a distal tip portion of the endovascular element to facilitate passage through the obstruction; and one or more damping features mechanically coupled to the endovascular element to attenuate lateral displacement of the endovascular element at a location remote from the distal tip portion.",VERSONO MEDICAL LLC,DOLAN FRANCIS;;O 'DONOGHUE HEATHER;;MOONEY IAIN;;CONNOLLY PATRICK;;SMEDLEY JOHN;;TRAPPE BORIS,,https://lens.org/175-249-568-068-498,Patent Application,no,0,0,30,30,0,A61B17/22012;;A61B2017/00469;;A61B2017/22014;;A61B2017/22038;;A61B2017/22094;;A61B2017/320088;;A61B17/320708;;A61B2017/22039;;A61B2017/22044;;A61B2017/22049;;A61B2090/0807;;A61B2090/3966;;A61B17/22012;;A61B2017/22015;;A61B2090/0808;;A61B90/39;;A61B17/2202;;A61B2017/00477;;A61B2017/22094;;A61B2017/22027;;A61B2017/22049;;A61B2090/3966;;A61B2017/22017;;A61B2017/22041;;A61B2217/007;;A61B2017/22014;;A61B2017/22044,A61B17/22,,0,0,,,,PENDING
322,US,B2,US 11877753 B2,059-671-941-192-322,2024-01-23,2024,US 202117376769 A,2021-07-15,US 202117376769 A;;US 201916292621 A;;US 201615089084 A;;US 201562141536 P,2015-04-01,Systems and methods for delivery of gel embolics,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/059-671-941-192-322,Granted Patent,yes,32,0,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
323,US,B2,US 9050750 B2,086-807-659-815-425,2015-06-09,2015,US 40652309 A,2009-03-18,EP 08152903 A,2008-03-18,Process for making a stretch-blow moulded container having an integrally moulded handle,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform ( 6 ) in a mold cavity ( 1 );b) stretch-blow molding the preform ( 6 ) to form an intermediate container ( 8 ) which comprises at least one, preferably two, convex bubble(s) ( 9 );c) deforming the or each convex bubble ( 9 ) by means of an inwardly moving plug ( 5 ) to form one or more concave gripping region(s), while maintaining the pressure within the intermediate container ( 8 ) above 1 bar and while the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g , and the melt temperature, T m ;d) releasing excess pressure within the container, preferably prior to withdrawing the plug ( 5 ) from within the container; ande) ejecting the finished container from the mold cavity ( 1, 3 ).",CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER;;PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,PROCTER & GAMBLE COMPANY THE (2008-06-03),https://lens.org/086-807-659-815-425,Granted Patent,yes,14,2,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/00;;B29C49/06;;B29C49/12;;B29C49/48;;B29C49/64;;B29K23/00;;B29K25/00;;B29K27/06;;B29K67/00;;B29L31/46,,2,0,,,"International Search Report mailed Jun. 24, 2009-7 pages.;;EP2103413 Opposition dated Dec. 9, 2014.",INACTIVE
324,MA,B1,MA 32152 B1,020-280-095-683-072,2011-03-01,2011,MA 33158 A,2010-09-09,EP 08152903 A;;IB 2009050889 W,2008-03-18,طريقة صنع قالب عن طريق يمتد ويحتوي على مقبض واحد,يهم هذا الاختراع بطريقة لصنع وعاء له مقبض بدعامة واحدة، تضم المراحل التالية: أ) وضع الشكل الأولي (6) في تجويف لقالب (1)؛ ب) صب القالب عن طريق النفخ مع تمديد الشكل الأولي (6) لتشكيل وعاء وسطي (8) يتضمن على الأقل بالونا واحد، ويفضل ، بالونين محدبين (9) ؛ج)تغيير شكل البالون أو البالونات المحدبة (9) بواسطة سدادة تتحرك في الداخل (5) لتشكيل منطقة واحدة أو مناطق عديدة للامساك مقعرة،كل هذا مع الحفاظ على ضغط وسطي في الوعاء الوسطي (8) في حدود 1 بار ،بينما يتم الحفاظ على حرارة المادة في منطقة الإمساك في درجة حرارة بين درجة حرارة الانتقال الزجاجية tg ودرجة حرارة الذوبان tm؛الإفراج عن الضغط الزائد في الوعاء، ويفضل قبل إزالة السدادة (5) من داخل الوعاء، هــ) قذف الوعاء النهائي من تجويف القالب (1، 3).,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/020-280-095-683-072,Granted Patent,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,ACTIVE
325,CA,A1,CA 2715819 A1,004-732-374-531-842,2009-09-24,2009,CA 2715819 A,2009-03-04,EP 08152903 A;;IB 2009050889 W,2008-03-18,A PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform (6) in a mould cavity (1); b) stretch-blow moulding the preform (6) to form an intermediate container (8) which comprises at least one, preferably two, convex bubble(s) (9); c) deforming the or each convex bubble (9) by means of an inwardly moving plug (5) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container (8) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g, and the melt temperature, T m; d) releasing excess pressure within the container, preferably prior to withdrawing the plug (5) from within the container; and e) ejecting the finished container from the mould cavity (1, 3).",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/004-732-374-531-842,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,INACTIVE
326,US,A1,US 2015/0239169 A1,132-315-383-476-295,2015-08-27,2015,US 201414574798 A,2014-12-18,US 201414574798 A;;EP 08152903 A;;US 40652309 A,2008-03-18,PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform ( 6 ) in a mould cavity ( 1 );b) stretch-blow moulding the preform ( 6 ) to form an intermediate container ( 8 ) which comprises at least one, preferably two, convex bubble(s) ( 9 );c) deforming the or each convex bubble ( 9 ) by means of an inwardly moving plug ( 5 ) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container ( 8 ) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g , and the melt temperature, T m ;d) releasing excess pressure within the container, preferably prior to withdrawing the plug ( 5 ) from within the container; ande) ejecting the finished container from the mould cavity ( 1, 3 ).",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/132-315-383-476-295,Patent Application,yes,3,9,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/42,,0,0,,,,DISCONTINUED
327,CN,B,CN 101977754 B,095-065-533-494-618,2014-12-03,2014,CN 200980109475 A,2009-03-04,IB 2009050889 W;;EP 08152903 A,2008-03-18,Process for making a stretch-blow moulded container having an integrally moulded handle,,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAN;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/095-065-533-494-618,Granted Patent,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,INACTIVE
328,CN,A,CN 113274615 A,114-369-383-118-181,2021-08-20,2021,CN 202110115544 A,2021-01-28,US 202062969835 P,2020-02-04,System and method of sleep induction,"The application relates to a system and method of sleep induction. A sleep induction device includes a headband, multiple transcranial stimulation electrodes, and control electronic devices to drive the electrodes. The sleep induction device may be worn by an awake user prior to attempting sleep. The control electronic devices are configured to cause the stimulation electrodes to emit a sequence of stimulation waveforms separated by interstimulus periods. The stimulation waveforms may have the characteristics of low-delta waveforms that may characterize non-REM stage 3 sleep. The stimulation period may last from about 4-8 seconds and the interstimulus period may last from about 10 to 30 seconds. A sleep induction session may include multiple alternating stimulation and non-stimulation periods. The sleep induction session may last for about 5 minutes to about 30 minutes.",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN B;;CONNOLLY PATRICK M;;SHIMIZU RENEE;;YANOSCHAK ALEXANDRA;;SCHMITT CRAIG;;WEISEND MICHAEL,,https://lens.org/114-369-383-118-181,Patent Application,no,0,0,3,3,0,A61M21/02;;A61M2021/0072;;A61M2021/0027;;A61M2021/0044;;A61N1/36025;;A61N1/36034;;A61M21/02;;A61N1/0456;;A61N1/0484;;A61M2021/0027;;A61M2021/0044;;A61B5/6803;;A61M2209/088;;A61M2210/06;;A61M2205/3569;;A61M2205/3592;;A61M2205/0216;;A61M2021/0072;;A61M2230/10;;A61M2205/587;;A61M2205/583;;A61M2205/52;;A61M2205/505;;A61M2205/80;;A61M2205/3375;;A61M2205/581;;A61B5/374;;A61B5/4812;;A61B5/4836;;A61N1/36031;;A61M21/02;;A61M2021/0027;;A61M2021/0044;;A61M2021/0072;;A61M2021/0083;;A61N1/0456;;A61N1/0484;;A61N1/08,A61M21/02,,0,0,,,,PENDING
329,CN,A,CN 101977754 A,024-849-176-846-135,2011-02-16,2011,CN 200980109475 A,2009-03-04,IB 2009050889 W;;EP 08152903 A,2008-03-18,Process for making a stretch-blow moulded container having an integrally moulded handle,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform (6) in a mould cavity (1); b) stretch-blow moulding the preform (6) to form an intermediate container (8) which comprises at least one, preferably two, convex bubble(s) (9); c) deforming the or each convex bubble (9) by means of an inwardly moving plug (5) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container (8) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, Tg, and the melt temperature, Tm; d) releasing excess pressure within the container, preferably prior to withdrawing the plug (5) from within the container; and e) ejecting the finished container from the mould cavity (1, 3).",PROCTER & GAMBLE,CLEVELAN CONNOLLY WILLIAM JOHN;;JEAN-FRANCOIS ETESSE PATRICK;;FRIEDRICH GERLACH CHRISTIAN GERHARD;;CHRISTOPHER LAMB,,https://lens.org/024-849-176-846-135,Patent Application,no,0,6,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,INACTIVE
330,AR,A1,AR 070917 A1,046-765-260-582-208,2010-05-12,2010,AR P090100945 A,2009-03-17,EP 08152903 A,2008-03-18,UN PROCESO PARA FABRICAR UN RECIPIENTE MOLDEADO POR SOPLADO POR ESTIRAMIENTO QUE TIENE UN MANGO MOLDEADO INTEGRALMENTE,"La presente se refiere a un proceso para fabricar un recipiente que tiene un mango integral, que comprende los pasos de: a) suministrar una preforma (6) en una cavidad de molde (1); b) moldear por soplado por estiramiento la preforma (6) para formar un recipiente intermedio (8) el que comprende al menos una, preferentemente dos burbujas convexa(s) (9); c) deformar la o cada burbuja convexa (9) por medio de un tapon que se mueve hacia adentro (5) para formar una o más region(es) de sujecion concavas, mientras que mantiene la presion en el recipiente intermedio (8) por encima de 0,1 MPa (1 bar) y mientras que la temperatura del material en la region de sujecion del recipiente intermedio se mantiene a una temperatura entre la temperatura de transicion vítrea, Tg, y la temperatura de fusion, Tm; d) liberar la presion en exceso en el recipiente, preferentemente, antes de retirar el tapon (5) del interior del recipiente; y e) expulsar el recipiente terminado de la cavidad del molde (1, 3).",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/046-765-260-582-208,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,,,0,0,,,,ACTIVE
331,WO,A1,WO 2009/115937 A1,068-407-443-954-498,2009-09-24,2009,IB 2009050889 W,2009-03-04,EP 08152903 A,2008-03-18,A PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform (6) in a mould cavity (1); b) stretch-blow moulding the preform (6) to form an intermediate container (8) which comprises at least one, preferably two, convex bubble(s) (9); c) deforming the or each convex bubble (9) by means of an inwardly moving plug (5) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container (8) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g , and the melt temperature, T m ; d) releasing excess pressure within the container, preferably prior to withdrawing the plug (5) from within the container; and e) ejecting the finished container from the mould cavity (1, 3).",PROCTER & GAMBLE;;CONNOLLY WILLIAM JOHN CLEVELAN;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIE;;LAMB CHRISTOPHER,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/068-407-443-954-498,Patent Application,yes,5,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/06;;B29C49/48;;B29C49/12;;B29C49/64,,0,0,,,,PENDING
332,KR,A,KR 20100103730 A,106-244-130-365-310,2010-09-27,2010,KR 20107019464 A,2009-03-04,EP 08152903 A;;IB 2009050889 W,2008-03-18,A PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/106-244-130-365-310,Patent Application,no,0,1,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,INACTIVE
333,AU,A1,AU 2009/227612 A1,021-110-582-145-962,2009-09-24,2009,AU 2009/227612 A,2009-03-04,EP 08152903 A;;IB 2009050889 W,2008-03-18,A process for making a stretch-blow moulded container having an integrally moulded handle,,PROCTER & GAMBLE,GERLACH CHRISTIAN GERHARD FRIEDRICH;;ETESSE PATRICK JEAN-FRANCOIS;;LAMB CHRISTOPHER;;CONNOLLY WILLIAM JOHN CLEVELAND,,https://lens.org/021-110-582-145-962,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,DISCONTINUED
334,MX,A,MX 2010010196 A,103-647-219-432-118,2010-10-04,2010,MX 2010010196 A,2009-03-04,EP 08152903 A;;IB 2009050889 W,2008-03-18,A PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE.,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform (6) in a mould cavity (1); b) stretch-blow moulding the preform (6) to form an intermediate container (8) which comprises at least one, preferably two, convex bubble(s) (9); c) deforming the or each convex bubble (9) by means of an inwardly moving plug (5) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container (8) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, Tg, and the melt temperature, Tm; d) releasing excess pressure within the container, preferably prior to withdrawing the plug (5) from within the container; and e) ejecting the finished container from the mould cavity (1, 3).",PROCTER & GAMBLE,LAMB CHRISTOPHER;;ETESSE PATRICK JEAN-FRANCOIS;;CONNOLLY WILLIAM JOHN CLEVELAND;;GERLACH CHRISTIAN GERHARD FRIEDRICH,,https://lens.org/103-647-219-432-118,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,ACTIVE
335,EP,A1,EP 2103413 A1,187-661-654-655-402,2009-09-23,2009,EP 08152903 A,2008-03-18,EP 08152903 A,2008-03-18,A process for making a stretch-blow moulded container having an integrally moulded handle,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: 
a) providing a preform (6) in a mould cavity (1); 
b) stretch-blow moulding the preform (6) to form an intermediate container (8) which comprises at least one, preferably two, convex bubble(s) (9); 
c) deforming the or each convex bubble (9) by means of an inwardly moving plug (5) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container (8) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g , and the melt temperature, T m ; 
d) releasing excess pressure within the container, preferably prior to withdrawing the plug (5) from within the container; and 
c) ejecting the finished container from the mould cavity (1, 3).
",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/187-661-654-655-402,Patent Application,yes,7,8,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,1,0,,,"""The Wiley Encyclopedia of Packaging Technology"", vol. 9, 1997, JOHN WILEY & SONS, pages: 14 - 921",ACTIVE
336,EP,B1,EP 3007530 B1,054-847-329-800-787,2021-01-20,2021,EP 15187171 A,2015-09-28,US 201414500530 A,2014-09-29,CIRCUIT CARD ASSEMBLY AND METHOD OF MANUFACTURING THEREOF,,GEN ELECTRIC,CHAUHAN SHAKTI SINGH;;CONNOLLY STUART;;SHAH BINOY MILAN;;HODEN BRIAN PATRICK;;KIM JOO HAN,,https://lens.org/054-847-329-800-787,Granted Patent,yes,2,0,4,4,0,H05K7/1461;;H05K7/20672;;H05K1/0204;;H05K1/181;;H05K3/30;;H05K3/368;;H05K7/1461;;H05K7/20672,H05K7/20;;H05K7/14,,0,0,,,,ACTIVE
337,PL,T3,PL 2103413 T3,058-109-499-966-481,2012-12-31,2012,PL 08152903 T,2008-03-18,EP 08152903 A,2008-03-18,A process for making a stretch-blow moulded container having an integrally moulded handle,,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/058-109-499-966-481,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/06;;B29C49/48;;B29C49/12;;B29C49/64,,0,0,,,,PENDING
338,EP,A1,EP 3007530 A1,112-933-331-180-532,2016-04-13,2016,EP 15187171 A,2015-09-28,US 201414500530 A,2014-09-29,CIRCUIT CARD ASSEMBLY AND METHOD OF MANUFACTURING THEREOF,"A circuit card assembly is provided. The assembly includes a first printed circuit board 120, at least one electronic component 128 mounted on the first printed circuit board 120 at a predetermined location, a frame 122 coupled to the first printed circuit board 120, and a heat transfer assembly 124 coupled to the frame 122. The heat transfer assembly 124 includes a first plate extending over at least a portion of the first printed circuit board, a heat pipe 160 coupled to the first plate, and a thermally conductive member 162 positioned between the at least one electronic component 128 and the heat pipe 160. The thermally conductive member is selectively mounted at predetermined locations along the first plate based on the predetermined location of the at least one electronic component.
",GEN ELECTRIC,CHAUHAN SHAKTI SINGH;;CONNOLLY STUART;;SHAH BINOY MILAN;;HODEN BRIAN PATRICK;;KIM JOO HAN,,https://lens.org/112-933-331-180-532,Patent Application,yes,2,0,4,4,0,H05K7/1461;;H05K7/20672;;H05K1/0204;;H05K1/181;;H05K3/30;;H05K3/368;;H05K7/1461;;H05K7/20672,H05K7/20;;H05K7/14,,0,0,,,,ACTIVE
339,US,A1,US 2021/0236806 A1,144-466-796-770-795,2021-08-05,2021,US 202117160442 A,2021-01-28,US 202117160442 A;;US 202062969835 P,2020-02-04,System and Method of Sleep Induction,"A sleep induction device includes a headband, multiple transcranial stimulation electrodes, and control electronics to drive the electrodes. The sleep induction device may be worn by an awake user prior to attempting sleep. The control electronics are configured to cause the stimulation electrodes to emit a sequence of stimulation waveforms separated by interstimulus periods. The stimulation waveforms may have the characteristics of low-delta waveforms that may characterize non-REM stage 3 sleep. The stimulation period may last from about 4-8 seconds and the interstimulus period may last from about 10 to 30 seconds. A sleep induction session may include multiple alternating stimulation and non-stimulation periods. The sleep induction session may last for about 5 minutes to about 30 minutes.",TELEDYNE SCIENT & IMAGING LLC,SIMONS STEPHEN B;;CONNOLLY PATRICK M;;SHIMIZU RENEE;;YANOSCHAK ALEXANDRA;;SCHMIDT CALVIN;;WEISEND MICHAEL,TELEDYNE SCIENTIFIC & IMAGING LLC (2020-04-08),https://lens.org/144-466-796-770-795,Patent Application,yes,0,2,3,3,0,A61M21/02;;A61M2021/0072;;A61M2021/0027;;A61M2021/0044;;A61N1/36025;;A61N1/36034;;A61M21/02;;A61N1/0456;;A61N1/0484;;A61M2021/0027;;A61M2021/0044;;A61B5/6803;;A61M2209/088;;A61M2210/06;;A61M2205/3569;;A61M2205/3592;;A61M2205/0216;;A61M2021/0072;;A61M2230/10;;A61M2205/587;;A61M2205/583;;A61M2205/52;;A61M2205/505;;A61M2205/80;;A61M2205/3375;;A61M2205/581;;A61B5/374;;A61B5/4812;;A61B5/4836;;A61N1/36031;;A61M21/02;;A61M2021/0027;;A61M2021/0044;;A61M2021/0072;;A61M2021/0083;;A61N1/0456;;A61N1/0484;;A61N1/08,A61N1/04;;A61M21/02;;A61N1/08;;A61N1/36,,0,0,,,,PENDING
340,EP,B1,EP 2103413 B1,152-634-956-108-144,2012-08-01,2012,EP 08152903 A,2008-03-18,EP 08152903 A,2008-03-18,A process for making a stretch-blow moulded container having an integrally moulded handle,,PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/152-634-956-108-144,Granted Patent,yes,5,3,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,ACTIVE
341,US,A1,US 2009/0236776 A1,177-004-188-243-562,2009-09-24,2009,US 40652309 A,2009-03-18,EP 08152903 A,2008-03-18,PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,"The present invention relates to a process for making a container having an integral handle, comprising the steps of: a) providing a preform ( 6 ) in a mould cavity ( 1 );b) stretch-blow moulding the preform ( 6 ) to form an intermediate container ( 8 ) which comprises at least one, preferably two, convex bubble(s) ( 9 );c) deforming the or each convex bubble ( 9 ) by means of an inwardly moving plug ( 5 ) to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container ( 8 ) above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g , and the melt temperature, T m ;d) releasing excess pressure within the container, preferably prior to withdrawing the plug ( 5 ) from within the container; ande) ejecting the finished container from the mould cavity ( 1, 3 ).",CONNOLLY WILLIAM JOHN CLEVELAN;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,CONNOLLY WILLIAM JOHN CLEVELAN;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,PROCTER & GAMBLE COMPANY THE (2008-06-03),https://lens.org/177-004-188-243-562,Patent Application,yes,7,8,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/00,264/521,0,0,,,,INACTIVE
342,CA,C,CA 2715819 C,131-532-771-833-80X,2013-07-23,2013,CA 2715819 A,2009-03-04,EP 08152903 A;;IB 2009050889 W,2008-03-18,A PROCESS FOR MAKING A STRETCH-BLOW MOULDED CONTAINER HAVING AN INTEGRALLY MOULDED HANDLE,"The present invention relates to a process for making a container having an integral handle, comprising the steps of : a) providing a preform in a mould cavity; b) stretch-blow moulding the preform to form an intermediate container which comprises at least one, preferably two, convex bubble(s); c) deforming the or each convex bubble by means of an inwardly moving plug to form one or more concave gripping region(s), whilst maintaining the pressure within the intermediate container above 1 bar and whilst the temperature of the material in the gripping region of the intermediate container is maintained at a temperature between the glass transition temperature, T g, and the melt temperature, T m; d) releasing excess pressure within the container, preferably prior to withdrawing the plug from within the container; and e) ejecting the finished container from the mould cavity.",PROCTER & GAMBLE,CONNOLLY WILLIAM JOHN CLEVELAND;;ETESSE PATRICK JEAN-FRANCOIS;;GERLACH CHRISTIAN GERHARD FRIEDRICH;;LAMB CHRISTOPHER,,https://lens.org/131-532-771-833-80X,Granted Patent,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/48;;B29C49/06;;B29C49/12;;B29C49/64,,0,0,,,,INACTIVE
343,BR,A2,BR PI0909761 A2,174-234-899-541-552,2019-03-06,2019,BR PI0909761 A,2009-03-04,IB 2009050889 W;;EP 08152903 A,2008-03-18,processo de produção de um recipiente moldado por sopro e estiramento tendo em cabo moldado integralmente,"processo de produção de um recipiente moldado por sopro e estiramento tendo um cabo molda-do integralmente"". 5 a presente invenção refere-se a um processo para produzir um recipiente com um cabo integral, compreendendo as etapas de: a) fornecer uma pré-forma (6) em uma cavidade de molde (1); b) estirar a pré-forma (6) por modelagem por sopro para formar um recipiente intermediário (8) que compreende ao menos uma, de prefe rência duas, bolhas convexas (9); c) deformar a ou cada bolha convexa (9) por meio de um plugue móvel voltado para dentro (5) para formar uma ou mais regiões de empunhar côncavas, e ao mesmo tempo manter a pressão no interior do recipiente in-termediário (8) acima de 100 kpa (1 bar) e manter a temperatura do material na região de empunhar do recipiente intermediário a uma temperatura entre a temperatura de transição vítrea, tg, e a temperatura de fusão, tm; d) liberar o excesso de pressão no interior do recipiente, de pre-ferência antes de retirar o plugue (5) do interior do recipiente; e e) ejetar o recipiente final pela cavidade do molde (1, 3).",PROCTER & GAMBLE,CHRISTIAN GERHARD FRIEDRICH GERLACH;;CHRISTOPHER LAMB;;PATRICK JEAN-FRANCOIS ETESSE;;WILLIAM JOHN CLEVELAND CONNOLLY,,https://lens.org/174-234-899-541-552,Patent Application,no,0,0,20,20,0,B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C49/4802;;B29C49/4812;;B29C49/18;;B29C49/6472;;B29C49/4283;;B29C2949/0715;;B29C49/4812;;B29C49/18;;B29C49/64;;B29C49/06;;B29C49/12;;B29C49/6472;;B29C49/4283;;B29D22/003;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/046;;B29L2031/463;;B29L2031/7158;;B29C2949/0715;;B29C49/06;;B29C49/12;;B29C2049/4807;;B29K2023/06;;B29K2023/12;;B29K2025/00;;B29K2027/06;;B29K2067/00;;B29K2067/046;;B29L2031/463;;B29C49/18;;B29C49/4812;;B29C49/6472;;B29C49/4802;;B29C49/4273;;B29D22/003;;B29L2031/7158,B29C49/06;;B29C49/12;;B29C49/48;;B29C49/64,,0,0,,,,DISCONTINUED
344,DE,A1,DE 2611503 A1,062-246-033-453-882,1976-11-18,1976,DE 2611503 A,1976-03-18,US 57268375 A;;US 60774675 A,1975-04-28,KORONA-LADEEINRICHTUNGEN IN ELEKTROSTATOGRAFISCHEN KOPIERGERAETEN,,XEROX CORP,MICHAELS THOMAS B;;PLACE JUN GEORGE H;;BOROSTYAN STEPHEN;;CONNOLLY DOUGLAS PATRICK;;FRISKE ALAN DALE,,https://lens.org/062-246-033-453-882,Patent Application,no,3,8,7,11,0,G03G15/1645;;G03G15/0266,G03G15/02;;G03G15/16,,0,0,,,,EXPIRED
345,US,A,US 4996875 A,069-038-448-254-701,1991-03-05,1991,US 45088889 A,1989-12-14,US 45088889 A,1989-12-14,Apparatus and method for evaluation of fluid flow within a combustion chamber,"The invention provides an apparatus which simulates fluid flow patterns within a chamber. The apparatus includes a chamber having a mechanism to enable viewing of the inside of the chamber. A simulated head member is associated with the chamber to enable fluid to pass through the member into the chamber. A mechanism to exhaust fluid from the chamber is also associated therewith. A member is positioned within the chamber to simulate a piston position within the chamber. Lightweight members are within the chamber to visually define the fluid flow patterns within the chamber. Also, a method of evaluating cylinder head port, combustion chamber, and valve head designs is disclosed.",CHRYSLER CORP,BAER PATRICK H;;CONNOLLY TIMOTHY F;;KOPINSKI GERALD P;;ROWLEY CURTIS E;;SENKOW ANTHONY W,CHRYSLER MOTORS CORPORATION (1989-12-07),https://lens.org/069-038-448-254-701,Granted Patent,yes,5,9,1,2,0,F01L1/46;;F02B77/08;;F02F2007/0092;;G01P13/008;;G01P13/0093;;G01P13/0093;;F01L1/46;;G01P13/008;;F02F2007/0092;;F02B77/08,F01L1/46;;F02B77/08;;G01P13/00,73119R;;73/865.6,0,0,,,,EXPIRED
346,US,B2,US 11432821 B2,191-213-365-560-250,2022-09-06,2022,US 201615064415 A,2016-03-08,US 201615064415 A;;US 201562130375 P,2015-03-09,Arterial-venous occlusion apparatus,"Expandable occlusive plugs and methods of using them are disclosed. The devices generally include a tubular body bearing multiple slits defining leaves, which expand radially outward when the ends of the device are brought toward one another.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK;;GROFF JOEL;;HARRISON KENT;;CONNOLLY JOSEPH;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;RAAB DAVID,BOSTON SCIENTIFIC SCIMED INC (2016-05-03),https://lens.org/191-213-365-560-250,Granted Patent,yes,13,0,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/12;;A61B17/00,,0,0,,,,ACTIVE
347,US,A1,US 2019/0201001 A1,194-343-429-031-695,2019-07-04,2019,US 201916292621 A,2019-03-05,US 201916292621 A;;US 201615089084 A;;US 201562141536 P,2015-04-01,SYSTEMS AND METHODS FOR DELIVERY OF GEL EMBOLICS,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/194-343-429-031-695,Patent Application,yes,0,1,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
348,US,A1,US 2003/0042313 A1,116-193-141-291-746,2003-03-06,2003,US 94113901 A,2001-08-28,US 94113901 A,2001-08-28,Method and system for acquiring bar code encoded information,"
   A method and system for acquiring bar code encoded information wherein a bar code is read using a portable bar code reader to produce bar code data which has a wireless communications transceiver for transmitting the bar code data. The bar code data is transmitted to a second bar code reader which has a wireless communications transceiver for receiving bar code data and has an output circuit for communicating bar code data by a cable to a host computer. The bar code data and additional bar code data produced by the second bar code reader is communicated by the cable or by a secondary wireless connection to the host computer. 
",KAHN JOEL;;SALATTO PATRICK;;MELICK DIANA J.;;SCHELLHAMMER STEPHEN J.;;CONNOLLY SEAN A.;;BOCCUZZI FRANK,KAHN JOEL;;SALATTO PATRICK;;MELICK DIANA J;;SCHELLHAMMER STEPHEN J;;CONNOLLY SEAN A;;BOCCUZZI FRANK,SYMBOL TECHNOLOGIES INC (2001-07-26),https://lens.org/116-193-141-291-746,Patent Application,yes,1,14,1,1,0,G06K17/0022;;G06K17/0022,G06K17/00,235/462.46,0,0,,,,DISCONTINUED
349,US,B2,US 8021428 B2,057-485-813-551-704,2011-09-20,2011,US 90876605 A,2005-05-25,US 90876605 A;;US 58405404 P,2004-06-30,Ceramic disc prosthesis,"A prosthetic is provided for replacing a vertebral disc. The prosthesis can comprise first and second endplates formed of a ceramic material, each including an articulating contact surface and a bone facing surface. The contact surface of the first endplate can have a shape complementary to the contact surface of the second endplate, thereby facilitating articulation of the first and second endplates while in contact with one another. The device can further include at least one non-ceramic bone attachment element mated with at least one of the bone facing surfaces, such that the bone attachment element covers less than a full area of the bone facing surface.",DEPUY SPINE INC,BARTISH JR CHARLES M;;BROUSSEAU JEFFREY;;FATYOL PATRICK;;MCCREA CONOR;;O'NEIL MICHAEL J;;CONNOLLY STEPHEN,DEPUY SPINE INC (2005-05-23),https://lens.org/057-485-813-551-704,Granted Patent,yes,106,8,10,10,0,A61F2/4425;;A61F2/4425;;A61F2/30767;;A61F2/30767;;A61F2/30965;;A61F2/30965;;A61F2/4611;;A61F2/4611;;A61F2002/30092;;A61F2002/30092;;A61F2002/30179;;A61F2002/30179;;A61F2002/305;;A61F2002/305;;A61F2002/30561;;A61F2002/30561;;A61F2002/30579;;A61F2002/30579;;A61F2002/30649;;A61F2002/30649;;A61F2002/30841;;A61F2002/30841;;A61F2002/30904;;A61F2002/30904;;A61F2002/443;;A61F2002/443;;A61F2210/0023;;A61F2210/0023;;A61F2220/0025;;A61F2220/0025;;A61F2230/0058;;A61F2230/0058;;A61F2310/00017;;A61F2310/00017;;A61F2310/00023;;A61F2310/00023;;A61F2310/00203;;A61F2310/00203;;A61F2310/00239;;A61F2310/00239;;A61F2310/00407;;A61F2310/00407;;A61F2310/00796;;A61F2310/00796,A61F2/44,623/17.15;;623/17.16;;606/297,2,0,,,"Int'l Search Report.;;Stoeckel, D., ""Forming of Nitinol-A Challenge"", New Developments in Forging Technology (ed.), K. Siegert, 2001, pp. 119-134.",INACTIVE
350,US,A1,US 2007/0162034 A1,091-971-458-917-391,2007-07-12,2007,US 49803606 A,2006-08-03,US 49803606 A;;US 70514705 P,2005-08-04,Annular repair method and device,"A method of repairing an annulus of an intervertebral disc includes excising, with a cutting tool, a damaged area of the annulus, thereby creating a space in the annulus, the space being defined by first and second annulus ends; making a partial incision at the first annulus end generally adjacent to the excised area, creating a flap of annulus; stretching the flap across the space, and attaching the flap to the second annulus end.",KOSTUIK JOHN;;CONNOLLY PATRICK;;STRAUSS KEVIN R;;WOODS RICHARD W;;HAMBURGER MARY P;;ROCK ANDY,KOSTUIK JOHN;;CONNOLLY PATRICK;;STRAUSS KEVIN R;;WOODS RICHARD W;;HAMBURGER MARY P;;ROCK ANDY,K2M INC (2006-12-15),https://lens.org/091-971-458-917-391,Patent Application,yes,5,2,1,1,0,A61B17/1671;;A61B17/1671;;A61B17/1604;;A61B17/1604;;A61B17/1617;;A61B17/1617;;A61B17/7071;;A61B17/7071,A61B17/16,606/80,0,0,,,,DISCONTINUED
351,US,B2,US 10265078 B2,000-518-638-411-842,2019-04-23,2019,US 201615089084 A,2016-04-01,US 201615089084 A;;US 201562141536 P,2015-04-01,Systems and methods for delivery of gel embolics,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/000-518-638-411-842,Granted Patent,yes,27,3,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
352,US,A,US 5072613 A,109-586-905-445-682,1991-12-17,1991,US 58782390 A,1990-09-24,US 58782390 A;;US 45088889 A,1989-12-14,Method for evaluation of fluid flow within a simulated combustion chamber,The invention concerns a method for evaluating port design of an engine cylinder head by viewing patterns of fluid flow therefrom into a transparent chamber simulating an engine combustion chamber. A permeable member in the chamber simulates the position of a piston in a related engine and allows a continuous flow to be generated through the chamber. Lightweight members are deposited within the chamber to be visually observed as they move with the fluid flow in the chamber.,CHRYSLER CORP,BAER PATRICK H;;CONNOLLY TIMOTHY F;;KOPINSKI GERALD P;;ROWLEY CURTIS E;;SENKOW ANTHONY W,CHRYSLER CORPORATION A DE CORP (1990-10-18),https://lens.org/109-586-905-445-682,Granted Patent,yes,5,15,1,2,0,F02B77/08;;F02B77/08;;F01L1/46;;F01L1/46;;F02F2007/0092;;F02F2007/0092;;G01P13/008;;G01P13/008;;G01P13/0093;;G01P13/0093,F01L1/46;;F02B77/08;;G01P13/00,73119R,0,0,,,,EXPIRED
353,US,B2,US 11090058 B2,080-273-557-862-990,2021-08-17,2021,US 201916292621 A,2019-03-05,US 201916292621 A;;US 201615089084 A;;US 201562141536 P,2015-04-01,Systems and methods for delivery of gel embolics,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/080-273-557-862-990,Granted Patent,yes,4,2,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
354,EP,A1,EP 3468452 A1,038-292-399-054-058,2019-04-17,2019,EP 17758017 A,2017-08-17,US 201662376361 P;;US 201662420950 P;;US 2017/0047349 W,2016-08-17,SYSTEM AND METHOD FOR NONINVASIVE IDENTIFICATION OF COGNITIVE AND BEHAVIORAL GOALS,,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;REYNOLDS WILLIAM;;AGUILAR-SIMON MARIO;;KRNAVEK DAVID,,https://lens.org/038-292-399-054-058,Patent Application,yes,0,0,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61B5/00;;A61B5/374;;G06F3/01,,0,0,,,,PENDING
355,CA,A1,CA 3030695 A1,078-746-767-811-96X,2018-02-22,2018,CA 3030695 A,2017-08-17,US 201662376361 P;;US 201662420950 P;;US 2017/0047349 W,2016-08-17,SYSTEM AND METHOD FOR NONINVASIVE IDENTIFICATION OF COGNITIVE AND BEHAVIORAL GOALS,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;REYNOLDS WILLIAM;;AGUILAR-SIMON MARIO;;KRNAVEK DAVID,,https://lens.org/078-746-767-811-96X,Patent Application,no,0,0,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61B5/00;;A61B5/374;;G06F3/01,,0,0,,,,DISCONTINUED
356,WO,A1,WO 2018/035327 A1,118-472-411-925-214,2018-02-22,2018,US 2017/0047349 W,2017-08-17,US 201662376361 P;;US 201662420950 P,2016-08-17,SYSTEM AND METHOD FOR NONINVASIVE IDENTIFICATION OF COGNITIVE AND BEHAVIORAL GOALS,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;REYNOLDS WILLIAM;;AGUILAR SIMON MARIO;;KRNAVEK DAVID,,https://lens.org/118-472-411-925-214,Patent Application,yes,5,0,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61B5/00;;A61B5/374;;G06F3/01,,9,8,024-041-709-764-756;;042-888-295-768-082;;002-248-109-991-664;;082-452-458-064-172;;027-300-822-051-312;;089-101-731-046-881;;170-388-291-607-732;;097-552-300-290-666,10.1088/1741-2560/12/1/016001;;25426805;;10.1088/1741-2560/8/5/056001;;21799241;;pmc3458432;;23055968;;10.3389/fneng.2012.00013;;10.1007/978-3-642-24955-6_17;;10.3390/s130303454;;pmc3658756;;23486216;;10.1016/s0925-2312(02)00821-4;;pmc2746074;;10.1088/1741-2560/6/1/016005;;19155552;;pmc3279116;;10.1088/1741-2560/8/3/036012;;21508492,"IL-HWA KIM ET AL: ""Detection of braking intention in diverse situations during simulated driving based on EEG feature combination"", JOURNAL OF NEURAL ENGINEERING, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 12, no. 1, 26 November 2014 (2014-11-26), pages 16001, XP020278521, ISSN: 1741-2552, [retrieved on 20141126], DOI: 10.1088/1741-2560/12/1/016001;;STEFAN HAUFE ET AL: ""EEG potentials predict upcoming emergency brakings during simulated driving;EEG potentials predict upcoming emergency brakings during simulated driving"", JOURNAL OF NEURAL ENGINEERING, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 8, no. 5, 28 July 2011 (2011-07-28), pages 56001, XP020212410, ISSN: 1741-2552, DOI: 10.1088/1741-2560/8/5/056001;;EILEEN LEW: ""Detection of self-paced reaching movement intention from EEG signals"", FRONTIERS IN NEUROENGINEERING, vol. 5, 1 January 2012 (2012-01-01), XP055427225, DOI: 10.3389/fneng.2012.00013;;JANG YOUNG-MIN ET AL: ""Recognition of Human's Implicit Intention Based on an Eyeball Movement Pattern Analysis"", 13 November 2011, NETWORK AND PARALLEL COMPUTING; [LECTURE NOTES IN COMPUTER SCIENCE; LECT.NOTES COMPUTER], SPRINGER INTERNATIONAL PUBLISHING, CHAM, PAGE(S) 138 - 145, ISBN: 978-3-642-24784-2, ISSN: 0302-9743, XP047379330;;JONG-SUK CHOI ET AL: ""Enhanced Perception of User Intention by Combining EEG and Gaze-Tracking for Brain-Computer Interfaces (BCIs)"", SENSORS, vol. 13, no. 3, 13 March 2013 (2013-03-13), CH, pages 3454 - 3472, XP055427230, ISSN: 1424-8220, DOI: 10.3390/s130303454;;L. PARRA ET AL.: ""Single Trial Detection in EEG and MEG: Keeping it Linear"", NEUROCOMPUTING, vol. 52-54, June 2003 (2003-06-01), pages 177 - 183, XP027136424;;L. PARRA ET AL.: ""Recipes for the Linear Analysis of EEG"", NEUROLMAGE, vol. 28, 2005, pages 242 - 353;;ROYER; AUDREY S.; BIN HE: ""Goal Selection Versus Process Control In A Brain-Computer Interface Based On Sensorimotor Rhythms"", JOURNAL OF NEURAL ENGINEERING, vol. 6, no. 016005, 2009, pages 12pp;;ROYER; AUDREY S.; MINN L. ROSE; BIN HE: ""Goal Selection Versus Process Control While Learning To Use A Brain-Computer Interface"", JOURNAL OF NEURAL ENGINEERING, vol. 8, no. 036012, 2011, pages 12pp",PENDING
357,US,A1,US 2018/0049896 A1,113-952-962-359-678,2018-02-22,2018,US 201715678848 A,2017-08-16,US 201715678848 A;;US 201662376361 P;;US 201662420950 P,2016-08-17,SYSTEM AND METHOD FOR NONINVASIVE IDENTIFICATION OF COGNITIVE AND BEHAVIORAL GOALS,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;AGUILAR SIMON MARIO;;REYNOLDS JR WILLIAM;;KRNAVEK DAVID,TELEDYNE SCIENTIFIC & IMAGING LLC (2018-12-20),https://lens.org/113-952-962-359-678,Patent Application,yes,2,10,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61F2/72;;A61B3/113;;A61B5/00;;A61B5/11;;A61B5/374;;G06F3/0484,,0,0,,,,ACTIVE
358,US,A1,US 2016/0287258 A1,056-523-039-851-377,2016-10-06,2016,US 201615089084 A,2016-04-01,US 201615089084 A;;US 201562141536 P,2015-04-01,SYSTEMS AND METHODS FOR DELIVERY OF GEL EMBOLICS,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON JR GARY JOHN;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,BOSTON SCIENTIFIC SCIMED INC (2016-04-14),https://lens.org/056-523-039-851-377,Patent Application,yes,28,1,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
359,EP,B1,EP 3277198 B1,172-886-239-093-089,2023-10-25,2023,EP 16716404 A,2016-04-01,US 201562141536 P;;US 2016/0025669 W,2015-04-01,SYSTEMS FOR DELIVERY OF GEL EMBOLICS,,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,,https://lens.org/172-886-239-093-089,Granted Patent,yes,1,0,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
360,EP,A3,EP 4299019 A3,109-590-722-625-244,2024-03-06,2024,EP 23202612 A,2016-04-01,US 201562141536 P;;US 2016/0025669 W;;EP 16716404 A,2015-04-01,SYSTEMS FOR DELIVERY OF GEL EMBOLICS,"Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.
",BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;ANDERSON MARY-CLAIRE;;RAAB DAVID;;PEDERSON GARY JOHN JR;;HAVERKOST PATRICK A;;SMITH MARK,,https://lens.org/109-590-722-625-244,Search Report,yes,8,0,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,PENDING
361,EP,A1,EP 3277198 A1,079-895-840-019-801,2018-02-07,2018,EP 16716404 A,2016-04-01,US 201562141536 P;;US 2016/0025669 W,2015-04-01,SYSTEMS AND METHODS FOR DELIVERY OF GEL EMBOLICS,,BOSTON SCIENT SCIMED INC,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,,https://lens.org/079-895-840-019-801,Patent Application,yes,0,0,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
362,WO,A1,WO 2016/161344 A1,015-956-217-820-546,2016-10-06,2016,US 2016/0025669 W,2016-04-01,US 201562141536 P,2015-04-01,SYSTEMS AND METHODS FOR DELIVERY OF GEL EMBOLICS,Delivery systems for liquid embolics and methods of using them are disclosed. The devices generally include a catheter and one or more retention elements to limit migration of the liquid embolic to non-target sites.,BOSTON SCIENT SCIMED INC;;CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;HAVERKOST PATRICK A;;RAAB DAVID;;SMITH MARK,,https://lens.org/015-956-217-820-546,Patent Application,yes,12,1,11,11,0,A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12186;;A61B17/1219;;A61B2017/12054;;A61B17/12022;;A61B17/12113;;A61B17/12172;;A61B2017/12063;;A61B2017/12068;;A61B17/12159;;A61B17/12186;;A61B17/1219;;A61B2017/1205;;A61B2017/12054,A61B17/12,,0,0,,,,PENDING
363,US,B2,US 10945864 B2,116-222-871-792-411,2021-03-16,2021,US 201715678848 A,2017-08-16,US 201715678848 A;;US 201662376361 P;;US 201662420950 P,2016-08-17,System and method for noninvasive identification of cognitive and behavioral goals,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;AGUILAR-SIMON MARIO;;REYNOLDS JR WILLIAM;;KRNAVEK DAVID,TELEDYNE SCIENTIFIC & IMAGING LLC (2018-12-20),https://lens.org/116-222-871-792-411,Granted Patent,yes,7,2,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61F2/72;;A61B3/113;;A61B5/00;;A61B5/11;;A61B5/16;;A61B5/374;;G06F3/01;;G06F3/0484,,14,10,042-888-295-768-082;;027-300-822-051-312;;002-248-109-991-664;;024-041-709-764-756;;089-101-731-046-881;;048-054-797-340-892;;170-388-291-607-732;;097-552-300-290-666;;026-575-356-878-924;;008-462-730-737-838,10.1088/1741-2560/8/5/056001;;21799241;;10.3390/s130303454;;pmc3658756;;23486216;;pmc3458432;;23055968;;10.3389/fneng.2012.00013;;10.1088/1741-2560/12/1/016001;;25426805;;10.1016/s0925-2312(02)00821-4;;10.1016/j.neuroimage.2005.05.032;;16084117;;pmc2746074;;10.1088/1741-2560/6/1/016005;;19155552;;pmc3279116;;10.1088/1741-2560/8/3/036012;;21508492;;10.1097/00000542-200011000-00029;;11046224;;10.1056/nejmc086136;;18650522,"Williams, Adam. Flying drone controlled with mind power. New Atlas. (Year: 2012).;;International Search Report and Written Opinion for International Application No. PCT/US2017/047349 dated Nov. 29, 2017.;;Haufe et al., “EEG potentials predict upcoming emergency brakings during simulated driving”, Journal of Neural Engineering, IOP Publishing, 2011, vol. 8, pp. 1-11.;;Jang et al., “Recognition of Human's Implicit Intention Based on an Eyeball Movement Pattern Analysis”, ICONIP, Springer-Verlag Berlin Heidelberg, Nov. 13, 2011, Part I, pp. 138-145.;;Choi et al., “Enhanced Perception of User Intention by Combining EEG and Gaze-Tracking for Brain-Computer Interfaces (BCIs)”, Sensors, vol. 13, Mar. 13, 2013, pp. 3454-3472.;;Lew, Eileen, “Detection of self-paced reaching movement intention from EEG signals”, Frontiers in Neuroengineering, vol. 5, Jul. 2012, Article 13, pp. 1-17.;;Kim et al., “Detection of braking intention in diverse situations during simulated driving based on EEG feature combination”, Journal of Neural Engineering, vol. 12, 2015, 12 pages.;;Parra et al., “Single-trial detection in EEG and MEG: Keeping it linear”, Neurocomputing, vols. 52-54, 2003, pp. 177-183.;;Parra et al., “Recipes for the linear analysis of EEG”, NeuroImage, vol. 28, 2005, pp. 326-341.;;Royer et al., “Goal selection vs. Process Control in a Brain-Computer Interface based on Sensorimotor Rhythms”, Journal of Neural Engineering, vol. 6, No. 1, 2009, 25 pages.;;Royer et al., “Goal Selection vs. Process Control while Learning to Use a Brain-Computer Interface”, Journal of Neural Engineering, 2011, vol. 8, No. 3, 20 pages.;;Johansen, et al., “Development and Clinical Application of Electroencephalographic Bispectrum Monitoring”, Anesthesiology, vol. 93, No. 5, Nov. 2000, pp. 1336-1344.;;Kelley et al., Anesthesia Awareness and the Bispectral Index, The New England Journal of Medicine, vol. 359, No. 4, Jul. 24, 2008, pp. 427-431.;;International Preliminary Report on Patentability for International Application No. PCT/US2017/047349 dated Feb. 19, 2019.",ACTIVE
364,US,B2,US 11672676 B2,131-144-122-566-129,2023-06-13,2023,US 202117141920 A,2021-01-05,US 202117141920 A;;US 201715678848 A;;US 201662376361 P;;US 201662420950 P,2016-08-17,System and method for noninvasive identification of cognitive and behavioral goals,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;AGUILAR-SIMON MARIO;;REYNOLDS JR WILLIAM D;;KRNAVEK DAVID,TELEDYNE SCIENTIFIC & IMAGING LLC (2018-12-20),https://lens.org/131-144-122-566-129,Granted Patent,yes,9,1,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61F2/72;;A61B3/113;;A61B5/00;;A61B5/11;;A61B5/16;;A61B5/246;;A61B5/316;;A61B5/374;;A61B5/378;;A61B5/38;;G06F3/01;;G06F3/04842,,18,13,061-719-041-606-229;;022-125-013-380-303;;010-913-404-731-90X;;042-888-295-768-082;;027-300-822-051-312;;002-248-109-991-664;;024-041-709-764-756;;089-101-731-046-881;;048-054-797-340-892;;170-388-291-607-732;;097-552-300-290-666;;026-575-356-878-924;;008-462-730-737-838,10.1016/j.procs.2016.04.086;;21436530;;10.1088/1741-2560/8/2/025014;;20466580;;10.1016/j.medengphy.2010.04.009;;10.1088/1741-2560/8/5/056001;;21799241;;10.3390/s130303454;;pmc3658756;;23486216;;pmc3458432;;23055968;;10.3389/fneng.2012.00013;;10.1088/1741-2560/12/1/016001;;25426805;;10.1016/s0925-2312(02)00821-4;;10.1016/j.neuroimage.2005.05.032;;16084117;;pmc2746074;;10.1088/1741-2560/6/1/016005;;19155552;;pmc3279116;;10.1088/1741-2560/8/3/036012;;21508492;;10.1097/00000542-200011000-00029;;11046224;;10.1056/nejmc086136;;18650522,"Das et al., “Multiple Feature Extraction of Electroencephalograph Signal for Motor Imagery Classification through Bispectral Analysis”, Procedia Computer Science, vol. 84, 2016, pp. 192-197.;;Shahid et al., “Bispectrum-based feature extraction technique for devising a practical brain-computer interface”, Mar. 24, 2011, IOP Publishing Ltd., Journal of Neural Engineering, vol. 8, No. 2, 25014, pp. 1-12.;;Chua et al., “Application of higher order statistics/spectra in biomedical signals: A Review”, Medical Engineering and Physics, vol. 32, No. 7, Sep. 2010, pp. 679-689.;;Communication pursuant to Article 94(3) from the Examining Division for European Patent Application No. 17758017.2, May 19, 2022, 7 pages.;;International Search Report and Written Opinion for International Application No. PCT/US201 7/047349 dated Nov. 29, 2017.;;International Preliminary Report on Patentability for International Application No. PCT/US2017/047349 dated Feb. 19, 2019.;;Haufe et al., “EEG potentials predict upcoming emergency brakings during simulated driving”, Journal of Neural Engineering, IOP Publishing, 2011, vol. 8, pp. 1-11.;;Jang et ai., “Recognition of Human's implicit Intention Based on an Eyeball Movement Pattern Analysis”, ICONIP, Springer-Verlag Berlin Heidelberg, Nov. 13, 2011, Part I, pp. 138-145.;;Choi et al., “Enhanced Perception of User Intention by Combining EEG and Gaze-Tracking for Brain-Computer Interfaces (BCIs)”, Sensors, vol. 13, Mar. 13, 2013, pp. 3454-3472.;;Lew, Eileen, “Detection of self-paced reaching movement intention from EEG signals”, Frontiers in Neuroengineering, vol. 5, Jul. 2012, Article 13, pp. 1-17.;;Kim et al., “Detection of braking intention in diverse situations during simulated driving based on EEG feature combination”, Journal of Neural Engineering, vol. 12, 2015, 12 pages.;;Parra et al., “Single-trial detection in EEG and MEG: Keeping it linear”, Neurocomputing. vols. 52-54, 2003, pp. 177-183.;;Parra et al., “Recipes for the linear analysis of EEG”, NeuroImage, vol. 28, 2005, pp. 326-341.;;Royer et al., “Goal selection vs. Process Control in a Brain-Computer Interface based on Sensorimotor Rhythms”, Journal of Neural Engineering, vol. 6, No. 1, 2009, 25 pages.;;Royer et al., “Goal Selection vs. Process Control while Learning to Use a Brain-Computer Interface”, Journal of Neural Engineering, 2011, vol. 8, No. 3, 20 pages.;;Johansen et al., “Development and Clinical Application of Electroencephalographic Bispectrum Monitoring”, Anesthesiology, vol. 93, No. 5, Nov. 2000, pp. 1336-1344.;;Kelley et al., Anesthesia Awareness and the Bispectral Index, The New England Journal of Medicine, vol. 359, No. 4, Jul. 24, 2008, pp. 427-431.;;Williams, Adam, Flying Drone Controlled with Mind Power, New Atlas, Sep. 1, 2012, 9 pages.https://newatlas.com/ar-drone-quadrocopter-thought-control/23960.",ACTIVE
365,US,A1,US 2021/0205104 A1,152-006-111-706-284,2021-07-08,2021,US 202117141920 A,2021-01-05,US 202117141920 A;;US 201715678848 A;;US 201662376361 P;;US 201662420950 P,2016-08-17,SYSTEM AND METHOD FOR NONINVASIVE IDENTIFICATION OF COGNITIVE AND BEHAVIORAL GOALS,A brain machine interface system for use with an electroencephalogram to identify a behavioral intent of a person is disclosed. The system includes an electroencephalogram configured to sense electromagnetic signals generated by a brain of a person. The electromagnetic signals include a time component and a frequency component. A monitor monitors a response of the person to a stimulus and a characteristic of the stimulus. A synchronization module synchronizes the sensed electromagnetic signals with the response and the characteristic to determine a set of electromagnetic signals corresponding to the monitored response and the characteristic. A processor processes the set of electromagnetic signals and extracts feature vectors. The feature vectors define a class of behavioral intent. The processor determines the behavioral intent of the person based on the feature vectors. A brain machine interface and a method for identifying a behavioral intent of a person is also disclosed.,TELEDYNE SCIENT & IMAGING LLC,CONNOLLY PATRICK M;;SIMONS STEPHEN;;ZACHERY KAREN;;AHRENS BARRY;;AGUILAR-SIMON MARIO;;REYNOLDS JR WILLIAM D;;KRNAVEK DAVID,TELEDYNE SCIENTIFIC & IMAGING LLC (2018-12-20),https://lens.org/152-006-111-706-284,Patent Application,yes,1,1,7,7,0,G06F3/013;;G06F3/015;;A61B5/16;;A61B3/113;;A61B5/7264;;A61F2/72;;G06F3/04842;;G16H50/20;;A61B5/246;;A61B5/316;;A61B5/378;;A61B5/38;;A61B5/374;;G06F3/013;;G06F3/015;;A61B5/16;;A61B5/38;;A61B5/246;;A61B5/374;;A61B5/378;;A61B3/113;;A61B5/11;;A61B5/7264;;A61F2/72;;G06F3/04842,A61F2/72;;A61B3/113;;A61B5/00;;A61B5/11;;A61B5/16;;A61B5/246;;A61B5/316;;A61B5/374;;A61B5/378;;A61B5/38;;G06F3/01;;G06F3/0484,,0,0,,,,ACTIVE
366,EP,A3,EP 1207654 A3,160-479-313-654-435,2004-06-09,2004,EP 01122651 A,2001-09-27,US 71480300 A,2000-11-16,Coexistence techniques in wireless networks,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/160-479-313-654-435,Search Report,yes,8,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04M1/725;;H04L12/28;;H04L12/46;;H04L12/56,,5,0,,,"KAMERMAN, A: ""Coexistence between Bluetooth and IEEE 802.11 CCK Solutions to avoid mutual interference"", IEEE 802.11-00/162, 30 June 2000 (2000-06-30), XP002256503, Retrieved from the Internet <URL:http://grouper.ieee.org/groups/802/11/index.html> [retrieved on 20031002];;NEGUS K J ET AL: ""HOME RF TM AND SWAP: WIRELESS NETWORKING FOR THE CONNECTED HOME"", MOBILE COMPUTING AND COMMUNICATIONS REVIEW, ACM, NEW YORK, NY, US, vol. 2, no. 4, 1 October 1998 (1998-10-01), pages 28 - 36, XP000786057, ISSN: 1091-1669;;""IEEE standard Part 11: wireless LAN medium access control (MAC) and physical layer (PHY) specification. (ISO/IEC 8802-11, ANSI/IEEE Std 802.11-1999) Chapter 11: MAC sublayer management entity"", ISO/IEC 8802-11 ANSI/IEEE STD 802.11, XX, XX, 20 August 1999 (1999-08-20), pages 123 - 137, XP002207975;;""Bluetooth Specification Version 1.0 B, Part B: Baseband, Chapters 1-4."", CORE, 29 November 1999 (1999-11-29), pages 33 - 66, XP002271445, Retrieved from the Internet <URL:https://www.bluetooth.org/docman2/ViewCategory.php?group_id=53&category_id=213> [retrieved on 20031014];;""IEEE standard Part 11: wireless LAN medium access control (MAC) and physical layer (PHY) specification. (ISO/IEC 8802-11, ANSI/IEEE Std 802.11-1999) Chapter 9: MAC sublayer functional description"", ISO/IEC 8802-11 ANSI/IEEE STD 802.11, XX, XX, 20 August 1999 (1999-08-20), pages 70 - 97, XP002207974",EXPIRED
367,AT,T1,AT E383014 T1,037-539-818-580-18X,2008-01-15,2008,AT 01122651 T,2001-09-27,US 71480300 A,2000-11-16,VERFAHREN ZUR KOEXISTENZ IN EINEM GATEWAY ZWISCHEN WLAN AND BLUETOOTH DRAHTLOSEN NETZEN.,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/037-539-818-580-18X,Granted Patent,no,0,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,EXPIRED
368,EP,A2,EP 1207654 A2,062-214-853-207-832,2002-05-22,2002,EP 01122651 A,2001-09-27,US 71480300 A,2000-11-16,Coexistence techniques in a gateway between Bluetooth and WLAN wireless networks.,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/062-214-853-207-832,Patent Application,yes,0,95,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04M1/725;;H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,EXPIRED
369,DE,T2,DE 60132156 T2,121-469-936-717-734,2009-01-02,2009,DE 60132156 T,2001-09-27,US 71480300 A,2000-11-16,Verfahren zur Koexistenz in einem Gateway zwischen WLAN and Bluetooth drahtlosen Netzen.,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/121-469-936-717-734,Granted Patent,no,0,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04L12/56;;H04M1/725;;H04L12/28;;H04L12/46,,0,0,,,,EXPIRED
370,AU,B2,AU 783921 B2,036-165-909-652-169,2005-12-22,2005,AU 2001/072045 A,2001-09-13,US 71480300 A,2000-11-16,Coexistence techniques in wireless networks,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/036-165-909-652-169,Granted Patent,no,3,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04L12/66;;H04M1/725;;H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,EXPIRED
371,US,A1,US 2006/0211372 A1,011-522-923-268-716,2006-09-21,2006,US 41614006 A,2006-05-02,US 41614006 A;;US 71480300 A;;US 17526200 P;;US 19697900 P,2000-01-10,Coexistence techniques in wireless networks,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/011-522-923-268-716,Patent Application,yes,16,61,2,13,0,H04W16/14;;H04W16/14;;Y02D30/70,H04M1/00;;H04B7/00,455/41.2;;455/552.1,0,0,,,,DISCONTINUED
372,EP,B1,EP 1207654 B1,058-457-420-332-269,2008-01-02,2008,EP 01122651 A,2001-09-27,US 71480300 A,2000-11-16,Coexistence techniques in a gateway between Bluetooth and WLAN wireless networks.,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/058-457-420-332-269,Granted Patent,yes,8,5,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04L12/56;;H04M1/725;;H04L12/28;;H04L12/46,,5,0,,,"KAMERMAN, A: ""Coexistence between Bluetooth and IEEE 802.11 CCK Solutions to avoid mutual interference"" IEEE 802.11-00/162, [Online] 30 June 2000 (2000-06-30), XP002256503 Retrieved from the Internet: <URL:http://grouper.ieee.org/groups/802/11 /index.html> [retrieved on 2003-10-02];;NEGUS K J ET AL: ""HOME RF TM AND SWAP: WIRELESS NETWORKING FOR THE CONNECTED HOME"" MOBILE COMPUTING AND COMMUNICATIONS REVIEW, ACM, NEW YORK, NY, US, vol. 2, no. 4, 1 October 1998 (1998-10-01), pages 28-36, XP000786057 ISSN: 1091-1669;;""IEEE standard Part 11: wireless LAN medium access control (MAC) and physical layer (PHY) specification. (ISO/IEC 8802-11, ANSI/IEEE Std 802.11-1999) Chapter 11: MAC sublayer management entity"" ISO/IEC 8802-11 ANSI/IEEE STD 802.11, XX, XX, 20 August 1999 (1999-08-20), pages 123-137, XP002207975;;""Bluetooth Specification Version 1.0 B, Part B: Baseband, Chapters 1-4. "" CORE, [Online] 29 November 1999 (1999-11-29), pages 33-66, XP002271445 Retrieved from the Internet: <URL:https://www.bluetooth.org/docman2/Vie wCategory.php?group_id=53&category_id=213> [retrieved on 2003-10-14];;""IEEE standard Part 11: wireless LAN medium access control (MAC) and physical layer (PHY) specification. (ISO/IEC 8802-11, ANSI/IEEE Std 802.11-1999) Chapter 9: MAC sublayer functional description"" ISO/IEC 8802-11 ANSI/IEEE STD 802.11, XX, XX, 20 August 1999 (1999-08-20), pages 70-97, XP002207974",EXPIRED
373,DE,D1,DE 60132156 D1,004-434-221-920-593,2008-02-14,2008,DE 60132156 T,2001-09-27,US 71480300 A,2000-11-16,Verfahren zur Koexistenz in einem Gateway zwischen WLAN and Bluetooth drahtlosen Netzen.,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/004-434-221-920-593,Granted Patent,no,0,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04L12/56;;H04M1/725;;H04L12/28;;H04L12/46,,0,0,,,,EXPIRED
374,CN,B,CN 1358003 B,000-877-102-161-659,2012-06-06,2012,CN 01137450 A,2001-11-13,US 71480300 A,2000-11-16,Transmission coordination device in radio network,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;JACOB SHARONY;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;WILLIAM SACKETT;;JOSEPH CABANA;;PATRICK TILLEY;;ROBERT BEACH,,https://lens.org/000-877-102-161-659,Granted Patent,no,0,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04M1/725;;H04W16/14;;H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,EXPIRED
375,US,B1,US 7039358 B1,048-889-265-631-387,2006-05-02,2006,US 71480300 A,2000-11-16,US 71480300 A;;US 17526200 P;;US 19697900 P,2000-01-10,Coexistence techniques in wireless networks,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,SYMBOL TECHNOLOGIES LLC (2001-04-26),https://lens.org/048-889-265-631-387,Granted Patent,yes,13,211,2,13,0,H04W16/14;;H04W16/14;;Y02D30/70,H04B7/00,455/41.2;;455/426.1,0,0,,,,EXPIRED
376,AU,A,AU 2001/072045 A,078-553-061-230-417,2002-05-23,2002,AU 2001/072045 A,2001-09-13,US 71480300 A,2000-11-16,Coexistence techniques in wireless networks,"Techniques are provided for frequency coordination among two different wireless network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver. <IMAGE>",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;BEACH ROBERT;;TILLEY PATRICK;;CABANA JOSEPH;;SACKETT WILLIAM;;CONNOLLY SEAN A;;BIUSO ANTHONY D;;SHARONY JACOB,,https://lens.org/078-553-061-230-417,Patent Application,no,0,0,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04M1/725;;H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,EXPIRED
377,JP,A,JP 2002185476 A,143-941-198-339-78X,2002-06-28,2002,JP 2001337161 A,2001-09-27,US 71480300 A,2000-11-16,COEXISTENCE TECHNIQUE IN WIRELESS NETWORK,"PROBLEM TO BE SOLVED: To provide a coexistence technique which is used for frequency coordination between two different network protocols, such as the IEEE 802.11 and Bluetooth protocols, operating in proximity with one another. SOLUTION: Coordination is accomplished by the use of a first radio transceiver operating in accordance with a first communication protocol (which may be the 802.11 protocol) and using a frequency band (which may be the 2.4 GHz band), a base station connected to a wired network and operating in accordance with the first communication protocol, a second radio transceiver operating in accordance with a second communication protocol (which may be the Bluetooth protocol) and using the frequency band, and a coordinator associated with the base station for, in turn, activating the first radio transceiver, deactivating the first radio transceiver, activating the second radio transceiver, and deactivating the second radio transceiver.",SYMBOL TECHNOLOGIES INC,SHELLHAMMER STEPHEN J;;SHARONY JACOB;;BIUSO ANTHONY D;;CONNOLLY SEAN A;;SACKETT WILLIAM;;CABANA JOSEPH;;TILLEY PATRICK;;BEACH ROBERT,,https://lens.org/143-941-198-339-78X,Patent Application,no,0,12,11,13,0,H04M1/725;;H04M2250/02;;H04W16/00;;H04W84/12;;H04W84/18;;H04W88/06;;H04W52/0216;;H04W52/0219;;H04W52/287;;Y02D30/70,H04M1/725;;H04L12/28;;H04L12/46;;H04L12/56,,0,0,,,,PENDING
378,EP,A1,EP 3407800 A1,027-725-114-006-610,2018-12-05,2018,EP 17726069 A,2017-05-15,US 201662337090 P;;US 2017/0032730 W,2016-05-16,ENDOSCOPIC SUTURE AND CINCH ANASTOMOTIC LEAK REPAIR DEVICE,,BOSTON SCIENT SCIMED INC,WILLARD MARTIN R;;TASSONI JR ANTHONY F;;TASSONI NICHOLAS L;;HAVERKOST PATRICK A;;PEDERSON JR GARY J;;CONNOLLY JOSEPH M,,https://lens.org/027-725-114-006-610,Patent Application,yes,0,0,5,5,0,A61B17/0466;;A61B17/0487;;A61B2017/0034;;A61B2017/00663;;A61B2017/0409;;A61B2017/0417;;A61B2017/0464;;A61B2017/0475;;A61B2017/0488;;A61B2017/0496;;A61B17/0401;;A61B2017/00575;;A61B2017/00623;;A61B17/0057;;A61B2017/00818;;A61B2017/0417;;A61B2017/0475;;A61B2017/0034;;A61B17/0466;;A61B2017/0409;;A61B17/0487;;A61B2017/00663;;A61B2017/0488;;A61B2017/0464;;A61B2017/0496;;A61B17/0401;;A61B2017/00623;;A61B2017/00575;;A61B17/00234;;A61B17/0057;;A61B17/083;;A61B17/1227;;A61B17/1285;;A61B2017/00238;;A61B2017/00659;;A61B2017/00818;;A61B2017/00862,A61B17/00;;A61B17/04,,0,0,,,,DISCONTINUED
379,WO,A1,WO 2017/200947 A1,069-435-300-560-461,2017-11-23,2017,US 2017/0032730 W,2017-05-15,US 201662337090 P,2016-05-16,ENDOSCOPIC SUTURE AND CINCH ANASTOMOTIC LEAK REPAIR DEVICE,"A system for treating tissue includes a first fastener including a first anchoring element at a distal end thereof for anchoring the first fastener in a first target portion of tissue extending about a periphery of a tissue defect to be treated and a first suture extending from a proximal end thereof. The system also includes a second fastener including a second anchoring element at a distal end thereof for anchoring the second fastener in a second target portion of tissue extending about a periphery of a tissue defect to be treated and a second suture extending from a proximal end thereof. Furthermore, the system includes a cinch element disposed about both of the first and second sutures and slidable therealong such that a tension applied to the first and second sutures draws the fist and second fasteners toward one another to close the tissue defect.",BOSTON SCIENT SCIMED INC,WILLARD MARTIN R;;TASSONI JR ANTHONY F;;TASSONI NICHOLAS L;;HAVERKOST PATRICK A;;PEDERSON JR GARY J;;CONNOLLY JOSEPH M,,https://lens.org/069-435-300-560-461,Patent Application,yes,5,0,5,5,0,A61B17/0466;;A61B17/0487;;A61B2017/0034;;A61B2017/00663;;A61B2017/0409;;A61B2017/0417;;A61B2017/0464;;A61B2017/0475;;A61B2017/0488;;A61B2017/0496;;A61B17/0401;;A61B2017/00575;;A61B2017/00623;;A61B17/0057;;A61B2017/00818;;A61B2017/0417;;A61B2017/0475;;A61B2017/0034;;A61B17/0466;;A61B2017/0409;;A61B17/0487;;A61B2017/00663;;A61B2017/0488;;A61B2017/0464;;A61B2017/0496;;A61B17/0401;;A61B2017/00623;;A61B2017/00575;;A61B17/00234;;A61B17/0057;;A61B17/083;;A61B17/1227;;A61B17/1285;;A61B2017/00238;;A61B2017/00659;;A61B2017/00818;;A61B2017/00862,A61B17/00;;A61B17/04,,0,0,,,,PENDING
380,CN,A,CN 109152571 A,141-448-526-889-464,2019-01-04,2019,CN 201780030197 A,2017-05-15,US 201662337090 P;;US 2017/0032730 W,2016-05-16,ENDOSCOPIC SUTURE AND CINCH ANASTOMOTIC LEAK REPAIR DEVICE,"A system for treating tissue includes a first fastener including a first anchoring element at a distal end thereof for anchoring the first fastener in a first target portion of tissue extending abouta periphery of a tissue defect to be treated and a first suture extending from a proximal end thereof. The system also includes a second fastener including a second anchoring element at a distal end thereof for anchoring the second fastener in a second target portion of tissue extending about a periphery of a tissue defect to be treated and a second suture extending from a proximal end thereof. Furthermore, the system includes a cinch element disposed about both of the first and second sutures and slidable therealong such that a tension applied to the first and second sutures draws the fist and second fasteners toward one another to close the tissue defect.",BOSTON SCIENT SCIMED INC,WILLARD MARTIN R;;TASSONI JR ANTHONY F;;TASSONI NICHOLAS L;;HAVERKOST PATRICK A;;PEDERSON JR GARY J;;CONNOLLY JOSEPH M,,https://lens.org/141-448-526-889-464,Patent Application,no,9,0,5,5,0,A61B17/0466;;A61B17/0487;;A61B2017/0034;;A61B2017/00663;;A61B2017/0409;;A61B2017/0417;;A61B2017/0464;;A61B2017/0475;;A61B2017/0488;;A61B2017/0496;;A61B17/0401;;A61B2017/00575;;A61B2017/00623;;A61B17/0057;;A61B2017/00818;;A61B2017/0417;;A61B2017/0475;;A61B2017/0034;;A61B17/0466;;A61B2017/0409;;A61B17/0487;;A61B2017/00663;;A61B2017/0488;;A61B2017/0464;;A61B2017/0496;;A61B17/0401;;A61B2017/00623;;A61B2017/00575;;A61B17/00234;;A61B17/0057;;A61B17/083;;A61B17/1227;;A61B17/1285;;A61B2017/00238;;A61B2017/00659;;A61B2017/00818;;A61B2017/00862,A61B17/00;;A61B17/04,,0,0,,,,DISCONTINUED
381,US,A1,US 2017/0325794 A1,134-457-959-764-457,2017-11-16,2017,US 201715595710 A,2017-05-15,US 201715595710 A;;US 201662337090 P,2016-05-16,Endoscopic Suture And Cinch Anastomotic Leak Repair Device,"A system for treating tissue includes a first fastener including a first anchoring element at a distal end thereof for anchoring the first fastener in a first target portion of tissue extending about a periphery of a tissue defect to be treated and a first suture extending from a proximal end thereof. The system also includes a second fastener including a second anchoring element at a distal end thereof for anchoring the second fastener in a second target portion of tissue extending about a periphery of a tissue defect to be treated and a second suture extending from a proximal end thereof. Furthermore, the system includes a cinch element disposed about both of the first and second sutures and slidable therealong such that a tension applied to the first and second sutures draws the first and second fasteners toward one another to close the tissue defect.",BOSTON SCIENT SCIMED INC,WILLARD MARTIN R;;TASSONI JR ANTHONY F;;TASSONI NICHOLAS L;;HAVERKOST PATRICK A;;PEDERSON JR GARY J;;CONNOLLY JOSEPH M,BOSTON SCIENTIFIC SCIMED INC (2017-04-28),https://lens.org/134-457-959-764-457,Patent Application,yes,3,1,5,5,0,A61B17/0466;;A61B17/0487;;A61B2017/0034;;A61B2017/00663;;A61B2017/0409;;A61B2017/0417;;A61B2017/0464;;A61B2017/0475;;A61B2017/0488;;A61B2017/0496;;A61B17/0401;;A61B2017/00575;;A61B2017/00623;;A61B17/0057;;A61B2017/00818;;A61B2017/0417;;A61B2017/0475;;A61B2017/0034;;A61B17/0466;;A61B2017/0409;;A61B17/0487;;A61B2017/00663;;A61B2017/0488;;A61B2017/0464;;A61B2017/0496;;A61B17/0401;;A61B2017/00623;;A61B2017/00575;;A61B17/00234;;A61B17/0057;;A61B17/083;;A61B17/1227;;A61B17/1285;;A61B2017/00238;;A61B2017/00659;;A61B2017/00818;;A61B2017/00862,A61B17/00;;A61B17/08;;A61B17/122;;A61B17/128,,0,0,,,,DISCONTINUED
382,US,A1,US 2019/0375781 A1,081-509-552-230-067,2019-12-12,2019,US 201816478864 A,2018-01-26,US 201816478864 A;;US 201762454131 P;;US 201762451285 P;;IB 2018050497 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1C , R 1D , B 1 , R 2A , R 2B , R 2C , R 2D , and R 2E are defined herein and Formula (II) wherein R 1H , R 1K , R 1J , and R 2L are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,JANSSEN BIOPHARMA INC (2019-07-30);;JANSSEN BIOTECH INC (2018-01-26),https://lens.org/081-509-552-230-067,Patent Application,yes,0,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,C07H21/00;;A61P31/12;;A61P35/00,,0,0,,,,ACTIVE
383,EP,A1,EP 3267898 A1,195-035-439-250-754,2018-01-17,2018,EP 16710616 A,2016-03-08,US 201562130375 P;;US 2016/0021386 W,2015-03-09,ARTERIAL - VENOUS OCCLUSION APPARATUS,,BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;HARRISON DAVID KENT;;CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;RAAB DAVID,,https://lens.org/195-035-439-250-754,Patent Application,yes,0,0,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/00,,0,0,,,,ACTIVE
384,ES,T3,ES 2891326 T3,124-431-879-666-103,2022-01-27,2022,ES 18703857 T,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,Dinucleótidos cíclicos como agonistas de la STING,El compuesto: **(Ver fórmula)** o una forma de sal farmacéuticamente aceptable del mismo.,JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/124-431-879-666-103,Granted Patent,no,0,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
385,CN,A,CN 110234404 A,181-835-955-817-910,2019-09-13,2019,CN 201880009027 A,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II), wherein R1H, R1K, R1J, and R2L are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/181-835-955-817-910,Patent Application,no,5,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,1,0,,,"丛晓燕: ""新型免疫佐剂环二鸟苷酸的制备与纯化"", 细胞与分子免疫学杂志, vol. 31, no. 10, pages 1354 - 1357",PENDING
386,EP,B1,EP 3573717 B1,187-729-534-304-964,2021-07-28,2021,EP 18703857 A,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/187-729-534-304-964,Granted Patent,yes,5,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,1,0,,,"THIERRY LIOUX ET AL: ""Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 22, 4 November 2016 (2016-11-04), pages 10253-10267, XP055457763, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01300",ACTIVE
387,US,A1,US 2022/0378438 A1,073-069-253-969-885,2022-12-01,2022,US 202217885117 A,2022-08-10,US 202217885117 A;;US 201615064415 A;;US 201562130375 P,2015-03-09,ARTERIAL-VENOUS OCCLUSION APPARATUS,"Expandable occlusive plugs and methods of using them are disclosed. The devices generally include a tubular body bearing multiple slits defining leaves, which expand radially outward when the ends of the device are brought toward one another.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;HARRISON KENT DAVID;;CONNOLLY JOSEPH MICHAEL;;PEDERSON JR GARY JOHN;;ANDERSON MARY-CLAIRE;;RAAB DAVID,,https://lens.org/073-069-253-969-885,Patent Application,yes,0,0,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/12;;A61B17/00,,0,0,,,,PENDING
388,EP,A1,EP 3573717 A1,110-126-836-997-587,2019-12-04,2019,EP 18703857 A,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/110-126-836-997-587,Patent Application,yes,0,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
389,EP,B1,EP 3267898 B1,073-724-981-386-280,2020-11-25,2020,EP 16710616 A,2016-03-08,US 201562130375 P;;US 2016/0021386 W,2015-03-09,ARTERIAL - VENOUS OCCLUSION APPARATUS,,BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;HARRISON DAVID KENT;;CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;RAAB DAVID,,https://lens.org/073-724-981-386-280,Granted Patent,yes,2,0,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/00,,0,0,,,,ACTIVE
390,AU,B2,AU 2018/212787 B2,008-121-497-741-674,2023-10-26,2023,AU 2018/212787 A,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/008-121-497-741-674,Granted Patent,no,0,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
391,US,A1,US 2016/0262768 A1,146-740-501-799-366,2016-09-15,2016,US 201615064415 A,2016-03-08,US 201615064415 A;;US 201562130375 P,2015-03-09,ARTERIAL-VENOUS OCCLUSION APPARATUS,"Expandable occlusive plugs and methods of using them are disclosed. The devices generally include a tubular body bearing multiple slits defining leaves, which expand radially outward when the ends of the device are brought toward one another.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;KENT DAVID HARRISON;;CONNOLLY JOSEPH MICHAEL;;PEDERSON JR GARY JOHN;;ANDERSON MARY-CLAIRE;;RAAB DAVID,BOSTON SCIENTIFIC SCIMED INC (2016-05-03),https://lens.org/146-740-501-799-366,Patent Application,yes,10,2,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/12,,0,0,,,,ACTIVE
392,AU,A1,AU 2018/212787 A1,172-288-608-398-137,2019-07-25,2019,AU 2018/212787 A,2018-01-26,US 201762451285 P;;US 201762454131 P;;IB 2018050497 W,2017-01-27,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/172-288-608-398-137,Patent Application,no,0,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
393,WO,A1,WO 2018/138684 A1,060-450-838-870-654,2018-08-02,2018,IB 2018050497 W,2018-01-26,US 201762451285 P;;US 201762454131 P,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1C , R 1D , B 1 , R 2A , R 2B , R 2C , R 2D , and R 2E are defined herein and Formula (II), wherein R 1H , R 1K , R 1J , and R 2L are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,,https://lens.org/060-450-838-870-654,Patent Application,yes,5,19,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61K31/7084;;A61P35/00;;A61P31/12;;C07H21/00,,22,20,066-720-424-156-341;;034-666-907-619-827;;102-034-121-002-023;;010-341-241-568-683;;006-540-796-046-165;;008-962-459-855-781;;060-000-705-511-414;;091-765-617-073-134;;002-895-644-883-279;;012-165-000-131-176;;006-911-733-023-062;;077-295-491-167-117;;077-295-491-167-117;;045-298-563-967-678;;040-887-679-477-746;;012-180-065-013-539;;029-641-974-701-191;;102-071-695-047-127;;018-874-474-967-696;;063-161-621-710-260,27783523;;10.1021/acs.jmedchem.6b01300;;10.1016/j.immuni.2008.09.003;;18818105;;10.1126/science.aaa2630;;25636800;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.1232458;;pmc3863629;;23258413;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;10.1002/0471220574;;10.1002/0471220574;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.2165/00003088-198106060-00002;;7032803;;10.1007/bf01952257;;6382953;;10.1016/0065-2571(84)90007-4;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1110/ps.8.4.921;;10211839;;pmc2144313,"THIERRY LIOUX ET AL: ""Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 22, 4 November 2016 (2016-11-04), pages 10253 - 10267, XP055457763, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01300;;ZHONG B ET AL.: ""The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation"", IMMUNITY, vol. 29, 2008, pages 538 - 550, XP055021580, DOI: doi:10.1016/j.immuni.2008.09.003;;LIU S ET AL.: ""Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation"", SCIENCE, 2015, pages 2630 - 2637;;CHEN H ET AL.: ""Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity"", CELL, vol. 14, 2011, pages 433 - 446;;CORRALES, L. ET AL.: ""Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity"", CELL REPORTS, vol. 11, 2015, pages 1 - 13;;KONNO, H. ET AL.: ""Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling"", CELL, vol. 155, 2013, pages 688 - 698, XP028758016, DOI: doi:10.1016/j.cell.2013.09.049;;SUN, L. ET AL.: ""Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway"", SCIENCE, vol. 339, 2013, pages 786 - 791, XP055294100, DOI: doi:10.1126/science.1232458;;BHAT N; FITZGERALD KA: ""Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors"", EUR J IMMUNOL., vol. 44, no. 3, March 2014 (2014-03-01), pages 634 - 40;;ZHANG X ET AL.: ""Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING"", MOLECULAR CELL, vol. 51, 2013, pages 226 - 235, XP055300246, DOI: doi:10.1016/j.molcel.2013.05.022;;DANILCHANKA, O; MEKALANOS, JJ: ""Cyclic Dinucleotides and the Innate Immune Response"", CELL, vol. 154, 2013, pages 962 - 970, XP028706417, DOI: doi:10.1016/j.cell.2013.08.014;;LIU S-Y ET AL.: ""Systematic identification of type I and type II interferon-induced antiviral factors"", PROC. NATL. ACAD. SCI., vol. 109, 2012, pages 4239 - 4244;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;VAN DER JEUGHT ET AL., ONCOTARGET, vol. 6, no. 3, 2015, pages 1359 - 1381;;MARABELLE, A. ET AL., CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1747 - 1756;;HOLFORD; SCHEINER, CLIN. PHARMACOKINET., vol. 6, pages 429 - 453;;LOEWE; MUISCHNEK, ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326;;CHOU; TALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;YI: ""Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides"", PLOS ONE, vol. 8, no. 10, 2013, pages e77846, XP055315013, DOI: doi:10.1371/journal.pone.0077846;;BECKETT ET AL.: ""A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation"", PROTEIN SCIENCE, vol. 8, 1999, pages 921 - 929, XP002971557",PENDING
394,US,B2,US 11021511 B2,075-996-129-805-760,2021-06-01,2021,US 201816478864 A,2018-01-26,US 201816478864 A;;US 201762454131 P;;US 201762451285 P;;IB 2018050497 W,2017-01-27,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1C , R 1D , B 1 , R 2A , R 2B , R 2C , R 2D , and R 2E are defined herein and Formula (II) wherein R 1H , R 1K , R 1J , and R 2L are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES,JANSSEN BIOPHARMA INC (2019-07-30);;JANSSEN BIOTECH INC (2018-01-26),https://lens.org/075-996-129-805-760,Granted Patent,yes,34,0,12,12,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00;;A61K31/708;;A61K31/7084;;A61K31/7076,A61K31/70;;A01N43/04;;A61K31/7076;;A61K31/708;;A61K31/7084;;A61P31/12;;A61P35/00;;C07H21/00,,23,21,012-274-059-938-348;;101-871-534-522-088;;034-712-095-409-65X;;066-720-424-156-341;;063-161-621-710-260;;091-765-617-073-134;;010-341-241-568-683;;006-540-796-046-165;;012-165-000-131-176;;101-871-534-522-088;;008-962-459-855-781;;102-034-121-002-023;;006-911-733-023-062;;066-720-424-156-341;;040-887-679-477-746;;060-000-705-511-414;;045-298-563-967-678;;040-926-671-971-706;;018-874-474-967-696;;002-895-644-883-279;;034-666-907-619-827,10.1080/15257770903091946;;20183608;;pmc4335851;;25512416;;10.1128/aac.04321-14;;pmc4547588;;26205674;;10.1016/j.antiviral.2015.07.006;;27783523;;10.1021/acs.jmedchem.6b01300;;10.1110/ps.8.4.921;;10211839;;pmc2144313;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;pmc4335851;;25512416;;10.1128/aac.04321-14;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.aaa2630;;25636800;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;27783523;;10.1021/acs.jmedchem.6b01300;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.1126/science.1232458;;pmc3863629;;23258413;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;10.1021/pr300408v;;23181431;;pmc3739059;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;10.1016/j.immuni.2008.09.003;;18818105,"Tiwari et al. Nucleosides, Nucleotides and Nucleic Acids (2009), vol. 28, Nos. 5-7, pp. 657-677.;;Guo, Fang, Yanxing Han, Xuesen Zhao, Jianghua Wang, Fei Liu, Chunxiao Xu, Lai Wei et al. “STING agonists induce an innate antiviral immune response against hepatitis B virus.” Antimicrobial agents and chemotherapy 59, No. 2 (2015): 1273-1281.;;Chang et al. Antiviral Research (2015), vol. 121, pp. 152-159.;;Lioux et al. Journal of Medicinal Chemistry (2016), vol. 59, pp. 10253-10267.;;International Search Report relating to International Patent Application No. PCT/IB2018/050497, filed Jan. 26, 2018. Date of Mailing of International Search Report: dated Jun. 11, 2018.;;Written Opinion of the International Searching Authority relating to International Patent Application no. PCT/IB2018/050497, filed Jan. 26, 2018. Date of Mailing of International Search Report: dated Jun. 11, 2018.;;Beckett et al., “A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation.”, Protein Science, 1999, pp. 921-929, vol. 8.;;Bhat, N. and Fitzgerald, K.A., “Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors.”, Eur J Immunol., Mar. 2014, pp. 634-640, vol. 44(3).;;Chen et al. “Activation of State by STING Is Critical for Antiviral Innate Immunity.”, Cell, Oct. 14, 2011, pp. 433-446, vol. 147.;;Corrales et al., “Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity.”, Cell Reports, May 19, 2015, pp. 1018-1030, vol. 11.;;Danilchanka, O. and Mekalanos, JJ., “Cyclic Dinucleotides and the Innate Immune Response.”, Cell, Aug. 29, 2013, pp. 962-970, vol. 154.;;Guo et al., “STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus.”, Antimicrobial Agents and Chemotherapy, Feb. 2015, pp. 1273-1281, vol. 59(2).;;Konno et al., “Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling.”, Cell, Oct. 24, 2013, pp. 688-698, vol. 155.;;Liu et al., “Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.”, Science, Mar. 13, 2015, pp. 2630-2637, vol. 347(6227).;;Liu et al., “Systematic identification of type I and type II interferon-induced antiviral factors.”, Proc. Natl. Acad. Sci., Mar. 13, 2012, pp. 4239-4244, vol. 109(11).;;Louix et al., “Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes.”, J. Med. Chem., Nov. 4, 2016, pp. 10253-10267, vol. 59(22).;;Marabelle et al., “Intratumoral Immunization: A New Paradigm for Cancer Therapy.”, Clinical Cancer Research, Apr. 1, 2014, pp. 1747-1756, vol. 20(7).;;Sun et al., “Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway.”, Science, Feb. 15, 2013, pp. 786-791, vol. 339.;;Van der Jeught et al., “Targeting the tumor microenviroment to enhance antitumor immune responses.”, Oncotarget, Dec. 26, 2014, pp. 1359-1381, vol. 6(3).;;Wu et al., “Novel Phosphorylation Sites in the S. cerevisiae Cdc13 Protein Reveal New Targets for Telomere Length Regulation.”, Journal of Proteome Research, 2013, pp. 316-327, vol. 12.;;Yi et. al., “Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides.”, PLOS ONE, Oct. 2013, pp. 1-15, vol. 8(10), e77846.;;Zhang et al., “Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING.”, Molecular Cell, Jul. 25, 2013, pp. 226-235, vol. 51.;;Zhong et al., “The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation.”, Immunity, Oct. 17, 2008, pp. 538-550, vol. 29.",ACTIVE
395,WO,A1,WO 2016/144965 A1,139-365-258-241-091,2016-09-15,2016,US 2016/0021386 W,2016-03-08,US 201562130375 P,2015-03-09,ARTERIAL - VENOUS OCCLUSION APPARATUS,"Expandable occlusive plugs and methods of using them are disclosed. The devices generally include a tubular body bearing multiple slits defining leaves, which expand radially outward when the ends of the device are brought toward one another.",BOSTON SCIENT SCIMED INC;;HAVERKOST PATRICK A;;GROFF JOEL N;;HARRISON DAVID KENT;;CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;RAAB DAVID,HAVERKOST PATRICK A;;GROFF JOEL N;;HARRISON DAVID KENT;;CONNOLLY JOSEPH MICHAEL;;PEDERSON GARY JOHN JR;;ANDERSON MARY-CLAIRE;;RAAB DAVID,,https://lens.org/139-365-258-241-091,Patent Application,yes,5,0,6,6,0,A61B17/0057;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B2017/00597;;A61B2017/00606;;A61B2017/00526;;A61B2017/00575;;A61B2017/00592;;A61B17/0057;;A61B2017/00606;;A61B2017/00597;;A61B17/12031;;A61B17/12036;;A61B17/12109;;A61B17/12172;;A61B2017/00867;;A61B2017/12054,A61B17/00,,0,0,,,,PENDING
396,US,B2,US 11607207 B2,047-773-018-835-330,2023-03-21,2023,US 201916658301 A,2019-10-21,US 201916658301 A;;US 201715593977 A;;US 201662336827 P,2016-05-16,Devices and methods for reducing a dimension of openings in tissue,"A clip for reducing a dimension of an opening in tissue may include a continuous member having a plurality of legs and a plurality of preformed bends connecting adjacent legs, wherein the plurality of legs form: a first group having two protrusions; a second group having two protrusions; and a third group having two protrusions, wherein each protrusion of each group includes two legs of the continuous member and a corresponding preformed bend connecting the two legs, and each protrusion of each group extends from a region adjacent a first end of the clip to a region adjacent a second end of the clip.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;WILLARD MARTIN R;;TASSONI JR ANTHONY FRANK;;TASSONI NICHOLAS LEE;;PEDERSON JR GARY JOHN;;CONNOLLY JOSEPH MICHAEL,BOSTON SCIENTIFIC SCIMED INC (2017-04-21),https://lens.org/047-773-018-835-330,Granted Patent,yes,39,0,4,4,0,A61B17/083;;A61B17/1227;;A61F5/0086;;A61B2017/00243;;A61B2017/00575;;A61B2017/00893;;A61B2017/00964;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B2017/00575;;A61B17/1227;;A61B2017/00964;;A61F5/0086;;A61B17/083;;A61B2017/00243;;A61B2017/00893,A61B17/122;;A61B17/00;;A61B17/08;;A61B17/128;;A61F5/00,,0,0,,,,ACTIVE
397,US,B2,US 10485526 B2,138-219-356-045-607,2019-11-26,2019,US 201715593977 A,2017-05-12,US 201715593977 A;;US 201662336827 P,2016-05-16,Devices and methods for reducing a dimension of openings in tissue,"A clip for reducing a dimension of an opening in tissue may include a continuous member having a plurality of legs and a plurality of preformed bends connecting adjacent legs, wherein the plurality of legs form: a first group having two protrusions; a second group having two protrusions; and a third group having two protrusions, wherein each protrusion of each group includes two legs of the continuous member and a corresponding preformed bend connecting the two legs, and each protrusion of each group extends from a region adjacent a first end of the clip to a region adjacent a second end of the clip.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;WILLARD MARTIN R;;TASSONI JR ANTHONY FRANK;;TASSONI NICHOLAS LEE;;PEDERSON JR GARY JOHN;;CONNOLLY JOSEPH MICHAEL,BOSTON SCIENTIFIC SCIMED INC (2017-04-21),https://lens.org/138-219-356-045-607,Granted Patent,yes,3,1,4,4,0,A61B17/083;;A61B17/1227;;A61F5/0086;;A61B2017/00243;;A61B2017/00575;;A61B2017/00893;;A61B2017/00964;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B2017/00575;;A61B17/1227;;A61B2017/00964;;A61F5/0086;;A61B17/083;;A61B2017/00243;;A61B2017/00893,A61B17/00;;A61B17/08;;A61B17/122;;A61B17/128;;A61F5/00,,0,0,,,,ACTIVE
398,US,A1,US 2020/0046332 A1,153-398-871-672-680,2020-02-13,2020,US 201916658301 A,2019-10-21,US 201916658301 A;;US 201715593977 A;;US 201662336827 P,2016-05-16,DEVICES AND METHODS FOR REDUCING A DIMENSION OF OPENINGS IN TISSUE,"A clip for reducing a dimension of an opening in tissue may include a continuous member having a plurality of legs and a plurality of preformed bends connecting adjacent legs, wherein the plurality of legs form: a first group having two protrusions; a second group having two protrusions; and a third group having two protrusions, wherein each protrusion of each group includes two legs of the continuous member and a corresponding preformed bend connecting the two legs, and each protrusion of each group extends from a region adjacent a first end of the clip to a region adjacent a second end of the clip.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;WILLARD MARTIN R;;TASSONI JR ANTHONY FRANK;;TASSONI NICHOLAS LEE;;PEDERSON JR GARY JOHN;;CONNOLLY JOSEPH MICHAEL,BOSTON SCIENTIFIC SCIMED INC (2017-04-21),https://lens.org/153-398-871-672-680,Patent Application,yes,0,1,4,4,0,A61B17/083;;A61B17/1227;;A61F5/0086;;A61B2017/00243;;A61B2017/00575;;A61B2017/00893;;A61B2017/00964;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B2017/00575;;A61B17/1227;;A61B2017/00964;;A61F5/0086;;A61B17/083;;A61B2017/00243;;A61B2017/00893,A61B17/00;;A61B17/122;;A61B17/128;;A61F5/00,,0,0,,,,ACTIVE
399,US,A1,US 2017/0325821 A1,076-899-322-263-109,2017-11-16,2017,US 201715593977 A,2017-05-12,US 201715593977 A;;US 201662336827 P,2016-05-16,DEVICES AND METHODS FOR REDUCING A DIMENSION OF OPENINGS IN TISSUE,"A clip for reducing a dimension of an opening in tissue may include a continuous member having a plurality of legs and a plurality of preformed bends connecting adjacent legs, wherein the plurality of legs form: a first group having two protrusions; a second group having two protrusions; and a third group having two protrusions, wherein each protrusion of each group includes two legs of the continuous member and a corresponding preformed bend connecting the two legs, and each protrusion of each group extends from a region adjacent a first end of the clip to a region adjacent a second end of the clip.",BOSTON SCIENT SCIMED INC,HAVERKOST PATRICK A;;GROFF JOEL N;;WILLARD MARTIN R;;TASSONI JR ANTHONY FRANK;;TASSONI NICHOLAS LEE;;PEDERSON JR GARY JOHN;;CONNOLLY JOSEPH MICHAEL,BOSTON SCIENTIFIC SCIMED INC (2017-04-21),https://lens.org/076-899-322-263-109,Patent Application,yes,0,1,4,4,0,A61B17/083;;A61B17/1227;;A61F5/0086;;A61B2017/00243;;A61B2017/00575;;A61B2017/00893;;A61B2017/00964;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B17/1285;;A61B17/0057;;A61B2017/00867;;A61B2017/00584;;A61B2017/00623;;A61B2017/00575;;A61B17/1227;;A61B2017/00964;;A61F5/0086;;A61B17/083;;A61B2017/00243;;A61B2017/00893,A61B17/122;;A61B17/00;;A61B17/128,,0,0,,,,ACTIVE
400,UY,A,UY 37495 A,191-739-987-843-286,2018-05-31,2018,UY 37495 A,2017-11-24,US 201662426350 P;;US 201762502983 P;;US 201762555232 P,2016-11-25,DINUCLEÓTIDOS CÍCLICOS COMO AGONISTAS DE STING,"Se describen compuestos, composiciones y métodos para tratar infecciones virales, enfermedades, síndromes o trastornos afectados por la modulación de STING. Tales compuestos se representan por la Fórmula (I) a continuación: en donde R1A, R1B, R1c, B1, R2A y R2B se definen en la presente descripción.",JANSSEN BIOTECH INC,LU TIANBAO;;JAMES PATRICK EDWARDS;;BIGNAN GILLES;;CONNOLLY PETER;;EMANUEL STUART;;LAQUERRE SYLVIE;;RICHTER MARK;;BEIGELMAN LEONID;;SANTHOSH KUMAR THATIKONDA;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/191-739-987-843-286,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,A61K31/683;;A61K31/7084;;A61P31/12;;C07F9/6574;;C07H21/00,,0,0,,,,PENDING
401,US,A1,US 2023/0144627 A1,041-280-121-824-37X,2023-05-11,2023,US 202217967443 A,2022-10-17,US 202217967443 A;;US 201715820592 A;;US 201762555232 P;;US 201762502983 P;;US 201662426350 P,2016-11-25,Cyclic Dinucleotides As Sting Agonists,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1C , B 1 , R 2A , and R 2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBAO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/041-280-121-824-37X,Patent Application,yes,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K9/00;;A61K9/10;;A61K31/7076;;A61P31/12;;A61P31/20;;A61P35/00,,0,0,,,,PENDING
402,US,A1,US 2018/0162899 A1,057-413-952-885-031,2018-06-14,2018,US 201715820592 A,2017-11-22,US 201715820592 A;;US 201762555232 P;;US 201762502983 P;;US 201662426350 P,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1c , B 1 , R 2A , and R 2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBAO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,JANSSEN BIOPHARMA INC (2018-08-29);;JANSSEN BIOTECH INC (2018-02-20),https://lens.org/057-413-952-885-031,Patent Application,yes,1,12,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K9/00;;A61K9/10;;A61P31/20;;A61P35/00,,0,0,,,,ACTIVE
403,JO,A1,JO P20170188 A1,103-637-681-840-77X,2019-01-30,2019,JO P20170188 A,2016-11-25,US 201662426350 P;;US 201762502983 P;;US 201762555232 P,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.",JANSSEN BIOTECH INC,MINGHONG ZHONG;;STUART EMANUEL;;MARK RICHTER;;GUANGYI WANG;;TIANBAO LU;;GILLES BIGNAN;;SYLVIE LAQUERRE;;PETER CONNOLLY;;JAMES PATRICK EDWARDS;;LEONID BEIGELMAN;;SANTHOSH KUMAR THATIKONDA,,https://lens.org/103-637-681-840-77X,Granted Patent,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,,,0,0,,,,ACTIVE
404,CN,A,CN 115720510 A,063-875-386-915-93X,2023-02-28,2023,CN 202180045821 A,2021-05-05,EP 2020081386 W;;EP 2020081399 W;;GB 202006665 A;;EP 2021061925 W,2020-05-05,Treatment of ischemia,"An intravascular device for traversing obstructions in a blood vessel is provided that includes an elongate intravascular element, such as a wire. The element has a proximal section, a distal tip section having a smaller diameter than the proximal section; and a distal tapered intermediate section extending between the proximal section and the distal tip section. The device includes an ultrasound transducer mechanically coupled to the proximal section of the element to ultrasonically activate the element, thereby exciting the distal tip section to traverse the obstruction. A catheter surrounds the element such that at least a portion of the distal tip section of the element projects distally beyond a distal end of the catheter.",VERSONO MEDICAL LLC,DOLAN FRANCIS;;O 'DONOGHUE HEATHER;;TRAPPE BORIS;;KIRBY ANDREW;;GILFOYLE DAVID;;KINSELLA BRIAN;;CONNOLLY PATRICK;;MOONEY IAIN;;O 'DONOGHUE MICHAEL;;KANE MICHAEL;;SMEDLEY JOHN,,https://lens.org/063-875-386-915-93X,Patent Application,no,0,0,30,30,0,A61B17/22012;;A61B2017/00469;;A61B2017/22014;;A61B2017/22038;;A61B2017/22094;;A61B2017/320088;;A61B17/320708;;A61B2017/22039;;A61B2017/22044;;A61B2017/22049;;A61B2090/0807;;A61B2090/3966;;A61B17/22012;;A61B2017/22015;;A61B2090/0808;;A61B90/39;;A61B17/2202;;A61B2017/00477;;A61B2017/22094;;A61B2017/22027;;A61B2017/22049;;A61B2090/3966;;A61B2017/22017;;A61B2017/22041;;A61B2217/007;;A61B2017/22014;;A61B2017/22044,A61B17/22,,0,0,,,,PENDING
405,US,B2,US 11472830 B2,001-747-603-441-975,2022-10-18,2022,US 201715820592 A,2017-11-22,US 201715820592 A;;US 201762555232 P;;US 201762502983 P;;US 201662426350 P,2016-11-25,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R 1A , R 1B , R 1c , B 1 , R 2A , and R 2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBAO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,JANSSEN BIOPHARMA INC (2018-08-29);;JANSSEN BIOTECH INC (2018-02-20),https://lens.org/001-747-603-441-975,Granted Patent,yes,17,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K9/00;;A61K9/10;;A61K31/7076;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00,,20,19,063-161-621-710-260;;091-765-617-073-134;;010-341-241-568-683;;102-071-695-047-127;;006-540-796-046-165;;012-165-000-131-176;;101-871-534-522-088;;089-814-558-522-45X;;012-180-065-013-539;;008-962-459-855-781;;102-034-121-002-023;;006-911-733-023-062;;040-887-679-477-746;;060-000-705-511-414;;045-298-563-967-678;;018-874-474-967-696;;002-895-644-883-279;;034-666-907-619-827;;037-864-303-934-240,10.1110/ps.8.4.921;;10211839;;pmc2144313;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.cell.2011.09.022;;22000020;;6382953;;10.1016/0065-2571(84)90007-4;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;pmc4335851;;25512416;;10.1128/aac.04321-14;;11516266;;10.1021/ja010078v;;10.2165/00003088-198106060-00002;;7032803;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.aaa2630;;25636800;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.1126/science.1232458;;pmc3863629;;23258413;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;10.1016/j.immuni.2008.09.003;;18818105;;25344812;;pmc4232468;;10.1038/nchembio.1661,"Beckett et al., “A Minimal Peptide Substrate in Biotin Holoenzyme Synthetase-Catalyzed Biotinylation”, Protein Science, 1999, 9, 921-929.;;Bhat et al., “Recognition of Cytosolic DNA by eGas and other STING-dependent sensors”, Eur. J. Immunol., Mar. 2014, 44(3), 634-640.;;Chen et al., “Activation of STAT6 by STING is Critical for Antiviral Innate Immunity”, Cell, 2011, vol. 14, 433-446.;;Chou et al., “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”, Enzyme Regul., 1984, 22, 27-55.;;Corrales et al., “Direct Activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity”, Cell Reports, 2015, vol. 11, 1-13.;;Danilchanka et al., “Cyclic Dinucleotides and the Innate Immune Response”, Cell, vol. 154, Aug. 29, 2013, pp. 962-970.;;Guo et al., “STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus”, Antimicrobial Agents and Chemotherapy vol. 59, No. 2, Feb. 1, 2015, 1273-1281.;;Hayakawa et al., “Acid/Azole Complexes as Highly Effective Promoters in the Synthesis of DNA and RNA Oligomers via the Phosphoramidite Method”, J. Am. Chem. Soc., 2001, 123, 8165-8176.;;Holford et al., “Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin. Pharmacokinet., 1981, 6, 429-453.;;Konno et al., “Cyclic dinucleotides trigger ULKI (ATGI) Phosphorylation of STING to prevent sustained innate immune signaling”, Cell, 2013, vol. 155, 688-698.;;Liu et al., “Phosphorylation of innate immune adaptor proteins MAVS, STING and TRIF induces IRF3 activation”, Science, 2015, 2630-2637.;;Liu et al., “Systematic Identification of Type I and Type II Interferon-induced antiviral factors”, Proc. Natl. Acad. Sci., 2012, vol. 109, 4239-4244.;;Loewe, et al., “On combination effects. Statement: Aids in framing the question” Pharmacological Institute at the University of Tartu-Dorpat, 1926, Arch. Exp. Pathol Pharmacol. 114: 313-326.;;Marabelle et al., “Intratumoral Immunization: A New Paradigm for Cancer Therapy”, Clinical Cancer Research, 2014, 20(7), 1747-1756.;;Sun et al., “Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway”, Science, 2013, vol. 339, 786-791.;;Van der Jeught et al., “Targeting the tumor microenvironment to enhance antitumor immune responses”, Oncotarget, 2015, 6(3), 1359-1381.;;Yi et al., “Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides”, Plos One, 2013, 8(10), e77846.;;Zhang et al., “Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages is an Endogenous High-Affinity Ligand foi STING”, Molecular Cell, 2013, vol. 51, 226-235.;;Zhong et al., “The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation”, Immunity, 2008, vol. 29, 538-550.;;Li L., “Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs,” Nat. Chem. Biol., 2014,vol. 10, No. 12,pp. 1043-1048.",ACTIVE
406,BR,A2,BR 112019010606 A2,004-507-975-885-960,2019-09-17,2019,BR 112019010606 A,2017-11-21,US 2017/0062901 W;;US 201662426350 P;;US 201762502983 P;;US 201762555232 P,2016-11-25,dinucleotídeos cíclicos como agonistas de sting,"a presente invenção refere-se a compostos, composições e métodos para o tratamento de infecções virais, doenças, síndromes ou distúrbios que são afetados pela modulação de sting. esses compostos são representados pela fórmula i a seguir: fórmula (i) em que r1a, r1b, r1c, b1, r2a, e r2b são como definidos aqui.",JANSSEN BIOTECH INC,GILLES C BIGNAN;;GUANGYI WANG;;JAMES PATRICK EDWARDS;;LEONID BEIGELMAN;;LU TIANBAO;;MARK RICHTER;;MINGHONG ZHONG;;PETER CONNOLLY;;SANTHOSH KUMAR THATIKONDA;;STUART EMANUEL;;SYLVIE LAQUERRE,,https://lens.org/004-507-975-885-960,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
407,AU,B2,AU 2017/365158 B2,008-405-791-659-991,2022-02-17,2022,AU 2017/365158 A,2017-11-21,US 201762502983 P;;US 201662426350 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;TIANBAO LU;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/008-405-791-659-991,Granted Patent,no,7,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,ACTIVE
408,EP,A1,EP 3544989 A1,090-615-417-626-304,2019-10-02,2019,EP 17825988 A,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/090-615-417-626-304,Patent Application,yes,0,1,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,A61K31/7084;;C07H21/02;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
409,TW,A,TW 201831192 A,114-914-861-369-761,2018-09-01,2018,TW 106140679 A,2017-11-23,US 201662426350 P;;US 201762502983 P;;US 201762555232 P,2016-11-25,Cyclic dinucleotides as STING agonists,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBAO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MING-HONG,,https://lens.org/114-914-861-369-761,Patent of Addition,no,0,1,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,A61K31/7084;;A61P31/20;;A61P35/00;;C07H19/207,,0,0,,,,PENDING
410,MX,A,MX 2019006082 A,025-118-033-032-342,2019-11-12,2019,MX 2019006082 A,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS.,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.",JANSSEN BIOTECH INC,GUANGYI WANG;;MARK RICHTER;;LEONID BEIGELMAN;;GILLES C BIGNAN;;PETER CONNOLLY;;JAMES PATRICK EDWARDS;;STUART EMANUEL;;SYLVIE LAQUERRE;;LU TIANBAO;;SANTHOSH KUMAR THATIKONDA;;MINGHONG ZHONG,,https://lens.org/025-118-033-032-342,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
411,WO,A1,WO 2018/098203 A1,192-349-133-651-486,2018-05-31,2018,US 2017/0062901 W,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R 1A , R 1B , R 1c , B 1 , R 2A , and R 2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;TIANBAO LU;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/192-349-133-651-486,Patent Application,yes,6,68,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,23,21,101-871-534-522-088;;034-666-907-619-827;;102-034-121-002-023;;010-341-241-568-683;;006-540-796-046-165;;008-962-459-855-781;;060-000-705-511-414;;091-765-617-073-134;;002-895-644-883-279;;012-165-000-131-176;;006-911-733-023-062;;077-295-491-167-117;;077-295-491-167-117;;045-298-563-967-678;;040-887-679-477-746;;012-180-065-013-539;;029-641-974-701-191;;102-071-695-047-127;;089-814-558-522-45X;;018-874-474-967-696;;063-161-621-710-260,pmc4335851;;25512416;;10.1128/aac.04321-14;;10.1016/j.immuni.2008.09.003;;18818105;;10.1126/science.aaa2630;;25636800;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.1232458;;pmc3863629;;23258413;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;10.1002/0471220574;;10.1002/0471220574;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.2165/00003088-198106060-00002;;7032803;;10.1007/bf01952257;;6382953;;10.1016/0065-2571(84)90007-4;;11516266;;10.1021/ja010078v;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1110/ps.8.4.921;;10211839;;pmc2144313,"FANG GUO ET AL: ""STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, no. 2, 1 February 2015 (2015-02-01), pages 1273 - 1281, XP055367110, ISSN: 0066-4804, DOI: 10.1128/AAC.04321-14;;ZHONG B ET AL.: ""The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation"", IMMUNITY, vol. 29, 2008, pages 538 - 550, XP055021580, DOI: doi:10.1016/j.immuni.2008.09.003;;LIU S ET AL.: ""Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation"", SCIENCE, 2015, pages 2630 - 2637;;CHEN H ET AL.: ""Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity"", CELL, vol. 14, 2011, pages 433 - 446;;CORRALES, L. ET AL.: ""Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity"", CELL REPORTS, vol. 11, 2015, pages 1 - 13;;KONNO, H. ET AL.: ""Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling"", CELL, vol. 155, 2013, pages 688 - 698, XP028758016, DOI: doi:10.1016/j.cell.2013.09.049;;SUN, L. ET AL.: ""Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway"", SCIENCE, vol. 339, 2013, pages 786 - 791, XP055294100, DOI: doi:10.1126/science.1232458;;BHAT N; FITZGERALD KA: ""Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors"", EUR J IMMUNOL., vol. 44, no. 3, March 2014 (2014-03-01), pages 634 - 40;;ZHANG X ET AL.: ""Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING"", MOLECULAR CELL, vol. 51, 2013, pages 226 - 235, XP055300246, DOI: doi:10.1016/j.molcel.2013.05.022;;DANILCHANKA, O; MEKALANOS, JJ: ""Cyclic Dinucleotides and the Innate Immune Response"", CELL, vol. 154, 2013, pages 962 - 970, XP028706417, DOI: doi:10.1016/j.cell.2013.08.014;;LIU S-Y ET AL.: ""Systematic identification of type I and type II interferon-induced antiviral factors"", PROC. NATL. ACAD. SCI., vol. 109, no. 423, 2012, pages 9 - 4244;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;VAN DER JEUGHT ET AL., ONCOTARGET, vol. 6, no. 3, 2015, pages 1359 - 1381;;MARABELLE, A. ET AL., CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1747 - 1756;;HOLFORD; SCHEINER, CLIN. PHARMACOKINET., vol. 6, pages 429 - 453;;LOEWE; MUISCHNEK, ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326;;CHOU; TALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;J. AM. CHEM. SOC., vol. 123, 2001, pages 8165 - 8176;;YI: ""Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides"", PLOS ONE, vol. 8, no. 10, 2013, pages e77846, XP055315013, DOI: doi:10.1371/journal.pone.0077846;;BECKETT ET AL.: ""A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation"", PROTEIN SCIENCE, vol. 8, 1999, pages 921 - 929, XP002971557",PENDING
412,CA,A1,CA 3044693 A1,089-983-096-694-966,2018-05-31,2018,CA 3044693 A,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;TIANBAO LU;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/089-983-096-694-966,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
413,KR,A,KR 20190085107 A,104-094-418-217-436,2019-07-17,2019,KR 20197018101 A,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,STING 작용제로서의 환상 다이뉴클레오티드,"STING의 조절에 의해 영향을 받는 바이러스 감염, 질환, 증후군 또는 장애를 치료하기 위한 화합물, 조성물 및 방법이 개시된다. 이러한 화합물은 하기와 같이 화학식 (I)으로 나타낸다:화학식 (I) 상기 식에서, RR, RBR및 R는 본 명세서 및 청구범위에서 정의된 바와 같다.",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;LU TIANBAO;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/104-094-418-217-436,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K9/00;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00,,0,0,,,,ACTIVE
414,CN,A,CN 110291096 A,041-491-266-061-529,2019-09-27,2019,CN 201780084645 A,2017-11-21,US 201662426350 P;;US 201762502983 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;TIANBAO LU;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/041-491-266-061-529,Patent Application,no,10,2,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
415,AU,A1,AU 2017/365158 A1,177-851-244-215-185,2019-06-06,2019,AU 2017/365158 A,2017-11-21,US 201762502983 P;;US 201662426350 P;;US 201762555232 P;;US 2017/0062901 W,2016-11-25,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: [Formula (I) should be inserted here] wherein R",JANSSEN BIOTECH INC,BIGNAN GILLES C;;CONNOLLY PETER;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIE;;TIANBAO LU;;RICHTER MARK;;BEIGELMAN LEONID;;THATIKONDA SANTHOSH KUMAR;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/177-851-244-215-185,Patent Application,no,0,0,18,19,0,A61P31/12;;C07H21/02;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61K9/10;;A61K31/7084;;A61P31/12;;A61P31/20;;A61P35/00;;C07H21/02;;A61K9/0095;;A61P31/20;;A61P35/00;;A61K9/10;;A61P31/12;;A61K31/7076,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,ACTIVE
416,PH,A1,PH 12020552206 A1,023-097-812-568-266,2021-06-28,2021,PH 12020552206 A,2020-12-15,US 201862686451 P;;IB 2019054965 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI;;LU TIANBAO,,https://lens.org/023-097-812-568-266,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,A61K31/4439;;A61P35/00;;C07D471/04,,0,0,,,,PENDING
417,CA,A1,CA 3104055 A1,125-491-171-232-853,2019-12-26,2019,CA 3104055 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI,,https://lens.org/125-491-171-232-853,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,0,0,,,,PENDING
418,AU,A1,AU 2019/289223 A1,033-771-562-327-973,2021-01-07,2021,AU 2019/289223 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI;;LU TIANBAO,,https://lens.org/033-771-562-327-973,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,0,0,,,,ACTIVE
419,WO,A1,WO 2019/243965 A1,064-628-373-445-316,2019-12-26,2019,IB 2019054965 W,2019-06-13,US 201862686451 P,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , G 1 and G 2 , are defined herein.",JANSSEN PHARMACEUTICA NV;;LU TIANBAO,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI,,https://lens.org/064-628-373-445-316,Patent Application,yes,2,1,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,20,12,001-676-197-805-749;;088-303-580-091-034;;105-129-409-527-399;;015-845-506-559-143;;087-192-267-012-779;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;149-087-447-664-064;;047-138-645-820-688;;077-295-491-167-117;;077-295-491-167-117,pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;10.1111/j.1600-065x.2012.01105.x;;pmc4094296;;22435566;;26787500;;10.1016/j.molmed.2015.12.004;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1126/science.1198946;;21273489;;pmc3124150;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1002/0471220574;;10.1002/0471220574,"JAWORSKI ET AL., CELL MOL LIFE SCIENCE, vol. 73, 2016, pages 459 - 473;;STAUDT, COLD SPRING HARB PERSPECT BIOL, 2010, pages 2;;LIM ET AL., IMMUNOL REV, vol. 246, 2012, pages 359 - 378;;FONTAN ET AL., CANCER CELL, vol. 22, 2012, pages 825 - 837;;DEMEYER ET AL., TRENDS MOL MED, vol. 22, 2016, pages 135 - 150;;ROSEBECK ET AL., WORLD J BIOL CHEM, vol. 7, 2016, pages 128 - 137;;ROSEBECK ET AL., SCIENCE, vol. 331, 2011, pages 468 - 472;;JAWORSKI M ET AL., CELL MOL LIFE SCI., 2016;;MC GUIRE ET AL., J. NEUROINFLAMMATION, vol. 11, 2014, pages 124;;JAWORSKI ET AL., EMBO J., 2014;;GEWIES ET AL., CELL REPORTS, 2014;;BORNANCIN ET AL., J. IMMUNOLOGY, 2015;;YU ET AL., PLOS ONE, 2015;;MCKINNON ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 133, 2014, pages 1458 - 1462;;JABARA ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 132, 2013, pages 151 - 158;;PUNWANI ET AL., J. CLIN. IMMUNOL., vol. 35, 2015, pages 135 - 146;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis,"", 1991, JOHN WILEY & SONS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS",PENDING
420,US,A1,US 2019/0381012 A1,068-981-994-348-423,2019-12-19,2019,US 201916440356 A,2019-06-13,US 201916440356 A;;US 201862686451 P,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , G 1 and G 2 , are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI,JANSSEN-CILAG (2019-06-26);;JANSSEN RESEARCH & DEVELOPMENT LLC (2019-06-24);;JANSSEN PHARMACEUTICA NV (2019-06-13),https://lens.org/068-981-994-348-423,Patent Application,yes,0,2,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/28,,0,0,,,,ACTIVE
421,MX,A,MX 2020013699 A,013-604-531-367-717,2021-05-12,2021,MX 2020013699 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS.,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, G<sub>1</sub> and G<sub>2</sub>, are defined herein.",JANSSEN PHARMACEUTICA NV,DIELS GASTON STANISLAS MARCELLA;;WU TONGFEI;;EDWARDS JAMES PATRICK;;LU TIANBAO;;CONNOLLY PETER J;;PHILIPPAR ULRIKE;;CUMMINGS MAXWELL DAVID;;THURING JAN WILLEM;;BERTHELOT DIDIER JEAN- CLAUDE,,https://lens.org/013-604-531-367-717,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,A61K31/4439;;A61P35/00;;C07D471/04,,0,0,,,,PENDING
422,KR,A,KR 20210024002 A,082-530-606-980-772,2021-03-04,2021,KR 20217001365 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,MALT1 억제제로서의 피라졸 유도체,"MALT1의 조절에 의해 영향을 받는 질환, 증후군, 병태 및 장애를 치료하기 위한 화합물, 조성물 및 방법이 개시된다. 그러한 화합물은 하기와 같이 화학식 (I)에 의해 나타내어진다: 상기 식에서, R1, R2,R3, R4, R5, R6, R7, G1, 및 G2는 본 명세서에 한정된다.",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN CLAUDE;;WU TONGFEI;;LU TIANBAO,,https://lens.org/082-530-606-980-772,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/444;;A61K31/519;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00,,0,0,,,,PENDING
423,AU,B2,AU 2019/289223 B2,177-689-025-233-110,2023-09-21,2023,AU 2019/289223 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI;;LU TIANBAO,,https://lens.org/177-689-025-233-110,Granted Patent,no,1,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,0,0,,,,ACTIVE
424,BR,A2,BR 112020025814 A2,162-604-522-407-046,2021-04-06,2021,BR 112020025814 A,2019-06-13,IB 2019054965 W;;US 201862686451 P,2018-06-18,derivados de pirazol como inibidores de malt1,"derivados de pirazol como inibidores de malt1. a presente invenção refere-se a compostos, composições e métodos para o tratamento de doenças, síndromes, condições e distúrbios que são afetados pela modulação de malt1. esses compostos são representados pela fórmula (i) como a seguir: em que r1, r2, r3, r4, r5, r6, r7, g1 e g2 são definidos aqui.",JANSSEN PHARMACEUTICA NV,DIDIER JEAN-CLAUDE BERTHELOT;;GASTON STANISLAS MARCELLA DIELS;;JAMES PATRICK EDWARDS;;JAN WILLEM THURING;;MAXWELL DAVID CUMMINGS;;PETER J CONNOLLY;;TIANBAO LU;;TONGFEI WU;;ULRIKE PHILIPPAR,,https://lens.org/162-604-522-407-046,Patent Application,no,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,0,0,,,,PENDING
425,US,B2,US 10888550 B2,020-694-413-416-800,2021-01-12,2021,US 201916440356 A,2019-06-13,US 201916440356 A;;US 201862686451 P,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , G 1 and G 2 , are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI,JANSSEN-CILAG (2019-06-26);;JANSSEN RESEARCH & DEVELOPMENT LLC (2019-06-24);;JANSSEN PHARMACEUTICA NV (2019-06-13),https://lens.org/020-694-413-416-800,Granted Patent,yes,16,1,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/28,,19,14,037-165-733-219-789;;105-129-409-527-399;;103-752-080-034-709;;051-588-339-916-553;;149-087-447-664-064;;007-268-478-416-294;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;125-728-925-514-092;;047-138-645-820-688;;087-192-267-012-779;;015-845-506-559-143;;081-511-682-994-308,25762782;;10.3410/f.725387389.793505358;;10.4049/jimmunol.1402254;;26787500;;10.1016/j.molmed.2015.12.004;;23238016;;10.1016/j.ccr.2012.11.003;;pmc3984478;;10.1016/j.celrep.2014.10.044;;25456129;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4282555;;10.15252/embj.201488987;;25319413;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;23238017;;10.1016/j.ccr.2012.11.002;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1126/science.1198946;;21273489;;pmc3124150;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1371/journal.pone.0127083;;25965667;;pmc4428694,"Bornancin, F., et al., “Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation”, J. Immunology, (2015), vol. 194, No. 8, pp. 3723-3734.;;Demeyer, A., et al., “Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?”, Trends Mol Med, (2016), vol. 22, No. 2, pp. 135-150.;;Fontan, L., et al., “MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo”, Cancer Cell, (2012), vol. 22, No. 6, pp. 812-824.;;Gewies, A., et al., “Uncoupling Malt1 Threshold Function from Paracaspase Activity Results in Destructive Autoimmune Inflammation”, Cell Reports, (2014), vol. 9, pp. 1292-1305.;;Jabara, H.H., et al., “A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency”, J. Allergy Clin. Immunol., (2013), vol. 132, pp. 151-158.;;Jaworski, M., et al., “Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity”, The EMBO Journal, (2014), vol. 33, No. 23, pp. 2765-2781.;;Jaworski, M., et al., “The paracaspase MALT1: biological function and potential for therapeutic inhibition”, Cell. Mol. Life Sci., (2016), vol. 73, pp. 459-473.;;Lim, K., et al., “Pathogentic importance and therapeutica implications of NF-Kβ in lymphoid malignancies”, Immunological Reviews, (2012), vol. 246, pp. 359-378.;;McGuire, C., et al., “Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis”, Journal of Neuroinflammation, (2014), vol. 11, No. 124, pp. 1-12.;;McKinnon et al., “Combined immunodeficiency associated with homozygous MALT1 mutations”, J. Allergy Clin. Immunol. (2014), vol. 133, No. 5, pp. 1458-1462.e7.;;Nagel, D., et al., “Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL”, Cancer Cell, (2012), vol. 22, pp. 825-837.;;Punwani, D., et al., “Combined Immunodeficiency Due to MALT1 Mutations, Treated by Hematopoietic Cell Transplantation”, J Clin Immunol, (2015), vol. 35, pp. 135-146.;;Rosebeck, S., et al., “Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF-kB Activation”, Science, (2011), vol. 331, pp. 468-472.;;Rosebeck, S., et al., “API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis”, World J Biol Chem, (2016), vol. 7, No. 1, pp. 128-137.;;Yu, J.W., et al., “MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses”, PLOS One, (2015), pp. 1-20.;;Bundgaard, H., “Design of Prodrugs”, (1985), Table of Contents.;;McOmie, J., “Protective Groups in Organic Chemistry”, (1973), Title Page and Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, Inc., (1991), Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc., (1999), Table of Contents.",ACTIVE
426,EP,A1,EP 3810609 A1,174-643-617-084-320,2021-04-28,2021,EP 19756241 A,2019-06-13,US 201862686451 P;;IB 2019054965 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,,JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE;;WU TONGFEI;;LU TIANBAO,,https://lens.org/174-643-617-084-320,Patent Application,yes,0,0,18,18,0,C07D471/04;;A61K31/437;;A61K31/519;;A61P35/00;;C07D471/04;;C07K16/2887;;C07K16/2896;;A61K2300/00;;A61K31/444;;A61P11/00;;A61P19/02;;A61P11/06;;A61K31/444;;A61K31/519;;A61K2300/00;;A61P11/00;;A61P11/06;;A61P19/02;;A61P35/00;;C07D471/04;;A61P35/00;;A61K31/437;;A61K31/519;;C07D471/04;;C07K16/2887;;C07K16/2896,C07D471/04;;A61K31/4439;;A61P35/00,,0,0,,,,PENDING
427,US,B1,US 6967244 B1,113-850-551-667-521,2005-11-22,2005,US 58046200 A,2000-05-26,US 58046200 A;;US 34995694 A;;US 89818592 A;;US 32138489 A;;US 17029588 A,1988-03-18,Neuronal nicotinic acetylcholine receptor compositions,"The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.",SALK INST FOR BIOLOGICAL STUDI,HEINEMANN STEPHEN FOX;;PATRICK JAMES WARNER;;BOULTER JAMES RICHARD;;DENERIS EVAN SAMUEL;;WADA KEIJI;;BALLIVET MARC CHARLES;;GOLDMAN DANIEL JAY;;CONNOLLY JOHN GERARD;;DUVOISIN ROBERT MICHAEL;;HEINEMANN EDEN DEER,,https://lens.org/113-850-551-667-521,Granted Patent,yes,1,1,5,19,0,C07K14/70571;;G01N33/944;;G01N2500/04;;C07K14/70571;;G01N33/944;;G01N2500/04,C07K14/705;;C12N15/12;;G01N33/566,536/23.5;;435/69.1;;435/252.3;;435/320.1,97,95,032-154-993-748-243;;038-426-107-403-502;;034-202-041-467-969;;001-910-735-875-801;;088-944-431-004-208;;002-941-512-853-937;;108-665-931-448-827;;014-445-493-084-951;;031-894-285-200-487;;040-995-442-192-126;;084-678-642-354-860;;006-600-008-545-863;;034-854-638-120-494;;080-389-547-198-365;;125-822-815-620-653;;013-437-955-677-617;;119-062-254-409-623;;010-359-077-037-383;;107-112-792-448-248;;080-684-683-067-679;;061-813-575-625-919;;002-471-216-132-744;;147-130-419-609-971;;019-109-310-909-826;;122-711-463-589-62X;;033-531-880-234-18X;;007-488-923-333-88X;;074-626-344-956-161;;020-328-503-259-335;;086-664-235-217-143;;063-740-685-113-437;;014-197-138-389-187;;013-907-848-182-655;;005-102-278-457-275;;154-616-911-445-28X;;047-067-609-947-248;;015-291-617-665-924;;027-323-818-442-275;;070-880-599-513-627;;009-105-479-184-17X;;001-122-805-546-388;;087-834-586-280-481;;054-827-597-793-765;;059-824-183-827-88X;;071-237-454-382-615;;065-785-617-279-55X;;043-548-538-728-049;;045-997-271-617-193;;046-379-499-766-548;;076-528-054-990-947;;039-849-604-670-303;;058-529-957-672-271;;061-039-447-776-026;;086-728-559-738-201;;051-371-151-120-361;;029-127-218-822-412;;052-007-492-168-174;;046-894-764-577-526;;035-667-841-445-027;;051-057-892-199-85X;;126-648-825-745-885;;099-508-175-195-962;;029-167-460-549-342;;039-700-450-238-220;;080-281-384-957-608;;014-495-669-186-034;;116-570-727-130-158;;072-973-092-186-351;;018-549-498-430-042;;013-529-430-516-421;;001-800-549-328-639;;050-392-839-319-076;;007-571-476-901-546;;009-823-812-896-004;;082-333-559-426-820;;117-450-833-942-811;;100-084-428-309-76X;;052-306-680-652-764;;021-479-574-647-612;;072-330-625-331-840;;021-721-900-216-133;;028-678-277-111-340;;047-302-961-865-636;;015-834-812-425-174;;031-852-916-835-740;;023-315-408-617-938;;022-474-872-506-870;;105-182-127-994-450;;005-423-992-450-588;;054-227-081-244-432;;019-531-252-128-872;;020-846-211-688-541;;030-461-226-783-811;;044-253-405-101-224;;084-996-304-110-55X,10.1002/cne.902160106;;6345598;;10.1073/pnas.82.23.8080;;3865218;;pmc391446;;10.1098/rspb.1982.0040;;6127706;;pmc6565314;;10.1523/jneurosci.05-09-02545.1985;;2993547;;10.1038/319368a0;;3753746;;10.1073/pnas.84.21.7763;;pmc299381;;2444984;;10.1016/0092-8674(87)90617-9;;3581171;;pmc432535;;1055412;;10.1073/pnas.72.4.1368;;194659;;10.1016/0006-8993(77)90981-7;;6481621;;10.1113/jphysiol.1984.sp015325;;pmc1193296;;3745150;;10.1016/s0021-9258(18)67264-3;;10.1073/pnas.75.2.1016;;pmc411391;;416436;;6093012;;10.1016/0304-3940(84)90492-0;;10.1523/jneurosci.05-05-01307.1985;;pmc6565049;;3998824;;10.1073/pnas.80.4.1111;;pmc393538;;6573658;;3860855;;10.1073/pnas.82.15.5208;;pmc390529;;6692991;;10.1016/0012-1606(84)90162-3;;3272154;;10.1016/0896-6273(88)90208-5;;10.1073/pnas.80.7.2067;;6572962;;pmc393754;;10.1016/s0021-9258(18)61283-9;;pmc5586536;;2435720;;pmc344629;;6320162;;10.1073/pnas.81.1.155;;10.1113/jphysiol.1980.sp013275;;6253617;;pmc1282881;;10.1021/bi00383a003;;3607023;;10.1523/jneurosci.05-09-02553.1985;;4032011;;pmc6565325;;pmc323669;;3012549;;10.1073/pnas.83.11.4076;;3829125;;10.1016/0092-8674(87)90705-7;;pmc369897;;6960240;;10.1128/mcb.2.9.1044-1051.1982;;10.1128/mcb.2.9.1044;;1065897;;10.1073/pnas.73.7.2424;;pmc430592;;3037383;;10.1038/328215a0;;pmc1435233;;6324907;;10.1016/s0006-3495(84)84152-1;;10.1016/0166-2236(87)90087-7;;10.1038/321171a0;;2422562;;5055788;;pmc2226074;;10.1085/jgp.60.3.248;;10.1126/science.3022377;;3022377;;10.1002/j.1460-2075.1986.tb04389.x;;pmc1166972;;16453690;;3298562;;pmc6568889;;10.1523/jneurosci.07-06-01792.1987;;6850348;;10.1016/0006-8993(83)91312-4;;10.1016/0014-5793(86)80881-x;;2427361;;2423885;;10.1038/321774a0;;3944622;;10.1523/jneurosci.06-01-00281.1986;;pmc6568606;;2432430;;10.1038/324670a0;;10.1128/mcb.6.8.2855;;10.1128/mcb.6.8.2855-2864.1986;;3785216;;pmc367853;;3722144;;10.1016/s0021-9258(19)83877-2;;10.1085/jgp.54.1.245;;pmc2225893;;19873644;;10.1016/0006-8993(85)90187-8;;4063809;;3821734;;10.1128/mcb.7.2.951;;10.1128/mcb.7.2.951-955.1987;;pmc365157;;2436944;;10.1016/0014-5793(87)80065-0;;7150959;;10.1016/0006-8993(82)90406-1;;10.1016/0028-3908(82)90107-1;;7145035;;10.1016/b978-0-12-185203-0.50018-5;;2423008;;10.1146/annurev.ne.09.030186.002123;;pmc6569057;;10.1523/jneurosci.07-03-00742.1987;;3549993;;10.1016/0012-1606(80)90494-7;;6254823;;10.1038/307604a0;;6320016;;10.1038/321406a0;;2423878;;3956748;;10.1016/0014-5793(86)81225-x;;pmc392276;;10.1073/pnas.81.24.7975;;6096871;;10.1007/978-3-642-71649-2_31;;3267226;;10.1002/j.1460-2075.1988.tb02852.x;;pmc454362;;10.1073/pnas.83.9.3008;;3458258;;pmc323436;;6182472;;10.1038/299793a0;;6188060;;10.1038/302528a0;;10.1038/308084d0;;7012663;;10.1016/0306-4522(81)90239-6;;pmc432013;;10.1073/pnas.74.10.4689;;270708;;925016;;10.1016/s0021-9258(19)75267-3;;10.1101/sqb.1983.048.01.009;;6202451;;6339004;;10.1016/0006-8993(83)90638-8;;10.1152/physrev.1984.64.4.1162;;6208568;;10.1113/jphysiol.1981.sp013571;;pmc1275396;;6267251;;287045;;10.1073/pnas.76.4.2072;;pmc383536;;10.1016/s0361-9230(81)80027-5;;7248816;;3816758;;10.1002/j.1460-2075.1986.tb04626.x;;pmc1167309;;10.1016/0896-6273(88)90145-6;;3272170;;10.1038/328221a0;;3037384;;10.1083/jcb.61.2.398;;pmc2109296;;4363958;;10.1016/s0021-9258(18)32860-6;;6826561;;10.1111/j.1432-1033.1985.tb08614.x;;3967651;;pmc6565130;;10.1523/jneurosci.05-10-02726.1985;;2413185;;10.1146/annurev.cb.01.110185.001533;;2435309;;10.1016/0006-8993(86)90311-2;;2424552;;10.1073/pnas.80.14.4532;;pmc384073;;6192437;;pmc6569159;;2822866;;10.1523/jneurosci.07-10-03334.1987;;3839289;;10.1038/315761a0;;10.1523/jneurosci.05-08-02212.1985;;4020435;;pmc6565290;;2832952;;10.1126/science.2832952;;10.1016/0006-291x(74)90254-x;;4451573;;3531428;;pmc6568798;;10.1523/jneurosci.06-10-03061.1986;;3707934;;10.1021/bi00356a037;;2435576;;10.1016/0014-5793(87)81464-3;;10.1038/327515a0;;2438558;;3609304;;10.1016/0014-5793(87)80272-7;;10.1073/pnas.84.2.595;;3467376;;pmc304257;;10.1073/pnas.82.24.8790;;3866252;;pmc391523;;10.1111/j.1471-4159.1986.tb13078.x;;3772372,"Armstrong et al., ""Distribution of Cholinergic Neurons in Rat Brain: Demonstrated by the Immunocytochemical Localization of Choline Acetyltransferase"" J. Comp. Neurol. 216:53-68 (1983).;;Baldwin et al., ""Structure, evolution and regulation of a fast skeletal muscle troponin I gene"" Proc. Natl. Acad. Sci., USA 82:8080-8084 (1985).;;Barnard et al., ""Translation of exogenous messenger RNA coding for nicotinic acetylcholine receptors produces functional receptors in Xenopus oocytes"" Proc. R. Soc. Lond. B. 215:241-246 (1982).;;Boulter et al., ""Isolation of a Clone Coding for the alpha-Subunit of a Mouse Acetylcholine Receptor"" J. Neurosci. 5 (9) :2545-2552 (1985).;;Boulter et al., ""Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor alpha-subunit"" Nature 319:368-374 (1986).;;Boulter et al., ""Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family"" Proc. Natl. Acad. Sci., USA 84:7763-7767 (1987).;;Breitbart and Nadal-Ginard, ""Developmentally Induced, Muscle-Specific Trans Factors Control the Differential Splicing of Alternative and Constitutive Troponin T Exons"" Cell 49:793-803 (1987).;;Brockes and Hall ""Synthesis of Acetylcholine Receptor by Denervated Rat Diaphragm Muscle"" Proc. Natl. Acad. Sci., USA 72 (4) :1368-1372 (1975).;;Brown and Fumagalli, ""Dissociation of alpha-bungarotoxin binding and receptor block in the rat superior cervical ganglion"" Brain Res. 129:165-168 (1977).;;Brown et al., ""The action of cholinomimetic substances on impulse conduction in the habenulointerpeduncular pathway of the rat in vitro"" J. Physiol. 353:101-109 (1984).;;Buonanno and Merlie, ""Transcriptional Regulation of Nicotinic Acetylcholine Receptor Genes during Muscle Development"" J. Biol. Chem. 261 (25):11452-11455 (1986).;;Carbonetto et al., ""Nonequivalence of alpha-bungarotoxin receptors and acetylcholine receptors in chick sympathetic neurons"" Proc. Natl. Acad. Sci., USA 75(2):1016-1020 (1978).;;Chiappinelli and Dryer, ""Nicotinic transmission in sympathetic ganglia: blockade by the snake venom neurotoxin kappa-bungarotoxin"" Neurosci. Lett. 50:239-244 (1984).;;Clarke et al., ""Nicotinic Binding in the Rat Brain: Autoradiographic Comparison of [<SUP>3</SUP>H]Acetylcholine, [<SUP>3</SUP>H]Nicotine, and [<SUP>125</SUP>H]-alpha-Bungarotoxin"" J. Neurosci. 5(5):1307-1315 (1985).;;Claudio et al., ""Nucleotide and deduced amino acid sequences of Torpedo californica acetylcholine receptor gamma subunit"" Proc. Natl. Acad. Sci., USA 80:1111-1115 (1983).;;Conti-Tronconi et al., ""Brain and muscle nicotinic acetylcholine receptors are different but homologous proteins"" Proc. Natl. Acad. Sci., USA 82:5208-5212 (1985).;;Cox et al., ""Detection of mRNAs in Sea Urchin Embryos by in Situ Hybridization Using Aasymmetric RNA Probes"" Dev. Biol. 101:485-502 (1984).;;Deneris et al., ""Primary Structure and Expression of beta2: A novel Subunit of Neuronal Nicotinic Acetylcholine Receptors"" Neuron 1:45-54 (1988).;;Devillers-Thiery et al., ""Complete mRNA coding sequence of the acetylcholine binding alpha-subunit of Torpedo marmorata acetylcholine receptor: A model for the transmembrane organization of the polypeptide chain"" Proc. Natl. Acad. Sci., USA 80:2067-2071 (1983).;;Evans et al., ""Muscle Acetylcholine Receptor Biosynthesis: Regulation by Transcript Availability"" J. Biol. Chem. 262(10):4911-4916 (1987).;;Finer-Moore and Stroud, ""Amphipathic analysis and possible formation of the ion channel in an acetylcholine receptor"" Proc. Natl. Acad. Sci., USA 81:155-159 (1984).;;Fischbach and Schuetze, ""A post-natal decrease in acetylcholine channel open time at rat end-plates"" J. Physiol. 303:125-137 (1980).;;Giraudat et al., ""Structure of the High-Affinity Binding Site for Noncompetitive Blockers of the Acetylcholine Receptor: [<SUP>3</SUP>H]-Chlorpromazine Labels Homologous Residues in the beta and delta Chains"" Biochem. 26:2410-2418 (1987).;;Goldman et al., ""Muscle Denervation Increases the Levels of Two mRNAs Coding for the Acetylcholine Receptor alpha-Subunit"" J. Neurosci. 5:2553-2558 (1985).;;Goldman et al., ""Mapping of brain areas expressing RNA homologous to two different acetylcholine receptor alpha-subunit cDNAs"" Proc. Natl. Acad. Sci., USA 83:4076-4080 (1986).;;Goldman et al., ""Members of a Nicotinic Acetylcholine Receptor Gene Family Are Expressed in Different Regions of the Mammalian Central Nervous System"" Cell 48:965-973 (1987).;;Gorman et al., ""Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells"" Mol. Cell Biol. 2(9):1044-1051 (1982).;;Greene and Tischler, ""Establishment of noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor"" Proc. Natl. Acad. Sci., USA 73:(7)2424-2428 (1976).;;Grenningloh et al., ""The strychnine-binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors"" Nature 328:215-220 (1987).;;Guy, H.R., ""A structural model of the acetylcholine receptor channel based on partition energy and helix packing calculations"" Biophys. J. 45:249-261 (1984).;;Guy and Hucho, ""The ion channel of the nicotinic acetylcholine receptor"" Trends Neurosci 10(8):318-321 (1987).;;Hanke and Breer, ""Channel properties of an insect neuronal acetylcholine receptor protein reconstituted in planar lipid bilayers"" Nature 321:171-174 (1986).;;Hartzell and Fambrough, ""Acetylcholine Receptors: Distribution and extrajunctional density in rat diaphragm after denervation correlated with acetylcholine sensitivity"" J. Gen. Physiol. 60:248-262 (1972).;;Heidmann et al., ""Chromosomal Localization of Muscle Nicotinic Acetylcholine Receptor Genes in the Mouse"" Science 234:866-868 (1986).;;Heinemann et al., ""Molecular Biology of the Muscle Land Neural Acetylocholine Receptors"" In: Nicotinic Acetylcholine Receptor: Structure and Function, NATO ASI Series H, A. Maelicke, ed. (Berlin: Springer-Verlag), H3:359-387 (1986).;;Hermans-Borgmeyer et al., ""Primary structure of a developmentally regulated nicotinic acetylcholine receptor protein from Drosophila"" EMBO J. 5:(7)1503-1508 (1986).;;Higgins and Berg, ""Immunological Identification of a Nicotinic Acetylcholine Receptor on Bovine Chromaffin Cells"" J. Neurosci. 7(6):1792-1798 (1987).;;Houser et al., ""Organization and Morphological Characteristics of Cholinergic Neurons: an Immunocytochemical Study with a Monoclonal Antibody to Choline Acetyltransferase"" Brain Res. 266:97-119 (1983).;;Hucho et al., ""The ion channel of the nicotinic acetylcholine receptor in formed by the homologous helices M II of the receptor subunits"" FEBS Lett. 205(1)137-142 (1986).;;Huganir et al., ""Phosphorylation of the nicotinic acetylcholine receptor regulates its rate of desensitization"" Nature 321:774-776 (1986).;;Ichikawa and Hirata, ""Organization of Choline Acetyltransferase-Containing Structures in the Forebrain of the Rat"" J. Neurosci. 6(1):281-292 (1986).;;Imoto et al., ""Location of a delta-subunit region determining ion transport through the acetylcholine receptor channel"" Nature 324:670-674 (1986).;;Jaynes et al., ""Transcriptional Regulation of the Mucsle Creatine Kinase Gene and Regulated Expression in Transfected Mouse Myoblasts"" Mol. Cell. Biol. 6(8):2855-2864 (1986).;;Kao and Karlin, ""Acetylcholine Receptor Binding Site Contains a Disulfide Cross-link between Adjacent Half-Cystinyl Residues"" J. Biol. Chem. 261(18):8085-8088 (1986).;;Karlin, A., ""Chemical Modification of the Active Site of Acetylcholine Receptor"" J. Gen. Phys. 54:245s-264s (1969).;;Kemp et al., ""Purification and Characterization of the alpha-Bungarotoxin Binding Protein from Rat Brain"" Brain Res. 347:274-283 (1985).;;Klarsfeld et al., ""A 5-Flanking Region of the Chicken Acetylcholine Receptor alpha-Subunit Gene Confers Tissue Specificity and Developmental Control of Expression in Transfected Cells"" Mol. Cell. Biol. 7(2):951-955 (1987).;;Kurosaki et al., ""Functional properties of nicotinic acetylcholine receptor subunits expressed in various combinations"" FEBS Lett. 214 (2):253-258 (1987).;;Lamour et al., ""Spread of acetylcholine sensitivity in the necocortex following lesion of the nucleus basalis"" Brain Res. 252:377-381 (1982).;;Lichtensteiger et al., ""Stimulation of Nigrostriatal Dopamine Neurones by Nicotine"" Neuropharmacol. 21:963-968 (1982).;;Martin, B.R., ""Nicotine Receptors in the Central Nervous System"" In: The Receptors, P.M. Conn, ed. (Orlando, FL: Academic Press) 3:393-415 (1986).;;Mauron et al., ""Structure of Chicken Genes Encoding the Nicotinic Acetylcholine Receptor Subunits and Their Variants"" Soc. for Neuroscience, 15th Annual Meeting, Abstract 55.10, p. 171 (1985).;;McCarthy et al., ""The molecular Neurobiology of the Acetylcholine Receptor"" Ann. Rev. Neurosci. 9:383-413 (1986).;;McCormick and Prince, ""Acetylcholine Causes Rapid Nicotinic Excitation in the Medial Habenular Nucleus of Guinea Pig, in vitro"" J. Neurosci. 7(3):742-752 (1987).;;Michler and Sakmann, ""Receptor Stability and Channel Conversion in the Subsynaptic Membrane of the Developing Mammalian Neuromuscular Junction"" Dev. Biol. 80:1-17 (1980).;;Mishina et al., ""Expression of functional acetylcholine receptor from cloned cDNAs"" Nature 307:604-608 (1984).;;Mishina et al., ""Molecular distinction between fetal and adult forms of muscle acetylcholine receptor"" Nature 321:406-411 (1986).;;Mulac-Jericevic and Atassi, ""Segment alpha182-198 of Torpedo californica acetylcholine receptor contains a second toxin-binding region and binds anti-receptor antibodies"" FEBS Lett. 199(1):68-74 (1986).;;Nef et al., ""Structure linkage, and sequence of the two genes encoding the delta and gamma subunits of the nicotinic acetylcholine receptor"" Proc. Natl. Acad. Sci., USA 81:7975-7979 (1984).;;Nef et al., ""Acetylcholine Receptor Related Genes Expressed in the Nervous System"" In: Nicotinic Acetylcholine Receptor: Structure and Function, NATO ASI Series, vol. H3, A. Maelicke, ed., (Springer-Verlag) pp. 417-422 (1986).;;Nef et al., ""Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors"" EMBO J. 7(3):595-601 (1988).;;Neumann et al., ""Mapping of the alpha-bungarotoxin binding site within the alpha subunit of the acetylcholine receptor"" Proc. Natl. Acad. Sci., USA 83:3008-3011 (1986).;;Noda et al., ""Primary structure of alpha-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence"" Nature 299:793-797 (1982).;;Noda et al., ""Structural homology of Torpedo californica acetylcholine receptor subunits"" Nature 302:528-532 (1983).;;Noda et al., ""Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor"" Nature 305:818-823 (1983).;;Oswald and Freeman, ""Alpha-Bungarotoxin Binding and Central Nervous System Nicotinic Acetylcholin Receptors"" Neuroscience 6:1-14 (1981).;;Patrick and Stallcup, ""Immunological distinction between acetylcholine receptor and the alpha-bungarotoxin-binding component on sympathetic neurons"" Proc. Natl. Acad. Sci., USA 74(10):4689-4692 (1977).;;Patrick and Stallcup, ""alpha-Bungarotoxin Binding and Cholinergic Receptor Function on a Rat Sympathetic Nerve Line"" J. Biol. Chem. 252:8629-8633 (1977).;;Patrick et al., ""Molecular Cloning of the Acetylcholine Receptor"" Cold Spring Harbor Symposia on Quantitative Biology XLVIII:71-79 (1983).;;Pearson et al., ""The cortical relationships of certain basal ganglia and the cholinergic basal forebrain nuclei"" Brain Res. 261:327-330 (1983).;;Popot and Changeux, ""Nicotinic Receptor of Acetylcholine: Structure of an Oligomeric Integral Membrane Protein"" Physiological Revs. 64(4):1162-1239 (1984).;;Rang, H.P., ""The Characteristics of Synaptic Currents and Responses to Acetylcholine of Rat Submandibular Ganglion Cells"" J. Physiol. 311:23-55 (1981).;;Ravdin and Berg, ""Inhibition of neuronal acetylcholine sensitivity by alpha-toxins from Bungarus multicinctus venom"" Proc. Natl. Acad. Sci., USA 76(4):2072-2076 (1979).;;Rotter and Jacobowitz, ""Neurochemical Identification of Cholinergic Forebrain Projection Sites of the Nucleus Tegmentalis Dorsalis Lateralis"" Brain Res. Bull. 6:525-529 (1981).;;Safran et al., ""Analysis of acetylcholine receptor phosphorylation sites using antibodies to synthetic peptides and monoclonal antibodies"" EMBO J. 5:3175-3178 (1986).;;Schoepfer et al., ""cDNA Clone Coding for the Structural Subunit of a Chicken Brain Nicotinic Acetylcholine Receptor"" Neuron 1:241-248 (1988).;;Schofield et al., ""Sequence and functional expression of the GABA<SUB>A </SUB>receptor shows a ligand-gated receptor super-family"" Nature 328:221-227 (1987).;;Schubert et al., ""Characterization of a Unique Muscle Cell Line"" J. Cell. Bio. 61:398-413 (1974).;;Sebbane et al., ""Characterization of the mRNA for Mouse Muscle Acetylcholine Receptor alpha Subunit by Quantitative Translation in Vitro"" J. Biol. Chem. 258:3294-3303 (1983).;;Shibahara et al,. ""Cloning and sequencing analysis of human genomic DNA encoding gamma subunit precursor of muscle acetylcholine receptor"" Eur. J. Biochem. 146:349-359 (1985).;;Smith et al., ""Characterization of a Component in Chick Ciliary Ganglia that Cross-reacts with Monoclonal Antibodies to Muscle and Electric Organ Acetylcholine Receptor"" J. Neurosci. 5(10):2726-2731 (1985).;;Stroud and Finer-Moore, ""Acetylcholine Receptor Structure, Function, and Evolution"" Ann. Rev. Cell. Biol. 1:317-351 (1985).;;Sugiyama and Yamashita, ""Characterization of Putative Nicotinic Acetylcholine Receptors Solubilized from Rat Brains"" Brain Res. 373:22-26 (1986).;;Swanson et al., ""Immunohistochemical localization of monoclonal antibodies to the nicotinic acetylcholine receptor in chick midbrain"" Proc. Natl. Acad. Sci., USA 80:4532-4536 (1983).;;Swanson et al., ""Immunohistochemical Localization of Neuronal Nicotinic Receptors in the Rodent Central Nervous System"" J. Neurosci. 7(10):3334-3342 (1987).;;Takai et al., ""Cloning, sequencing and expression of cDNA for a novel subunit of acetylcholine receptor from calf muscle"" Nature 315:761-764 (1985).;;Vicini and Schuetze, ""Gating Properties of Acetylcholine Receptors at Developing Rat Endplates"" J. Neurosci. 5(8):2212-2224 (1985).;;Wada et al,. ""Functional Expression of a New Pharmacological Subtype of Brain Nicotinic Acetylcholine Receptor"" Science 240:330-334 (1988).;;Weill et al., ""Affinity-Labeling of Purified Acetylcholine Receptor From Torpedo Californica"" Biochem. Biophys. Res. Commun. 61(3):997-1003 (1974).;;Whiting and Lindstrom, ""Pharmacological Properties of Immuno-Isolated Neuronal Nicotinic Receptors"" J. Neurosci. 6(10):3061-3069 (1986).;;Whiting and Lindstrom, ""Purification and Characterization of a Nicotinic Acetylcholine Receptor from Chick Brain"" Biochem. 25:2082-2093 (1986).;;Whiting and Lindstrom, ""Affinity labelling of neuronal acetylcholine receptors localizes acetylcholine-binding sites to their beta-subunits"" FEBS Lett. 213(1):55-60 (1987).;;Whiting et al., ""Functional acetylcholine receptor in PC12 cells reacts with a monoclonal antibody to brain nicotinic receptors"" Nature 327:515-518 (1987).;;Whiting et al., ""Neuronal nicotinic acetylcholine receptor beta-subunit is coded for by the cDNA clone alpha<SUB>4</SUB>"" FEBS Lett. 219(2):459-463 (1987).;;Whiting and Lindstrom, ""Purification and characterization of a nicotinic acetylcholine receptor from rat brain"" Proc. Natl. Acad. Sci., USA 84:595-599 (1987).;;Wilson et al., ""Determination of the primary amino acid sequence specifying the alpha-bungarotoxin binding site on the alpha subunit of the acetylcholine receptor for Torpedo californica"" Proc. Natl. Acad. Sci., USA 82:8790-8794 (1985).;;Wonnacott, S., ""alpha-Bungarotoxin Binds to Low-Affinity Nicotine Binding Sites in Rat Brain"" J. Neurochem. 47:1706-1712 (1986).",EXPIRED
428,CA,C,CA 1341554 C,132-069-644-153-806,2007-10-09,2007,CA 1341554 A,1989-03-20,US 32138489 A;;US 17029588 A,1988-03-18,NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR COMPOSITIONS AND ASSAY,,SALK INST FOR BIOLOGICAL STUDI,HEINEMANN EDEN DEER;;DUVOISIN ROBERT MICHAEL;;PATRICK JAMES WARNER;;HEINEMANN STEPHEN FOX;;DENERIS EVAN SAMUEL;;WADA KEIJI;;CONNOLLY JOHN GERARD;;BALLIVET MARC CHARLES;;GOLDMAN DANIEL JAY;;BOULTER JAMES RICHARD,,https://lens.org/132-069-644-153-806,Granted Patent,no,0,0,5,19,0,C07K14/70571;;G01N33/944;;G01N2500/04;;C07K14/70571;;G01N33/944;;G01N2500/04,C12N15/12;;C07K14/705;;C12N5/10;;G01N33/566;;G01N33/567,,0,0,,,,INACTIVE
429,US,A,US 6136550 A,068-935-055-963-228,2000-10-24,2000,US 34995694 A,1994-12-06,US 34995694 A;;US 89818592 A;;US 32138489 A;;US 17029588 A,1988-03-18,Neuronal nicotinic acetylcholihne receptor compositions,"The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.",SALK INST FOR BIOLOGICAL STUDI,HEINEMANN STEPHEN FOX;;PATRICK JAMES WARNER;;BOULTER JAMES RICHARD;;DENERIS EVAN SAMUEL;;WADA KEIJI;;BALLIVET MARC CHARLES;;GOLDMAN DANIEL JAY;;CONNOLLY JOHN GERARD;;DUVOISIN ROBERT MICHAEL;;HEINEMANN EDEN DEER,MERCK SHARP & DOHME CORP (2009-11-02),https://lens.org/068-935-055-963-228,Granted Patent,yes,1,3,5,19,0,C07K14/70571;;G01N33/944;;G01N2500/04;;C07K14/70571;;G01N33/944;;G01N2500/04,C07K14/705;;C12N15/12;;G01N33/566,435/7.21;;435/69.1;;435/252.3;;435/320.1;;436/501;;536/23.5,6,4,086-728-559-738-201;;030-461-226-783-811;;088-944-431-004-208;;019-531-252-128-872,10.1038/307604a0;;6320016;;10.1073/pnas.84.2.595;;3467376;;pmc304257;;10.1038/319368a0;;3753746;;10.1038/327515a0;;2438558,"Mishina et al. Expression of Functional Acetylcholine receptor . . . . Nature 307:604 608, Feb. 1984.;;Whiting et al. Proc. Natl. Acad. Sci. USA 84:595 599, Jan. 1987.;;Boulter et al. Isolation of a cDNA clone coding fpr a possible neural nicotinic acetylcholine receptor alpha subunit , Nature 319:368 374, Jan. 1986.;;Goldman et al. Members of a Nicotine Acetylcholine receptor gene family . . . . Cell 48:204 213, Mar. 1987.;;Whiting et al. Functional acetylcholine receptor in PC12 cells . . . . Nature 327:515 518, Jun. 1987.;;Whiting et al. Affinity Labeling of Neuronal acetylcholine receptors . . . . FEBS Letters 23(1):55 60, Feb. 1984.",EXPIRED
430,US,A,US 5371188 A,042-214-497-438-03X,1994-12-06,1994,US 89818592 A,1992-06-12,US 89818592 A;;US 66447391 A;;US 32138489 A;;US 17029588 A,1988-03-18,Neuronal nicotinic acetylcholine receptor compositions,"The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.",SALK INST FOR BIOLOGICAL STUDI,HEINEMANN STEPHEN F;;PATRICK JAMES W;;BOULTER JAMES R;;DENERIS EVAN S;;WADA KEIJI;;BALLIVET MARC C;;GOLDMAN DANIEL J;;CONNOLLY JOHN G;;DUVOISIN ROBERT M;;HEINEMANN EDEN D,,https://lens.org/042-214-497-438-03X,Granted Patent,yes,1,24,5,19,0,C07K14/70571;;G01N33/944;;G01N2500/04;;C07K14/70571;;G01N33/944;;G01N2500/04,C07K14/705;;C12N15/12;;G01N33/566,530/350;;435/6;;435/62.1;;435/252.3;;435/320.1,6,6,086-728-559-738-201;;030-461-226-783-811;;088-944-431-004-208;;033-531-880-234-18X;;019-531-252-128-872;;054-227-081-244-432,10.1038/307604a0;;6320016;;10.1073/pnas.84.2.595;;3467376;;pmc304257;;10.1038/319368a0;;3753746;;3829125;;10.1016/0092-8674(87)90705-7;;10.1038/327515a0;;2438558;;2435576;;10.1016/0014-5793(87)81464-3,"Mishina, M. et al. Expression of Functional Acetylcholine receptor . . . Nature vol. 307, pp. 604 608 Feb. 16, 1984.;;Whiting & Lindstrom, Proc. Natl. Acad. Sci. USA vol. 84, pp. 595 599, Jan. 1987.;;Boulter, J. et al. Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor subunit Nature vol. 319 pp. 368 374 Jan. 30, 1986.;;Goldman, D. et al. Members of a Nicotine Acetylcholine receptor gene family . . . Cell vol. 48, pp. Mar. 27, 1987.;;Whiting, P. J. et al. Functional acetylcholine receptor in PC12 cells . . . Nature vol. 327 pp. 515 518 Jun. 11, 1987.;;Whiting, Paul & Lindstrom, Jon Affinity Labelling of Neuronal acetylcholine receptors . . . FEBS Letters vol. 23(1) pp. 55 60 Mar. 1987.",EXPIRED
431,US,A,US 5591590 A,194-631-895-736-656,1997-01-07,1997,US 47298995 A,1995-06-06,US 47298995 A;;US 34995694 A;;US 89818592 A;;US 32138489 A;;US 17029588 A,1988-03-18,Neuronal nicotinic acetylcholine receptor assay,"The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.",SALK INST FOR BIOLOGICAL STUDI,HEINEMANN STEPHEN F;;PATRICK JAMES W;;BOULTER JAMES R;;DENERIS EVAN S;;CONNOLLY JOHN G;;DUVOISIN ROBERT M;;HEINEMANN EDEN D;;WADA KEIJI;;BALLIVET MARC C;;GOLDMAN DANIEL J,,https://lens.org/194-631-895-736-656,Granted Patent,yes,1,12,5,19,0,C07K14/70571;;G01N33/944;;G01N2500/04;;C07K14/70571;;G01N33/944;;G01N2500/04,C07K14/705;;C12N15/12;;G01N33/566,435/7.1;;435/6;;435/7.2;;436/501,99,98,032-154-993-748-243;;038-426-107-403-502;;034-202-041-467-969;;001-910-735-875-801;;088-944-431-004-208;;002-941-512-853-937;;108-665-931-448-827;;014-445-493-084-951;;031-894-285-200-487;;040-995-442-192-126;;084-678-642-354-860;;006-600-008-545-863;;034-854-638-120-494;;080-389-547-198-365;;125-822-815-620-653;;013-437-955-677-617;;119-062-254-409-623;;010-359-077-037-383;;107-112-792-448-248;;080-684-683-067-679;;061-813-575-625-919;;002-471-216-132-744;;147-130-419-609-971;;019-109-310-909-826;;122-711-463-589-62X;;033-531-880-234-18X;;007-488-923-333-88X;;074-626-344-956-161;;020-328-503-259-335;;086-664-235-217-143;;063-740-685-113-437;;014-197-138-389-187;;013-907-848-182-655;;005-102-278-457-275;;034-401-501-920-130;;047-067-609-947-248;;015-291-617-665-924;;027-323-818-442-275;;070-880-599-513-627;;009-105-479-184-17X;;001-122-805-546-388;;087-834-586-280-481;;054-827-597-793-765;;059-824-183-827-88X;;071-237-454-382-615;;065-785-617-279-55X;;043-548-538-728-049;;045-997-271-617-193;;046-379-499-766-548;;076-528-054-990-947;;039-849-604-670-303;;058-529-957-672-271;;061-039-447-776-026;;086-728-559-738-201;;051-371-151-120-361;;029-127-218-822-412;;052-007-492-168-174;;046-894-764-577-526;;035-667-841-445-027;;051-057-892-199-85X;;126-648-825-745-885;;099-508-175-195-962;;029-167-460-549-342;;039-700-450-238-220;;080-281-384-957-608;;014-495-669-186-034;;116-570-727-130-158;;072-973-092-186-351;;018-549-498-430-042;;013-529-430-516-421;;001-800-549-328-639;;050-392-839-319-076;;007-571-476-901-546;;009-823-812-896-004;;082-333-559-426-820;;117-450-833-942-811;;100-084-428-309-76X;;052-306-680-652-764;;021-479-574-647-612;;072-330-625-331-840;;021-721-900-216-133;;028-678-277-111-340;;047-302-961-865-636;;015-834-812-425-174;;031-852-916-835-740;;023-315-408-617-938;;022-474-872-506-870;;105-182-127-994-450;;005-423-992-450-588;;054-227-081-244-432;;019-531-252-128-872;;020-846-211-688-541;;030-461-226-783-811;;044-253-405-101-224;;084-996-304-110-55X;;080-281-384-957-608;;031-617-041-391-20X;;030-461-226-783-811,10.1002/cne.902160106;;6345598;;10.1073/pnas.82.23.8080;;3865218;;pmc391446;;10.1098/rspb.1982.0040;;6127706;;pmc6565314;;10.1523/jneurosci.05-09-02545.1985;;2993547;;10.1038/319368a0;;3753746;;10.1073/pnas.84.21.7763;;pmc299381;;2444984;;10.1016/0092-8674(87)90617-9;;3581171;;pmc432535;;1055412;;10.1073/pnas.72.4.1368;;194659;;10.1016/0006-8993(77)90981-7;;6481621;;10.1113/jphysiol.1984.sp015325;;pmc1193296;;3745150;;10.1016/s0021-9258(18)67264-3;;10.1073/pnas.75.2.1016;;pmc411391;;416436;;6093012;;10.1016/0304-3940(84)90492-0;;10.1523/jneurosci.05-05-01307.1985;;pmc6565049;;3998824;;10.1073/pnas.80.4.1111;;pmc393538;;6573658;;3860855;;10.1073/pnas.82.15.5208;;pmc390529;;6692991;;10.1016/0012-1606(84)90162-3;;3272154;;10.1016/0896-6273(88)90208-5;;10.1073/pnas.80.7.2067;;6572962;;pmc393754;;10.1016/s0021-9258(18)61283-9;;pmc5586536;;2435720;;pmc344629;;6320162;;10.1073/pnas.81.1.155;;10.1113/jphysiol.1980.sp013275;;6253617;;pmc1282881;;10.1021/bi00383a003;;3607023;;10.1523/jneurosci.05-09-02553.1985;;4032011;;pmc6565325;;pmc323669;;3012549;;10.1073/pnas.83.11.4076;;3829125;;10.1016/0092-8674(87)90705-7;;pmc369897;;6960240;;10.1128/mcb.2.9.1044-1051.1982;;10.1128/mcb.2.9.1044;;1065897;;10.1073/pnas.73.7.2424;;pmc430592;;3037383;;10.1038/328215a0;;pmc1435233;;6324907;;10.1016/s0006-3495(84)84152-1;;10.1016/0166-2236(87)90087-7;;10.1038/321171a0;;2422562;;5055788;;pmc2226074;;10.1085/jgp.60.3.248;;10.1126/science.3022377;;3022377;;10.1007/978-3-642-71649-2_29;;3298562;;pmc6568889;;10.1523/jneurosci.07-06-01792.1987;;6850348;;10.1016/0006-8993(83)91312-4;;10.1016/0014-5793(86)80881-x;;2427361;;2423885;;10.1038/321774a0;;3944622;;10.1523/jneurosci.06-01-00281.1986;;pmc6568606;;2432430;;10.1038/324670a0;;10.1128/mcb.6.8.2855;;10.1128/mcb.6.8.2855-2864.1986;;3785216;;pmc367853;;3722144;;10.1016/s0021-9258(19)83877-2;;10.1085/jgp.54.1.245;;pmc2225893;;19873644;;10.1016/0006-8993(85)90187-8;;4063809;;3821734;;10.1128/mcb.7.2.951;;10.1128/mcb.7.2.951-955.1987;;pmc365157;;2436944;;10.1016/0014-5793(87)80065-0;;7150959;;10.1016/0006-8993(82)90406-1;;10.1016/0028-3908(82)90107-1;;7145035;;10.1016/b978-0-12-185203-0.50018-5;;2423008;;10.1146/annurev.ne.09.030186.002123;;pmc6569057;;10.1523/jneurosci.07-03-00742.1987;;3549993;;10.1016/0012-1606(80)90494-7;;6254823;;10.1038/307604a0;;6320016;;10.1038/321406a0;;2423878;;3956748;;10.1016/0014-5793(86)81225-x;;pmc392276;;10.1073/pnas.81.24.7975;;6096871;;10.1007/978-3-642-71649-2_31;;3267226;;10.1002/j.1460-2075.1988.tb02852.x;;pmc454362;;10.1073/pnas.83.9.3008;;3458258;;pmc323436;;6182472;;10.1038/299793a0;;6188060;;10.1038/302528a0;;10.1038/308084d0;;7012663;;10.1016/0306-4522(81)90239-6;;pmc432013;;10.1073/pnas.74.10.4689;;270708;;925016;;10.1016/s0021-9258(19)75267-3;;10.1101/sqb.1983.048.01.009;;6202451;;6339004;;10.1016/0006-8993(83)90638-8;;10.1152/physrev.1984.64.4.1162;;6208568;;10.1113/jphysiol.1981.sp013571;;pmc1275396;;6267251;;287045;;10.1073/pnas.76.4.2072;;pmc383536;;10.1016/s0361-9230(81)80027-5;;7248816;;3816758;;10.1002/j.1460-2075.1986.tb04626.x;;pmc1167309;;10.1016/0896-6273(88)90145-6;;3272170;;10.1038/328221a0;;3037384;;10.1083/jcb.61.2.398;;pmc2109296;;4363958;;10.1016/s0021-9258(18)32860-6;;6826561;;10.1111/j.1432-1033.1985.tb08614.x;;3967651;;pmc6565130;;10.1523/jneurosci.05-10-02726.1985;;2413185;;10.1146/annurev.cb.01.110185.001533;;2435309;;10.1016/0006-8993(86)90311-2;;2424552;;10.1073/pnas.80.14.4532;;pmc384073;;6192437;;pmc6569159;;2822866;;10.1523/jneurosci.07-10-03334.1987;;3839289;;10.1038/315761a0;;10.1523/jneurosci.05-08-02212.1985;;4020435;;pmc6565290;;2832952;;10.1126/science.2832952;;10.1016/0006-291x(74)90254-x;;4451573;;3531428;;pmc6568798;;10.1523/jneurosci.06-10-03061.1986;;3707934;;10.1021/bi00356a037;;2435576;;10.1016/0014-5793(87)81464-3;;10.1038/327515a0;;2438558;;3609304;;10.1016/0014-5793(87)80272-7;;10.1073/pnas.84.2.595;;3467376;;pmc304257;;10.1073/pnas.82.24.8790;;3866252;;pmc391523;;10.1111/j.1471-4159.1986.tb13078.x;;3772372;;pmc432013;;10.1073/pnas.74.10.4689;;270708;;10.1007/bf00582635;;2432468;;10.1073/pnas.84.2.595;;3467376;;pmc304257,"Armstrong et al., Distribution of Cholinergic Neurons in Rat Brain: Demonstrated by the Immunocytochemical Localizaton of Choline Acetyltransferase J. Comp. Neurol. 216:53 68 (1983).;;Baldwin et al., Structure, evolution and regulation of a fast skeletal muscle troponin I gene Proc. Natl. Acad. Sci., USA 82:8080 8084 (1985).;;Barnard et al., Translation of exogenous messenger RNA coding for nicotinic acetylcholine receptors produces functional receptors in Xenopus oocytes Proc. R. Soc. Lond. B. 215:241 246 (1982).;;Boulter et al., Isolation of a Clone Coding for the Subunit of a Mouse Acetylcholine Receptor J. Neurosci. 5(9):2545 2552 (1985).;;Boulter et al., Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor subunit Nature 319:368 374 (1986).;;Boulter et al., Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family Proc. Natl. Acad. Sci., USA 84:7763 7767 (1987).;;Breitbart and Nadal Ginard, Developmentally Induced, Muscle Specific Trans Factors Control the Differential Splicing of Alternative and Constitutive Troponin T Exons Cell 49:793 803 (1987).;;Brockes and Hall Synthesis of Acetylcholine Receptor by Denervated Rat Diaphragm Muscle Proc. Natl. Acad. Sci., USA 72(4):1368 1372 (1975).;;Brown and Fumagalli, Dissociation of bungarotoxin binding and receptor block in the rat superior cervical ganglion Brain Res. 129:165 168 (1977).;;Brown et al., The action of cholinomimetic substances on impulse conduction in the habenulointerpeduncular pathway of the rat in vitro J. Physiol. 353:101 109 (1984).;;Buonanno and Merlie, Transcriptional Regulation of Nicotinic Acetylcholine Receptor Genes during Muscle Develoment J. Biol. Chem. 261(25):11452 11455 (1986).;;Carbonetto et al., Nonequivalence of bungarotoxin receptors and acetylcholine receptors in chick sympathetic neurons Proc. Natl Acad. Sci., USA 75(2):1016 1020 (1978).;;Chiappinelli and Dryer, Nicotinic transmission in sympathetic ganglia: blockade by the snake venom neurotoxin kappa bungarotoxin Neurosci. Lett. 50:239 244 (1984).;;Clarke et al., Nicotinic Binding in the Rat Brain: Autoradiographic Comparison of 3 H Acetylcholine, 3 H Nicotine, and 125 H Bungarotoxin J. Neurosci. 5(5):1307 1315 (1985).;;Claudio et al., Nucleotide and deduced amino acid sequences of Torpedo californica acetylcholine receptor subunit Proc. Natl. Acad. Sci., USA 80:1111 1115 (1983).;;Conti Tronconi et al., Brain and muscle nicotinic acetylcholine receptors are different but homologous proteins Proc. Natl. Acad. Sci., USA 82:5208 5212 (1985).;;Cox et al., Detection of mRNAs in Sea Urchin Embryos by in Situ Hybridizaton Using Aasymmetric RNA Probes Dev. Biol. 101:485 502 (1984).;;Deneris et al., Primary Structure and Expression of 2: A novel Subunit of Neuronal Nicotinic Acetylcholine Receptors Neuron 1:45 54 (1988).;;Devillers Thiery et al., Complete mRNA coding sequence of the acetylcholine binding subunit of Torpedo marmorata acetylcholine receptor: A model for the transmembrane organization of the polypeptide chain Proc. Natl Acad. Sci., USA 80:2067 2071 (1983).;;Evans et al., Muscle Acetylcholine Receptor Biosynthesis: Regulation by Transcript Availability J. Biol. Chem. 262(10):4911 4916 (1987).;;Finer Moore and Stroud, Amphipathic analysis and possible formation of the ion channel in an acetylcholine receptor Proc. Natl. Acad. Sci., USA 81:155 159 (1984).;;Fischbach and Schuetze, A post natal decrease in acetylcholine channel open time at rat end plates J. Physiol. 303:125 137 (1980).;;Giraudat et al., Structure of the High Affinity Binding Site for Noncompetitive Blockers of the Acetylcholine Receptor: 3 H Chlorpromazine Labels Homologous Residues in the and Chains Biochem. 26:2410 2418 (1987).;;Goldman et al., Muscle Denervation Increases the Levels of Two mRNAs Coding for the Acetylcholine Receptor Subunit J. Neurosci. 5:2553 2558 (1985).;;Goldman et al., Mapping of brain areas expressing RNA homologous to two different acetylcholine receptor subunit cDNAs Proc. Natl. Acad. Sci., USA 83:4076 4080 (1986).;;Goldman et al., Members of a Nicotinic Acetylcholine Receptor Gene Family Are Expressed in Different Regions of the Mammalian Central Nervous System Cell 48:965 973 (1987).;;Gorman et al., Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells Mol. Cell. Biol. 2(9):1044 1051 (1982).;;Greene and Tischler, Establishment of noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor Proc. Natl. Acad. Sci., USA 73:(7)2424 2428 (1976).;;Grenningloh et al., The strychnine binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors Nature 328:215 220 (1987).;;Guy, H. R., A structural model of the acetylcholine receptor channel based on partition energy and helix packing calculations Biophys. J. 45:249 261 (1984).;;Guy and Hucho, The ion channel of the nicotinic acetylcholine receptor Trends Neurosci 10(8):318 321 (1987).;;Hanke and Breer, Channel properties of an insect neuronal acetylcholine receptor protein reconstituted in planar lipid bilayers Nature 321:171 174 (1986).;;Hartzell and Fambrough, Acetylcholine Receptors: Distribution and extrajunctional density in rat diaphragm after denervation correlated with acetylcholine sensitivity J. Gen. Physiol. 60:248 262 (1972).;;Heidmann et al., Chromosomal Localizaton of Muscle Nicotinic Acetylcholine Receptor Genes in the Mouse Science 234:866 868 (1986).;;Heinemann et al., Molecular Biology of the Muscle Land Neural Acetylcholine Receptors In: Nicotinic Acetylcholine Receptor: Structure and Function, NATO ASI Series H, A. Maelicke, ed. (Berlin: Springer Verlag), H3:359 387 (1986).;;Higgins and Berg, Immunological Identification of a Nicotinic Acetylcholine Receptor on Bovine Chromaffin Cells J. Neurosci. 7(6):1792 1798 (1987).;;Houser et al., Organization and Morphological Characteristics of Cholinergic Neurons: an Immunocytochemical Study with a Monoclonal Antibody to Choline Acetyltransferase Brain Res. 266:97 119 (1983).;;Hucho et al., The ion channel of the nicotinic acetylcholine receptor in formed by the homologous helices M II of the receptor subunits FEBS Lett. 205(1)137 142 (1986).;;Huganir et al., Phosphorylation of the nicotinic acetylcholine receptor regulates its rate of desensitization Nature 321:774 776 (1986).;;Ichikawa and Hirata, Organization of Choline Acetyltransferase Containing Structures in the Forebrain of the Rat J. Neurosci. 6(1):281 292 (1986).;;Imoto et al., Location of a subunit region determining ion transport through the acetylcholine receptor channel Nature 324:670 674 (1986).;;Jaynes et al., Transcriptional Regulation of the Muscle Creatine Kinase Gene and Regulated Expression in Transfected Mouse Myoblasts Mol. Cell. Biol. 6(8):2855 2864 (1986).;;Kao and Karlin, Acetylcholine Receptor Binding Site Contains a Disulfide Cross link between Adjacent Half Cystinyl Residues J. Biol. Chem. 261(18):8085 8088 (1986).;;Karlin, A., Chemical Modification of the Active Site of Acetylcholine Receptor J. Gen. Phys. 54:245s 264s (1969).;;Kemp et al., Purification and Characterization of the Bungarotoxin Binding Protein from Rat Brain Brain Res. 347:274 283 (1985).;;Klarsfeld et al., A 5 Flanking Region of the Chicken Acetylcholine Receptor Subunit Gene Confers Tissue Specificity and Develomental Control of Expression in Transfected Cells Mol. Cell. Biol. 7(2):951 955 (1987).;;Kurosaki et al., Functional properties of nicotinic acetylcholine receptor subunits expressed in various combinations FEBS Lett. 214(2):253 258 (1987).;;Lamour et al., Spread of acetylcholine sensitivity in the necocortex following lesion of the nucleus basalis Brain Res. 252:377 381 (1982).;;Lichtensteiger et al., Stimulation of Nigrostriatal Dopamine Neurones by Nicotine Neuropharmacol. 21:963 968 (1982).;;Martin, B. R., Nicotine Receptors n the Central Nervous System In: The Receptors, P. M. Conn, ed. (Orlando, FL: Academic Press) 3:393 415 (1986).;;Mauron et al., Structure of Chicken Genes Encoding the Nicotinic Acetylcholine Receptor Subunits and Their Variants Soc. for Neuroscience, 15th Annual Meeting, Abstract 55.10, p. 171 (1985).;;McCarthy et al., The molecular Neurobiology of the Acetylcholine Receptor Ann. Rev. Neurosci. 9:383 413 (1986).;;McCormick and Prince, Acetylcholine Causes Rapid Nicotinic Excitation in the Medial Habenular Nucleus of Guinea Pig, in vitro J. Neurosci. 7(3):742 752 (1987).;;Michler and Sakmann, Receptor Stability and Channel Conversion in the Subsynaptic Membrane of the Developing Mammalian Neuromuscular Junction Dev. Biol. 80:1 17 (1980).;;Mishina et al., Expression of functional acetylcholine receptor from cloned cDNAs Nature 307:604 608 (1984).;;Mishina et al., Molecular distinction between fetal and adult forms of muscle acetylcholine receptor Nature 321:406 411 (1986).;;Mulac Jercevic and Atassi, Segment 182 198 of Torpedo californica acetylcholine receptor contains a second toxin binding region and binds anti receptor antibodies FEBS Lett. 199(1):68 74 (1986).;;Nef et al., Structure linkage, and sequence of the two genes encoding the and subunits of the nicotinic acetylcholine receptor Proc. Natl. Acad. Sci., USA 81:7975 7979 (1984).;;Nef et al., Acetylcholine Receptor Related Genes Expressed in the Nervous System In: Nicotinic Acetylcholine Receptor: Structure and Function, NATO ASI Series, vol. H3, A. Maelicke, ed., (Springer Verlag) pp. 417 422 (1986).;;Nef et al., Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors EMBO J. 7(3):595 601 (1988).;;Neumann et al., Mapping of the bungarotoxin binding site within the subunit of the acetylcholine receptor Proc. Natl. Acad. Sci., USA 83:3008 3011 (1986).;;Noda et al., Primary structure of subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence Nature 299:793 797 (1982).;;Noda et al,. Structural homology of Torpedo californica acetylcholine receptor subunits Nature 302:528 532 (1983).;;Noda et al., Cloning and sequence analysis of calf cDNA and human genomic DNA encoding subunit precursor of muscle acetylcholine receptor Nature 305:818 823 (1983).;;Oswald and Freeman, Alpha Bungarotoxin Binding and Central Nervous System Nicotinic Acetylcholine Receptors Neuroscience 6:1 14 (1981).;;Patrick and Stallcup, Immunological distinction between acetylcholine receptor and the bungarotoxin binding component on sympathetic neurons Proc. Natl. Acad. Sci., USA 74(10):4689 4692 (1977).;;Patrick and Stallcup, Bungarotoxin Binding and Cholinergic Receptor Function on a Rat Sympathetic Nerve Line J. Biol. Chem. 252:8629 8633 (1977).;;Patrick et al., Molecular Cloning of the Acetylcholine Receptor Cold Spring Harbor Symposia on Quantitative Biology XLVIII:71 79 (1983).;;Pearson et al., The cortical relationships of certain basal ganglia and the cholinergic basal forebrain nuclei Brain Res. 261:327 330 (1983).;;Popot and Changeux, Nicotinic Receptor of Acetylcholine: Structure of an Oligomeric Integral Membrane Protein Physiological Revs. 64(4):1162 1239 (1984).;;Rang, H. P., The Characteristics of Synaptic Currents and Responses to Acetylcholine of Rat Submandibular Ganglion Cells J. Physiol. 311:23 55 (1981).;;Ravdin and Berg, Inhibition of neuronal acetylcholine sensitivity by toxins from Bungarus multicinctus venom Proc. Natl. Acad. Sci., USA 76(4):2072 2076 (1979).;;Rotter and Jacobowitz, Neurochemical Identification of Cholinergic Forebrain Projection Sites of the Nucleus Tegmentalis Dorsalis Lateralis Brain Res. Bull. 6:525 529 (1981).;;Safran et al,. Analysis of acetylcholine receptor phosphorylation sites using antibodies to synthetic peptides and monoclonal antibodies EMBO J. 5:3175 3178 (1986).;;Schoepfer et al., cDNA Clone Coding for the Structural Subunit of a Chicken Brain Nicotinic Acetylcholine Receptor Neuron 1:241 248 (1988).;;Schofield et al., Sequence and functional expression of the GABA A receptor shows a ligand gated receptor super family Nature 328:221 227 (1987).;;Schubert et al., Characterization of a Unique Muscle Cell Line J. Cell. Bio. 61:398 413 (1974).;;Sebbane et al., Characterization of the mRNA for Mouse Muscle Acetylcholine Receptor Subunit by Quantitative Translation in Vitro J. Biol. Chem. 258:3294 3303 (1983).;;Shibahara et al,. Cloning and sequencing analysis of human genomic DNA encoding subunit precursor of muscle acetylcholine receptor Eur. J. Biochem. 146:349 359 (1985).;;Smith et al., Characterization of a Component in Chick Ciliary Ganglia that Cross reacts with Monoclonal Antibodies to Muscle and Electric Organ Acetylcholine Receptor J. Neurosci. 5(10):2726 2731 (1985).;;Stroud and Finer Moore, Acetylcholine Receptor Structure, Function, and Evolution Ann. Rev. Cell. Biol. 1:317 351 (1985).;;Sugiyama and Yamashita, Characterization of Putative Nicotinic Acetylcholine Receptors Solubilized from Rat Brains Brain Res. 373:22 26 (1986).;;Swanson et al., Immunohistochemical localization of monoclonal antibodies to the nicotinic acetylcholine receptor in chick midbrain Proc. Natl. Acad. Sci., USA 80:4532 4536 (1983).;;Swanson et al., Immunohistochemical Localization of Neuronal Nicotinic Receptors in the Rodent Central Nervous System J. Neurosci. 7(10):3334 3342 (1987).;;Takai et al., Cloning, sequencing and expression of cDNA for a novel subunit of acetylcholine receptor from calf muscle Nature 315:761 764 (1985).;;Vicini and Schuetze, Gating Properties of Acetylcholine Receptors at Developing Rat Endplates J. Neurosci. 5(8):2212 2224 (1985).;;Wada et al,. Functional Expression of a New Pharmacological Subtype of Brain Nicotinic Acetylcholine Receptor Science 240:330 334 (1988).;;Weill et al., Affinity Labeling of Purified Acetylcholine Receptor from Torpedo Californica Biochem. Biophys. Res. Commun. 61(3):997 1003 (1974).;;Whiting and Lindstrom, Pharmacological Properties of Immuno Isolated Neuronal Nicotinic Receptors J. Neurosci. 6(10):3061 3069 (1986).;;Whiting and Lindstrom, Purification and Characterization of a Nicotinic Acetylcholine Receptor from Chick Brain Biochem. 25:2082 2093 (1986).;;Whiting and Lindstrom, Affinity labelling of neuronal acetylcholine receptors localizes acetylcholine binding sites to their subunits FEBS Lett. 213(1):55 60 (1987).;;Whiting et al., Functional acetylcholine receptor in PC12 cells reacts with a monoclonal antibody to brain nicotinic receptors Nature 327:515 518 (1987).;;Whiting et al., Neuronal nicotinic acetylcholine receptor subunit is coded for by the cDNA clone 4 FEBS Lett. 219(2):459 463 (1987).;;Whiting and Lindstrom, Purification and characterization of a nicotinic acetylcholine receptor from rat brain Proc. Natl. Acad. Sci., USA 84:595 599 (1987).;;Wilson et al., Determination of the primary amino acid sequence specifying the bungarotoxin binding site on the subunit of the acetylcholine receptor for Torpedo californica Proc. Natl. Acad. Sci., USA 82:8790 8794 (1985).;;Wonnacott, S., Bungarotoxin Binds to Low Affinity Nicotine Binding Sites in Rat Brain J. Neurochem. 47:1706 1712 (1986).;;Patrick et al, P.N.A.S. 74:4689 4692, Oct. 1977.;;Mothfessel et al., Pflugers Arch. 407(6):577 588, Dec. 1986, Abstract.;;Whiting et al., P.N.A.S. 84:595 599, Jan. 1987.",EXPIRED
432,EP,C0,EP 3807266 C0,030-390-307-793-223,2023-10-25,2023,EP 19756240 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,,JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,JANSSEN PHARMACEUTICA NV (2023-09-27),https://lens.org/030-390-307-793-223,Unknown,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,ACTIVE
433,AU,A1,AU 2019/289222 A1,077-107-839-259-039,2021-01-07,2021,AU 2019/289222 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,,https://lens.org/077-107-839-259-039,Patent Application,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,ACTIVE
434,WO,A3,WO 2018/138685 A3,032-445-372-085-264,2018-10-04,2018,IB 2018050498 W,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R 1B , R 1C , R 2B , R 2C , B 1 , W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/032-445-372-085-264,Search Report,yes,11,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61K31/7084;;A61P35/00;;A61P31/12;;C07H21/00,,1,1,066-720-424-156-341,27783523;;10.1021/acs.jmedchem.6b01300,"THIERRY LIOUX ET AL: ""Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 22, 4 November 2016 (2016-11-04), pages 10253 - 10267, XP055457763, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01300",PENDING
435,AU,A1,AU 2004/255581 A1,124-868-888-460-053,2005-01-20,2005,AU 2004/255581 A,2004-06-28,US 48457003 P;;EP 2004006973 W,2003-07-02,Arylamine-substituted quinazolinone compounds,,HOFFMANN LA ROCHE,KEITZ PAUL FRANCIS;;LI JIM;;NITZAN DOV;;WEINHARDT KLAUS KURT;;O'YANG COUNDE;;LOPEZ-TAPIA FRANCISCO JAVIER;;LEE EUN KYUNG;;CONNOLLY TERRENCE JOSEPH;;MELVILLE CHRIS RICHARD;;PADILLA FERNANDO;;MCGARRY PATRICK FINBAR,,https://lens.org/124-868-888-460-053,Patent Application,no,0,0,17,17,0,C07D239/90;;C07D239/95;;C07D285/24;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D239/95;;C07D285/24;;C07D401/14;;C07D403/12;;C07D405/12;;C07D401/12;;C07D413/12;;C07D417/12;;A61K31/517;;C07D401/12;;C07D239/90;;C07D239/95;;C07D417/12;;C07D401/14;;C07D405/12;;C07D413/12;;C07D285/24;;C07D403/12,C07D417/12;;A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02,,0,0,,,,DISCONTINUED
436,BR,A,BR PI0412285 A,159-705-011-326-37X,2006-09-19,2006,BR PI0412285 A,2004-06-28,US 48457003 P;;EP 2004006973 W,2003-07-02,os compostos de quinazolinona substituìda por arilamina,"""OS COMPOSTOS DE QUINAZOLINONA SUBSTITUìDA POR ARILAMINA"". Compostos representados pela Fórmula I que são úteis como antagonistas de adrenoceptor alfa-1A/B, para métodos de tratar condições associadas com a atividade de acrenoceptores alfa-1A/B, e a métodos de preparar os referidos compostos, onde Ar, Z, R, R<39>, R¬ 5¬ e R¬ 10¬ são como aqui definido.",HOFFMANN LA ROCHE,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/159-705-011-326-37X,Patent Application,no,0,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,0,0,,,,DISCONTINUED
437,KR,A,KR 20060031675 A,155-264-381-939-572,2006-04-12,2006,KR 20067000014 A,2006-01-02,US 48457003 P,2003-07-02,ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS,"Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R5 and R10 are as defined herein.",HOFFMANN LA ROCHE,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/155-264-381-939-572,Patent Application,no,0,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,C07D239/90;;A61K31/517;;A61K31/549;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,0,0,,,,INACTIVE
438,WO,A2,WO 2018/138685 A2,023-734-049-375-821,2018-08-02,2018,IB 2018050498 W,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R 1B , R 1C , R 2B , R 2C , B 1 , W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/023-734-049-375-821,Patent Application,yes,1,35,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00,,22,19,034-666-907-619-827;;102-034-121-002-023;;010-341-241-568-683;;006-540-796-046-165;;008-962-459-855-781;;060-000-705-511-414;;091-765-617-073-134;;002-895-644-883-279;;012-165-000-131-176;;006-911-733-023-062;;077-295-491-167-117;;077-295-491-167-117;;045-298-563-967-678;;040-887-679-477-746;;012-180-065-013-539;;029-641-974-701-191;;102-071-695-047-127;;018-874-474-967-696;;063-161-621-710-260,10.1016/j.immuni.2008.09.003;;18818105;;10.1126/science.aaa2630;;25636800;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.1232458;;pmc3863629;;23258413;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;10.1002/0471220574;;10.1002/0471220574;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.2165/00003088-198106060-00002;;7032803;;10.1007/bf01952257;;6382953;;10.1016/0065-2571(84)90007-4;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1110/ps.8.4.921;;10211839;;pmc2144313,"ZHONG B ET AL.: ""The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation"", IMMUNITY, vol. 29, 2008, pages 538 - 550, XP055021580, DOI: doi:10.1016/j.immuni.2008.09.003;;LIU S ET AL.: ""Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation"", SCIENCE, 2015, pages 2630 - 2637;;CHEN H ET AL.: ""Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity"", CELL, vol. 14, 2011, pages 433 - 446;;CORRALES, L. ET AL.: ""Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity"", CELL REPORTS, vol. 11, 2015, pages 1 - 13;;KONNO, H. ET AL.: ""Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling"", CELL, vol. 155, 2013, pages 688 - 698, XP028758016, DOI: doi:10.1016/j.cell.2013.09.049;;SUN, L. ET AL.: ""Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway"", SCIENCE, vol. 339, 2013, pages 786 - 791, XP055294100, DOI: doi:10.1126/science.1232458;;BHAT N; FITZGERALD KA: ""Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors"", EUR J IMMUNOL., vol. 44, no. 3, March 2014 (2014-03-01), pages 634 - 40;;ZHANG X ET AL.: ""Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING"", MOLECULAR CELL, vol. 51, 2013, pages 226 - 235, XP055300246, DOI: doi:10.1016/j.molcel.2013.05.022;;DANILCHANKA, O; MEKALANOS, JJ: ""Cyclic Dinucleotides and the Innate Immune Response"", CELL, vol. 154, 2013, pages 962 - 970, XP028706417, DOI: doi:10.1016/j.cell.2013.08.014;;LIU S-Y ET AL.: ""Systematic identification of type I and type II interferon-induced antiviral factors"", PROC. NATL. ACAD. SCI., vol. 109, 2012, pages 4239 - 4244;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;VAN DER JEUGHT ET AL., ONCOTARGET, vol. 6, no. 3, 2015, pages 1359 - 1381;;MARABELLE, A. ET AL., CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1747 - 1756;;HOLFORD; SCHEINER, CLIN. PHARMACOKINET., vol. 6, pages 429 - 453;;LOEWE; MUISCHNEK, ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326;;CHOU; TALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 30, 1993, pages 1213 - 1220;;YI: ""Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides"", PLOS ONE, vol. 8, no. 10, 2013, pages e77846, XP055315013, DOI: doi:10.1371/journal.pone.0077846;;BECKETT ET AL.: ""A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation"", PROTEIN SCIENCE, vol. 8, 1999, pages 921 - 929, XP002971557",PENDING
439,KR,A,KR 20210024548 A,047-212-823-300-654,2021-03-05,2021,KR 20217001463 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,MALT1 억제제로서의 피라졸 유도체,"MALT1의 조절에 의해 영향을 받는 질환, 증후군, 상태 및 장애를 치료하기 위한 화합물, 조성물 및 방법이 개시된다. 이러한 화합물은 하기와 같이 화학식 (I)으로 나타낸다: TIFFpct00621.tif2747 화학식 (I) 상기 식에서, R1, R2,R3, R4, R5 및 G는 본 명세서 및 청구범위에 정의된 바와 같다.",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,,https://lens.org/047-212-823-300-654,Patent Application,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K39/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,PENDING
440,DE,C2,DE 2611503 C2,051-745-547-540-42X,1986-09-04,1986,DE 2611503 A,1976-03-18,US 57268375 A;;US 60774675 A,1975-04-28,DE 2611503 C2,,"XEROX CORP., ROCHESTER, N.Y., US","MICHAELS, THOMAS B., PITTSFORD, N.Y., US;;PLACE JUN., GEORG H., WEBSTER, N.Y., US;;BOROSTYAN, STEPHEN, VICTOR, N.Y., US;;CONNOLLY, DOUGLAS PATRICK, WEBSTER, N.Y., US;;FRISKE, ALAN DALE, ROCHESTER, N.Y., US",,https://lens.org/051-745-547-540-42X,Granted Patent,no,0,0,7,11,0,G03G15/1645;;G03G15/0266,G03G15/02;;G03G15/16,,0,0,,,,EXPIRED
441,EP,B1,EP 3807266 B1,141-765-323-172-307,2023-10-25,2023,EP 19756240 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,,JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,JANSSEN PHARMACEUTICA NV (2023-09-27),https://lens.org/141-765-323-172-307,Granted Patent,yes,5,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,ACTIVE
442,EP,A2,EP 1644369 A2,160-852-588-657-179,2006-04-12,2006,EP 04740373 A,2004-06-28,EP 2004006973 W;;US 48457003 P,2003-07-02,ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS,,HOFFMANN LA ROCHE,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/160-852-588-657-179,Patent Application,yes,0,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,1,0,,,See references of WO 2005005395A3,DISCONTINUED
443,US,B2,US 11492367 B2,166-997-023-348-673,2022-11-08,2022,US 201816478866 A,2018-01-26,US 201816478866 A;;US 201762454135 P;;US 201762451351 P;;US 201762451301 P;;IB 2018050498 W,2017-01-27,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R 1B , R 1C , R 2B , R 2C , B 1 , W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,JANSSEN PHARMACEUTICA NV (2019-07-30);;JANSSEN BIOPHARMA INC (2019-07-30);;JANSSEN BIOTECH INC (2018-01-26),https://lens.org/166-997-023-348-673,Granted Patent,yes,34,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61K48/00;;C07H21/02;;A61P31/12;;A61P35/00;;C07H21/00,,21,19,090-735-845-630-568;;002-412-431-300-173;;063-161-621-710-260;;091-765-617-073-134;;010-341-241-568-683;;006-540-796-046-165;;012-165-000-131-176;;101-871-534-522-088;;008-962-459-855-781;;102-034-121-002-023;;006-911-733-023-062;;055-198-608-617-554;;040-887-679-477-746;;060-000-705-511-414;;045-298-563-967-678;;040-926-671-971-706;;018-874-474-967-696;;002-895-644-883-279;;034-666-907-619-827,10.1007/978-981-10-5987-2_8;;28921470;;10.1016/j.lfs.2021.120263;;34971697;;10.1110/ps.8.4.921;;10211839;;pmc2144313;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;pmc4335851;;25512416;;10.1128/aac.04321-14;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.aaa2630;;25636800;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;10.1158/1538-7445.am2020-592;;10.1021/acs.jmedchem.6b01300.s001;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.1126/science.1232458;;pmc3863629;;23258413;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;10.1021/pr300408v;;23181431;;pmc3739059;;24204993;;pmc3804601;;10.1371/journal.pone.0077846;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;10.1016/j.immuni.2008.09.003;;18818105,"Pepin et al. (Advances in Experimental Medicine and Biology, vol. 1024, Springer, Singapore, 175-194).;;Rech et al. (Life Sciences, 291, 2022, 120263, 1-6).;;International Search Report relating to International Patent Application No. PCT/IB2018/050498, filed Jan. 26, 2018. International Search Report: dated Jul. 30, 2018.;;Written Opinion of the International Searching Authority relating to International Patent Application No. PCT/IB2018/050498, filed Jan. 26, 2018. International Search Report: dated Jul. 30, 2018.;;Beckett et al., “A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation.”, Protein Science, 1999, pp. 921-929, vol. 8.;;Bhat, N. and Fitzgerald, K.A., “Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors.”, Eur J Immunol., Mar. 2014, pp. 634-640, vol. 44(3).;;Chen et al. “Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity.”, Cell, Oct. 14, 2011, pp. 433-446, vol. 147.;;Corrales et al., “Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity.”, Cell Reports, May 19, 2015, pp. 1018-1030, vol. 11.;;Danilchanka, O. and Mekalanos, JJ., “Cyclic Dinucleotides and the Innate Immune Response.”, Cell, Aug. 29, 2013, pp. 962-970, vol. 154.;;Guo et al., “STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus.”, Antimicrobial Agents and Chemotherapy, Feb. 2015, pp. 1273-1281, vol. 59(2).;;Konno et al., “Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling.”, Cell, Oct. 24, 2013, pp. 688-698, vol. 155.;;Liu et al., “Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.”, Science, Mar. 13, 2015, pp. 2630-2637, vol. 347(6227).;;Liu et al., “Systematic identification of type I and type II interferon-induced antiviral factors.”, Proc. Natl. Acad. Sci., Mar. 13, 2012, pp. 4239-4244, vol. 109(11).;;Louix et al., “Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-lnosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes.”, J. Med. Chem., Nov. 4, 2016, pp. 10253-10267, vol. 59(22).;;Marabelle et al., “Intratumoral Immunization: A New Paradigm for Cancer Therapy.”, Clinical Cancer Research, Apr. 1, 2014, pp. 1747-1756, vol. 20(7).;;Sun et al., “Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway.”, Science, Feb. 15, 2013, pp. 786-791, vol. 339.;;Van der Jeught et al., “Targeting the tumor microenviroment to enhance antitumor immune responses.”, Oncotarget, Dec. 26, 2014, pp. 1359-1381, vol. 6(3).;;Wu et al., “Novel Phosphorylation Sites in the S. cerevisiae Cdc13 Protein Reveal New Targets for Telomere Length Regulation.”, Journal of Proteome Research, 2013, pp. 316-327, vol. 12.;;Yi et. al., “Single Nucleotide Polymorphisms of Human STING can affect innate immune response to cyclic dinucleotides.”, PLOS ONE, Oct. 2013, pp. 1-15, vol. 8(10), e77846.;;Zhang et al., “Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING.”, Molecular Cell, Jul. 25, 2013, pp. 226-235, vol. 51.;;Zhong et al., “The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation.”, Immunity, Oct. 17, 2008, pp. 538-550, vol. 29.",ACTIVE
444,US,A1,US 2019/0375782 A1,039-022-137-770-595,2019-12-12,2019,US 201816478866 A,2018-01-26,US 201816478866 A;;US 201762454135 P;;US 201762451351 P;;US 201762451301 P;;IB 2018050498 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R 1B , R 1C , R 2B , R 2C , B 1 , W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,JANSSEN PHARMACEUTICA NV (2019-07-30);;JANSSEN BIOPHARMA INC (2019-07-30);;JANSSEN BIOTECH INC (2018-01-26),https://lens.org/039-022-137-770-595,Patent Application,yes,0,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,C07H21/00;;A61P31/12;;A61P35/00,,0,0,,,,ACTIVE
445,WO,A1,WO 2019/243964 A1,057-926-866-477-887,2019-12-26,2019,IB 2019054964 W,2019-06-13,US 201862686447 P,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and G, are defined herein.",JANSSEN PHARMACEUTICA NV;;LU TIANBAO,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG,,https://lens.org/057-926-866-477-887,Patent Application,yes,5,1,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,19,11,001-676-197-805-749;;088-303-580-091-034;;105-129-409-527-399;;015-845-506-559-143;;087-192-267-012-779;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;149-087-447-664-064;;047-138-645-820-688;;077-295-491-167-117,pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;10.1111/j.1600-065x.2012.01105.x;;pmc4094296;;22435566;;26787500;;10.1016/j.molmed.2015.12.004;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1126/science.1198946;;21273489;;pmc3124150;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1002/0471220574,"JAWORSKI ET AL., CELL MOL LIFE SCIENCE, vol. 73, 2016, pages 459 - 473;;STAUDT, COLD SPRING HARB PERSPECT BIOL, 2010, pages 2;;LIM ET AL., IMMUNOL REV, vol. 246, 2012, pages 359 - 378;;FONTAN ET AL., CANCER CELL, vol. 22, 2012, pages 825 - 837;;DEMEYER ET AL., TRENDS MOL MED, vol. 22, 2016, pages 135 - 150;;ROSEBECK ET AL., WORLD J BIOL CHEM, vol. 7, 2016, pages 128 - 137;;ROSEBECK ET AL., SCIENCE, vol. 331, 2011, pages 468 - 472;;JAWORSKI M ET AL., CELL MOL LIFE SCI., 2016;;MC GUIRE ET AL., J. NEUROINFLAMMATION, vol. 11, 2014, pages 124;;JAWORSKI ET AL., EMBO J., 2014;;GEWIES ET AL., CELL REPORTS, 2014;;BORNANCIN ET AL., J. IMMUNOLOGY, 2015;;YU ET AL., PLOS ONE, 2015;;MCKINNON ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 133, 2014, pages 1458 - 1462;;JABARA ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 132, 2013, pages 151 - 158;;PUNWANI ET AL., J. CLIN. IMMUNOL., vol. 35, 2015, pages 135 - 146;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS",PENDING
446,CN,A,CN 110234403 A,022-791-319-912-573,2019-09-13,2019,CN 201880009026 A,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P;;IB 2018050498 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/022-791-319-912-573,Patent Application,no,12,1,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,3,1,055-198-608-617-554,10.1158/1538-7445.am2020-592;;10.1021/acs.jmedchem.6b01300.s001,"THIERRY LIOUX ET AL.: ""Design, synthesis, and biological evaluation of novel cyclic adenosine-inosine monophosphate (cAIMP) analogs that activate stimulator of interferon genes (STING)"", 《J. MED. CHEM.》, pages 3;;CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US: ""STN Registry"", 《STN REGISTRY》, pages 1 - 4;;沈国栋等: ""固有免疫信号分子STING研究进展"", 《免疫学杂志》, vol. 29, no. 7, pages 624 - 627",PENDING
447,CA,A1,CA 2530312 A1,025-353-946-902-648,2005-01-20,2005,CA 2530312 A,2004-06-28,US 48457003 P;;EP 2004006973 W,2003-07-02,ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS,"Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R5 and R10 are as defined herein.",HOFFMANN LA ROCHE,NITZAN DOV;;MELVILLE CHRIS RICHARD;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;LEE EUN KYUNG;;LI JIM;;WEINHARDT KLAUS KURT;;CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;PADILLA FERNANDO;;O'YANG COUNDE,,https://lens.org/025-353-946-902-648,Patent Application,no,0,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,C07D417/12;;A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02,,0,0,,,,DISCONTINUED
448,WO,A2,WO 2005/005395 A2,106-360-502-509-660,2005-01-20,2005,EP 2004006973 W,2004-06-28,US 48457003 P,2003-07-02,ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS,"Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R&apos;, R5 and R10 are as defined herein.",HOFFMANN LA ROCHE;;CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/106-360-502-509-660,Patent Application,yes,0,12,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,0,0,,,,PENDING
449,US,A1,US 2005/0038016 A1,119-053-525-809-203,2005-02-17,2005,US 88476804 A,2004-07-02,US 88476804 A;;US 48457003 P,2003-07-02,Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists,"Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.",CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FRENANDO;;WEINHARDT KLAUS KURT,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FRENANDO;;WEINHARDT KLAUS KURT,ROCHE PALO ALTO LLC (2004-08-05),https://lens.org/119-053-525-809-203,Patent Application,yes,3,7,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,514/223.2;;514/266.2;;514/266.3;;544/13;;544/284;;544/287,0,0,,,,INACTIVE
450,EP,A2,EP 3573718 A2,044-789-583-696-326,2019-12-04,2019,EP 18703858 A,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P;;IB 2018050498 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/044-789-583-696-326,Patent Application,yes,0,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
451,AU,A1,AU 2018/212788 A1,146-847-813-300-27X,2019-07-25,2019,AU 2018/212788 A,2018-01-26,US 201762454135 P;;US 201762451301 P;;US 201762451351 P;;IB 2018050498 W,2017-01-27,Cyclic dinucleotides as STING agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/146-847-813-300-27X,Patent Application,no,0,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,PENDING
452,US,A1,US 2023/0146410 A1,049-010-812-972-700,2023-05-11,2023,US 202217982218 A,2022-11-07,US 202217982218 A;;US 201916478866 A;;IB 2018050498 W;;US 201762454135 P;;US 201762451351 P;;US 201762451301 P,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R 1B , R 1C , R 2B , R 2C , B 1 , W, X, Y, Z are defined herein.",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/049-010-812-972-700,Patent Application,yes,0,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,C07H21/00;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
453,CA,A1,CA 3104053 A1,064-207-762-544-806,2019-12-26,2019,CA 3104053 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1, R2, R3, R4, R5, and G, are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG,,https://lens.org/064-207-762-544-806,Patent Application,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,PENDING
454,WO,A3,WO 2005/005395 A3,093-681-977-573-743,2005-05-06,2005,EP 2004006973 W,2004-06-28,US 48457003 P,2003-07-02,ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS,"Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R&apos;, R5 and R10 are as defined herein.",HOFFMANN LA ROCHE;;CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/093-681-977-573-743,Search Report,yes,5,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,4,3,049-879-731-388-212;;104-392-733-342-179;;021-240-043-840-494,5637156;;10.1021/jm00307a028;;10.1021/jm00155a007;;3084783;;12423172;;10.1021/jo026217o,"HESS, HANS J. ET AL: ""Antihypertensive 2-amino-4(3H)-quinazolinones"", JOURNAL OF MEDICINAL CHEMISTRY , 11(1), 130-6 CODEN: JMCMAR; ISSN: 0022-2623, 1968, XP002300297;;DERUITER, JACK ET AL: ""Design and synthesis of 2-(arylamino)-4(3H)-quinazolinones as novel inhibitors of rat lens aldose reductase"", JOURNAL OF MEDICINAL CHEMISTRY , 29(5), 627-9 CODEN: JMCMAR; ISSN: 0022-2623, 1986, XP002300298;;M.B.ANDRUS ET AL.: ""A Modified Synthesis of Iodoazidoaryl Prazosin"", J.ORG.CHEM., vol. 67, 19 October 2002 (2002-10-19), pages 8284 - 8286, XP002315227;;DATABASE BEILSTEIN XP002315228, Database accession no. 489679 (REACTION ID)",PENDING
455,US,B2,US 11040031 B2,016-083-882-217-911,2021-06-22,2021,US 201916440302 A,2019-06-13,US 201916440302 A;;US 201862686447 P,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and G, are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG,JANSSEN RESEARCH & DEVELOPMENT LLC (2019-06-28);;JANSSEN PHARMACEUTICA NV (2019-06-26),https://lens.org/016-083-882-217-911,Granted Patent,yes,33,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/395;;A61P35/00;;C07D403/14;;C07D407/14;;C07D413/14,,35,20,037-165-733-219-789;;105-129-409-527-399;;103-752-080-034-709;;051-588-339-916-553;;149-087-447-664-064;;007-268-478-416-294;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;125-728-925-514-092;;047-138-645-820-688;;087-192-267-012-779;;015-845-506-559-143;;081-511-682-994-308;;007-820-533-816-52X;;012-994-617-927-80X;;054-269-121-291-520;;101-361-821-876-436;;158-222-326-747-571;;001-516-175-552-397,25762782;;10.3410/f.725387389.793505358;;10.4049/jimmunol.1402254;;26787500;;10.1016/j.molmed.2015.12.004;;23238016;;10.1016/j.ccr.2012.11.003;;pmc3984478;;10.1016/j.celrep.2014.10.044;;25456129;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4282555;;10.15252/embj.201488987;;25319413;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;23238017;;10.1016/j.ccr.2012.11.002;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1126/science.1198946;;21273489;;pmc3124150;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1371/journal.pone.0127083;;25965667;;pmc4428694;;21091654;;10.1111/j.1476-5381.2010.01127.x;;pmc3058157;;10.1039/b504668h;;16027897;;10.1038/nrd1031;;12612646;;10.1002/0471238961.0318251918152119.a01.pub2;;10.1021/cg030084y;;10.1016/s0169-409x(01)00097-7;;11325474,"STN Registry Database, record for RN 1808788-01-3, entered into STN on Sep. 29, 2015. (Year: 2015).;;International Preliminary Report on Patentability, International Application PCT/IB2019/054964, dated Dec. 22, 2020. 7 Pages. (Year: 2020).;;Bornancin, F., et al., “Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation”, J. Immunology, (2015), vol. 194, No. 8, pp. 3723-3734.;;Demeyer, A., et al., “Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?”, Trends Mol Med, (2016), vol. 22, No. 2, pp. 135-150.;;Fontan, L., et al., “MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo”, Cancer Cell, (2012), vol. 22, No. 6, pp. 812-824.;;Gewies, A., et al., “Uncoupling Malt1 Threshold Function from Paracaspase Activity Results in Destructive Autoimmune Inflammation”, Cell Reports, (2014), vol. 9, pp. 1292-1305.;;Jabara, H.H., et al., “A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency”, J. Allergy Clin. Immunol., (2013), vol. 132, pp. 151-158.;;Jaworski, M., et al., “Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity”, The EMBO Journal, (2014), vol. 33, No. 23, pp. 2765-2781.;;Jaworski, M., et al., “The paracaspase MALT1: biological function and potential for therapeutic inhibition”, Cell. Mol. Life Sci., (2016), vol. 73, pp. 459-473.;;Lim, K., et al., “Pathogentic importance and therapeutica implications of NF-κß in lymphoid malignancies”, Immunological Reviews, (2012), vol. 246, pp. 359-378.;;Mc Guire, C., et al., “Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis”, Journal of Neuroinflammation, (2014), vol. 11, No. 124, pp. 1-12.;;McKinnon et al., “Combined immunodeficiency associated with homozygous MALT1 mutations”, J. Allergy Clin. Immunol. (2014), vol. 133, No. 5, pp. 1458-1462.e7.;;Nagel, D., et al., “Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL”, Cancer Cell, (2012), vol. 22, pp. 825-837.;;Punwani, D., et al., “Combined Immunodeficiency Due to MALT1 Mutations, Treated by Hematopoietic Cell Transplantation”, J Clin Immunol, (2015), vol. 35, pp. 135-146.;;Rosebeck, S., et al., “Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF-kB Activation”, Science, (2011), vol. 331, pp. 468-472.;;Rosebeck, S., et al., “API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis”, World J Biol Chem, (2016), vol. 7, No. 1, pp. 128-137.;;Yu, J.W., et al., “MALT1 Protease Activity is Required for Innate and Adaptive Immune Responses”, PLOS One, (2015), pp. 1-20.;;Bundgaard, H., “Design of Prodrugs”, (1985), Table of Contents.;;McOmie, J., “Protective Groups in Organic Chemistry”, (1973), Title Page and Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, Inc., (1991), Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc., (1999), Table of Contents.;;Hughes, J.P., et al., “Principles of early drug discovery”, British Journal of Pharmacology, (2011), vol. 162, pp. 1239-1249.;;International Search Report from PCT/IB2019/054964 dated Oct. 18, 2019.;;Bernstein, J., “Polymorphism in Molecular Crystals”, (2002), Clarendon Press Oxford, pp. 115-118 & 272.;;Braga, D., et al., “Making crystals from crystals: a green route to crystal engineering and polymorphism”, (2005), J. Royal Soc. Chem. Commun., pp. 3635-3645.;;Davidovich, M., et al., “Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation”, (2004), Am. Pharm. Rev, vol. 7, No. 1, pp. 10, 12, 14, 16, 100.;;Dean, “Analytical Chem . . .”(1995), pp. 10.24-10.26.;;Guillory, J.K., “Polymorphism in Pharmaceutical Solids”, (in Brittain ed.), (1999), NY: Mercel Dekker, Inc., 1-2, 125-181, 183-226.;;Ivanisevic, I., et al., “Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry”, (2010), Pharm. Sci. Encycl., pp. 1-42.;;Jain, N.K., et al., “Polymorphism in Pharmacy”, (1986), Indian Drugs, vol. 23, No. 6, pp. 315-329.;;Jordan, V.C., “Tamoxifen: A Most Unlikely Pioneering Medicine”, (2003), Nature Reviews, vol. 2, pp. 205-213.;;Kirk-Othmer, “Crystallization”, (2002), Encyclopedia of Chemical, vol. 8, pp. 95-147.;;Seddon, K.R., “Pseudopolymorph: A Polemic”, (2004), Crystal Growth & Design, vol. 4, No. 6, p. 108 (two pages from internet).;;Vippagunta, S.R., et al., “Crystalline solids”, (2001), Advanced Drug Delivery Review, vol. 48, pp. 3-26.;;Yu, L., et al., “Physical characterization of polymorphic drugs: an integrated characterization strategy”, (1998), PSTT, vol. 1, No. 3, pp. 118-127.",ACTIVE
456,MX,A,MX 2020013899 A,048-725-355-249-789,2021-05-27,2021,MX 2020013899 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS.,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and G, are defined herein.",JANSSEN PHARMACEUTICA NV,BARBAY JOSEPH KENT;;DIELS GASTON STANISLAS MARCELLA;;WU TONGFEI;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;PHILIPPAR ULRIKE;;THURING JAN WILLEM;;SHEN FANG,,https://lens.org/048-725-355-249-789,Patent Application,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,A61K31/4439;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,PENDING
457,EP,B1,EP 3573718 B1,076-126-782-825-462,2022-06-01,2022,EP 18703858 A,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P;;IB 2018050498 W,2017-01-27,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/076-126-782-825-462,Granted Patent,yes,11,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,1,0,,,"THIERRY LIOUX ET AL: ""Design, Synthesis, and Biological Evaluation of Novel Cyclic Adenosine-Inosine Monophosphate (cAIMP) Analogs That Activate Stimulator of Interferon Genes (STING)"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 22, 4 November 2016 (2016-11-04), pages 10253-10267, XP055457763, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01300",ACTIVE
458,US,B2,US 7244738 B2,109-801-629-784-627,2007-07-17,2007,US 88476804 A,2004-07-02,US 88476804 A;;US 48457003 P,2003-07-02,Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists,"Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.",ROCHE PALO ALTO LLC,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,ROCHE PALO ALTO LLC (2004-08-05),https://lens.org/109-801-629-784-627,Granted Patent,yes,16,1,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,A61K31/517;;A01N43/54;;A61K31/549;;C07D239/72;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,514/266.3;;514/266.2;;544/287,6,5,049-879-731-388-212;;104-392-733-342-179;;064-942-802-802-381;;049-879-731-388-212;;021-240-043-840-494,5637156;;10.1021/jm00307a028;;10.1021/jm00155a007;;3084783;;3143909;;5637156;;10.1021/jm00307a028;;12423172;;10.1021/jo026217o,"Hess, H. et. al., ""Antihypertensive 2-Amino-4(3H)-quinazolinones"", J. Med. Chem., 1968, vol. 11, pp. 130-136.;;DeRuiter, et al., Design and Synthesis of 2-(Arylamino)-4(3H)-quinazolinones as Novel Inhibitors of Rat Lens Aldose Reductase, J. Med. Chemical, (1986), pp. 627-629, 29(5).;;Klopman, et al., ""An Artificial Intelligence Approach to the Study of the Structural Moieties Relevant to Drug-Receptor Interactions in Aldose Reductase Inhibitors,"" Mol. Pharmacol., (1988), pp. 852-862, 34(6).;;Hess, et al., ""Antihypertensive 2-Amino-4(3H)-quinazolinones,"" J. Med. Chemical, (1968), pp. 130-136, 11(1).;;Andrus M.B., et al., ""A Modified Synthesis of Iodoazidoaryl Prazosin"", Journal Organic Chemistry (2002) pp. 8284-8286, vol. 67.;;ABSTRACT Database Beilstein XP002315228 Szabo, Vinkler, S., Acta Chim. Acad. Sci. Hung., (1958) pp. 201-207, vol. 17.",INACTIVE
459,US,A1,US 2019/0381019 A1,191-342-550-932-248,2019-12-19,2019,US 201916440302 A,2019-06-13,US 201916440302 A;;US 201862686447 P,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and G, are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG,JANSSEN RESEARCH & DEVELOPMENT LLC (2019-06-28);;JANSSEN PHARMACEUTICA NV (2019-06-26),https://lens.org/191-342-550-932-248,Patent Application,yes,7,2,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/395;;A61P35/00;;C07D403/14;;C07D407/14;;C07D413/14,,0,0,,,,ACTIVE
460,ES,T3,ES 2924186 T3,159-543-533-317-615,2022-10-05,2022,ES 18703858 T,2018-01-26,US 201762451301 P;;US 201762451351 P;;US 201762454135 P;;IB 2018050498 W,2017-01-27,Dinucleótidos cíclicos como agonistas de STING,"Se describen compuestos, composiciones y métodos para el tratamiento de enfermedades, síndromes o trastornos que se ven afectados por la modulación de STING. Dichos compuestos están representados por la fórmula (I) como sigue: en la que R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z se definen aquí. (Traducción automática con Google Translate, sin valor legal)",JANSSEN BIOTECH INC,EMANUEL STUART;;RICHTER MARK;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;WANG GUANGYI;;THATIKONDA SANTHOSH KUMAR;;BEIGELMAN LEONID;;ZHONG MINGHONG;;BIGNAN GILLES;;SCHEPENS WIM;;VIELLEVOYE MARCEL;;THURING JOHANNES WILHELMUS JOHN FITZGERALD,,https://lens.org/159-543-533-317-615,Granted Patent,no,0,0,13,13,0,C07H21/00;;A61P35/00;;A61P31/12;;A61P31/12;;A61P35/00;;C07H21/00,A61P35/00;;A61K31/7084;;A61P31/12;;C07H21/00,,0,0,,,,ACTIVE
461,EP,A1,EP 3807266 A1,075-479-101-031-307,2021-04-21,2021,EP 19756240 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,,JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,JANSSEN PHARMACEUTICA NV (2023-09-27),https://lens.org/075-479-101-031-307,Patent Application,yes,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,ACTIVE
462,AU,B2,AU 2019/289222 B2,004-109-257-630-943,2023-07-13,2023,AU 2019/289222 A,2019-06-13,US 201862686447 P;;IB 2019054964 W,2018-06-18,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;BARBAY JOSEPH KENT;;KREUTTER KEVIN D;;WU TONGFEI;;DIELS GASTON STANISLAS MARCELLA;;THURING JAN WILLEM;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;SHEN FANG;;LU TIANBAO,,https://lens.org/004-109-257-630-943,Granted Patent,no,1,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,ACTIVE
463,BR,A2,BR 112020025844 A2,053-398-198-319-944,2021-03-23,2021,BR 112020025844 A,2019-06-13,IB 2019054964 W;;US 201862686447 P,2018-06-18,derivados de pirazol como inibidores de malt1,"a presente invenção refere-se a compostos, composições e métodos para o tratamento de doenças, síndromes, condições e distúrbios que são afetados pela modulação de malt1. esses compostos são repre-sentados pela fórmula i a seguir, em que r1, r2, r3, r4, r5 e g são conforme definidos neste documento. fórmula (i)",JANSSEN PHARMACEUTICA NV,FANG SHEN;;GASTON STANISLAS MARCELLA DIELS;;JAMES PATRICK EDWARDS;;JAN WILLEM THURING;;JOSEPH KENT BARBAY;;KEVIN D KREUTTER;;MAXWELL DAVID CUMMINGS;;PETER J CONNOLLY;;TIANBAO LU;;TONGFEI WU;;ULRIKE PHILIPPAR,,https://lens.org/053-398-198-319-944,Patent Application,no,0,0,20,20,0,C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D491/056;;A61P11/00;;A61K31/506;;A61K31/536;;A61P29/02;;A61P29/00;;A61K45/06;;A61K31/4439;;A61K2039/505;;A61K31/4439;;A61K31/444;;A61K31/506;;A61K31/519;;A61K31/536;;A61K45/06;;A61K2039/505;;A61P11/00;;A61P29/00;;A61P29/02;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D491/056;;A61P35/00;;A61K31/444;;A61K31/519;;A61K31/5377;;A61K39/3955;;C07D403/14;;C07D407/14;;C07D413/14,C07D401/14;;A61K31/4439;;A61P35/00;;C07D405/14;;C07D413/14;;C07D491/056,,0,0,,,,PENDING
464,US,A1,US 2007/0265446 A1,116-400-709-523-896,2007-11-15,2007,US 82149307 A,2007-06-22,US 82149307 A;;US 88476804 A;;US 48457003 P,2003-07-02,Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists,"Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.",CONNOLLY TERRENCE J;;KEITZ PAUL F;;LEE EUN K;;LI JIM;;LOPEZ-TAPIA FRANCISCO J;;MCGARRY PATRICK F;;MELVILLE CHRIS R;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS K,CONNOLLY TERRENCE J;;KEITZ PAUL F;;LEE EUN K;;LI JIM;;LOPEZ-TAPIA FRANCISCO J;;MCGARRY PATRICK F;;MELVILLE CHRIS R;;NITZAN DOV;;O'YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS K,,https://lens.org/116-400-709-523-896,Patent Application,yes,1,3,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,C07D239/88;;A61K31/517;;A61K31/549;;C07D239/90;;C07D239/95;;C07D285/24;;C07D285/26;;C07D401/02;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,544/284;;544/287,0,0,,,,DISCONTINUED
465,TW,A,TW 200519097 A,062-878-799-767-004,2005-06-16,2005,TW 93119909 A,2004-07-01,US 48457003 P,2003-07-02,Arylamine-substituted quinazolinone compounds,"Compounds represented by Formula I which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R5, and R10 are as defined herein.",HOFFMANN LA ROCHE,CONNOLLY TERRENCE JOSEPH;;KEITZ PAUL FRANCIS;;LEE EUN-KYUNG;;LI JIM;;LOPEZ-TAPIA FRANCISCO JAVIER;;MCGARRY PATRICK FINBAR;;MELVILLE CHRIS RICHARD;;NITZAN DOV;;O' YANG COUNDE;;PADILLA FERNANDO;;WEINHARDT KLAUS KURT,,https://lens.org/062-878-799-767-004,Patent of Addition,no,0,0,17,17,0,A61K31/517;;A61P13/00;;A61P13/08;;A61P15/10;;A61P25/04;;A61P43/00;;C07D239/90;;C07D401/12;;C07D401/12;;C07D239/90;;C07D239/90;;C07D239/95;;C07D239/95;;C07D239/95;;C07D285/24;;C07D285/24;;C07D285/24;;C07D401/12;;C07D401/14;;C07D401/14;;C07D401/14;;C07D403/12;;C07D403/12;;C07D403/12;;C07D405/12;;C07D405/12;;C07D405/12;;C07D413/12;;C07D413/12;;C07D413/12;;C07D417/12;;C07D417/12;;C07D417/12,C07D239/95;;A61K31/517;;A61K31/549;;A61P13/00;;C07D239/90;;C07D285/24;;C07D285/26;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/02;;C07D417/12,,0,0,,,,PENDING
466,UY,A,UY 37537 A,094-827-801-266-710,2018-06-29,2018,UY 37537 A,2017-12-21,US 201662437384 P,2016-12-21,DERIVADOS DE PIRAZOL COMO INHIBIDORES MALT1,"Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes, afecciones y trastornos afectados por la modulación de MALT1. Tales compuestos se representan por la Fórmula (I) a continuación: en donde R1, R2, R3, R4, R5, R6, R5, G1, y G2 se definen en la presente descripción.",JANSSEN BIOTECH INC,LU TIANBAO;;JOSEPH KENT BARBAY;;BRETT DOUGLAS ALLISON;;PETER J CONNOLLY;;MAXWELL DAVID CUMMINGS;;DIELS GASTON;;JAMES PATRICK EDWARDS;;PHILIPPAR ULRIKE;;SHEN FANG;;JOHANNES WILHELMUS JOHN FITZGERALD THURING;;WU TONGFEI;;KEVIN D KREUTTER,,https://lens.org/094-827-801-266-710,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,A61P1/00;;A61K31/4355;;A61K31/4365;;A61K31/437;;A61K31/4375;;A61K31/4439;;A61K31/4709;;A61K31/498;;A61K31/4985;;A61K31/502;;A61K31/519;;A61K31/53;;A61K31/536;;A61K31/538;;A61P11/00;;A61P17/06;;A61P35/00;;A61P37/08;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D491/048;;C07D495/04;;C07D513/04,,0,0,,,,PENDING
467,WO,A1,WO 2018/119036 A1,144-638-073-251-519,2018-06-28,2018,US 2017/0067516 W,2017-12-20,US 201662437384 P,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.",JANSSEN BIOTECH INC,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI,,https://lens.org/144-638-073-251-519,Patent Application,yes,2,49,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,21,15,001-676-197-805-749;;013-637-149-384-082;;088-303-580-091-034;;103-752-080-034-709;;125-728-925-514-092;;105-129-409-527-399;;015-845-506-559-143;;087-192-267-012-779;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;149-087-447-664-064;;047-138-645-820-688;;077-295-491-167-117;;077-295-491-167-117,pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc2869521;;20516126;;10.1101/cshperspect.a000109;;10.1111/j.1600-065x.2012.01105.x;;pmc4094296;;22435566;;23238016;;10.1016/j.ccr.2012.11.003;;pmc3984478;;23238017;;10.1016/j.ccr.2012.11.002;;26787500;;10.1016/j.molmed.2015.12.004;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1126/science.1198946;;21273489;;pmc3124150;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1002/0471220574;;10.1002/0471220574,"JAWORSKI ET AL., CELL MOL LIFE SCIENCE, vol. 73, 2016, pages 459 - 473;;STAUDT: ""Perspect Biol"", vol. 2, 2010, COLD SPRING HARB;;LIM ET AL., IMMUNOL REV, vol. 246, 2012, pages 359 - 378;;FONTAN ET AL., CANCER CELL, vol. 22, 2012, pages 812 - 824;;NAGEL ET AL., CANCER CELL, vol. 22, 2012, pages 825 - 837;;DEMEYER ET AL., TRENDS MOL MED, vol. 22, 2016, pages 135 - 150;;ROSEBECK ET AL., WORLD J BIOL CHEM, vol. 7, 2016, pages 128 - 137;;ROSEBECK ET AL., SCIENCE, vol. 331, 2011, pages 468 - 472;;JAWORSKI M ET AL., CELL MOL LIFE SCI., 2016;;MC GUIRE ET AL., J. NEUROINFLAMMATION, vol. 11, 2014, pages 124;;JAWORSKI ET AL., EMBO J., 2014;;GEWIES ET AL., CELL REPORTS, 2014;;BORNANCIN ET AL., J. IMMUNOLOGY, 2015;;YU ET AL., PLOS ONE, 2015;;MCKINNON ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 133, 2014, pages 1458 - 1462;;JABARA ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 132, 2013, pages 151 - 158;;PUNWANI ET AL., J. CLIN. IMMUNOL., vol. 35, 2015, pages 135 - 146;;""Design of Prodrugs"", 1985, ELSEVIER;;J.F.W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis,"", 1991, JOHN WILEY & SONS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis,"", 1999, JOHN WILEY & SONS",PENDING
468,TW,A,TW 201835067 A,037-332-008-602-166,2018-10-01,2018,TW 106144535 A,2017-12-19,US 201662437384 P,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN BIOTECH INC,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGE;;WU TONGFEI,,https://lens.org/037-332-008-602-166,Patent of Addition,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/14;;A61K31/438;;A61K31/4439;;A61P35/00;;A61P37/02;;C07D405/14;;C07D413/14,,0,0,,,,ACTIVE
469,US,A1,US 2018/0170909 A1,046-466-225-138-961,2018-06-21,2018,US 201715847999 A,2017-12-20,US 201715847999 A;;US 201662437384 P,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.",JANSSEN BIOTECH INC,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI,JANSSEN-CILAG (2019-05-10);;JANSSEN PHARMACEUTICA NV (2018-12-19);;JANSSEN BIOTECH INC (2017-12-19),https://lens.org/046-466-225-138-961,Patent Application,yes,0,12,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/14;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12,,0,0,,,,ACTIVE
470,TW,B,TW I795381 B,098-014-785-874-018,2023-03-11,2023,TW 106144535 A,2017-12-19,US 201662437384 P,2016-12-21,Pyrazole derivatives as malt1 inhibitors,,JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGE;;WU TONGFEI,,https://lens.org/098-014-785-874-018,Granted Patent,no,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,,,0,0,,,,ACTIVE
471,EP,A1,EP 3724205 A1,089-789-905-225-109,2020-10-21,2020,EP 18830620 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/089-789-905-225-109,Patent Application,yes,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,ACTIVE
472,US,A1,US 2021/0009630 A1,190-310-920-945-474,2021-01-14,2021,US 201816771480 A,2018-12-14,US 201816771480 A;;US 201762599111 P;;US 2018/0065677 W,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B 2 , X 2 , R 2a , R 2b , R 2c , Z-M-Y, Y 1 -M 1 Z 1 , B 1 , X 1 , R 1a , R 1b , R 1c are as defined herein.",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,JANSSEN PHARMACEUTICA NV (2019-07-30);;JANSSEN BIOPHARMA INC (2019-08-08);;JANSSEN BIOTECH INC (2019-07-29),https://lens.org/190-310-920-945-474,Patent Application,yes,0,1,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/04;;A61K9/00;;A61K31/7084;;A61P35/00;;C07K16/08,,0,0,,,,DISCONTINUED
473,KR,A,KR 20200099178 A,074-205-908-991-419,2020-08-21,2020,KR 20207020280 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,STING 작용제로서의 환상 다이뉴클레오티드,"STING의 조절에 의해 영향을 받는 질환, 증후군 또는 장애를 치료하기 위한 화합물, 조성물 및 방법이 개시된다. 이러한 화합물은 하기와 같이 화학식 (I)으로 나타낸다:화학식 (I) 상기 식에서, B, X, R, R, RZ-M-Y, Y-MZ, B, X, R, R, R는 본 명세서 및 청구범위에서 정의된 바와 같다.",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/074-205-908-991-419,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/00;;A61K31/7084;;A61P31/12;;A61P35/00,,0,0,,,,DISCONTINUED
474,BR,A2,BR 112020010941 A2,008-396-236-563-382,2020-11-17,2020,BR 112020010941 A,2018-12-14,US 2018/0065677 W;;US 201762599111 P,2017-12-15,dinucleotídeos cíclicos como agonistas de sting,"a presente invenção refere-se aos compostos, às composições e aos métodos para o tratamento de doenças, síndromes ou distúrbios, que são afetados pela modulação de sting. tais compostos são representados pela fórmula (i) da seguinte forma: em que b2, x2, r2a, r2b, r2c, z-m-y, y1-m1z1, b1, x1, r1a, r1b e r1c são como definidos aqui.",JANSSEN BIOTECH INC,GILLES BIGNAN;;GUANGYI WANG;;JAMES PATRICK EDWARDS;;JOHANNES WILHELMUS JOHN FITZGERALD THURING;;LEONID BEIGELMAN;;MARCEL VIELLEVOYE;;MARK RICHTER;;MINGHONG ZHONG;;PETER J CONNOLLY;;SANTHOSH KUMAR THATIKONDA;;STUART EMANUEL;;SYLVIE LAQUERRE;;WIM GERT GRIET SCHEPENS,,https://lens.org/008-396-236-563-382,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,PENDING
475,AU,A1,AU 2018/386222 A1,054-044-402-676-112,2020-06-04,2020,AU 2018/386222 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/054-044-402-676-112,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,ACTIVE
476,MX,A,MX 2020006290 A,027-479-137-681-992,2020-12-03,2020,MX 2020006290 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS.,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B<sub>2</sub>,X<sub>2</sub>, R<sub>2a</sub>, R<sub>2b</sub>, R<sub>2c,</sub> Z-M-Y, Y<sub>1</sub>-M<sub>1</sub>Z<sub>1</sub>, B<sub>1</sub>, X<sub>1</sub>, R<sub>1a</sub>, R<sub>1b</sub>, R<sub>1c</sub> are as defined herein.",JANSSEN BIOTECH INC,WANG GUANGYI;;RICHTER MARK;;BEIGELMAN LEONID;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;THATIKONDA SANTHOSH KUMAR;;CONNOLLY PETER J;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;BIGNAN GILLES;;LAQUERRE SYLVIA;;SCHEPENS WIM GERT GRIET;;VIELLEVOYE MARCEL;;ZHONG MINGHONG,,https://lens.org/027-479-137-681-992,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,PENDING
477,WO,A1,WO 2019/118839 A1,116-937-635-657-583,2019-06-20,2019,US 2018/0065677 W,2018-12-14,US 201762599111 P,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B 2 ,X 2 , R 2a , R 2b , R 2c, Z-M-Y, Y 1 -M 1 Z 1 , B 1 , X 1 , R 1a , R 1b , R 1c are as defined herein.",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/116-937-635-657-583,Patent Application,yes,8,11,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,21,16,034-666-907-619-827;;102-034-121-002-023;;010-341-241-568-683;;006-540-796-046-165;;008-962-459-855-781;;060-000-705-511-414;;091-765-617-073-134;;002-895-644-883-279;;012-165-000-131-176;;006-911-733-023-062;;077-295-491-167-117;;077-295-491-167-117;;045-298-563-967-678;;040-887-679-477-746;;029-641-974-701-191;;102-071-695-047-127,10.1016/j.immuni.2008.09.003;;18818105;;10.1126/science.aaa2630;;25636800;;10.1016/j.cell.2011.09.022;;22000020;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;pmc3881181;;10.1016/j.cell.2013.09.049;;24119841;;10.1126/science.1232458;;pmc3863629;;23258413;;24356864;;pmc4621431;;10.1002/eji.201344127;;10.1016/j.molcel.2013.05.022;;23747010;;pmc3808999;;pmc3931520;;10.1016/j.cell.2013.08.014;;23993090;;10.1073/pnas.1114981109;;22371602;;pmc3306696;;10.1002/0471220574;;10.1002/0471220574;;pmc4359300;;25682197;;10.18632/oncotarget.3204;;pmc3979477;;24691639;;10.1158/1078-0432.ccr-13-2116;;10.1007/bf01952257;;6382953;;10.1016/0065-2571(84)90007-4,"ZHONG B ET AL.: ""The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation"", IMMUNITY, vol. 29, 2008, pages 538 - 550, XP055021580, DOI: doi:10.1016/j.immuni.2008.09.003;;LIU S ET AL.: ""Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation"", SCIENCE, 2015, pages 2630 - 2637;;CHEN H ET AL.: ""Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity"", CELL, vol. 14, 2011, pages 433 - 446;;CORRALES, L. ET AL.: ""Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity"", CELL REPORTS, vol. 1, no. 1, 2015, pages 1 - 13;;KONNO, H. ET AL.: ""Cyclic dinucleotides trigger ULK1 (ATGl) phosphorylation of STING to prevent sustained innate immune signaling"", CELL, vol. 155, 2013, pages 688 - 698, XP028758016, DOI: doi:10.1016/j.cell.2013.09.049;;SUN, L. ET AL.: ""Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway"", SCIENCE, vol. 339, 2013, pages 786 - 791, XP055294100, DOI: doi:10.1126/science.1232458;;BHAT N; FITZGERALD KA: ""Recognition of Cytosolic DNA by cGAS and other STING-dependent sensors"", EUR J IMMUNOL., vol. 44, no. 3, March 2014 (2014-03-01), pages 634 - 40;;ZHANG X ET AL.: ""Cyclic GMP-A]\;UJ Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING"", MOLECULAR CELL, vol. 51, 2013, pages 226 - 235, XP055300246, DOI: doi:10.1016/j.molcel.2013.05.022;;DANILCHANKA, O; MEKALANOS, JJ: ""Cyclic Dinucleotides and the Innate Immune Response"", CELL, vol. 154, 2013, pages 962 - 970, XP028706417, DOI: doi:10.1016/j.cell.2013.08.014;;LIU S-Y ET AL.: ""Systematic identification of type I and type II interferon-induced antiviral factors"", PROC. NATL. ACAD. SCI., vol. 109, 2012, pages 4239 - 4244;;""Design of Prodrugs"", 1985, ELSEVIER;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY & SONS;;VAN DER JEUGHT ET AL., ONCOTARGET, vol. 6, no. 3, 2015, pages 1359 - 1381;;MARABELLE, A. ET AL., CLINICAL CANCER RESEARCH, vol. 20, no. 7, 2014, pages 1747 - 1756;;HOLFORD; SCHEINER, CLIN. PHARMACOKINET., vol. 6, 1998, pages 429 - 453;;LOEWE; MUISCHNEK, ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326;;CHOU; TALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;J. CHEM. SOC., PERKIN TRANS., vol. 1, 2002, pages 485 - 495;;CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 170871-87-1",PENDING
478,CN,A,CN 111712509 A,030-724-969-351-843,2020-09-25,2020,CN 201880089451 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,Cyclic dinucleotides as STING agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. The compounds are represented by Formula (I) as follows, wherein B2,X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/030-724-969-351-843,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,PENDING
479,EP,B1,EP 3724205 B1,193-361-749-657-69X,2022-06-22,2022,EP 18830620 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS,,JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/193-361-749-657-69X,Granted Patent,yes,1,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,ACTIVE
480,CA,A1,CA 3085337 A1,047-491-579-225-350,2019-06-20,2019,CA 3085337 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,CYCLIC DINUCLEOTIDES AS STING AGONISTS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2,X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM BERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/047-491-579-225-350,Patent Application,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,PENDING
481,ES,T3,ES 2927194 T3,068-274-078-903-302,2022-11-03,2022,ES 18830620 T,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,Dinucleótidos cíclicos como agonistas de STING,"Se describen compuestos, composiciones y métodos para el tratamiento de enfermedades, síndromes o trastornos que se ven afectados por la modulación de STING. Dichos compuestos están representados por la fórmula (I) como sigue: en la que B2, X2, R2a, R2b, R2c, ZMY, Y1-M1Z1, B1, X1, R1a, R1b, R1c son como se definen aquí. (Traducción automática con Google Translate, sin valor legal)",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/068-274-078-903-302,Granted Patent,no,0,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,ACTIVE
482,AU,B2,AU 2018/386222 B2,151-748-886-609-072,2023-04-20,2023,AU 2018/386222 A,2018-12-14,US 201762599111 P;;US 2018/0065677 W,2017-12-15,Cyclic dinucleotides as sting agonists,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B",JANSSEN BIOTECH INC,BEIGELMAN LEONID;;BIGNAN GILLES;;CONNOLLY PETER J;;EDWARDS JAMES PATRICK;;EMANUEL STUART;;LAQUERRE SYLVIA;;RICHTER MARK;;SCHEPENS WIM GERT GRIET;;THATIKONDA SANTHOSH KUMAR;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;VIELLEVOYE MARCEL;;WANG GUANGYI;;ZHONG MINGHONG,,https://lens.org/151-748-886-609-072,Granted Patent,no,1,0,16,16,0,A61K31/7084;;C07H21/02;;C07H21/04;;C07H21/00;;A61K31/7084;;A61P35/00;;A61P31/12;;A61P35/00;;A61K9/0053;;A61K31/7084;;C07H21/04;;C07K16/082,C07H21/02;;A61K31/7084;;A61P31/00;;A61P31/12;;A61P35/00;;C07H21/04,,0,0,,,,ACTIVE
483,BR,A2,BR 112019012355 A2,031-085-229-291-767,2019-11-26,2019,BR 112019012355 A,2017-12-20,US 2017/0067516 W;;US 201662437384 P,2016-12-21,derivados de pirazol como inibidores de malt1,"a presente invenção se refere a compostos, composições e métodos para o tratamento de doenças, síndromes, condições e distúrbios que são afetados pela modulação de malt1. tais compostos são representados pela fórmula (i): fórmula (i) em que r1, r2, r3, r4, r5, r6, r5, g1 e g2 são aqui definidos.",JANSSEN PHARMACEUTICA NV,BRETT DOUGLAS ALLISON;;DIDIER JEAN-CLAUDE BERTHELOT;;FANG SHEN;;GASTON DIELS;;JAMES PATRICK EDWARDS;;JOHANNES WILHELMUS JOHN FITZGERALD THURING;;JOSEPH KENT BARBAY;;KEVIN D KREUTTER;;MAXWELL DAVID CUMMINGS;;PETER J CONNOLLY;;TIANBAO LU;;TONGFEI WU;;ULRIKE PHILIPPAR,,https://lens.org/031-085-229-291-767,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
484,MX,A,MX 2022005827 A,170-094-558-405-096,2022-06-08,2022,MX 2022005827 A,2019-06-21,US 201662437384 P,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS.,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN PHARMACEUTICA NV,BARBAY JOSEPH KENT;;WU TONGFEI;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;LU TIANBAO;;ALLISON BRETT DOUGLAS;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;PHILIPPAR ULRIKE;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;BERTHELOT DIDIER JEAN- CLAUDE;;SHEN FANG,,https://lens.org/170-094-558-405-096,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
485,CL,A1,CL 2019001709 A1,004-411-629-758-639,2019-10-04,2019,CL 2019001709 A,2019-06-19,US 201662437384 P,2016-12-21,Derivados pirazol como inhibidores de malt1.,"SE DESCRIBEN COMPUESTOS, COMPOSICIONES Y MÉTODOS PARA TRATAR ENFERMEDADES, SÍNDROMES, CONDICIONES O TRASTORNOS QUE SON AFECTADOS POR LA MODULACIÓN DE MALT1. TALES COMPUESTOS SE REPRESENTAN MEDIANTE LA FÓRMULA (I), EN DONDE R1, R2, R3, R4, R5, R6, R5, G1, Y G2 SE DEFINEN EN LA PRESENTE DESCRIPCIÓN.",JANSSEN PHARMACEUTICA NV,WU TONGFEI;;KREUTTER KEVIN D;;LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/004-411-629-758-639,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/12;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D495/04,,0,0,,,,PENDING
486,EP,A1,EP 3558969 A1,014-253-903-272-642,2019-10-30,2019,EP 17851862 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,,JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/014-253-903-272-642,Patent Application,yes,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
487,PE,A1,PE 20191755 A1,036-481-429-962-541,2019-12-12,2019,PE 2019001288 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,DERIVADOS DE PIRAZOL COMO INHIBIDORES DE MALT 1,"Referido a un compuesto de formula (I), en donde R1 se selecciona de i) naftalen-1-ilo, opcionalmente sustituido con fluoro o amino; y ii) un heteroarilo de nueve a diez miembros que contiene de uno a cuatro heteroatomos seleccionados de O, N y S, opcionalmente sustituido; R2 se selecciona de alquilo C1-4, 1-metoxi-etilo, entre otros; G1 es N o C(R4); G2 es N o C(R3); R3 se selecciona de trifluorometilo, ciano, entre otros; R4 se selecciona de H, alcoxi C1-4, ciano, entre otros; R5 se selecciona de H, Cl, fluoro, entre otros; R6 es H, alquilo C1-4; R7 es H o fluoro. Son compuestos preferidos: N-(2-cianopiridin-4-il)-1-(naftalen-1-il) -5- (trifluorometil)-1H-pirazol-4-carboxamida, N-(5-cloro-6-(2H-1,2,3-triazol-2-il)piridin-3-il)-1-(naftalen-1-il)-5-(trifluorometil)-7H-pirazol-4-carboxamida, entre otros. Dichos compuestos son inhibidores de MALT1 (proteina de translocacion de linfoma de tejido linfoide asociado a las mucosas 1), siendo utiles para el tratamiento de una enfermedad, sindrome, afeccion, condicion o trastorno, relacionado con MALT1, incluyendo el cancer y enfermedades inmunologicas. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/036-481-429-962-541,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
488,AU,A1,AU 2022/201352 A1,140-882-334-770-296,2022-03-24,2022,AU 2022/201352 A,2022-02-28,AU 2022/201352 A;;AU 2017/382185 A;;US 201662437384 P;;US 2017/0067516 W,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of the MALT1. Such compounds are represented by Formula (1) wherein R1, R2, R3, R4, R5, R6, Gi and G2 are defined herein. G 'O R I R, N ,N",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/140-882-334-770-296,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
489,AU,C9,AU 2017/382185 C9,170-366-194-000-739,2022-08-04,2022,AU 2017/382185 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/170-366-194-000-739,Amended Patent,no,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,ACTIVE
490,CO,A2,CO 2019006622 A2,008-225-496-592-167,2019-06-28,2019,CO 2019006622 A,2019-06-21,US 2017/0067516 W;;US 201662437384 P,2016-12-21,Derivados de pirazol como inhibidores de malt1,"Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes, condiciones o trastornos que son afectados por la modulación de MALT1. Tales compuestos se representan mediante la Fórmula (I): Fórmula (I) en donde R1, R2, R3, R4, R5, R6, R5, G1, y G2 se definen en la presente descripción.",JANSSEN PHARMACEUTICA NV,ALLISON BRETT DOUGLAS;;LU TIANBAO;;CONNOLLY PETER J;;BARBAY JOSEPH KENT;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;EDWARDS JAMES PATRICK;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/008-225-496-592-167,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
491,PH,A1,PH 12019501212 A1,013-781-413-379-933,2019-12-16,2019,PH 12019501212 A,2019-05-31,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/013-781-413-379-933,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D413/14;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
492,CN,A,CN 110214136 A,199-158-262-840-745,2019-09-06,2019,CN 201780079706 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula(I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN BIOTECH INC,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/199-158-262-840-745,Patent Application,no,4,4,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,2,0,,,"CHRISTOPHE BOLDRON 等: ""N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist"", 《JOURNAL OF MEDICINAL CHEMISTRY》;;孙晓杰 等: ""《肿瘤分子诊断与靶向治疗》"", 31 July 2009",PENDING
493,UA,C2,UA 127920 C2,104-381-141-897-951,2024-02-14,2024,UA A201908268 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/104-381-141-897-951,Limited Patent,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,,,0,0,,,,ACTIVE
494,TN,A1,TN 2019000192 A1,128-640-062-232-729,2020-10-05,2020,TN 2019000192 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) : wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R <sub>6</sub>, R<sub>7</sub>, G<sub>1</sub>, and G<sub>2</sub> are defined herein.",JANSSEN PHARMACEUTICA NV,CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;WU TONGFEI;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;LU TIANBAO;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;EDWARDS JAMES PATRICK;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/128-640-062-232-729,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,A61K31/538,,0,0,,,,PENDING
495,AU,A1,AU 2017/382185 A1,076-872-431-309-743,2019-06-13,2019,AU 2017/382185 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/076-872-431-309-743,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,ACTIVE
496,AU,B2,AU 2017/382185 B2,193-027-125-176-317,2021-12-02,2021,AU 2017/382185 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/193-027-125-176-317,Granted Patent,no,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,ACTIVE
497,US,A1,US 2022/0315557 A1,074-926-372-272-589,2022-10-06,2022,US 202017104081 A,2020-11-25,US 202017104081 A;;US 201715847999 A;;US 201662437384 P,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,JANSSEN-CILAG (2019-05-10);;JANSSEN PHARMACEUTICA NV (2018-12-19);;JANSSEN BIOTECH INC (2017-12-19),https://lens.org/074-926-372-272-589,Patent Application,yes,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/14;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
498,MX,A,MX 2019007540 A,143-211-938-176-249,2019-10-24,2019,MX 2019007540 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS.,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN PHARMACEUTICA NV,FANG SHEN;;JOSEPH KENT BARBAY;;DIDIER JEAN- CLAUDE BERTHELOT;;TONGFEI WU;;JAMES PATRICK EDWARDS;;KEVIN D KREUTTER;;TIANBAO LU;;BRETT DOUGLAS ALLISON;;PETER J CONNOLLY;;MAXWELL DAVID CUMMINGS;;GASTON DIELS;;ULRIKE PHILIPPAR;;JOHANNES WILHELMUS JOHN FITZGERALD THURING,,https://lens.org/143-211-938-176-249,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,A61P1/00;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
499,AU,C1,AU 2017/382185 C1,134-555-885-728-38X,2022-08-11,2022,AU 2017/382185 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/134-555-885-728-38X,Amended Patent,no,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,ACTIVE
500,KR,A,KR 20190093669 A,139-147-870-001-187,2019-08-09,2019,KR 20197021137 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,MALT1 억제제로서의 피라졸 유도체,"MALT1의 조절에 의해 영향을 받는 질환, 증후군, 상태 및 장애를 치료하기 위한 화합물, 조성물 및 방법이 개시된다. 이러한 화합물은 화학식 (I)으로 나타낸다:(I) 상기 식에서, R, R,R, R, R, R, R, G및 G는 본 명세서 및 청구범위에 정의된 바와 같다.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN CLAUDE,,https://lens.org/139-147-870-001-187,Patent Application,no,2,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D405/14;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04,,3,0,,,"DATABASE REGISTRY [Online], CAS Registry Number: 1907875-04-0 (2016.05.11.)*;;DATABASE REGISTRY [Online], CAS Registry Number: 1907028-26-5 (2016.05.10.)*;;DATABASE REGISTRY [Online], CAS Registry Number: 1898933-19-1 (2016.04.27.)*",ACTIVE
501,US,B2,US 10954214 B2,150-960-270-048-942,2021-03-23,2021,US 201715847999 A,2017-12-20,US 201715847999 A;;US 201662437384 P,2016-12-21,Pyrazole derivatives as MALT1 inhibitors,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,JANSSEN-CILAG (2019-05-10);;JANSSEN PHARMACEUTICA NV (2018-12-19);;JANSSEN BIOTECH INC (2017-12-19),https://lens.org/150-960-270-048-942,Granted Patent,yes,21,1,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/14;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,31,17,012-994-617-927-80X;;054-269-121-291-520;;001-516-175-552-397;;037-165-733-219-789;;105-129-409-527-399;;103-752-080-034-709;;051-588-339-916-553;;149-087-447-664-064;;007-268-478-416-294;;001-676-197-805-749;;078-519-855-308-942;;016-279-471-633-683;;125-728-925-514-092;;047-138-645-820-688;;087-192-267-012-779;;015-845-506-559-143;;081-511-682-994-308,10.1039/b504668h;;16027897;;10.1038/nrd1031;;12612646;;10.1016/s0169-409x(01)00097-7;;11325474;;25762782;;10.3410/f.725387389.793505358;;10.4049/jimmunol.1402254;;26787500;;10.1016/j.molmed.2015.12.004;;23238016;;10.1016/j.ccr.2012.11.003;;pmc3984478;;10.1016/j.celrep.2014.10.044;;25456129;;pmc3700575;;23727036;;10.1016/j.jaci.2013.04.047;;pmc4282555;;10.15252/embj.201488987;;25319413;;pmc4713714;;10.1007/s00018-015-2059-z;;26507244;;pmc4112826;;10.1186/1742-2094-11-124;;25043939;;10.1016/j.jaci.2013.10.045;;24332264;;23238017;;10.1016/j.ccr.2012.11.002;;pmc4352191;;25627829;;10.1007/s10875-014-0125-1;;10.1126/science.1198946;;21273489;;pmc3124150;;10.4331/wjbc.v7.i1.128;;26981201;;pmc4768116;;10.1371/journal.pone.0127083;;25965667;;pmc4428694,"Yu et al., “Physical characterization of, etc.,” PSTT, vl. 1(3), 118-127). (Year: 1998).;;Braga et al., “Making crystals from . . . ” J. Royal Soc. Chem. Commun. p. 3635-3645. (Year: 2005).;;Bernstein, “Polymorphism in . . . ” p. 115-118, 272. (Year: 2002).;;Davidovich et al., “Detection of polymorphism . . . ” Am. Pharm. Rev. v.&(1) p. 10, 12, 14, 16, 100). (Year: 2004).;;Dean “Analytical Chem . . . ” p. 10.24-10.26. (Year: 1995).;;Ivanisevic et al. “Use of X-ray . . . ” Pharm. Sci. Encycl. p. 1-42. (Year: 2010).;;Seddon “Pseudopolynnorph . . . ” Crystal Growth & design v.4(6) p. 108 (2 pages from internet) (Year: 2004).;;Jain et al., “Polymorphism in Pharmacy”, Indian Drugs 23(6) 315-329. (Year: 1986).;;Jordan “Tamoxifen . . . ” Nature Rev. v.2, p. 205-213. (Year: 2003).;;Kirk-Othmer Encyclopedia of Chemical Technology, 8, pp. 95-147. (Year: 2002).;;Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews 48 3-26. (Year: 2001).;;Guillory (in Brittain ed.), “Polymorphism in Pharmaceutical Solids.,” NY: Marcel Dekker, Inc., 1-2, 125-181, 183-226. (Year: 1999).;;Bornancin et al., “Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation.”, J. Immunology, Apr. 15, 2015, vol. 194(8), pp. 3723-3734.;;Demeyer et al., “Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?”, Trends Mol Med, 2016, vol. 22(2), pp. 135-150.;;Fontan et al., “MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo.”, Cancer Cell, Dec. 11, 2012, vol. 22(6), pp. 812-824.;;Gewies et al., “Uncoupling Malt1 Threshold Function from Paracaspase Activity Results in Destructive Autoimmune Inflammation.”, Cell Reports, Nov. 20, 2014, 9, pp. 1292-1305.;;Jabara et al., “A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency.”, J. Allergy Clin. Immunol., Jul. 2013, vol. 132, pp. 151-158.;;Jaworski et al., “Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.”, The EMBO Journall , 2014, vol. 33(23), pp. 2765-2781.;;Jaworski et al., “The paracaspase MALT1: biological function and potential for therapeutic inhibition.”, Cell Mol Life Science, 2016, vol. 73, pp. 459-473.;;McGuire et al., “Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.”, J. Neuroinflammation, 2014, vol. 11, p. 124.;;McKinnon et al., “Combined immunodeficiency associated with homozygous MALT1 mutations.”, J. Allergy Clin. Immunol. 2014, vol. 133, pp. 1458-1462.;;Nagel et al., “Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL.”, Cancer Cell, Dec. 11, 2012, vol. 22, pp. 825-837.;;Punwani et al., “Combined Immunodeficiency Due to MALT1 Mutations, Treated by Hematopoietic Cell Transplantation.”, J. Clin. Immunol., 2015, vol. 35, pp. 135-146.;;Rosebeck et al., “Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NK-kB Activation.”, Science, Jan. 28, 2011, vol. 331, pp. 468-472.;;Rosebeck et al., “API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.”, World J Biol Chem, Feb. 26, 2016, vol. 7(1), pp. 128-137.;;Yu et al., “MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.”, PLOS One, May 12, 2015, pp. 1-20.;;Lim, K., et al., “Pathogentic importance and therapeutica implications of NK-Kβ in lymphoid malignancies”, Immunological Reviews, (2012), vol. 246, pp. 359-378.;;Bundgaard, H., “Design of Prodrugs”, (1985), Table of Contents.;;McOmie, J., “Protective Groups in Organic Chemistry”, (1973), Title Page and Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, Inc., (1991), Table of Contents.;;T.W. Greene & P.G.M. Wutz (eds.), Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc., (1999), Table of Contents.",ACTIVE
502,CA,A1,CA 3048027 A1,033-112-740-050-649,2018-06-28,2018,CA 3048027 A,2017-12-20,US 201662437384 P;;US 2017/0067516 W,2016-12-21,PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS,"Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.",JANSSEN PHARMACEUTICA NV,LU TIANBAO;;ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI;;BERTHELOT DIDIER JEAN-CLAUDE,,https://lens.org/033-112-740-050-649,Patent Application,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,C07D401/12;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
503,MA,A,MA 47125 A,181-469-525-506-250,2021-04-28,2021,MA 47125 A,2017-12-20,US 201662437384 P,2016-12-21,DÉRIVÉS DE PYRAZOLE EN TANT QU'INHIBITEURS DE MALT1,,JANSSEN PHARMACEUTICA NV,ALLISON BRETT DOUGLAS;;BARBAY JOSEPH KENT;;BERTHELOT DIDIER JEAN-CLAUDE;;CONNOLLY PETER J;;CUMMINGS MAXWELL DAVID;;DIELS GASTON;;EDWARDS JAMES PATRICK;;KREUTTER KEVIN D;;LU TIANBAO;;PHILIPPAR ULRIKE;;SHEN FANG;;THURING JOHANNES WILHELMUS JOHN FITZGERALD;;WU TONGFEI,,https://lens.org/181-469-525-506-250,Unknown,no,0,0,33,33,0,A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D401/14;;C07D417/14;;A61P19/02;;A61P1/00;;C07D413/14;;C07D491/04;;A61P37/00;;C07D495/04;;C07D487/04;;A61P35/00;;C07D405/14;;C07D471/04;;C07D401/12;;A61P11/06;;C07D405/14;;A61K31/4439;;A61K31/437;;A61K31/444;;A61K31/4725;;A61K31/538;;C07D401/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P35/00;;A61P37/00;;C07D401/14;;C07D401/12;;A61P35/00;;A61P37/00;;A61P1/00;;A61P11/06;;A61P19/02;;C07D487/04;;C07D405/14;;C07D491/04;;C07D495/04;;C07D413/14;;C07D471/04;;C07D417/14,A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/538;;A61P35/00;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D471/04;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
